hqdcaivajotavqwarixoiijsrclibarsyegilcvq length 6 753081 page 753081 
        <!doctype html>
        <html lang="en"lang="en">
            <head>
                <!-- NATGEO | 993991df7ade | 3484 | bfa4aecbdc63cc1fd792827646291c9a8c1fd981 | www.nationalgeographic.com | Sun, 05 May 2024 04:10:31 GMT -->
                <meta charSet="utf-8" />
                <meta name="viewport" content="initial-scale=1.0, maximum-scale=1.0, user-scalable=no" />
                <meta http-equiv="x-ua-compatible" content="IE=edge,chrome=1" />
                <meta property="og:locale" content="en_US" />
                <script src="https://dcf.espn.com/TWDC-DTCI/prod/Bootstrap.js" async></script>
                
                <link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/fusion-d44ee4ef.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/2611-e4f72c35.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/natgeo-c05299b9.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/3460-8ff104de.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1156-52e2914a.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1551-74bf7284.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/5427-d6305e79.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/4162-313cf2d3.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/9381-70992203.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/4135-c77030ec.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/7023-52a0e8dc.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/533-43a9546c.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1575-5ae1fd34.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/9991-fa6749ac.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/3641-672ae602.css"/><link data-react-helmet="true" rel="stylesheet" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/prismarticle-635a74d8.css"/><link data-react-helmet="true" rel="canonical" href="https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"/><link data-react-helmet="true" rel="alternate" hreflang="en-us" href="https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"/><link data-react-helmet="true" rel="mask-icon" href="https://assets-cdn.nationalgeographic.com/natgeo/static/icons/mask-icon.svg" color="#FFCC00"/><link data-react-helmet="true" rel="shortcut icon" href="https://assets-cdn.nationalgeographic.com/natgeo/static/icons/favicon.ico"/><link data-react-helmet="true" rel="apple-touch-icon" href="https://assets-cdn.nationalgeographic.com/natgeo/static/icons/favicon-32x32.png"/><link data-react-helmet="true" rel="apple-touch-icon-precomposed" sizes="32x32" href="https://assets-cdn.nationalgeographic.com/natgeo/static/icons/favicon-32x32.png"/><link data-react-helmet="true" rel="apple-touch-icon-precomposed" sizes="180x180" href="https://assets-cdn.nationalgeographic.com/natgeo/static/icons/favicon-180x180.png"/>
                <script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/runtime-8e78a3d0.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/2611-b3d18e55.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/9479-8e515628.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/7708-e245d62e.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/2919-7dbda4b0.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3460-d596d2df.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/5437-3035472d.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/19-a19cabee.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4257-3ac25efc.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1156-e472ade1.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1551-561798d8.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1636-3f742790.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3021-90467b73.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/8330-6af310aa.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/5427-0bf927ab.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4162-192c0a75.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/9381-56e8d894.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/533-7f729090.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4343-b87c7e66.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3641-760c8582.js" defer></script>
                <link rel="prefetch" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/_manifest.js" as="script" /><link rel="prefetch" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/natgeo-fce9ec0b.js" as="script" />
<link rel="prefetch" href="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/prismarticle-27bb034e.js" as="script" />
                <title data-react-helmet="true">Here’s the latest on COVID-19 vaccines</title>
                <meta data-react-helmet="true" name="title" content="Here’s the latest on COVID-19 vaccines"/><meta data-react-helmet="true" name="description" content="Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout."/><meta data-react-helmet="true" name="medium" content="website"/><meta data-react-helmet="true" name="guid" content="drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a"/><meta data-react-helmet="true" property="og:site_name" content="Science"/><meta data-react-helmet="true" property="og:title" content="Here’s the latest on COVID-19 vaccines"/><meta data-react-helmet="true" property="og:description" content="Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout."/><meta data-react-helmet="true" property="og:url" content="https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"/><meta data-react-helmet="true" property="og:image" content="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg?w=1200"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="675"/><meta data-react-helmet="true" property="og:type" content="article"/><meta data-react-helmet="true" name="referrer" content="origin"/><meta data-react-helmet="true" name="theme-color" content="#ffffff"/><meta data-react-helmet="true" name="tax:audiences" content="General"/><meta data-react-helmet="true" name="tax:concepts" content/><meta data-react-helmet="true" name="tax:events" content/><meta data-react-helmet="true" name="tax:firstSubject" content="Coronavirus"/><meta data-react-helmet="true" name="tax:genres" content="News"/><meta data-react-helmet="true" name="tax:locations" content/><meta data-react-helmet="true" name="tax:organizations" content/><meta data-react-helmet="true" name="tax:otherSubjects" content="Vaccination, Immune System, Public Health, Diseases, Epidemics"/><meta data-react-helmet="true" name="tax:people" content/><meta data-react-helmet="true" name="tax:series" content="Coronavirus Coverage"/><meta data-react-helmet="true" name="tax:source" content="Science"/><meta data-react-helmet="true" name="twitter:site" content="@NatGeo"/><meta data-react-helmet="true" name="twitter:title" content="Here’s the latest on COVID-19 vaccines"/><meta data-react-helmet="true" name="twitter:description" content="Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout."/><meta data-react-helmet="true" name="twitter:url" content="https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"/><meta data-react-helmet="true" name="twitter:image:src" content="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg?w=1200"/><meta data-react-helmet="true" name="twitter:card" content="summary_large_image"/><meta data-react-helmet="true" name="twitter:creator" content="@NatGeo"/><meta data-react-helmet="true" name="twitter:image:alt" content="Here’s the latest on COVID-19 vaccines"/><meta data-react-helmet="true" name="twitter:app:id:iphone" content="418671597"/><meta data-react-helmet="true" name="twitter:app:name:iphone" content="National Geographic"/><meta data-react-helmet="true" name="twitter:app:id:googleplay" content="com.natgeomobile.ngmagazine"/><meta data-react-helmet="true" name="twitter:app:name:googleplay" content="National Geographic"/><meta data-react-helmet="true" name="robots" content="max-image-preview:large"/><meta data-react-helmet="true" name="article:published_time" content="10-29-2021"/><meta data-react-helmet="true" name="article:modified_time" content="11-05-2021"/><meta data-react-helmet="true" name="article:section" content="Science"/><meta data-react-helmet="true" name="article:publisher" content="https://www.facebook.com/natgeo"/>
                <script data-react-helmet="true" src="https://scripts.webcontentassessor.com/scripts/340714530193d9627afecb7a2bab115079ee90db012cba398ac76b3339880fdc"></script><script data-react-helmet="true" type="application/ld+json">{"@context":"http://schema.org/","@type":"NewsArticle","mainEntityOfPage":{"@id":"","@type":"WebPage"},"author":[{"name":"Amy McKeever","@type":"Person"},{"name":"National Geographic Staff","@type":"Person"}],"dateline":null,"datePublished":"2021-10-29T19:32:02.702Z","description":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","headline":"Here’s the latest on COVID-19 vaccines","image":{"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg","@type":"ImageObject"},"publisher":{"name":"","logo":{"url":"","width":0,"height":0,"@type":"ImageObject"},"@type":"Organization"}}</script>
                
                <script data-nr-type="legacy" data-nr-pct="100">(() => {function gc(n){n=document.cookie.match("(^|;) ?"+n+"=([^;]*)(;|$)");return n?n[2]:null}function sc(n){document.cookie=n}function smpl(n){n/=100;return!!n&&Math.random()<=n}var _nr=!1,_nrCookie=gc("_nr");null!==_nrCookie?"1"===_nrCookie&&(_nr=!0):smpl(100)?(_nr=!0,sc("_nr=1; path=/")):(_nr=!1,sc("_nr=0; path=/"));_nr && (() => {;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}};;NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","sa":1,"licenseKey":"5985ced6ff","applicationID":"703643455"};__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(31),s={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,o.indexOf("dev")!==-1&&(s.dev=!0),o.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&i.on("internal-error",function(t){r(t.stack)}),s.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{l?l-=1:o(s||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:c.now();i("err",[t,n])}var i=t("handle"),a=t(32),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError";if(!c.disabled){var l=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(14),t(13),"addEventListener"in window&&t(7),c.xhrWrappable&&t(15),d=!0)}s.on("fn-start",function(t,e,n){d&&(l+=1)}),s.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),s.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),s.on("internal-error",function(t){i("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){U++,L=g.hash,this[u]=y.now()}function o(){U--,g.hash!==L&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var s="-start",c="-end",f="-body",u="fn"+s,d="fn"+c,p="cb"+s,l="cb"+c,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable&&!y.disabled){var x=t(11),b=t(12),E=t(9),R=t(7),O=t(14),T=t(8),S=t(15),P=t(10),M=t("ee"),C=M.get("tracer"),N=t(23);t(17),y.features.spa=!0;var L,U=0;M.on(u,r),b.on(p,r),P.on(p,r),M.on(d,o),b.on(l,o),P.on(l,o),M.buffer([u,d,"xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+c,"clearTimeout"+s,u]),S.buffer([u,"new-xhr","send-xhr"+s]),T.buffer([m+s,m+"-done",m+f+s,m+f+c]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+s]),C.buffer([u,"no-"+u]),P.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(T,m+s),a(T,m+"-done"),a(P,"new-jsonp"),a(P,"jsonp-end"),a(P,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,N(!0)),w[v]("load",i,N(!0)),w[v]("popstate",function(){i(0,U>1)},N(!0))}},{}],5:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function o(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+p])try{window.performance[h](m,o,!1)}catch(t){}else try{window.performance[h]("webkit"+m,o,!1)}catch(t){}}function i(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(14),f=t(13),u=t(6),d=t(23),p="learResourceTimings",l="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",O=t("loader");if(!O.disabled){O.features.stn=!0,t(9),"addEventListener"in window&&t(7);var T=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof T&&(this.bstStart=O.now())}),a.on(b,function(t,e){var n=t[0];n instanceof T&&s("bst",[n,e,this.bstStart,O.now()])}),c.on(x,function(t,e,n){this.bstStart=O.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),this.bstType])}),f.on(x,function(){this.bstStart=O.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=O.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):l in window.performance&&(window.performance["c"+p]?window.performance[l](m,o,d(!1)):window.performance[l]("webkit"+m,o,d(!1))),document[l]("scroll",i,d(!1)),document[l]("keypress",i,d(!1)),document[l]("click",i,d(!1))}}},{}],6:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],7:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){s.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],8:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return o.emit(n+"start",[t,a],s),s.then(function(t){return o.emit(n+"end",[null,t],s),t},function(t){throw o.emit(n+"end",[t],s),t})})}var o=t("ee").get("fetch"),i=t(32),a=t(31);e.exports=o;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,p=s.Response,l=s.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(s,"fetch",c),o.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(c+"done",[null,e],n)}else o.emit(c+"done",[t],n)}))},{}],9:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],10:[function(t,e,n){function r(t){function e(){f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}function n(){f.emit("jsonp-error",[],l),f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var d=s(a),p="function"==typeof d.parent[d.key];if(p){var l={};u.inPlace(d.parent,[d.key],"cb-",l),t.addEventListener("load",e,c(!1)),t.addEventListener("error",n,c(!1)),f.emit("new-jsonp",[t.src],l)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(d);return e?e[1]:null}function a(t,e){var n=t.match(l),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(p);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t(23),f=t("ee").get("jsonp"),u=t("wrap-function")(f);if(e.exports=f,o()){var d=/[?&](?:callback|cb)=([^&#]+)/,p=/(.*).([^.]+)/,l=/^(w+)(.|$)(.*)$/,h=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?u.inPlace(Node.prototype,h,"dom-"):(u.inPlace(HTMLElement.prototype,h,"dom-"),u.inPlace(HTMLHeadElement.prototype,h,"dom-"),u.inPlace(HTMLBodyElement.prototype,h,"dom-")),f.on("dom-start",function(t){r(t[0])})}},{}],11:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],12:[function(t,e,n){function r(t){var e=i.context(),n=s(t,"executor-",e,null,!1),r=new f(n);return i.context(r).getCtx=function(){return e},r}var o=t("wrap-function"),i=t("ee").get("promise"),a=t("ee").getOrSetContext,s=o(i),c=t(31),f=NREUM.o.PR;e.exports=i,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){i.emit("propagate",[null,!o],a,!1,!1),o=o||!t}}var o=!1;c(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var a=e.apply(f,arguments),s=f.resolve(a);return s}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&i.emit("propagate",[t,!0],n,!1,!1),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),c(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),o.wrapInPlace(f.prototype,"then",function(t){return function(){var e=this,n=o.argsToArray.apply(this,arguments),r=a(e);r.promise=e,n[0]=s(n[0],"cb-",r,null,!1),n[1]=s(n[1],"cb-",r,null,!1);var c=t.apply(this,n);return r.nextPromise=c,i.emit("propagate",[e,!0],c,!1,!1),c}}),i.on("executor-start",function(t){t[0]=s(t[0],"resolve-",this,null,!1),t[1]=s(t[1],"resolve-",this,null,!1)}),i.on("executor-err",function(t,e,n){t[1](n)}),i.on("cb-end",function(t,e,n){i.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),i.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=i.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],13:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],14:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(c+u,r),i.on(s+u,o)},{}],15:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function i(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,O.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(7);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=t(23),l=NREUM.o,h=l.XHR,m=l.MO,v=l.PR,w=l.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,o,p(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,O=document.createTextNode(R);new m(a).observe(O,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],16:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",s=1,c="",f="";return o+"@nr="+i+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(s.d.tk=i),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(28),h=t(18);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],17:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);return e.protocol&&"data"===e.protocol?void g("Ajax/DataUrl/Excluded"):void(e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this)))}}function o(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(18),f=t(16).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(24),m=t(22),v=t(19),w=t(23),g=t(25).recordSupportability,y=NREUM.o.REQ,x=window.XMLHttpRequest;a.features.xhr=!0,t(15),t(8),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){i(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<p;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof x&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},i=this.target;if("string"==typeof i?n=i:"object"==typeof i&&i instanceof y?n=i.url:window.URL&&"object"==typeof i&&i instanceof URL&&(n=i.href),o(this,n),"data"!==this.params.protocol){var s=(""+(i&&i instanceof y&&i.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}}),u.on("fetch-done",function(t,e){if(this.endTime=a.now(),this.params||(this.params={}),"data"===this.params.protocol)return void g("Ajax/DataUrl/Excluded");this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],18:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];if(0===(t||"").indexOf("data:"))return{protocol:"data"};var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||s),"/"===o.pathname&&(r[t]=o),o}},{}],19:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(22);e.exports=r},{}],20:[function(t,e,n){function r(){}function o(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),i(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var i=t("handle"),a=t(31),s=t(32),c=t("ee").get("tracer"),f=t("loader"),u=t(25),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",h=l+"ixn-";a(p,function(t,e){d[e]=o(l,e,!0,"api")}),d.addPageAction=o(l,"addPageAction",!0),d.setCurrentRouteName=o(l,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=o(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),i("err",[t,f.now(),!1,e])}},{}],21:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],22:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],23:[function(t,e,n){var r=!1;try{var o=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,o),window.removeEventListener("testPassive",null,o)}catch(i){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],24:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[/s](d+.d+)/);o&&(r=+o[1]),e.exports=r},{}],25:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return i("storeMetric",n,null,"api"),n}function o(t,e){var n=[s,t,{name:t},e];return i("storeEventMetrics",n,null,"api"),n}var i=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:o}},{}],26:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(i=Math.max((new Date).getTime(),i))-a}function o(){return i}var i=(new Date).getTime(),a=i,s=t(33);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=o},{}],27:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?l("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&l("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(f&&f<r.startTime)return;var o=[r],i=a({});i&&o.push(i),l("lcp",o)}}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||l("cls",[t])})}function a(t){var e=navigator.connection||navigator.mozConnection||navigator.webkitConnection;if(e)return e.type&&(t["net-type"]=e.type),e.effectiveType&&(t["net-etype"]=e.effectiveType),e.rtt&&(t["net-rtt"]=e.rtt),e.downlink&&(t["net-dlink"]=e.downlink),t}function s(t){if(t instanceof w&&!y){var e=Math.round(t.timeStamp),n={type:t.type};a(n),e<=h.now()?n.fid=h.now()-e:e>h.offset&&e<=Date.now()?(e-=h.offset,n.fid=h.now()-e):e=h.now(),y=!0,l("timing",["fi",e,n])}}function c(t){"hidden"===t&&(f=h.now(),l("pageHide",[f]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var f,u,d,p,l=t("handle"),h=t("loader"),m=t(30),v=t(23),w=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){u=new PerformanceObserver(r);try{u.observe({entryTypes:["paint"]})}catch(g){}d=new PerformanceObserver(o);try{d.observe({entryTypes:["largest-contentful-paint"]})}catch(g){}p=new PerformanceObserver(i);try{p.observe({type:"layout-shift",buffered:!0})}catch(g){}}if("addEventListener"in document){var y=!1,x=["click","keydown","mousedown","pointerdown","touchstart"];x.forEach(function(t){document.addEventListener(t,s,v(!1))})}m(c)}},{}],28:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<i.length;s++)o=i[s],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(t)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],29:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(o="Safari",i=c[1])}e.exports={agent:o,version:i,match:r}},{}],30:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[i]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,o(!1))}var o=t(23);e.exports=r;var i,a,s;"undefined"!=typeof document.hidden?(i="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],31:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],32:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],33:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,o,i,a){if(a!==!1&&(a=!0),!l.aborted||i){t&&a&&t(n,r,o);for(var s=e(o),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var p=d[y[n]];return p&&p.push([x,n,r,s]),s}}function i(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return p[t]=p[t]||o(n)}function w(t,e){l.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:i,addEventListener:i,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function i(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",f=t("gos"),u=t(31),d={},p={},l=e.exports=o();e.exports.getOrSetContext=i,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!T++){var t=O.info=NREUM.info,e=m.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(E,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+O.offset],null,"api"),s("timing",["load",n]);var r=m.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=l+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===m.readyState&&i()}function i(){s("mark",["domContent",a()+O.offset],null,"api")}var a=t(26),s=t("handle"),c=t(31),f=t("ee"),u=t(29),d=t(21),p=t(23),l=d.getConfiguration("ssl")===!1?"http":"https",h=window,m=h.document,v="addEventListener",w="attachEvent",g=h.XMLHttpRequest,y=g&&g.prototype,x=!1;NREUM.o={ST:setTimeout,SI:h.setImmediate,CT:clearTimeout,XHR:g,REQ:h.Request,EV:h.Event,PR:h.Promise,MO:h.MutationObserver};var b=""+location,E={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1216.min.js"},R=g&&y&&y[v]&&!/CriOS/.test(navigator.userAgent),O=e.exports={offset:a.getLastTimestamp(),now:a,origin:b,features:{},xhrWrappable:R,userAgent:u,disabled:x};if(!x){t(20),t(27),m[v]?(m[v]("DOMContentLoaded",i,p(!1)),h[v]("load",r,p(!1))):(m[w]("onreadystatechange",o),h[w]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var T=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var i,a,u,p;try{a=this,i=d(arguments),u="function"==typeof r?r(i,a):r||{}}catch(l){o([l,"",[i,a,c],u],t)}s(n+"start",[i,a,c],u,f);try{return p=e.apply(a,i)}catch(h){throw s(n+"err",[i,a,h],u,f),h}finally{s(n+"end",[i,a,p],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,i(e,nrWrapper,t),nrWrapper)}function r(t,e,r,o,i){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,o,c,i))}function s(n,r,i,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,i,e,a)}catch(c){o([c,n,r,i],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=p,n}function o(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function i(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(i){o([i],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function s(t,e){var n=e(t);return n[p]=t,i(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(32),p="nr@original",l=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,17,5,3,4]);;NREUM.info={"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","sa":1,"licenseKey":"8d01ff17d1","applicationID":"415461361"}})();})();</script>

                <link href="//assets-cdn.nationalgeographic.com" rel="preconnect" />

                

            </head>
            <body>
                
                <div id="natgeo"><div id="fitt-analytics"><div></div><div><div class="ResponsiveWrapper"><div class="GlobalNav"><div class="StickyBar"><div class="StickyBar--sticky"><nav class="NavBar"><div class="NavBar__Left__Container"><div class="NavBar__Logo__Container"><div data-track-event_name="natgeo logo" class="fitt-tracker"><a class="AnchorLink" tabindex="0" title="National Geographic" href="/"><picture><source srcSet="https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png?w=109&amp;h=32, https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png?w=218&amp;h=64 2x"/><img alt="National Geographic Logo - Home" class="Image Logo NavBar__Logo Logo__lg" data-mptype="image" src="https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png?w=109&amp;h=32"/></picture></a></div></div></div><button aria-label="Skip to content" class="Button--unstyled SkipNav" tabindex="0">Skip to content</button><div class="NavBar__Spacer"></div><ul class="NavBar__List" role="presentation"><li class="NavBar__List--item"></li><li class="NavBar__List--item "><div data-track-event_name="global nav interaction" data-track-nav_item="search" data-track-nav_type="default" data-track-nav_layer="top nav" class="fitt-tracker"><a class="AnchorLink NavBar__List--search" tabindex="0" aria-label="Search" href="/search"><svg aria-hidden="true" class="NavBar__list--searchIcon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__search"></use></svg></a></div></li><li class="NavBar__List--item NavBar__List--renew"><div data-track-event_name="global nav interaction" data-track-nav_item="newsletters" data-track-nav_type="default" data-track-nav_layer="top nav" class="fitt-tracker"><a class="AnchorLink NavBar__List--link" tabindex="0" href="https://www.nationalgeographic.com/newsletters/signup">Newsletters</a></div></li><li class="NavBar__List--item"><div data-track-event_name="global nav interaction" data-track-nav_item="subscribe" data-track-nav_type="default" data-track-nav_layer="top nav" class="fitt-tracker"><a class="AnchorLink Button Button--anchorLink Button--default FillButton FillButton--link FillButton--secondary FillButton--large" tabindex="0" href="/subscribe" title="Subscribe"><span class="fillOne"></span><span class="fillTwo"></span><span class="content"><span>Subscribe</span></span></a></div></li><li class="NavBar__List--item"><div class="MenuModal NavBar__Menu--item"><button aria-label="Menu" aria-expanded="false" class="Button Button--default Button--icon MenuModal__MenuButton NavBar__Menu--item" tabindex="0"><svg focusable="false" aria-hidden="true" class="icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__double-chevron__down"></use></svg>Menu</button></div></li></ul></nav></div></div></div></div></div><div class="stickyFrame stickyFrame--bottom"></div><div class="bp-mobileMDPlus bp-mobileLGPlus bp-tabletPlus bp-desktopPlus bp-desktopLGPlus" data-fitt-page-type="prismarticle"><div class="ResponsiveWrapper"><div class="PageLayout page-container cf PageLayout--desktopLg PageLayout--prismarticle fitt-fade-in"><div class="PageLayout__Main" role="main" tabindex="-1"><div class=""><div><div id="natgeo-template1-frame-1-module-1" class="StackModule"><div class="ScrollSpy_container"><span></span><main class="Article-container"><div id="themeProvider" class="theme-natgeo "><div class="FITT_Article_outer-container iJVrZ lqtkC glxIO HfYhe vUYNV  dHdHP jLREf zXXje aGO " id="FITTArticle" style="--spacing-top:initial;--spacing-bottom:80px;--spacing-compact-top:initial;--spacing-compact-bottom:48px"><div class="FITT_Article_top"><div style="--spacing-top:40px;--spacing-bottom:initial;--spacing-child-top:initial;--spacing-child-bottom:initial;--spacing-firstChild-top:initial;--spacing-firstChild-bottom:initial;--spacing-lastChild-top:initial;--spacing-lastChild-bottom:initial;--spacing-compact-top:40px;--spacing-compact-bottom:initial;--spacing-firstChild-compact-top:initial;--spacing-firstChild-compact-bottom:initial;--spacing-child-compact-top:initial;--spacing-child-compact-bottom:initial;--spacing-lastChild-compact-top:initial;--spacing-lastChild-compact-bottom:initial" class="dHdHP jLREf zXXje aGO eCClZ nTLv jLsYA gmuro TOSFd VmeZt sCkVm hkQai wGrlE MUuGM fciaN qQjt DhNVo Tgcqk IGLAf tWjkv "><div data-testid="prism-ad-wrapper" data-ad-placeholder="true"></div></div></div><div class="FITT_Article_main  "><div class="VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><div style="--spacing-top:40px;--spacing-bottom:0px;--spacing-child-top:initial;--spacing-child-bottom:24px;--spacing-firstChild-top:initial;--spacing-firstChild-bottom:initial;--spacing-lastChild-top:initial;--spacing-lastChild-bottom:24px;--spacing-compact-top:24px;--spacing-compact-bottom:0px;--spacing-firstChild-compact-top:initial;--spacing-firstChild-compact-bottom:initial;--spacing-child-compact-top:initial;--spacing-child-compact-bottom:24px;--spacing-lastChild-compact-top:initial;--spacing-lastChild-compact-bottom:24px" class="dHdHP jLREf zXXje aGO eCClZ nTLv jLsYA gmuro TOSFd VmeZt sCkVm hkQai wGrlE MUuGM fciaN qQjt DhNVo Tgcqk IGLAf tWjkv "><div class="InlineImage GpQCA lZur asrEW " data-testid="prism-inline-image"><figure class="kzIjN GNmeK pYrtp dSqFO " data-testid="prism-figure"><div class="GpQCA lZur gIjeL " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><picture data-testid="prism-picture"><source media="(max-width: 374px)" srcSet="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=374&amp;h=249, https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=748&amp;h=498 2x"/><source media="(min-width: 375px) and (max-width: 413px)" srcSet="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=413&amp;h=275, https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=826&amp;h=550 2x"/><source media="(min-width: 414px)" srcSet="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=718&amp;h=479, https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=1436&amp;h=958 2x"/><img alt="A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston." class="hsDdd vBqtr KrDt SjwtZ hakZw HlUVI " data-testid="prism-image" draggable="false" fetchpriority="high" src="https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg"/></picture></div></div><figcaption><div class="nMMea bNYiy Mjgpa dGwha DDmxa jgKNG RGHCC aBIU PriDW lZur " data-testid="prism-caption"><div class="HXPPJ barbu IzgMt VcHIt uhSzI YGNMU cRAsZ xqMcl QtRul "><span class="hsDdd OOSI GpQCA lZur VlFaz " data-testid="prism-truncate"><span><span class="gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ ">A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech COVID-19 vaccine at Boston Medical Center.</span></span></span></div><div class="qinlA IpWvx oqZz tylGM lyWxS nWcVF UhTug PPcLh "><span class="YNujN JGtjI aZFDu rkKLh  gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ ">Photograph by Adam Glanzman, Bloomberg via Getty Images</span></div></div></figcaption></figure></div><div class=" " data-testid="prism-badge-tag-wrapper"><div class="IKUxI xFOBK YsVzB NuCDJ fMJDZ ZCNuU "><div class="jVJih nAZp " data-testid="prism-tags"><ul class="VZTD UeCOM dAmzA ltDkr qBPOY uoPjL "><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="https://www.nationalgeographic.com/science" data-pos="0"><span class="QXDKT rGjeC tuAKv iMbiE ">SCIENCE</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="https://www.nationalgeographic.com/science/topic/coronavirus-coverage" data-pos="1"><span class="QXDKT rGjeC tuAKv iMbiE ">CORONAVIRUS COVERAGE</span></a></li></ul></div></div></div><div class="kCTVx qtHut lqtkC HkWF HfYhe kGyAC " data-testid="prism-headline"><h1 class="vMjAx UdOCY WaKtx xZEw mTgUP WimTs "><span class="gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ ">Here’s the latest on COVID-19 vaccines</span></h1><p class="jxTEW Poyse uieav lqtkC HkWF HfYhe kGyAC "><span class="gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ ">Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.</span></p></div><div class="QHblV nkdHX hTosT whbOj " data-testid="prism-byline"><div class="VZTD mLASH OcxMG oJce "><div class="kKfXc VZTD rEPuv "><div class="TQPvQ HUcap UamUc WxHIR HhZOB yaUf VOJBn KMpjV XSbaH Umfib ukdDD "><span class="tChGB zbFav ">By</span><span>Amy McKeever<span class="EpNlu "> and </span></span><span>National Geographic Staff</span></div><div class="VZTD mLASH "><div class="xAPpq JQYD ZdbeE  jTKbV pCRh ">October 29, 2021</div><span class="Kizia EATCz OKAOH PSAs " aria-hidden="true">•</span><span class="OcATF jSKRU ">55 min read</span></div></div></div><div class="RwkLV Wowzl FjRYD " data-testid="prism-share"><div class="JpUfa aYoBt "><ul class="MZaCt dUXCH nyWZo RnMws Hdwln WBHfo tAchw UDeQM XMkl NUfbq kqfZ "><li class="WEJto "><button aria-label="Share Story on Facebook" class="theme-EWITS mLASH egFzk qXWHA ScoIf ZXRVe jIRH NoTgg OJpwZ uklrk wSPfd ofvJb nMRSd YIauu gGlNh ARCOA kyjTO xqlN aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo UVTAB ihLsD niWVk AAqU fctVp ENhiS kCffO kOEGk WMbJE eVJEc TElCQ ZAqMY enocc pJSQ pvoyF aaksc OKklU ATKRo RfOGv neOGk fuOso DwqSE fnpin ArvQf dUniT Mzjkf Niff NKnwO ijAAn dEuPM vwJ JmUFf sgyq cRbVn sBVbK fCfdG oMkBz aOwuK XsORH EgRXa hMVHb LTwlP jJbTO CnYjj TiUFI qeCAC xqvdn JaQpT dAfv PNgfG fIWCu NewES UJNbG EgBCK UvFHa lCCRi XDQHW spAMS TPSuu sbdDW askuE VsLUC YHsrW pYmVc eHvZI qRTXS odcNV NzKLB DbNtg nKDCU gTRVo iCOvJ znFR hjDDH JboFf OBVry " data-testid="prism-Button" type="button" aria-expanded="false" aria-haspopup="dialog"><span class="CSJky pdAzW JSFPu "><svg aria-hidden="true" class=" " data-testid="prism-iconography" height="1em" role="presentation" viewBox="0 0 32 32" width="1em" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" data-icon="social-facebook"><path fill="currentColor" d="M16 2.667c-7.364 0-13.333 6.006-13.333 13.415 0 6.696 4.876 12.245 11.25 13.252V19.96h-3.385v-3.878h3.385v-2.955c0-3.362 1.991-5.219 5.036-5.219 1.459 0 2.985.262 2.985.262v3.301h-1.681c-1.656 0-2.173 1.034-2.173 2.095v2.516h3.698l-.591 3.878h-3.107v9.374c6.374-1.006 11.25-6.556 11.25-13.252 0-7.409-5.969-13.415-13.333-13.415z"/></svg></span></button></li><li class="WEJto "><button aria-label="Share Story on X" class="theme-EWITS mLASH egFzk qXWHA ScoIf ZXRVe jIRH NoTgg OJpwZ uklrk wSPfd ofvJb nMRSd YIauu gGlNh ARCOA kyjTO xqlN aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo UVTAB ihLsD niWVk AAqU fctVp ENhiS kCffO kOEGk WMbJE eVJEc TElCQ ZAqMY enocc pJSQ pvoyF aaksc OKklU ATKRo RfOGv neOGk fuOso DwqSE fnpin ArvQf dUniT Mzjkf Niff NKnwO ijAAn dEuPM vwJ JmUFf sgyq cRbVn sBVbK fCfdG oMkBz aOwuK XsORH EgRXa hMVHb LTwlP jJbTO CnYjj TiUFI qeCAC xqvdn JaQpT dAfv PNgfG fIWCu NewES UJNbG EgBCK UvFHa lCCRi XDQHW spAMS TPSuu sbdDW askuE VsLUC YHsrW pYmVc eHvZI qRTXS odcNV NzKLB DbNtg nKDCU gTRVo iCOvJ znFR hjDDH JboFf OBVry " data-testid="prism-Button" type="button" aria-expanded="false" aria-haspopup="dialog"><span class="CSJky pdAzW JSFPu "><svg aria-hidden="true" class=" " data-testid="prism-iconography" height="1em" role="presentation" viewBox="0 0 32 32" width="1em" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" data-icon="social-x"><path fill="currentColor" d="M23.668 4h4.089l-8.933 10.21 10.509 13.894h-8.23l-6.445-8.427-7.375 8.427H3.191l9.555-10.921L2.665 4h8.436l5.826 7.702L23.664 4zm-1.437 21.657h2.266L9.874 6.319H7.443l14.791 19.338z"/></svg></span></button></li><li class="WEJto "><button aria-label="Share Story by Email" class="theme-EWITS mLASH egFzk qXWHA ScoIf ZXRVe jIRH NoTgg OJpwZ uklrk wSPfd ofvJb nMRSd YIauu gGlNh ARCOA kyjTO xqlN aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo UVTAB ihLsD niWVk AAqU fctVp ENhiS kCffO kOEGk WMbJE eVJEc TElCQ ZAqMY enocc pJSQ pvoyF aaksc OKklU ATKRo RfOGv neOGk fuOso DwqSE fnpin ArvQf dUniT Mzjkf Niff NKnwO ijAAn dEuPM vwJ JmUFf sgyq cRbVn sBVbK fCfdG oMkBz aOwuK XsORH EgRXa hMVHb LTwlP jJbTO CnYjj TiUFI qeCAC xqvdn JaQpT dAfv PNgfG fIWCu NewES UJNbG EgBCK UvFHa lCCRi XDQHW spAMS TPSuu sbdDW askuE VsLUC YHsrW pYmVc eHvZI qRTXS odcNV NzKLB DbNtg nKDCU gTRVo iCOvJ znFR hjDDH JboFf OBVry " data-testid="prism-Button" type="button" aria-expanded="false" aria-haspopup="dialog"><span class="CSJky pdAzW JSFPu "><svg aria-hidden="true" class=" " data-testid="prism-iconography" height="1em" role="presentation" viewBox="0 0 32 32" width="1em" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" data-icon="social-email"><path fill="currentColor" d="M28.148 6.667c.655 0 1.185.531 1.185 1.185v17.185c0 .655-.531 1.185-1.185 1.185H3.852a1.185 1.185 0 01-1.185-1.185V7.852c0-.655.531-1.185 1.185-1.185h24.296zm-.592 1.917v-.139H4.445v.358l11.391 7.595 11.72-7.814zm0 2.136l-11.063 7.375a1.187 1.187 0 01-1.315 0L4.444 10.939v13.505h23.111V10.72z"/></svg></span></button></li><li class="WEJto "><div><button aria-label="Copy Link" class="theme-EWITS mLASH egFzk qXWHA ScoIf ZXRVe jIRH NoTgg OJpwZ uklrk wSPfd ofvJb nMRSd YIauu gGlNh ARCOA kyjTO xqlN aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo UVTAB ihLsD niWVk AAqU fctVp ENhiS kCffO kOEGk WMbJE eVJEc TElCQ ZAqMY enocc pJSQ pvoyF aaksc OKklU ATKRo RfOGv neOGk fuOso DwqSE fnpin ArvQf dUniT Mzjkf Niff NKnwO ijAAn dEuPM vwJ JmUFf sgyq cRbVn sBVbK fCfdG oMkBz aOwuK XsORH EgRXa hMVHb LTwlP jJbTO CnYjj TiUFI qeCAC xqvdn JaQpT dAfv PNgfG fIWCu NewES UJNbG EgBCK UvFHa lCCRi XDQHW spAMS TPSuu sbdDW askuE VsLUC YHsrW pYmVc eHvZI qRTXS odcNV NzKLB DbNtg nKDCU gTRVo iCOvJ znFR hjDDH JboFf OBVry " data-testid="prism-Button" type="button" aria-expanded="false" aria-haspopup="dialog"><span class="CSJky pdAzW JSFPu "><svg aria-hidden="true" class=" " data-testid="prism-iconography" height="1em" role="presentation" viewBox="0 0 32 32" width="1em" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" data-icon="social-link"><path fill="currentColor" d="M26.244 5.756c-.6-.6-1.285-1.029-1.971-1.329s-1.5-.429-2.271-.429-1.543.129-2.271.429-1.415.729-1.971 1.329l-5.486 5.486c-1.029 1.2-1.5 2.656-1.457 4.114s.644 2.914 1.757 4.029c.257.256.556.514.856.686.3.215.6.385.944.514l2.057-2.056c-.385-.043-.771-.129-1.115-.3s-.685-.385-.943-.686c-.644-.644-.943-1.457-.986-2.271s.214-1.671.771-2.356l5.4-5.4c.343-.256.729-.514 1.115-.686a3.442 3.442 0 011.285-.256c.471 0 .9.085 1.329.256s.771.429 1.115.729c.685.685 1.029 1.585 1.029 2.444s-.343 1.756-.985 2.444l-1.157 1.114-1.157 1.157.256 1.029c.044.343.085.729.085 1.071 0 .215 0 .429-.043.644 0 .215-.044.429-.086.644l3.944-3.857c1.157-1.156 1.757-2.7 1.757-4.244s-.643-3.085-1.8-4.244z"/><path fill="currentColor" d="M20.415 13.9c-.044-.085-.085-.171-.129-.256s-.085-.129-.129-.215l-.085-.085c-.044-.043-.085-.129-.129-.171s-.085-.086-.129-.171-.129-.129-.171-.215-.171-.129-.215-.214a4.228 4.228 0 00-.857-.685c-.3-.215-.6-.386-.943-.514l-2.057 2.056c.386.044.771.171 1.115.3.343.171.644.386.943.644.044.043.129.129.171.214s.129.129.171.214c0 .043.044.043.044.086s.043.043.043.085.086.129.129.171.085.129.085.171c0 0 0 .043.044.085 0 .043 0 .043.043.086s.044.129.086.171c.043.085.043.129.086.214v.086c0 .085.043.171.043.214 0 .086.044.171.044.256.085.514.043 1.029-.129 1.543s-.429.944-.814 1.329l-5.4 5.4a3.13 3.13 0 01-1.029.6c-.429.044-.856.129-1.244.129-.471 0-.9-.085-1.329-.256s-.771-.429-1.114-.729c-.644-.644-.944-1.457-.986-2.271s.214-1.671.771-2.356L9.83 17.33c-.171-.556-.256-1.157-.3-1.714-.043-.6 0-1.156.129-1.757l-4.2 4.2c-1.029 1.2-1.5 2.656-1.456 4.156a5.968 5.968 0 001.757 4.029c.6.6 1.244 1.029 1.971 1.329s1.5.429 2.271.429c.685 0 1.414-.129 2.056-.386a6.063 6.063 0 001.886-1.114l5.486-5.485a5.955 5.955 0 001.715-3.471 6.156 6.156 0 00-.729-3.644z"/></svg></span></button><div class="xdNAs rMQsN cELo NoeP BtinW YHmbu hWtE "></div></div></li></ul></div></div></div><div class="natgeoDivider XQpSH " data-testid="prism-divider"></div></div></div></div></div><div style="--spacing-top:0px;--spacing-bottom:32px;--spacing-child-top:initial;--spacing-child-bottom:24px;--spacing-firstChild-top:initial;--spacing-firstChild-bottom:24px;--spacing-lastChild-top:initial;--spacing-lastChild-bottom:initial;--spacing-compact-top:24px;--spacing-compact-bottom:32px;--spacing-firstChild-compact-top:initial;--spacing-firstChild-compact-bottom:24px;--spacing-child-compact-top:initial;--spacing-child-compact-bottom:24px;--spacing-lastChild-compact-top:initial;--spacing-lastChild-compact-bottom:initial" class="dHdHP jLREf zXXje aGO eCClZ nTLv jLsYA gmuro TOSFd VmeZt sCkVm hkQai wGrlE MUuGM fciaN qQjt DhNVo Tgcqk IGLAf tWjkv "><div class="PrismArticleBody SingleColumn StartsWithInline xvlfx ZRifP TKoO eaKKC bOdfO " data-testid="prism-article-body"><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><div class="oLzSq MvWXB fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY rPLsU iulOd NIuqO zzscu lzDCc aHUBM IEgzD OjMNy eQqcx SVqKB GQmdz jaoD VWDdR ONJdw vrZxD OnRTz gbbfF roDbV GPGwb oMlSS gfNzt oJhud eXZcf zhVlX ebVHC "><div class="SDgng miqYR PMJVQ QtdQF WYbZw hwQoR SkUsC UlTly FxKvG BOli LbgCH nvgXD qZlJZ hdCKb " data-testid="prism-editors-note"><div class="fIerE gzgIi sbNwD wyNiH oGaak mIoBf HPTnC SyFCf KSVzn EMccI MTazT TWYO pxDKL syqKH AAxjg AGdf YLpQy UPQXr OWaqr MWqqQ rhuiH sYoWw jOwXI GfFUP iLdhU GuqqH UXCTR ExGxl CPrEb  gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ "><p><b>Editor’s note:</b> As of November 2021, this COVID-19 vaccine tracker is no longer being updated. <a href="https://www.nationalgeographic.com/science/article/covid-vaccines-latest-updates" rel="noopener noreferrer" target="_blank">Stay up-to-date on the latest vaccine developments and other COVID-19 news here</a>.</p></div></div></div><div class="oLzSq QrHMO fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY rPLsU iulOd NIuqO zzscu lzDCc aHUBM IEgzD OjMNy eQqcx SVqKB GQmdz jaoD VWDdR ONJdw vrZxD OnRTz gbbfF roDbV GPGwb oMlSS gfNzt oJhud eXZcf zhVlX "><div class=" " data-testid="prism-static-embed" role="region"><div class="kUPWF evNvN "></div></div></div><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">COVID-19 vaccines have reached consumers in record time. Though the process can typically take <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.weforum.org/agenda/2020/06/vaccine-development-barriers-coronavirus/">10 to 15 years</a>, the U.S. Food and Drug Administration has granted emergency authorization to vaccines made by Pfizer, Moderna, and Johnson <!-- -->&amp;<!-- --> Johnson in less than a year. Before now, the fastest-ever vaccine—for mumps—<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/why-coronavirus-vaccine-could-take-way-longer-than-a-year">took four years</a> to develop in the 1960s.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Fortunately, scientists had started working on the seeds of these vaccines long before COVID-19 emerged–teams were doing <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/these-scientists-spent-twelve-years-solving-puzzle-yielded-coronavirus-vaccines" target="_blank">breakthrough work on mRNA technology for 12 years</a> before the pandemic, and a global push to make clinical trials for COVID-19 more efficient helped ensure the world had safe, effective drugs in record time.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Even after a vaccine is authorized or fully licensed, it faces potential roadblocks when it comes to scaling up production and distribution, which also includes <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://hub.jhu.edu/2020/07/01/covid-vaccine-ethics-faden/">deciding which populations should get it first</a>—and at what cost.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-1"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Here’s everything you need to know—including primers on how vaccines and clinical trials work, the latest news on vaccine distribution and safety, and a detailed breakdown of the early candidates.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq">Vaccines and clinical trials<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" id="vaccineclinicaltrials"></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Vaccines go through <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/vaccines/basics/test-approve.html" target="_blank">a three-stage clinical trial process</a> that’s required before they are sent to regulatory agencies for approval. Given the urgent need, some vaccine developers compressed the clinical process for SARS-CoV-2 by running trial phases simultaneously.</p><div class="oLzSq QrHMO fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY rPLsU iulOd NIuqO zzscu lzDCc aHUBM IEgzD OjMNy eQqcx SVqKB GQmdz jaoD VWDdR ONJdw vrZxD OnRTz gbbfF roDbV GPGwb oMlSS gfNzt oJhud eXZcf zhVlX "><div class="LoCYw blgIc QcZAj wGwCE XfBPw McMna ubPuV pdYhu RBrva " role="complementary" data-testid="prism-listicle"><h3 class="wCqmG oFFrS lqtkC ">VACCINE CLINICAL TRIAL PROCESS</h3><div class="gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ wMUi BSxhF Qcvvy Rmxn qLtV "><p><b>Phase one:</b> Checks the safety of a vaccine and determines whether it triggers an immune response in a small group of healthy humans.&nbsp;</p><p><b>Phase two:</b> Widens the testing pool to include groups of people who may have the disease or be more likely to catch it, to gauge the vaccine’s effectiveness.&nbsp;</p><p><b>Phase three:</b> Expands the pool up to the thousands to make sure the vaccine is safe and effective among a wider array of people, given that immune response can vary by age, ethnicity, or by underlying health conditions.</p></div></div></div><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The COVID-19 candidates, like all vaccines, essentially aim to instruct the immune system to mount a defense, which is sometimes <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-safety/immune-system-and-health">stronger than what would be provided through natural infection</a> and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/">comes</a> with <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html">fewer health consequences</a>.</p><div class="oLzSq QrHMO fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY VvTxJ iulOd NIuqO zzscu lzDCc aHUBM hbvnu OjMNy eQqcx SVqKB GQmdz jaoD iShaE ONJdw vrZxD OnRTz gbbfF roDbV kRoBe oMlSS gfNzt oJhud eXZcf zhVlX "><div><section class="prism-commerce-container hsDdd lZur TPpRg NoUSU uMOq igcMP DtJWr QgBvn DFdlJ WRJzh GncOR mXJqX thTdv WdEvu LRKrZ qsCyh sDkEV tRUvJ vfgxB ociKu IOfvt RcyCh CpheS zVlcO ZWLsD UVJuH sOydf VTxHd hGand ZiTJ vOQON aygTJ NzAWG OejfS jfBYg fDzwm jzmm usAIt risvF PCBpE XKtIC lICdk ClHI TBmkq bztlJ sxSDk FELyU tCzGV JMHqu RcIjh yeJKB HByAZ WlrAp NXcCQ HOQgX GthuU ZNHlY raGQJ ojgJ ykgPT gMhY cjaUf nChRr wbElK XrAN dlWeV fglRi  hsDdd lZur TPpRg NoUSU uMOq igcMP DtJWr QgBvn DFdlJ HOQgX " data-testid="prism-card"><div class="rEPuv seFhp WtEci "><div class="hsDdd GpQCA lZur TmzDJ ENRZV RneNA nMMea HUUqs afvUV IqYrv VeeKr GpGfl KScHo dAvpS YPkqL ZRifP juqIh LWFYs piYIm lfJwv EUwyR a-DCQg " data-testid="prism-background-image"><div class="GpQCA lZur lIngG " data-testid="prism-ratio-frame"></div><span class="NqeUA iWsMV UzzHi FvQLF iLTd gSlSZ osmqx TmzDJ reDgC IYTvt " style="background-position:center center;background-image:url(&quot;https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg&quot;)"></span><span class="NqeUA iWsMV UzzHi FvQLF iLTd gSlSZ osmqx TmzDJ HoXXr " style="background-position:center center;background-image:url(&quot;undefined&quot;);transition:transform .25s ease, opacity .5s ease"></span><div class="FvQLF VZTD rEPuv WtILi rTBG NqeUA YOODG "><div class="VZTD rEPuv QXDKT UoVV LtWyG " data-testid="prism-meta"><div class="CJAFL gDeX "><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr GFCVr aNfxH WAxtr kYnwv " id="ForHungryMindsheadline">For Hungry Minds</h3></div></div><div class="VZTD rEPuv QXDKT sAjcO rrXie hFudi vQpSZ " data-testid="prism-meta"><div class="CJAFL gDeX "><p class="PFoxV eBpQD KMxLo GpQCA tuAKv zuqUq WTxSK HxnoC JmHQS KlMT BEWVm GFCVr aNfxH WAxtr kYnwv " id="ForHungryMindsbody"> </p></div></div><div class="RVPG cTzRP UzlIl VXIwh hCp lZur YOODG mloN NftqZ qifZe PQZuE VLitc ANdlY "><div class="VZTD EmSkh yXaxe ZnHKW BINFW YJPbO "><div><a class="mLASH egFzk qXWHA ScoIf bnIxg jIRH wNxoc OJpwZ BOFPn wSPfd ofvJb bMrzT YIauu gGlNh ARCOA kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX IpIxr zLlWU niWVk yayQB vXSTR ENhiS dQa-Du kOEGk WMbJE eVJEc TElCQ ZAqMY enocc pJSQ kRybH aaksc OKklU ATKRo RfOGv neOGk fuOso DwqSE Azhsg wtRmE hajyU Niff NKnwO ijAAn dEuPM vwJ JmUFf sgyq cRbVn sBVbK fCfdG oMkBz aOwuK XsORH EgRXa hMVHb LTwlP jJbTO CnYjj JnpQQ gVcnK jxliL avVsD pFiVP jfXGy AoOfK TbYxC qZkdS mcVdC QdzCO SUIG ucaQa jXKi pHVeO NjTGy zghmi IFnPK dDnSO bLlrT  " data-testid="prism-Button" aria-label="GIFT NAT GEO KIDS, For Hungry Minds" href="https://ngkidsubs.nationalgeographic.com/servlet/OrdersGateway?cds_mag_code=NKD&amp;cds_page_id=276847&amp;cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=bau_kids_may2024::int_add=article_promo"><span class="QXDKT rGjeC tuAKv iMbiE ">GIFT NAT GEO KIDS</span></a></div></div></div></div></div></div></section></div></div><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">To do so, traditional vaccines use the whole coronavirus, but in a killed or weakened state. Others use only part of the virus—whether a protein or a fragment. Some transfer the instructions for coronavirus proteins into an unrelated virus that is unlikely or even incapable of causing disease. Finally, cutting-edge vaccines under development rely on deploying pieces of the coronavirus’s genetic material, enabling our cells to temporarily make coronavirus proteins needed to stimulate our immune systems. (<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/searching-for-coronavirus-vaccine-how-would-it-work">Find out more about vaccines and how they work</a>.)</p><div class="oLzSq QrHMO fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY rPLsU iulOd NIuqO zzscu lzDCc aHUBM IEgzD OjMNy eQqcx SVqKB GQmdz jaoD VWDdR ONJdw vrZxD OnRTz gbbfF roDbV GPGwb oMlSS gfNzt oJhud eXZcf zhVlX "><div class="LoCYw blgIc QcZAj wGwCE XfBPw McMna ubPuV pdYhu RBrva " role="complementary" data-testid="prism-listicle"><h3 class="wCqmG oFFrS lqtkC ">TYPES OF VACCINES</h3><div class="gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ wMUi BSxhF Qcvvy Rmxn qLtV "><p><b>Nucleic acid:</b> Relies on injecting snippets of a virus’s genetic material, either DNA or messenger RNA (mRNA), into human cells. It spurs the production of viral proteins that mimic features of the coronavirus, training the immune system to recognize its presence.&nbsp;</p><p><b>Knocked-out virus:</b> Uses a non-infectious form of the coronavirus that can no longer cause full-blown disease but can still provoke an immune response. The virus can either be fully inactivated or weakened. These modes are considered the most classic ways to make vaccines.</p><p><b>Viral vector:</b> Essentially a “Trojan horse” presented to the immune system. One type involves introducing a piece of DNA from SARS-CoV-2 into another unrelated germ—for example, an adenovirus, which typically causes the common cold. When this modified adenovirus is injected into humans, the hope is that it will instruct cells to make coronavirus proteins and will trigger an immune response.</p><p><b>Protein:</b> These vaccines are typically made from coronavirus proteins, which can be synthesized or brewed in labs like beer. Some versions involve coating a carrier—such as nanoparticles—with proteins to better aid delivery and uptake by cells.</p></div></div></div><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq">U.S. vaccine rollout<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" id="vaccinerollout"></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Three COVID-19 vaccines are available for use in the United States. U.S. regulators have approved Pfizer’s vaccine for adults and authorized it for emergency use in children and adolescents ages five to 17. The U.S. has also granted emergency use authorization to administer the Moderna and Johnson <!-- -->&amp;<!-- --> Johnson vaccines to adults.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Some populations in the country are eligible for booster doses. Anyone who received a Johnson <!-- -->&amp;<!-- --> Johnson single-shot jab can get a second dose after at least two months. People who received the Pfizer and Moderna vaccines are eligible for a third dose after six months if they are over 65 or have an underlying condition that makes them more susceptible to severe COVID-19. People whose institutional or occupational settings put them at high risk of exposure to the coronavirus may also get a booster shot. U.S. regulators have permitted people to mix-and-match their jabs in the wake of data suggesting that people who originally received the Johnson <!-- -->&amp;<!-- --> Johnson vaccine are protected by a booster dose of the Pfizer or Moderna vaccines.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">U.S. regulators have also recommended a third dose of the Pfizer and Moderna vaccines for people with compromised immune systems. This extra dose is considered part of their primary vaccination series; CDC guidance <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nbcnews.com/health/health-news/immunocompromised-people-can-receive-4th-covid-shot-cdc-says-rcna3933" target="_blank">suggests</a> that immunocompromised people will be able to get a fourth booster dose six months after completing the primary series.<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.npr.org/sections/health-shots/2021/09/02/1033299418/cdc-warns-against-off-label-use-of-covid-vaccine" target="_blank"></a></p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq">Global vaccine rollout</h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The World Health Organization is coordinating global efforts to administer vaccines, with an eye toward <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/news-room/detail/26-06-2020-act-accelerator-update" target="_blank">delivering two billion doses</a> by the end of 2021. It is leading an initiative through the COVAX Facility to ensure that all countries have equitable access. The WHO has approved the Pfizer-BioNTech, AstraZeneca-Oxford, Johnson <!-- -->&amp;<!-- --> Johnson, Moderna, Sinopharm, Sinovac, and Bharat Biotech vaccines for emergency use.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq">Vaccine safety</h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On July 13, the U.S. Food and Drug Administration <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021" target="_blank">added a warning label</a> to Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine after it was linked to rare cases of Guillain-Barré Syndrome, an autoimmune disorder that can lead to paralysis. There have been 100 preliminary reports of the syndrome among the approximately 12.5 million people who have received the vaccine. The FDA said that the benefits of receiving the vaccine outweigh the risks.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The FDA has also added a warning label to the Pfizer and Moderna vaccines about <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly" target="_blank">rare cases of heart inflammation</a> in adolescents and young adults. The move came after the CDC’s Advisory Committee on Immunization Practices <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly" target="_blank">announced</a> that it has identified more than 300 cases of myocarditis and pericarditis that it acknowledged are likely linked to the vaccines. The agency says these cases are rare but higher than expected. It also said the benefits of the shots outweigh the risks.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-2"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"> <!-- -->In April, the European Medicines Agency issued statements saying that unusual blood clots should be listed as a very rare but possible side effect of both the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood" target="_blank">AstraZeneca</a> and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood" target="_blank">Johnson <!-- -->&amp;<!-- --> Johnson</a> vaccines. In a review of 86 reported cases related to the AstraZeneca vaccine, the EMA’s safety committee found a potential link between it and the clots, with most known cases occurring in women under age 60 within two weeks of receiving the first dose. The EMA stressed that the odds of developing a clot after vaccination are extremely low, and that the benefits of getting vaccinated outweigh the risks. They also recommend that people seek immediate medical attention if they experience symptoms related to clotting, including persistent pain, shortness of breath, and headaches or blurred vision.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On August 27, a study published in the <i>British Medical Journal</i> affirmed the EMA’s risk-benefit analysis, showing that there’s <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bmj.com/content/374/bmj.n1931" target="_blank">a much higher risk of developing blood clots after SARS-CoV-2</a> infection than after immunization with the AstraZeneca or Pfizer vaccines.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On August 11, the CDC officially recommended that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/media/releases/2021/s0811-vaccine-safe-pregnant.html" target="_blank">people who are pregnant, breastfeeding, or may become pregnant get a COVID-19 vaccine</a>. A new analysis of data from the vaccine rollout found no increased risk of miscarriage among people who received an mRNA vaccine before 20 weeks of pregnancy. Earlier studies also showed that the vaccine is safe later in pregnancy as well—for both pregnant people and their babies. The CDC <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://emergency.cdc.gov/han/2021/han00453.asp" target="_blank">emphasized the urgency of vaccination among these groups</a> in a health alert issued on September 29, reporting new data showing a rise in COVID-19-related deaths among pregnant people.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq">Vaccine prospects<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" id="vaccineprospects"></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Here are some of the vaccines that have made it to phase three and beyond:</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/science/coronavirus/vaccine" target="_blank"><b class="cXscX">Pfizer</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>BNT162b2<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-3"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> One of the world’s largest pharmaceutical companies, based in New York, in collaboration with German biotech company BioNTech.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:<!-- --> </b>A nucleic-acid vaccine that requires two doses taken 21 days apart.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> On December 2, the U.K. became <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine" target="_blank">the first Western country</a> to approve any COVID-19 vaccine when it authorized the Pfizer-BioNTech candidate—making the drug the first mRNA vaccine in history allowed for human use. The FDA <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html?action=click&amp;module=Top%20Stories&amp;pgtype=Homepage" target="_blank">granted emergency use authorization<!-- --> </a>to this vaccine on December 11, 2020, and fully approved it on August 23, 2021. The vaccine has also been <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cbc.ca/news/politics/vaccine-rollout-plan-phac-1.5833912" target="_blank">granted emergency approval</a> in Canada, the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union" target="_blank">European Union</a>, and other countries.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">U.S. regulators have also approved Pfizer’s vaccine for emergency use in children and adolescents ages five to 15. U.K. regulators have also <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/world/uk/uk-approves-pfizerbiontech-covid-shot-12-15-year-olds-2021-06-04/" target="_blank">approved</a> this vaccine for use among adolescents ages 12 to 15, while the European Union <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european" target="_blank">granted conditional authorization</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">As of September 24 U.S. regulators granted emergency use authorization of a third dose of Pfizer’s vaccine—but only for certain subgroups of the national population, including older people and those with underlying conditions that put them at higher risk of disease and for people in occupational or institutional settings that put them at high risk of infection, such as health-care workers and teachers.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> Globally, Pfizer expects to be able to produce up to 1.3 billion doses by the end of 2021. Questions have been raised over the vaccine’s storage, which requires ultra-cold freezers set at minus 70 degrees Celsius (-94 degrees F). On February 19, however, Pfizer and BioNTech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data" target="_blank">said</a> that their vaccine can remain stable for two weeks at temperatures between minus 25℃ and minus 15℃ (-13℉ to 5℉), a common range in pharmaceutical freezers and refrigerators. The finding would allow for easier distribution of the vaccine in communities where ultra-cold storage requirements present a challenge.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy:<!-- --> </b>On September 20, Pfizer <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results" target="_blank">announced</a> that a study of its clinical trials shows its vaccine is safe and highly effective in children ages five to 11. Researchers determined that two low doses administered three weeks apart elicit high levels of neutralizing antibodies among children, with side effects comparable to those seen in people ages 16 to 25. The 10-milligram doses of vaccine are a third of what has been approved among older age groups. The company later <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/media/153409/download" target="_blank">released</a> an analysis of its clinical trials showing that the vaccine is 90.7 percent effective in preventing symptomatic disease among kids in this age group.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Pfizer also expects to release data soon on how well its vaccine works among children ages six months to five years, according to CEO Albert Bourla. In a public forum, he said the data <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2021/09/14/pfizers-covid-vaccine-data-for-kids-under-age-5-may-come-in-late-october-ceo-says-.html" target="_blank">could be available as early as the end of October</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On August 25, Pfizer announced new data showing that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission" target="_blank">a third dose of its vaccine generates robust quantity of neutralizing antibodies</a> that is more than three times higher than what was observed one month after the second dose.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">A preprint study out of the United Kingdom shows that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf" target="_blank">but that their efficacy wanes over time</a>. Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, the both vaccines still significantly reduce the risk of infection.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On July 8, a study published in <i>Nature</i> demonstrated that people who have received both doses of the Pfizer or AstraZeneca vaccines <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03777-9" target="_blank">remain fully protected against severe disease, hospitalization, and death</a> from the Delta and Beta variants. However, a single dose of either vaccine was not as protective.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The findings corroborate an earlier study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03738-2_reference.pdf" target="_blank">published in <i>Nature</i></a> showing that the Pfizer and Moderna vaccines elicit “robust and prolonged” immune responses. <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/06/28/health/coronavirus-vaccines-immunity.html?partner=slack&amp;smid=sl-share" target="_blank">As the <i>New York Times</i> reported at the time</a>, the findings suggested that people who are immunized with these vaccines may not need booster shots as protection may last for years so long as the virus doesn’t mutate to evade it.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On June 10, a study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03693-y" target="_blank">published in the journal <i>Nature</i></a> showed that two doses of the Pfizer vaccine protects against several virus variants, including the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/" target="_blank">Delta and Eta variants</a>. The news came a few days after the CDC <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html" target="_blank">announced</a> that the Pfizer and Moderna vaccines reduce the risk of infection by 91 percent for fully vaccinated people.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">In April, the CDC <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_e&amp;ACSTrackingID=USCDC_921-DM53321&amp;ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20March%2029%2C%202021&amp;deliveryName=USCDC_921-DM53321" target="_blank">released a study</a> of the U.S. vaccine rollout showing that the Pfizer-BioNTech and Moderna vaccines are 90 percent effective in preventing symptomatic COVID-19 in real-world conditions. The study analyzed the efficacy of the two mRNA vaccines among nearly 4,000 health-care workers, first responders, and other frontline workers who were the first to receive the jab in the U.S. It also showed the vaccines are 80-percent effective after one dose. The findings confirmed earlier studies from <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/live/2021/02/26/world/covid-19-coronavirus#pfizer-vaccine-protection" target="_blank">the U.K.</a> and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900448-7" target="_blank">Israel</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On December 10, the <i>New England Journal of Medicine</i> <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2034577" target="_blank">published</a> the results of Pfizer’s phase three study, showing the vaccine was safe and 95-percent effective in protecting against COVID-19 in people 16 and older. Pfizer and BioNTech have also <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal" target="_blank">announced</a> that a phase three trial shows that their vaccine is safe and 100 percent efficacious among children between the ages of 12 and 15, and that it elicited robust antibody responses.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-4"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety:<!-- --> </b>On June 23, the U.S. Food and Drug Administration <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/" target="_blank">said</a> it plans to add a warning label to the Pfizer and Moderna vaccines about <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly" target="_blank">rare cases of heart inflammation</a> in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Severe allergic reactions following immunization with the Pfizer-BioNTech vaccine have been reported in many countries. White House advisor Anthony Fauci <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/video/2020/12/16/dr-anthony-fauci-with-meg-tirrell-for-special-edition-of-healthy-returns.html" target="_blank">told CNBC</a> in December that some adverse reactions are expected when a vaccine is distributed to a wider population. Regulators in the U.S. and U.K. have also released reports offering reassurances that severe reactions are rare.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On November 18, Pfizer and BioNTech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine" target="_blank">announced</a> the conclusion of their phase three trials. The trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0" target="_blank">launched in July</a>, enrolling a diverse population in areas with significant SARS-CoV-2 transmission. Pfizer later <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19" target="_blank">expanded the trial<!-- --> </a>to include 44,000 people across multiple countries.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On February 18, Pfizer and BioNTech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate" target="_blank">announced</a> the launch of a phase two/three clinical trial to study the vaccine’s safety and efficacy among 4,000 pregnant women over the age of 18. The companies also launched a phase 1/2/3 study in children between the ages of six months and 11 years.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On June 8, Pfizer <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-start-large-study-test-covid-19-vaccine-children-below-12-2021-06-08/" target="_blank">said</a> that it would expand its clinical trials to a larger group of children under age 12. After a phase one study showed that the vaccine was safe and effective in a group of 144 children, the clinical trials enrolled up to 4,500 children at more than 90 sites in the U.S., Finland, Poland, and Spain. Pfizer tested a dose of 10 micrograms in children ages 5 to 11, and three micrograms for children from six months to five years old.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-5"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On July 8, Pfizer and Biotech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-provide-update-booster-program-light-delta" target="_blank">announced</a> that they are developing an updated version of the vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://cdn.pfizer.com/pfizercom/2021-07/Delta_Variant_Study_Press_Statement_Final_7.8.21.pdf?IPpR1xZjlwvaUMQ9sRn2FkePcBiRPGqw" target="_blank">that specifically targets the Delta variant</a>.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/coronavirus" target="_blank"><b class="cXscX">Johnson <!-- -->&amp;<!-- --> Johnson</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>JNJ-78436735</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>One of the world’s largest multinational corporations, based in New Jersey, specializing in healthcare and pharmaceutical products.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A single-dose vector vaccine. (<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/johnson-johnson-us-third-vaccine-how-it-works" target="_blank">Here’s how the Johnson <!-- -->&amp;<!-- --> Johnson vaccine works</a>.)</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Approved for use in the U.S., <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-bahrain/bahrain-first-to-approve-johnson-johnson-covid-19-vaccine-for-emergency-use-regulator-idUSKBN2AP21X?feedType=RSS&amp;feedName=healthNews" target="_blank">Bahrain</a>, Canada, and the European Union.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On October 21 the CDC cleared the way for the U.S. to begin rolling out booster shots of Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine for all people ages 18 and older at least two months after a first dose.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">U.S. regulators also authorized mixing and matching vaccines—such as administering booster doses of the either Moderna or Pfizer vaccine to people who originally received the Johnson <!-- -->&amp;<!-- --> Johnson vaccine. A <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf" target="_blank">preprint analysis of a National Institutes of Health study</a> shows that a booster dose of the mRNA vaccines elicit a stronger immune response than another dose of the Johnson <!-- -->&amp;<!-- --> Johnson shot.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> On March 2, the U.S. <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.washingtonpost.com/politics/2021/03/02/joe-biden-live-updates/" target="_blank">announced</a> that Johnson <!-- -->&amp;<!-- --> Johnson has partnered with its competitor Merck to increase the supply of its COVID-19 vaccine. Merck will dedicate two facilities to producing the vaccine, which could double the amount of available doses. Biden said that the additional doses will allow the U.S. to vaccinate all adults by the end of May.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On June 11, the <i>New York Times</i> reported that the FDA <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/live/2021/06/11/world/covid-vaccine-coronavirus-mask" target="_blank">has told</a> Johnson <!-- -->&amp;<!-- --> Johnson to throw out 60 million doses made at its plant in Baltimore. The news came a day after <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine" target="_blank">CNN reported</a> that the U.S. hasn’t sent any shipments of the vaccine since the first week of May due to a lack of supply caused by earlier issues at the plant. On June 10, Johnson <!-- -->&amp;<!-- --> Johnson also <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine" target="_blank">announced</a> that the FDA has approved an extension of the shelf life of its vaccine from three to four and a half months.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy:</b> In September 2021 Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s" target="_blank">announced</a> results of its studies of booster doses. When administered two months after the first jab, the booster is 100 percent effective against severe disease and causes antibody levels to rise four to six times higher than after the first shot. The second dose was also shown to be 75 percent effective against all symptomatic disease globally and 94 percent effective in the U.S. The company said that a booster shot administered six months after the first dose produced a 12-fold increase in antibody levels.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The company also said that real-world evidence shows that its single-dose vaccine remains effective against COVID-19. The press release cited <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2021.09.10.21263385v2" target="_blank">a study published to a preprint server</a>, which shows that the vaccine remains 79 percent effective in preventing COVID-19 and 81 percent effective in preventing hospitalizations. An earlier study conducted by Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response" target="_blank">shows</a> that its vaccine offers strong protection against Delta that lasts for at least eight months.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">However, on July 20, the <i>New York Times</i> reported on a preliminary study showing that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html?partner=slack&amp;smid=sl-share" target="_blank">Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine is less effective against the Delta and Lambda variants</a> than it was against the original virus strain. The paper notes that the results were obtained in a lab experiment and may not reflect the vaccine’s real-world efficacy.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On February 24, an FDA analysis <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/media/146217/download" target="_blank">confirmed</a> Johnson <!-- -->&amp;<!-- --> Johnson’s earlier report that its vaccine is safe and effective in preventing COVID-19. The report found the vaccine is 72-percent effective in preventing COVID-19 based on U.S. trials, and 85-percent effective in preventing severe disease across all regions. It also shows that the vaccine was 64-percent effective in preventing disease in the company’s South African trials, which is higher than had previously been reported.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On June 9, a study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03681-2" target="_blank">published in the journal <i>Nature</i></a> showed that Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine is effective in protecting against virus variants, including the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/" target="_blank">Beta and Gamma variants of concern</a>. The study showed that the vaccine elicits neutralizing antibodies and a T-cell response among people who live in areas where the variants are widely circulating, including Brazil and South Africa.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety:</b> On July 13, U.S. regulators <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021" target="_blank">added a warning to Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine</a> in response to rare reports linking the shot to Guillain-Barré Syndrome, a disorder in which the body’s immune system attacks the nerves. The FDA said there have been about a hundred preliminary reports of the syndrome among the 12.8 million people who have received the Johnson <!-- -->&amp;<!-- --> Johnson vaccine. It added that the benefits of receiving the vaccine still outweigh the risks.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-6"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">CDC officials told the <i>Washington Post</i> that the cases <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.washingtonpost.com/health/2021/07/12/johnson-and-johnson-warning/" target="_blank">have mostly been reported about two weeks after vaccination among men</a>, many aged 50 or older, and that these cases will be discussed during an upcoming meeting of the CDC’s advisory committee.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">In the spring, the vaccine’s rollout was briefly halted <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine" target="_blank">in the U.S.</a> and across Europe as regulators investigated reports of blood clotting among people who have received the shot. The FDA and CDC reviewed 15 cases of blood clots. The cases—which the agencies noted are “extremely rare”—occurred in women between the ages of 18 and 48 within six to 13 days after vaccination. The Europeans Medicines Agency also said that the cases it <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021" target="_blank">reviewed</a> occurred in people under 60—mostly women—within three weeks of vaccination.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On April 23, the U.S. FDA and CDC <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough" target="_blank">lifted the pause</a> on Johnson <!-- -->&amp;<!-- --> Johnson’s vaccine and said that immunizations can resume immediately. The agencies said that the risk of blood clots is “very low” and that the benefits of getting the vaccine outweigh the risks. It will add information about the increased risk of blood clots to the vaccine’s label. The decision came days after the European Medicines Agency <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood" target="_blank">said</a> that blood clots should be listed as a “very rare” side effect of Johnson <!-- -->&amp;<!-- --> Johnson’s COVID-19 vaccine.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On September 23, 2020, Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate" target="_blank">announced</a> the launch of its phase three “ENSEMBLE” trial to evaluate the safety of the vaccine—and how well it works—among up to 60,000 adults from a variety of countries. The trial included “significant representation” from older populations and those with underlying conditions that make them more susceptible to COVID-19.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On October 12, 2020, Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials" target="_blank">announced</a> that it paused phase three trials for an independent safety review due to an unexplained illness in a participant. The company didn’t provide any details, in part to protect the patient’s privacy, but said that illnesses and accidents are expected in large clinical studies. What’s more, study pauses are routine for clinical trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/" target="_blank">and aren’t typically reported</a>. Later that month, the company <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us" target="_blank">announced</a> it would resume trials, which were <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled" target="_blank">fully enrolled</a> with 45,000 participants by December 17.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-7"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On November 15, 2020, Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate" target="_blank">launched a second phase three trial</a> to study the safety and efficacy of a two-dose regimen of its vaccine candidate in up to 30,000 volunteers worldwide. The study intends to assess whether a second dose of the vaccine will offer longer-lasting protection.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On April 2, Johnson <!-- -->&amp;<!-- --> Johnson <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jnj.com/johnson-johnson-expands-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents" target="_blank">announced</a> that it has begun vaccinating children age 12 to 17 as part of its phase 2a clinical trial. The company said it will initially test the vaccine in adolescents age 16 to 17 before expanding it to younger children.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.modernatx.com/" target="_blank"><b class="cXscX">Moderna Therapeutics</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> mRNA-1273<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>A Massachusetts-based biotech company, in collaboration with the National Institutes of Health.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A nucleic-acid vaccine that requires two doses.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> On December 18, the FDA <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.washingtonpost.com/health/2020/12/17/covid-fda-moderna-vaccine-2/" target="_blank">granted emergency approval</a> to Moderna’s COVID-19 vaccine, making it the second available in the United States. The vaccine has also been approved in the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnn.com/2021/01/06/europe/moderna-approval-eu-intl/index.html" target="_blank">European Union</a>, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/health-canada-authorizes-moderna-covid-19-vaccine-canada" target="_blank">Canada</a>, the <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator" target="_blank">U.K.</a>, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use" target="_blank">Israel</a>, and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified" target="_blank">by the WHO</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On October 21 the CDC cleared the way for some people to get booster shots of the Moderna vaccine. The agency endorsed the FDA’s emergency use authorization of booster doses for all people ages 65 and older, as well as those ages 18 to 64 who are at risk of severe COVID-19 because of their underlying conditions. It also includes people ages 18 to 64 who are at high risk of exposure because of where they work or live, such as health-care workers or incarcerated people.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Moderna has <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-initiation-rolling-submission-biologics" target="_blank">applied for full FDA approval</a> of its COVID-19 vaccine for use in people age 18 and older. The company also plans to file for emergency use authorization for teens ages 12 to 17.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On October 5, Moderna <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-european-medicines-agency-authorizes-third" target="_blank">announced</a> that European Union regulators have authorized a third dose of its COVID-19 vaccine for “severely immunocompromised” people ages 12 and older.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> The FDA has said that Moderna’s vaccine can now be kept at room temperature for up to a day. The vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/2020/11/moderna-edges-pfizer-coronavirus-efficacy-and-refrigeration/" target="_blank">can otherwise be safely stored on ice</a> or in a normal refrigerator for 30 days. These changes are expected to help the company distribute its vaccine more quickly.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The company plans to deliver at least 500 million doses globally per year beginning in 2021, thanks in part to <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.lonza.com/news/2020-05-01-04-50" target="_blank">a deal it has struck with Swiss manufacturer Lonza</a> that will allow it to manufacture up to a billion doses a year.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy:</b> A <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine" target="_blank">study</a> of clinical trials among adolescents ages 12 to 17 shows that its vaccine is safe and 100 percent effective. The study also showed the vaccine is 93 percent effective among participants in this age group two weeks after the first dose.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Moderna <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-submission-initial-data-us-fda-its-covid-19" target="_blank">has said</a> that the phase two clinical trials of its booster dose showed that a third dose administered six months after the second “induce robust antibody responses” and increased protections against the variants of concern. It has also said that a study of the phase two clinical trials of its three booster candidates produced robust antibody responses against the virus, including the Gamma, Beta, and Delta variants of concern.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">However, there is some doubt about whether people who received the Moderna shot will need boosters. A study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03738-2_reference.pdf" target="_blank">published in the journal <i>Nature</i></a> in June 2021 showed that the vaccine elicits “robust and prolonged” immune responses—indicating that protection may last for years so long as the virus doesn’t mutate to evade it.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On September 10, the CDC <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w" target="_blank">released a study</a> of more than 32,000 real-world cases suggesting that Moderna’s vaccine is more effective at preventing hospitalizations than the Pfizer or Johnson <!-- -->&amp;<!-- --> Johnson vaccines. The overall efficacy of Moderna’s vaccine was 95 percent, compared to 80 percent for Pfizer and 60 percent for Johnson <!-- -->&amp;<!-- --> Johnson. <!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-8"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The study backed up earlier studies suggesting that Moderna’s vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://jamanetwork.com/journals/jama/fullarticle/2783797?guestAccessKey=6ead80fe-bf08-4d53-8c5c-607249932480&amp;utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_alert-jama&amp;utm_content=olf&amp;utm_term=083021" target="_blank">may provide stronger protection than Pfizer’s</a> jab. A study published on August 30 found that Moderna’s vaccine produces significantly more neutralizing antibodies than Pfizer’s, which might be attributed to the higher dosage or the longer interval between the first and second doses. On August 8, a preliminary <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf" target="_blank">Mayo Clinic study of more than 50,000 patients</a> showed that the efficacy of Moderna’s vaccine dropped from 86 percent in early 2021 to 76 percent in July, when the Delta variant was predominant. Meanwhile, the Pfizer vaccine’s efficacy dropped over the same time period from 76 percent to 42 percent.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">An earlier preprint analysis of Moderna’s vaccine also suggested that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4" target="_blank">antibody levels can predict the vaccine’s efficacy</a> against COVID-19. The study showed that people with breakthrough infections who had lower levels of antibodies in their blood were more likely to develop symptomatic infections than those with higher levels of antibodies. The study authors tell <i>Nature</i> that the data doesn’t suggest a threshold of antibodies that ensures protection but it does show <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/d41586-021-02237-8#ref-CR1" target="_blank">a relationship between higher levels of antibodies and lower risk of infection</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On August 12, a study published in the journal <i>Science</i> showed that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://science.sciencemag.org/content/early/2021/08/11/science.abj4176?_ga=2.235822593.145620917.1628696888-1399774036.1602427045" target="_blank">Moderna’s vaccine protects against COVID-19 for at least six months</a> and is effective against the Delta variant. The findings confirm <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nejm.org/doi/full/10.1056/NEJMc2103916?query=featured_home" target="_blank">earlier studies</a> and announcements made by the company that its vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial" target="_blank">remains 93 percent effective for at least six months</a> after administration of the second dose.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On July 9, <i>Nature</i> reported on a study showing that <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/d41586-021-01893-0" target="_blank">two quarter-doses of Moderna’s vaccine generates long-lasting neutralizing antibodies and T cells</a>. The results suggest that it might be possible to administer fractional doses to help stretch the world’s vaccine supply, particularly in low- and middle-income countries that are facing shortages.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On February 17, the <i>New England Journal of Medicine</i> <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nejm.org/doi/full/10.1056/NEJMc2102179?query=featured_home" target="_blank">published</a> a preliminary report showing that Moderna’s vaccine remains effective in protecting against the virus variant found in the U.K. However, it may be less effective in protecting against the South African variant—although researchers noted that further study is needed.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-9"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">In December 2020, an FDA <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.fda.gov/media/144434/download" target="_blank">analysis</a> of the phase three study of Moderna’s vaccine confirmed that it is 94.1-percent effective in preventing mild cases of COVID-19 and 100-percent effective at preventing severe cases after taking two doses.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety:<!-- --> </b>On June 23, 2021, the U.S. Food and Drug Administration <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/" target="_blank">said</a> it planned to add a warning label to the Pfizer and Moderna vaccines about <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly" target="_blank">rare cases of heart inflammation</a> in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> Moderna announced on December 17, 2020, that it was launching clinical trials to evaluate the vaccine’s safety in <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_d8ba867ebfe7300a65bda99cc2e2babd" target="_blank">children and people with cancer</a>; it will also <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_9a24ba453f4fd361f19264327ac63a1a" target="_blank">establish a “pregnancy registry</a>” to track the vaccine’s safety in people who are pregnant.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The company <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid" target="_blank">started</a> the third phase of its clinical trials in July 2020. Preliminary findings from its phase one trials showed that healthy subjects—<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2020/08/26/moderna-says-its-coronavirus-vaccine-shows-promising-results-in-small-trial-of-elderly-patients.html" target="_blank">including elderly patients</a>—produced coronavirus antibodies and a reaction from T cells, another part of the human immune response. Phase three tested the vaccine in 30,000 U.S. participants.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On February 24, Moderna <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine" target="_blank">announced</a> that it has shipped doses of a booster vaccine to the U.S. National Institutes of Health for clinical trials. The phase one trial will determine whether the booster can improve immunity against the South Africa variant. Moderna is also investigating using a third dose of its approved vaccine to protect against variants.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ovg.ox.ac.uk" target="_blank"><b class="cXscX">AstraZeneca-University of Oxford</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> ChAdOx1 nCoV-19<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> The U.K. university, in collaboration with the biopharmaceutical company AstraZeneca.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A viral vector vaccine that requires two doses.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:<!-- --> </b>Approved for use in the United Kingdom, the European Union, Argentina, India, and other countries. It has also been authorized by the World Health Organization.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy:</b> In August 2021 a preprint study out of the United Kingdom showed that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf" target="_blank">but that their efficacy wanes over time</a>. Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, both vaccines still significantly reduce the risk of infection.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On July 8, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41586-021-03777-9" target="_blank">a study published in <i>Nature</i></a> demonstrated that people who have received both doses of the AstraZeneca of Pfizer vaccines remain fully protected from the Delta and Beta variants. However, a single dose of either vaccine was not as protective.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On June 25, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3874014" target="_blank">preliminary results from a British study</a> showed that mixing doses of the AstraZeneca and Pfizer vaccines provides strong protection against COVID-19. Researchers <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/06/28/health/mixing-pfizer-astrazeneca-results.html" target="_blank">told the <i>New York Times</i></a> that the protection is strong regardless of the order in which the vaccines are administered. The findings will be useful for those who are unable to get a second AstraZeneca vaccine due to production delays and safety concerns, although researchers say it’s still best to get two doses of the same vaccine for now.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On March 24, AstraZeneca <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html" target="_blank">released</a> the primary analysis of its U.S. phase three clinical trials showing that its vaccine is 76 percent effective at preventing COVID-19, slightly lower than the 79 percent efficacy it had announced two days earlier based on a partial analysis of the data. It is also 85 percent effective in people 65 and older and 100 percent effective at preventing severe cases of the disease.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">U.S. health officials had taken the unusual step of <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nih.gov/news-events/news-releases/niaid-statement-astrazeneca-vaccine" target="_blank">questioning the decision to release the interim results</a>, describing them as “outdated and potentially misleading.” In a letter <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html" target="_blank">obtained by the <i>Washington Post</i></a>, an independent panel of experts at the National Institutes of Health that oversees U.S. clinical trials said that it had recommended the company release a later analysis instead, showing the vaccine may be 69 to 74 percent effective.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The companies <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html#!" target="_blank">also said</a> that the vaccine’s efficacy increased to 82 percent when the second dose was taken after 12 weeks or longer, rather than the originally recommended four-week interval. The British government has recommended the longer gap in its rollout of the vaccine to prioritize getting the first shot to as many at-risk people as possible.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-10"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On February 7, South Africa <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/02/07/world/africa/covid-vaccine-astrazeneca-south-africa.html" target="_blank">halted</a> its use of the AstraZeneca-Oxford vaccine after preliminary laboratory studies showed it offered only minimal protection against the virus variant that is dominant in that country. The finding was later confirmed by <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nejm.org/doi/10.1056/NEJMoa2102214" target="_blank">a study published in the <i>New England Journal of Medicine</i></a> showing that the vaccine does not protect against mild to moderate cases of COVID-19 caused by the South African variant. <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/uk-health-coronavirus-britain-vaccines-v/data-on-astrazeneca-vaccine-and-south-african-variant-should-come-soon-uk-expert-says-idUSKBN29I18P" target="_blank">Early data suggested<!-- --> </a>that the vaccine will still effectively protect against the variant that is prevalent throughout the U.K. <!-- --> <!-- --> <!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety:</b> On June 9, a study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/s41591-021-01408-4" target="_blank">published in the journal <i>Nature Medicine</i></a> found that people who have received the AstraZeneca vaccine have a slightly increased risk of a bleeding disorder. The analysis of 2.53 million people who received the vaccine found an incidence of 1.13 cases per 100,000 vaccines. Researchers said the benefits of getting the vaccine outweigh the risks. The study echoed an earlier <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood" target="_blank">safety review conducted by the European Medicines Agency</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">In Canada, meanwhile, on June 29 regulatory officials advised people with a history of capillary leak syndrome against receiving the AstraZeneca vaccine. Health Canada i<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.theglobeandmail.com/canada/article-heath-canada-adds-warning-of-very-rare-serious-condition-as-potential/" target="_blank">s also updating the vaccine’s label</a> to add the syndrome as a potential side effect.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> Project members say their candidate can be stored at temperatures seen in common refrigeration. Oxford and AstraZeneca expect to produce up to three billion doses of the vaccine in 2021.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On December 30, the U.K. <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator" target="_blank">announced</a> changes to its vaccine delivery plan to prioritize delivering the first dose of either vaccine to as many at-risk people as possible, based on data <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948334/Information_for_UK_healthcare_professionals_on_COVID-19_Vaccine_AstraZeneca.pdf" target="_blank">provided to and released by</a> health regulators. It did so by delaying administration of the second dose of the AstraZeneca-Oxford drug. A similar rule was issued for the Pfizer-BioNTech vaccine, but regulators didn’t provide<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948338/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020.pdf" target="_blank"> <!-- -->data to back the<!-- --> </a>new regimen. Overall, the U.K. still recommends that recipients receive two doses of either vaccine for maximum benefit.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-11"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:<!-- --> </b>On December 11, AstraZeneca and Russia’s Gamaleya Institute <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html" target="_blank">announced</a> plans to work together to study the possibility of combining Oxford’s vaccine with Gamaleya’s Sputnik V vaccine. Since both use the same adenovirus, researchers will investigate whether a combination of the two will improve efficacy.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">The AstraZeneca-Oxford vaccine’s phase three trial aimed to recruit up to 50,000 volunteers in Brazil, the U.K., the United States, and South Africa. On September 8, AstraZeneca paused the trials for a safety review due to an adverse reaction in one participant in the U.K., which the company described as a “routine action.” After an investigation by independent regulators, the trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html" target="_blank">resumed</a> in the U.K., Brazil, South Africa, and India in September and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923" target="_blank">resumed in the U.S.</a> a month later.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://novavax.com/" target="_blank"><b class="cXscX">Novavax</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>NVX-CoV2373</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A biotechnology company based in Gaithersburg, Maryland.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A protein vaccine that involves a nanoparticle carrier to better aid delivery and uptake by cells. The vaccine is administered in two doses, 21 days apart.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Authorized for emergency use in Indonesia.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Novavax has not yet submitted <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-again-delays-seeking-us-approval-covid-19-vaccine-2021-08-05/" target="_blank">its vaccine to the FDA for emergency use authorization, but it is planning to do so</a>. Reuters reports that Novavax also said that it will file a separate application for booster shots once the emergency use authorization submission is processed; the company said its booster shot given six months after the two-dose regimen elicited a 4.6-fold increase in antibodies. The company has filed for authorization from regulators in India and the Philippines.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On June 14, Novavax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and" target="_blank">announced</a> that its vaccine is safe and 90.4 percent effective in protecting against COVID-19—including the more contagious virus variants that are circulating. The vaccine is also 100 percent effective at preventing moderate and severe disease among 29,960 clinical trial participants age 18 and older in the U.S. and Mexico.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On March 11, Novavax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and" target="_blank">announced</a> that a final analysis of its phase three clinical trials in the U.K. shows that its vaccine is 96.4-percent effective in preventing COVID-19. It also announced the findings of its phase 2b clinical trial in South Africa, which showed the vaccine was only 48.6-percent effective against the strains circulating there. Both trials showed the vaccine is 100-percent effective at preventing severe cases of the disease.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On January 28, 2021, Novavax had <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3" target="_blank">announced</a> preliminary results of its phase three trials in the U.K., which showed at the time that its vaccine is 89.3-percent effective in preventing COVID-19. On September 2, 2020, a study of the company’s phase one trial <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2026920" target="_blank">published in the <i>New England Journal of Medicine</i></a> found that the vaccine was safe and produced coronavirus antibodies at a higher level than is seen among those who have recovered from COVID-19. It also stimulated T cells, another arm of the human immune response.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On September 24, 2020, Novavax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united" target="_blank">announced</a> the launch of its phase three trial in the United Kingdom, which evaluated the vaccine in up to 10,000 people, both with and without underlying conditions. Up to 400 participants were also vaccinated against the seasonal flu as part of a sub-study to <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html" target="_blank">help determine</a> whether it is safe to give patients both vaccines at the same time. On November 30, Novavax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress" target="_blank">said it had completed enrollment</a> in its phase three trial in the U.K.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On December 28, 2020, Novavax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-initiation-prevent-19-pivotal-phase-3-efficacy" target="_blank">announced</a> the launch of a phase three study in the U.S. and Mexico, which evaluated the safety and efficacy of its vaccine in up to 30,000 adults.<!-- --> </p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.sinopharm.com/1156.html" target="_blank"><b class="cXscX">Sinopharm</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> None<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> China’s state-run pharmaceutical company, in collaboration with the Wuhan Institute of Biological Products.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> Two inactivated SARS-CoV-2 vaccines.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-12"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> China has approved one of the company’s vaccines for general use and another for limited use. One of the Sinopharm vaccines has also been approved by the World Health Organization as well as in Bahrain, the United Arab Emirates, and other countries.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Sinopharm <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.scmp.com/news/china/society/article/3111347/coronavirus-sinopharm-applies-regulatory-approval-china-launch" target="_blank">filed for final regulatory approval</a> from China in late November, two months after the <i>New Yorker</i> <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.newyorker.com/news/news-desk/the-november-surprise-of-chinas-coronavirus-vaccine" target="_blank">reported</a> that hundreds of thousands of Chinese civilians have already been vaccinated under the government’s emergency-use approval. China began to innoculate medical workers and other high-risk groups with the Sinopharm trial vaccines in July, making it the first experimental vaccine available to civilians beyond clinical volunteers.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:<!-- --> </b>On July 19 preliminary results from a study conducted in Sri Lanka found that Sinopharm’s vaccine was less effective against the Delta variant than the original SARS-CoV-2 strain. As Reuters reported, the study showed that the vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sinopharms-covid-19-shot-induces-weaker-antibody-responses-delta-study-2021-07-21/" target="_blank">elicited a 1.38-fold reduction in antibody levels</a> against the variant.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On May 7, the World Health Organization <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations" target="_blank">estimated</a> the Sinopharm vaccine’s efficacy to be 79 percent among all age groups, affirming the company’s earlier <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2020/12/29/world/a-chinese-covid-19-vaccine-has-proved-effective-its-maker-said.html?referringSource=articleShare" target="_blank">announcement</a> of the results of its phase three study.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">Preliminary findings from two randomized trials, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://jamanetwork.com/journals/jama/fullarticle/2769612" target="_blank">published in the <i>Journal of the American Medical Association</i></a>, have shown the vaccine can trigger an antibody response with no serious adverse effects. The study did not measure T cell-mediated immune responses. These results are significant, though, as they are the first published data from human clinical trials for a COVID-19 vaccine that uses a whole, inactivated virus.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-13"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> Sinopharm <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-uae-idUSKCN24H14T" target="_blank">launched its first phase three trial</a> in July 2020 among 15,000 volunteers—aged 18 to 60, with no serious underlying conditions—in the UAE. The company <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.businesswire.com/news/home/20200717005085/en/World%E2%80%99s-Phase-III-Clinical-Trial-COVID-19-Inactivated" target="_blank">selected the UAE because</a> it has a diverse population made up of approximately 200 nationalities, making it an ideal testing ground. Sinopharm also conducted phase three trials in locations such as <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9" target="_blank">Peru</a> and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-bahrain-vaccine/chinas-sinopharm-starts-phase-iii-trial-of-covid-19-vaccine-in-bahrain-idUSKCN2561V1" target="_blank">Bahrain</a>.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.sinovac.com/" target="_blank"><b class="cXscX">Sinovac</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>CoronaVac<!-- --> </p><div class="oLzSq QrHMO QBoFd pvsTF EhJPu vPlOC zNYgW OsTsW AkFWX daRVX ISNQ sKyCY eRftA acPPc BZygj nFwaT MCnQE mEeeY SmBjI xegrY VvTxJ iulOd NIuqO zzscu lzDCc aHUBM hbvnu OjMNy eQqcx SVqKB GQmdz jaoD iShaE ONJdw vrZxD OnRTz gbbfF roDbV kRoBe oMlSS gfNzt oJhud eXZcf zhVlX "><div class="zzkIM UtCfs sXthe lyRMG  XQpSH " data-testid="prism-divider"></div><div><section class="CHWlW ZgZTu FlDNH hQfuy feniZ wBpop uAyYK yJYJo OGgqj tQHio PCVZs  Kiog iKqXF eeiyR " data-testid="prism-collection"><header class="mLASH VZTD bhaVx "><div><h2 class="KuBvM lFzlq GbVC HkWF exKgG kGyAC SwCrv RTkZF ">You May Also Like</h2></div></header><div class="rRTs EwJTR UpiKB sKbok RsAxh msYPt zKjNI SXHxp OaElp KzevM LFuuA jLoop  liAe uMOq zYIfP pYgZk Mxrkk VZTD lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ QGHKv HNQqj " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv HNQqj ICwhc xuArw ZLXw kSqqG " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/covid-19-can-ruin-your-sleep-in-many-different-waysheres-why" aria-label="COVID-19 can ruin your sleep in many different ways—here&#x27;s why" aria-describedby="COVID19canruinyoursltags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ iRFVw qrShQ ZZxEf jCA-DP TucPs MWLZF PEVz zHngH VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur oVsVV uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_square.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq xuArw ZLXw kSqqG "><div class="VZTD rEPuv QXDKT aimoN " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="COVID19canruinyoursltags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr dMSoH tuAKv " id="COVID19canruinyourslheadline">COVID-19 can ruin your sleep in many different ways—here&#x27;s why</h3></div></div></div></a></div><div class="rRTs EwJTR UpiKB sKbok RsAxh msYPt zKjNI SXHxp OaElp KzevM LFuuA jLoop  liAe uMOq zYIfP pYgZk Mxrkk VZTD lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ QGHKv HNQqj " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv HNQqj ICwhc xuArw ZLXw kSqqG " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/vaccines-immune-system-inflammation" aria-label="How the additives in your vaccines rev up your immune system" aria-describedby="Howtheadditivesinyoutags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ iRFVw qrShQ ZZxEf jCA-DP TucPs MWLZF PEVz zHngH VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur oVsVV uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_square.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq xuArw ZLXw kSqqG "><div class="VZTD rEPuv QXDKT aimoN " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="Howtheadditivesinyoutags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr dMSoH tuAKv " id="Howtheadditivesinyouheadline">How the additives in your vaccines rev up your immune system</h3></div></div></div></a></div><div class="EwJTR UpiKB sKbok RsAxh msYPt zKjNI SXHxp OaElp KzevM LFuuA jLoop  liAe uMOq zYIfP pYgZk Mxrkk VZTD lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ QGHKv HNQqj " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv HNQqj ICwhc xuArw ZLXw kSqqG " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/covid-reinfections-chronic-booster-vaccine" aria-label="Multiple COVID infections can lead to chronic health issues. Here’s what to know." aria-describedby="MultipleCOVIDinfectitags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ iRFVw qrShQ ZZxEf jCA-DP TucPs MWLZF PEVz zHngH VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur oVsVV uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_square.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq xuArw ZLXw kSqqG "><div class="VZTD rEPuv QXDKT aimoN " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="MultipleCOVIDinfectitags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr dMSoH tuAKv " id="MultipleCOVIDinfectiheadline">Multiple COVID infections can lead to chronic health issues. Here’s what to know.</h3></div></div></div></a></div></section></div><div class="zzkIM UtCfs Ufjyt  XQpSH " data-testid="prism-divider"></div></div><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>A Chinese biopharmaceutical company, in collaboration with Brazilian research center Butantan.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated vaccine.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:<!-- --> </b>Approved for limited use by the WHO as well as in China, Indonesia, Brazil, and other countries.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On July 15 Reuters reported that the leaders of a Chilean study have <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/world/americas/chilean-sinovac-trial-leaders-recommend-third-dose-covid-19-vaccine-2021-07-15/" target="_blank">recommended administering a third dose of Sinovac’s vaccine</a> as its efficacy has waned in the face of the Delta variant. The vaccine’s level of protection is lower than others—late-stage trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bbc.com/news/world-latin-america-55642648" target="_blank">found that it is 51 percent effective</a> in preventing COVID-19. Still, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/d41586-021-01497-8" target="_blank"><i>Nature</i> reports</a> that it is 100 percent effective at preventing severe disease and therefore is key to helping curb the pandemic.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On April 7, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1" target="_blank">a preliminary study</a> of CoronaVac’s vaccine rollout in Brazil showed that the vaccine is about 50 percent effective in protecting against COVID-19 in a region where the highly transmissible P.1 variant is circulating.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> CoronaVac <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.sinovac.com/?optionid=754&amp;auto_id=907" target="_blank">entered phase three trials</a> in July, with plans to recruit nearly 9,000 healthcare professionals in Brazil, in addition to phase three trials in <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine/sinovac-launches-phase-3-trial-for-covid-19-vaccine-in-indonesia-reports-phase-2-details-idUSKCN2570E9" target="_blank">Indonesia</a>. A planned trial in Bangladesh was delayed, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://asia.nikkei.com/Spotlight/Coronavirus/China-forges-on-with-vaccine-diplomacy-amid-Pfizer-fanfare" target="_blank">after Bangladesh refused in October</a> to co-finance a late-stage trial.<!-- --> </p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://biomed.cigb.edu.cu/" target="_blank"><b class="cXscX">Center for Genetic Engineering and Biotechnology</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Abdala</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A government-run research institute in Cuba.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A protein subunit vaccine that’s administered in three doses.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Approved for emergency use in Cuba and Vietnam. Prior to granting emergency use authorization, Cuba <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1" target="_blank">had already begun</a> administering the vaccine among health workers as part of an “intervention study.”</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On June 22 Cuba announced that the Abdala vaccine is 92.28 percent effective against COVID-19.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> In March Cuba <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm" target="_blank">launched</a> phase three clinical trials for the Abdala vaccine among 48,000 volunteers.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.finlay.edu.cu/en" target="_blank"><b class="cXscX">Finlay Institute for Vaccines</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Soberana-02</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-14"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A government-run research institute in Cuba.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A conjugate vaccine that uses part of the virus spike protein.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Authorized for emergency use in Cuba and Iran.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy:</b> On June 22 the <i>New York Times</i> <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/06/22/world/americas/cuba-vaccine-abdala.html" target="_blank">reported</a> that the Soberana-02 vaccine was 62 percent effective at preventing COVID-19 after two of its three required doses.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:<!-- --> </b>On March 4, Cuba became the first country in Latin America to <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.miamiherald.com/news/nation-world/world/americas/cuba/article249696913.html" target="_blank">announce the launch of a phase three clinical trial</a> for one of its COVID-19 vaccines, the <i>Miami Herald</i> reported. The Cuban government said the phase three trial would be conducted in Havana among 44,000 volunteers.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:728px;min-height:90px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-outstream" data-testid="prism-ad"><div class="Ad fitt-article-inline-outstream  ad-slot  " data-slot-type="fitt-article-inline-outstream" data-slot-kvps="pos=fitt-article-inline-outstream-15"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/" target="_blank"><b class="cXscX">CureVac</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> CVnCoV</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>A German biopharmaceutical company <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/2021/01/07/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/" target="_blank">in partnership with Bayer</a>, a German multinational pharmaceutical company.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An mRNA vaccine that’s administered in two doses taken 28 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use. On October 12, 2021, CureVac <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-withdraw-first-generation-covid-19-vaccine-candidate-2021-10-12/" target="_blank">announced</a> that it was withdrawing its COVID-19 vaccine candidate months after it <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/" target="_blank">reported</a> disappointing results from a study of its clinical trials showing its vaccine was only 47 percent effective in preventing COVID-19, falling short of the company’s own criteria for success. CureVac attributed its results to the virus variants that were circulating at the time. It sequenced 124 cases of COVID-19 among clinical trial participants and found only one case was caused by the original SARS-CoV-2 virus and more than half were caused by variants of concern.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:<!-- --> </b>On January 11, CureVac <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/2021/01/11/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-primates-during-sars-cov-2-challenge-infection/" target="_blank">announced</a> that preliminary results show its vaccine prompted robust antibody and T-cell responses in rhesus macaques.<!-- --> </p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On December 14, 2020, CureVac <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/2020/12/14/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/" target="_blank">announced</a> it had begun enrolling participants in a phase 2b/3 study to assess its vaccine’s safety and efficacy in more than 35,000 participants in Europe and Latin America. One week later, the company <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.curevac.com/en/2020/12/21/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/" target="_blank">launched</a> a separate phase three trial in healthcare workers in Mainz, Germany.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-2-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate" target="_blank"><b class="cXscX">Sanofi and GSK</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> None</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>A global biopharmaceutical company in partnership with a global healthcare company.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An adjuvant-supported recombinant-protein vaccine.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use.</p></div></div></div><div class="NYwzQ vUYNV glxIO ilAoG HPkGR "><div class="natgeo-ad" data-testid="prism-ad-wrapper" style="min-width:300px;min-height:250px;transition:min-height 0.3s linear 0s" data-ad-placeholder="true"><div data-box-type="fitt-adbox-fitt-article-inline-box" data-testid="prism-ad"><div class="Ad fitt-article-inline-box  ad-slot  " data-slot-type="fitt-article-inline-box" data-slot-kvps="pos=fitt-article-inline-box"></div></div></div></div><div class="FITT_Article_main_group_wrapper VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs iJVrZ " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On May 17, the companies <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-17-07-30-00-2230312" target="_blank">announced</a> that a study of their phase two clinical trials shows the vaccine generated a high level of neutralizing antibodies with no safety concerns.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> On May 27, 2021, Sanofi and GSK <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-27-07-30-00-2236989#" target="_blank">announced</a> that they had started to enroll participants in a phase three clinical study to test the safety and efficacy of their vaccine in 35,000 volunteers ages 18 and older in the U.S., Asia, Africa, and Latin America. The study’s broad geographic range was intended to allow the companies to evaluate the vaccine’s efficacy against variants of concern.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://biologicale.com/index.html" target="_blank"><b class="cXscX">Biological E. Limited</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> None</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> An Indian vaccine and pharmaceutical company in partnership with the Baylor College of Medicine.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A protein-based subunit vaccine that requires two doses administered 28 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Latest news:</b> On April 26, the companies <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bcm.edu/news/biological-e-limited-to-begin-phase-iii-clinical-trials-with-baylor-and-texas-childrens-vaccine" target="_blank">announced</a> that they received approval to launch a phase three clinical trial of their vaccine candidate. The trial will evaluate the efficacy and safety of the vaccine among more than 1,200 volunteers ages 18 to 80 at 15 sites across India.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> If the vaccine is approved for use, it <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/" target="_blank">will be distributed</a> through the COVAX Facility, a global effort to ensure the equitable distribution of COVID-19 vaccines.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://valneva.com/research-development/covid-19-vla2001/" target="_blank"><b class="cXscX">Valneva SE</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> VLA2001</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A vaccine developer based in France.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated virus, adjuvant-supported vaccine, with two doses administered three weeks apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use. The company has initiatied rolling submission for approval with U.K. and European regulators.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety and efficacy:<!-- --> </b>On October 18 Valneva <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/" target="_blank">announced</a> that its vaccine elicited higher antibody levels than the AstraZeneca vaccine and “significantly fewer” adverse events among participants age 30 and older.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On April 6, Valneva <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://valneva.com/press-release/valneva-reports-positive-phase-1-2-data-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/" target="_blank">announced</a> that a study of its phase 1 and 2 clinical trials show that its vaccine prompted a strong immune response with no safety concerns.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> On April 21 Valneva <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://valneva.com/press-release/valneva-initiates-phase-3-clinical-trial-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/#_ftn2" target="_blank">announced</a> the launch of phase three clinical trials to study the safety and efficacy of its COVID-19 vaccine compared to that of AstraZeneca’s conditionally approved vaccine. Approximately 4,000 volunteers were expected to receive two doses of either vaccine to determine the immune response of each. Valneva says it hopes to file for regulatory approval in the fall of 2021.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://en.biokangtai.com/" target="_blank"><b class="cXscX">Shenzhen Kangtai Biological Products</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> None.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A China-based pharmaceuticals company</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated vaccine that requires two doses administered 28 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Authorized for emergency use in China. The country <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6" target="_blank">approved</a> the Kangtai shot for emergency use in May 2021, just weeks after the vaccine launched its phase three clinical trials.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:<!-- --> </b>Kangtai’s phase three clinical trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://clinicaltrials.gov/ct2/show/NCT04852705?term=kangtai&amp;draw=2&amp;rank=3" target="_blank">are underway</a>, testing the vaccine’s safety and efficacy among 28,000 adults age 18 and older.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://medicago.com/en/" rel="noopener noreferrer" target="_blank"><b class="cXscX">Medicago</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> CoVLP</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:<!-- --> </b>A Canadian biotechnology company, in partnership with British multinational pharmaceutical company GlaxoSmithKline.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A plant-derived recombinant vaccine with an adjuvant that requires two doses administered 21 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:<!-- --> </b>In May 2021 Medicago <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://medicago.com/en/press-release/1751/" target="_blank">reported</a> that interim data from its phase two clinical trial showed that its COVID-19 vaccine elicited high levels of neutralizing antibodies with no severe adverse reactions.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> On March 16, Medicago and GlaxoSmithKline <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/" target="_blank">announced</a> that their vaccine had entered phase three clinical trials to study its safety and efficacy in up to 30,000 volunteers in 10 countries, including Canada and the U.S.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bharatbiotech.com/covaxin.html" target="_blank"><b class="cXscX">Bharat Biotech</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>COVAXIN</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> An Indian biotechnology company, in collaboration with the Indian Council of Medical Research and the National Institute of Virology.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:<!-- --> </b>An inactivated vaccine, which <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf" target="_blank">requires two doses</a> that are administered 28 days apart.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:<!-- --> </b>Authorized for emergency use <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html" target="_blank">in India</a>, Mexico, the Philippines, and other countries. The WHO has also listed the vaccine for emergency use.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> In November 2021 the WHO<a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine" target="_blank"> <!-- -->said</a> that its analysis of COVAXIN shows the vaccine is 78 percent effective against COVID-19 and “is extremely suitable for low-and-middle-income countries due to easy storage requirements.”<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On March 3 Bharat Biotech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf" target="_blank">announced</a> that an interim analysis of its phase three trial showed its vaccine is 81-percent effective in protecting against COVID-19 after the second dose. A separate preliminary study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2.full" target="_blank">also indicated</a> that the vaccine produces antibodies that can neutralize the virus variant that originated in the U.K.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On January 21, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext#seccestitle180" target="_blank"><i>The Lancet</i></a> published interim findings from COVAXIN’s phase one study that showed the vaccine elicited an immune response in participants. The study identified only one serious adverse event, and it was unrelated to the vaccine.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On November 16, Bharat Biotech <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf" target="_blank">announced</a> it had begun phase three trials involving 26,000 participants at more than 25 centers across India.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://sputnikvaccine.com/" target="_blank"><b class="cXscX">The Gamaleya National Center of Epidemiology and Microbiology</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Sputnik V</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Russian research institution, in partnership with the state-run Russian Direct Investment Fund.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A viral vector vaccine that uses two strains of adenovirus and requires a second injection after 21 days to boost the immune response.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:<!-- --> </b>In August, Russia cleared the Sputnik V vaccine for widespread use and <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2020/08/11/russia-claims-to-have-registered-first-coronavirus-vaccine.html" target="_blank">claimed it</a> as the first registered COVID-19 vaccine on the market—before the vaccine’s phase three trials had begun and despite the lack of published evidence at the time. It has since been approved in Belarus, Argentina, Venezuela, and other countries. <!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy">On March 4 the European Union <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine" target="_blank">announced</a> that it would begin a rolling review of the Sputnik V vaccine. The announcement came after a handful of European countries said they would consider approving the vaccine without E.U. approval. Hungary has already authorized the vaccine. But on October 21 Reuters <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/world/europe/exclusive-eu-decision-russias-sputnik-v-shot-impossible-this-year-source-2021-10-21/" target="_blank">reported</a> that European regulators are unlikely to make a final decision until early 2022.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On February 2, the medical journal <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext" target="_blank"><i>The Lancet</i> published the results</a> of a phase three trial in Moscow that found the Sputnik V vaccine is safe and 91.6-percent effective in preventing COVID-19. The study, which involved more than 22,000 participants, also showed the vaccine is 100-percent effective in preventing moderate or severe cases of the disease, as no such cases were confirmed at least 21 days after receiving the first dose.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> Global demand for Sputnik V <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://fortune.com/2021/02/08/international-sputnik-russia-demand/" target="_blank">soared</a> in the weeks after the vaccine’s efficacy data was published. The vaccine makers <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.businessinsider.com/russia-sputnik-vaccine-40-countries-west-hoards-shots-2021-3" target="_blank">reached deals</a> with more than 40 countries in Latin America, Eastern Europe, Asia, and Africa. On February 19, the African Union <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/uk-health-coronavirus-africa-idUSKBN2AJ0ZP" target="_blank">announced</a> that Russia has offered them 300 million doses of the Sputnik V vaccine.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On December 11, the Gamaleya Institute and biopharmaceutical company AstraZeneca <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html" target="_blank">announced</a> they will work together to study the possibility of combining Sputnik V with the candidate that AstraZeneca has developed with the University of Oxford. Since both candidates use the same adenovirus, researchers will investigate whether combining them will improve efficacy of the AstraZeneca vaccine, which is 70.4-percent effective in preventing COVID-19.<!-- --> </p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.chumakovs.ru/en/" target="_blank"><b class="cXscX">Chumakov Center</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:<!-- --> </b>CoviVac</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Russian research center.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated vaccine given in two doses, 14 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> On February 20, Russia <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-russia-vaccine/russia-approves-its-third-covid-19-vaccine-pm-idUSKBN2AK07H" target="_blank">approved</a> the CoviVac vaccine for use even though late-stage clinical trials to test its safety and efficacy have not yet begun. Reuters reports that early-stage trials with 200 participants showed the vaccine has no side effects.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Distribution:</b> The Chumakov Center plans to produce half a million doses per month.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.mcri.edu.au/BRACE" target="_blank"><b class="cXscX">Murdoch Children’s Research Institute</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Bacillus Calmette-Guerin BRACE trial<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> The largest child health research institute in Australia, in collaboration with the University of Melbourne.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> For nearly a hundred years, the Bacillus Calmette-Guerin (BCG) vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.gavi.org/vaccineswork/can-bcg-vaccine-protect-against-covid-19" target="_blank">has been used</a> to prevent tuberculosis by exposing patients to <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.uofmhealth.org/health-library/d08998a1#:~:text=BCG%20vaccine%20works%20by%20exposing,from%20disease%20in%20every%20person." target="_blank">a small dose of live bacteria</a>. Evidence has emerged over the years that this vaccine may boost the immune system and help the body fight off other diseases as well.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:<!-- --> </b>On November 10, 2020, a U.S. study <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.jci.org/articles/view/145157" target="_blank">published in the <i>Journal of Clinical Investigation</i></a> found that among 6,201 healthcare workers in Los Angeles, those who had previously received the BCG vaccine reported symptoms of COVID-19 less often than those who hadn’t, a finding that study authors say strengthens the case for further research. In October of that year, the U.K. <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/health-coronavirus-britain-bcg/uk-study-tests-if-bcg-vaccine-protects-against-covid-idINKBN26W08C" target="_blank">launched a study</a> of the BCG vaccine that is part of the Australian-led trials. The study is seeking to recruit a thousand frontline health-care workers to test the vaccine’s effectiveness against COVID-19.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> In Apri 2020, researchers from the Murdoch Children’s Research Institute <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nytimes.com/2020/04/03/health/coronavirus-bcg-vaccine.html" target="_blank">began a series of randomized controlled trials</a> that will test whether BCG might work on the coronavirus as well. They aim to recruit <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.mcri.edu.au/BRACE" target="_blank">10,000 healthcare workers</a> in the study. In an April 2020 scientific brief, the World Health Organization found that there is <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.who.int/publications/i/item/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19" target="_blank">no current evidence that the BCG vaccine protects</a> people against infection with the coronavirus.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.cansinotech.com/" target="_blank"><b class="cXscX">CanSino Biologics</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Ad5-nCoV</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Chinese biopharmaceutical company.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A viral vector vaccine.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> On June 25, 2020, CanSino <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.nature.com/articles/d41586-020-02244-1" target="_blank">became the first company to receive limited approval</a> to use its vaccine in people even though it was still in the second phase of its clinical trials. At the time, the Chinese government <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ" target="_blank">pproved</a> the vaccine for military use only, for a period of one year. Since then, the vaccine <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://covid19.trackvaccines.org/vaccines/2/" target="_blank">has been approved</a> in China, Argentina, Hungary, and other countries.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> Preliminary results from phase two trials, <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext" target="_blank">published in <i>The Lancet</i></a>, have shown that the vaccine produces “significant immune responses in the majority of recipients after a single immunisation.” There were no serious adverse reactions documented.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> On December 21, CanSino <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio/china-cansinobios-covid-19-vaccine-trials-recruit-over-20000-people-idUSKBN28V1N8" target="_blank">announced</a> that it has recruited more than 20,000 participants for its phase three trials in Pakistan, Russia, Mexico, and Chile. On August 15, Russian biopharmaceutical company Petrovax <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://petrovax.com/press_centre/news/2020/1878/" target="_blank">announced</a> it had launched the first phase three clinical trial of Ad5-nCoV.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.vector.nsc.ru/" target="_blank"><b class="cXscX">Vector Institute</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> EpiVacCorona</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Russian biotechnology institute.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A protein vaccine, namely it uses small fragments of viral antigens called peptides to produce an immune response.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> On October 14, 2020, Russia <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html" target="_blank">granted</a> regulatory approval to EpiVacCorona even though the vaccine candidate had not published any results and had not entered phase three of its clinical trials. It is the second vaccine candidate that Russia approved for use despite a lack of published evidence about its safety and efficacy. It has since been approved for use in Turkmenistan and authorized for emergency use in Belarus.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> On January 13, 2021, Russian state news agency TASS <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://tass.com/society/1244333" target="_blank">reported</a> that of the more than 2,000 volunteers who had received both doses of EpiVacCorona’s two-dose regimen, none reported adverse reactions from the vaccine.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> In November 2020 Russia <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.reuters.com/article/us-health-coronavirus-russia-cases-idUSKBN28A0P0" target="_blank">launched</a> mass trials of its EpiVacCorona vaccine; the trials will inoculate 150 people over the age of 60 and 3,000 volunteers over the age of 18.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://zyduscadila.com/research" target="_blank"><b class="cXscX">Zydus Cadila</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> ZyCoV-D</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> An Indian pharmaceutical company.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> A DNA-based vaccine that is <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://timesofindia.indiatimes.com/india/vaccines-that-can-help-india-in-its-fight-against-covid-19/articleshow/79303893.cms" target="_blank">delivered by a skin patch</a>.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Approved for emergency use in India.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety and efficacy:</b> In December 2020 Zydus Cadila <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://timesofindia.indiatimes.com/india/zydus-cadila-seeks-govt-nod-to-start-phase-iii-clinical-trials-of-covid-19-vaccine/articleshow/79944346.cms" target="_blank">said</a> that a combined phase one/two study of its vaccine showed it was safe and prompted an immunogenic response, but the company did not share any data.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> On January 3, 2021, Zydus Cadila <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_receives_approvals_from_the_DCGI_to_start_Phase_III_Clinical_Trial_of_ZyCoV_D_fully_indigenously_developed_vaccine_-3_1_2021.pdf" target="_blank">announced</a> it had received approval from Indian regulators to launch a phase three trial testing the safety and efficacy of its vaccine in about 30,000 volunteers.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://en.zhifeishengwu.com/about/zfgk/" target="_blank"><b class="cXscX">Anhui Zhifei</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> ZF2001</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Chinese biopharmaceutical company, in partnership with the Institute of Microbiology at the Chinese Academy of Sciences.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:<!-- --> </b>A subunit vaccine that uses pieces of protein from a pathogen to trigger an immune response.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Approved for use in China, Indonesia, and Uzbekistan.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:</b> In August 2021 a study of the company’s phase one and two clinical trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://linkinghub.elsevier.com/retrieve/pii/S1473309921001274" target="_blank">published in <i>The Lancet</i> </a>showed that the vaccine elicited neutralizing antibodies and that the most common adverse reactions were cough, fever, and headache.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> In November 2020 Chinese health officials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://en.nhc.gov.cn/2020-11/20/c_82209.htm" target="_blank">announced</a> the launch of phase three trials for the Anhui Zhifei vaccine. The trials—which aimed to recruit 29,000 volunteers aged 18 or older—were expected to be conducted in China, Indonesia, Pakistan, and Ecuador.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.biosafety.kz/en/" target="_blank"><b class="cXscX">Research Institute for Biological Safety Problems</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> QazCovid-in</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A research institute in Kazakhstan.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated vaccine.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Granted temporary registration in Kazakhstan in January 2021 despite a lack of data from its phase three clinical trials.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Efficacy and safety:<!-- --> </b>In August 2021 a study of the vaccines phase one and phase two clinical trials <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00358-8/fulltext" target="_blank">published in <i>The Lancet</i></a> found that the vaccine was safe with no severe adverse events recorded. The studies also found the vaccine elicited a neutralizing antibody response as well as a T-cell response.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials status:</b> In December 2020, the institute <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.biosafety.kz/en/uncategorized/%d1%80%d0%b0%d0%b1%d0%be%d1%87%d0%b8%d0%b9-%d0%b2%d0%b8%d0%b7%d0%b8%d1%82-%d0%b2-%d0%bd%d0%b8%d0%b8%d0%bf%d0%b1%d0%b1-%d0%bf%d1%80%d0%b5%d0%bc%d1%8c%d0%b5%d1%80-%d0%bc%d0%b8%d0%bd%d0%b8%d1%81%d1%82-2/" target="_blank">announced</a> that the Kazakh Ministry of Health approved the launch of phase three trials to assess the vaccine’s safety and efficacy in 3,000 volunteers.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="http://www.imb.com.cn/en/about.aspx" target="_blank"><b class="cXscX">Institute of Medical Biology at the Chinese Academy of Medical Sciences</b></a></h2><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Name:</b> Unknown</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Who:</b> A Chinese research institute.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">What:</b> An inactivated vaccine that requires two doses taken 14 days apart.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Approval status:</b> Not approved for use.</p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Clinical trials:</b> In December 2020, researchers <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://clinicaltrials.gov/ct2/show/NCT04659239" target="_blank">launched phase three clinical trials</a> to test the efficacy and safety of the vaccine in 34,020 participants in Malaysia and Brazil.<!-- --> </p><p class="EkqkG nlgHS yuUao lqtkC TjIXL aGjvy"><b class="cXscX">Safety and efficacy:</b> Preliminary results of the vaccine’s phase one trial <a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf" target="_blank">showed</a> that it prompted an immune response with no serious adverse incidents.</p><h2 class="RxNCg PvZ nIjPJ PMXYp LmsHF SfAHY mNgye lNbol LBPRq"><a class="zZygg UbGlr iFzkS qdXbA WCDhQ DbOXS tqUtK GpWVU iJYzE " data-testid="prism-linkbase" href="https://www.pfizer.com/science/coronavirus/vaccine" rel="noopener noreferrer" target="_blank"></a></h2><div class="eTIW QrHMO fnRUo pvsTF EhJPu vPlOC zNYgW OsTsW RMeqy daRVX ISNQ sKyCY eRftA acPPc MENS nFwaT MCnQE mEeeY SmBjI xegrY rPLsU iulOd NIuqO zzscu lzDCc aHUBM IEgzD OjMNy eQqcx SVqKB GQmdz jaoD VWDdR ONJdw vrZxD OnRTz gbbfF roDbV GPGwb oMlSS gfNzt oJhud eXZcf zhVlX sUzSN "><div class="SDgng miqYR PMJVQ QtdQF WYbZw hwQoR SkUsC UlTly FxKvG BOli LbgCH nvgXD qZlJZ hdCKb " data-testid="prism-editors-note"><div class="fIerE gzgIi sbNwD wyNiH oGaak mIoBf HPTnC SyFCf KSVzn EMccI MTazT TWYO pxDKL syqKH AAxjg AGdf YLpQy UPQXr OWaqr MWqqQ rhuiH sYoWw jOwXI GfFUP iLdhU GuqqH UXCTR ExGxl CPrEb  gtOSm FbbUW tUtYa vOCwz EQwFq yCufu eEak Qmvg nyTIa SRXVc vzLa jgBfc WXDas CiUCW kqbG zrdEG txGfn ygKVe BbezD UOtxr CVfpq xijV soGRS XgdC sEIlf daWqJ "><p><b>Editor's note:</b> This story was originally published on July 31, 2020. It was regularly updated as developments occurred until November 2021.</p></div></div></div></div></div></div></div></div></div><div class="FITT_Article_end  "><div class="VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:20;--grid-column-span-lg:16;--grid-column-span-xl:16;--grid-column-span-xxl:14;--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:3;--grid-column-start-lg:5;--grid-column-start-xl:5;--grid-column-start-xxl:6"><div style="--spacing-top:32px;--spacing-bottom:0px;--spacing-child-top:initial;--spacing-child-bottom:32px;--spacing-firstChild-top:initial;--spacing-firstChild-bottom:initial;--spacing-lastChild-top:initial;--spacing-lastChild-bottom:32px;--spacing-compact-top:32px;--spacing-compact-bottom:0px;--spacing-firstChild-compact-top:initial;--spacing-firstChild-compact-bottom:initial;--spacing-child-compact-top:initial;--spacing-child-compact-bottom:32px;--spacing-lastChild-compact-top:initial;--spacing-lastChild-compact-bottom:32px" class="dHdHP jLREf zXXje aGO eCClZ nTLv jLsYA gmuro TOSFd VmeZt sCkVm hkQai wGrlE MUuGM fciaN qQjt DhNVo Tgcqk IGLAf tWjkv "><div><div data-testid="prism-tags"><h2 class="QOIir pZjYK JKlkC RZhHM ">Related Topics</h2><ul class="VZTD UeCOM dAmzA ltDkr qBPOY uoPjL "><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/f8408099-1b29-30de-af0d-3c172303e501/coronavirus" data-pos="0"><span class="QXDKT rGjeC tuAKv iMbiE ">CORONAVIRUS</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/26945195-72a1-3529-9d2a-cc4d85de992a/vaccination" data-pos="1"><span class="QXDKT rGjeC tuAKv iMbiE ">VACCINATION</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/4ae5b950-6a04-33cd-94ed-b34a8ab3beba/immune-system" data-pos="2"><span class="QXDKT rGjeC tuAKv iMbiE ">IMMUNE SYSTEM</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/c1e8ee84-032b-3fb7-992e-8380b2ef0e13/public-health" data-pos="3"><span class="QXDKT rGjeC tuAKv iMbiE ">PUBLIC HEALTH</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/f01c74a1-1ac8-3227-aec9-a76ea1805776/diseases" data-pos="4"><span class="QXDKT rGjeC tuAKv iMbiE ">DISEASES</span></a></li><li class=" "><a class="theme-HLysv theme-HReFq mLASH egFzk qXWHA ScoIf zYXIH jIRH wNxoc OJpwZ eqFg wSPfd ofvJb bMrzT LaUnX EgONj ibBnq kyjTO lvyBv aANqO aNnIu GDslh LjPJo RpDvg YYtC rTpcz EDgo SIwmX oIWqB mzm sXtkB yayQB vXSTR ENhiS dQa-Du SVBll bpBbX GpQCA tuAKv xTell wdAqb ZqGqs LVAIE TnrRA uECag DcwSV XnBOJ cELRj SUAFz XzYk zkmjG aSyef pFen hoNVj TQOOL Haltu NafGB KpEhF jyjDy kZHqU FZKIw QddLR SKDYB UmcQM giepU cTjQC aRMla MMxXy fFMcX PbMFf hJRbU MRTyf iFJTR koyYF TkdYt DZNRX MALjb VUFMN  " data-testid="prism-Tag" href="/related/f13ad5d0-f78b-39ea-a136-f8064e68bc33/epidemics" data-pos="5"><span class="QXDKT rGjeC tuAKv iMbiE ">EPIDEMICS</span></a></li></ul></div></div></div></div></div></div><div class="VZTD UeCOM jIRH oimqG UwdmX Xmrlz ReShI KaJdY lqtkC ssImf HfYhe RTHNs " data-testid="prism-GridContainer"><div class="Kiog kNVGM nvpSA qwdi bmjsw " data-testid="prism-GridRow"><div class="theme-e oBTii mrzah " data-testid="prism-GridColumn" style="--grid-column-span-xxs:var(--grid-columns);--grid-column-span-xs:var(--grid-columns);--grid-column-span-sm:var(--grid-columns);--grid-column-span-md:var(--grid-columns);--grid-column-span-lg:var(--grid-columns);--grid-column-span-xl:var(--grid-columns);--grid-column-span-xxl:var(--grid-columns);--grid-column-start-xxs:auto;--grid-column-start-xs:auto;--grid-column-start-sm:auto;--grid-column-start-md:auto;--grid-column-start-lg:auto;--grid-column-start-xl:auto;--grid-column-start-xxl:auto"><div style="--spacing-top:0px;--spacing-bottom:initial;--spacing-child-top:initial;--spacing-child-bottom:32px;--spacing-firstChild-top:initial;--spacing-firstChild-bottom:32px;--spacing-lastChild-top:initial;--spacing-lastChild-bottom:initial;--spacing-compact-top:0px;--spacing-compact-bottom:initial;--spacing-firstChild-compact-top:initial;--spacing-firstChild-compact-bottom:32px;--spacing-child-compact-top:initial;--spacing-child-compact-bottom:32px;--spacing-lastChild-compact-top:initial;--spacing-lastChild-compact-bottom:initial" class="dHdHP jLREf zXXje aGO eCClZ nTLv jLsYA gmuro TOSFd VmeZt sCkVm hkQai wGrlE MUuGM fciaN qQjt DhNVo Tgcqk IGLAf tWjkv "><div><div class=" " data-testid="prism-card-grid"><h2 class="VZTD TuKxa DHUQQ yyrtW ">You May Also Like</h2><div class="HUcap qJZvo cHNTo bIHPn mtdWM kwGcU UrPsH RDaaw lNBjL FqbDc tNvrX fihXm "><div class="liAe uMOq zYIfP pYgZk Mxrkk hsDdd lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ MpFZk " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv rEPuv ICwhc seFhp WtEci dVINO " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/rising-measles-cases" aria-label="What is &#x27;immune amnesia?&#x27; This long-term side effect of measles is newly relevant." aria-describedby="WhatisimmuneamnesiaTtags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur lIngG uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_4x3.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq seFhp WtEci "><div class="VZTD rEPuv QXDKT sAjcO " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="WhatisimmuneamnesiaTtags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr " id="WhatisimmuneamnesiaTheadline">What is &#x27;immune amnesia?&#x27; This long-term side effect of measles is newly relevant.</h3></div></div></div></a></div><div class="liAe uMOq zYIfP pYgZk Mxrkk hsDdd lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ MpFZk " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv rEPuv ICwhc seFhp WtEci dVINO " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/covid-19-risk-heart-attack-stroke" aria-label="Now we know how COVID attacks your heart" aria-describedby="NowweknowhowCOVIDatttags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur lIngG uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_4x3.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq seFhp WtEci "><div class="VZTD rEPuv QXDKT sAjcO " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="NowweknowhowCOVIDatttags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr " id="NowweknowhowCOVIDattheadline">Now we know how COVID attacks your heart</h3></div></div></div></a></div><div class="liAe uMOq zYIfP pYgZk Mxrkk hsDdd lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ MpFZk " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv rEPuv ICwhc seFhp WtEci dVINO " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/different-types-of-pneumonia-risk-treatments" aria-label="What is white lung syndrome? Here&#x27;s what to know about pneumonia" aria-describedby="Whatiswhitelungsyndrtags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur lIngG uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_4x3.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq seFhp WtEci "><div class="VZTD rEPuv QXDKT sAjcO " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="Whatiswhitelungsyndrtags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr " id="Whatiswhitelungsyndrheadline">What is white lung syndrome? Here&#x27;s what to know about pneumonia</h3></div></div></div></a></div><div class="liAe uMOq zYIfP pYgZk Mxrkk hsDdd lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ MpFZk " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv rEPuv ICwhc seFhp WtEci dVINO " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/long-covid-inflammation-immune-recover" aria-label="Is long COVID forever? A new study has clues." aria-describedby="IslongCOVIDforeverAntags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur lIngG uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_4x3.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq seFhp WtEci "><div class="VZTD rEPuv QXDKT sAjcO " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="IslongCOVIDforeverAntags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr " id="IslongCOVIDforeverAnheadline">Is long COVID forever? A new study has clues.</h3></div></div></div></a></div><div class="liAe uMOq zYIfP pYgZk Mxrkk hsDdd lZur TPpRg NoUSU igcMP DtJWr QgBvn DFdlJ MpFZk " data-testid="prism-card"><a class="iVcn UbGlr ibBnq qdXbA VZTD DbOXS tqUtK GpWVU iJYzE QGHKv rEPuv ICwhc seFhp WtEci dVINO " data-testid="prism-linkbase" href="https://www.nationalgeographic.com/premium/article/why-does-covid-19-cause-brain-fog-answer-immune-inflammation-synapse" aria-label="Why does COVID-19 cause brain fog? Scientists may finally have an answer." aria-describedby="WhydoesCOVID19causebtags"><div class="hsDdd GpQCA lZur BOsoU YMZw dihEb srtah LmIPo JzlZQ VbrfA zZsl kjmkg OwbFk QuuaM "><div class="GpQCA lZur lIngG uMOq " data-testid="prism-ratio-frame"><div class="FvQLF iLTd NqeUA UzzHi iWsMV "><img alt="" class="hsDdd " data-testid="prism-image" draggable="false" src="https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_4x3.jpg"/></div></div></div><div class="QGHKv iVcn VZTD rEPuv ICwhc ibBnq seFhp WtEci "><div class="VZTD rEPuv QXDKT sAjcO " data-testid="prism-meta"><div class="CJAFL gDeX "><div class="mLASH VZTD UeCOM wSnmx ltDkr MjHGf rmiAn vvBSK " id="WhydoesCOVID19causebtags"><div class="oFFrS ICOPq wPGsL ">SCIENCE</div></div><h3 class="PFoxV eBpQD rcQBv bQtjQ lQUdN GpQCA mAkiF FvMyr " id="WhydoesCOVID19causebheadline">Why does COVID-19 cause brain fog? Scientists may finally have an answer.</h3></div></div></div></a></div></div></div></div></div></div></div></div></div></div></div></main></div></div></div><div></div><div></div><div></div><div></div><div><div id="freemium-module-1" class="StackModule"><div class="ResponsiveWrapper" data-wrapping="Slider"></div></div></div><div><div id="8ab2946b-6e26-4eea-a4fa-e631c49cb678" class="StackModule"></div></div><div></div><div class="FrameBackgroundFull"><div class="FrameBackgroundFull__BackgroundImage" aria-hidden="true"><div class="BackgroundImage"><div class="RatioFrame aspect-ratio--16x9"></div></div></div><div class="GeneralContainer"><div></div></div></div><div class="FrameBackgroundFull"><div class="FrameBackgroundFull__BackgroundImage" aria-hidden="true"><div class="BackgroundImage"><div class="RatioFrame aspect-ratio--16x9"></div></div></div><div class="GeneralContainer"></div></div><div class="FrameBackgroundFull FrameBackgroundFull--dark"><div class="FrameBackgroundFull__BackgroundImage" aria-hidden="true"><div class="BackgroundImage"><div class="RatioFrame aspect-ratio--16x9"></div></div></div><div class="GeneralContainer GeneralContainer--fullWidth"><div id="natgeo-globalpromo-frame1-headline" class="StackModule"><div class="GeneralHeading GeneralHeading--dark"><h2 class="GeneralHeading__Header GeneralHeading__Header--caps">Go Further</h2><div class="GeneralHeading__Line"></div></div></div><div class="CarouselModule CarouselModule--dark"><div class="CarouselModule__CarouselContainer"><section class="Carousel relative Carousel--dark CarouselModule__Carousel--undefined CarouselModule__Carousel--center" aria-labelledby="CarouselModule__Carousel-natgeo-globalpromo-frame1-animals"><div class="Carousel__Header Carousel__Header--visible"><h3 id="CarouselModule__Carousel-natgeo-globalpromo-frame1-animals" class="Carousel__Heading">Animals</h3></div><div class="Carousel__Wrapper relative"><button aria-hidden="false" tabindex="0" type="button" class="CarouselArrow CarouselArrow--dark CarouselArrow--right"><svg focusable="false" aria-hidden="true" aria-label="Next" class="CarouselArrow__Icon icon__svg icon__svg--dark" viewBox="0 0 24 24"><use xlink:href="#icon__caret__right"></use></svg></button><div style="display:block;flex-grow:1;width:auto"><div class="Carousel__Outer relative flex overflow-hidden" role="listbox"><ul class="Carousel__Inner flex CarouselModule__Inner--padding items-center" style="transition:transform 350ms cubic-bezier(0.0, 0.0, 0.2, 1);margin-left:-20px;transform:translateX(0px)"><li class="CarouselSlide relative pointer CarouselSlide--active" style="margin:0 0 0 20px" role="option" data-carousel-id="0" aria-selected="true"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:top 4 myths about wolves, busted by experts" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/animals/article/myths-gray-wolves-north-america-predators"><span class="sr-only">Top 4 myths about wolves, busted by experts</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Top 4 myths about wolves, busted by experts</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="1" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:5 ways orcas are surprising scientists" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/orcas-hunting-sharks-killer-whales"><span class="sr-only">5 ways orcas are surprising scientists</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">5 ways orcas are surprising scientists</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="2" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:orangutan seen using plants to heal wound for first time" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/first-report-wound-treatment-wild-orangutan-using-medicinal-plant"><span class="sr-only">Orangutan seen using plants to heal wound for first time</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Orangutan seen using plants to heal wound for first time</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="3" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:what la palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/environment/article/life-lava-volcanic-eruption-la-palma"><span class="sr-only">What La Palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">What La Palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="4" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:this fungus turns cicadas into zombies who procreate—then die" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/animals/article/cicadas-fungus-massospora-parasite"><span class="sr-only">This fungus turns cicadas into zombies who procreate—then die</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">This fungus turns cicadas into zombies who procreate—then die</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="5" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:how can we protect grizzlies from their biggest threat—trains?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/animals/article/grizzly-bear-train-strikes-northern-rockies"><span class="sr-only">How can we protect grizzlies from their biggest threat—trains?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">How can we protect grizzlies from their biggest threat—trains?</div></div></div></div></li></ul></div></div></div></section></div></div><div class="CarouselModule CarouselModule--dark"><div class="CarouselModule__CarouselContainer"><section class="Carousel relative Carousel--dark CarouselModule__Carousel--undefined CarouselModule__Carousel--center" aria-labelledby="CarouselModule__Carousel-natgeo-globalpromo-frame1-environment"><div class="Carousel__Header Carousel__Header--visible"><h3 id="CarouselModule__Carousel-natgeo-globalpromo-frame1-environment" class="Carousel__Heading">Environment</h3></div><div class="Carousel__Wrapper relative"><button aria-hidden="false" tabindex="0" type="button" class="CarouselArrow CarouselArrow--dark CarouselArrow--right"><svg focusable="false" aria-hidden="true" aria-label="Next" class="CarouselArrow__Icon icon__svg icon__svg--dark" viewBox="0 0 24 24"><use xlink:href="#icon__caret__right"></use></svg></button><div style="display:block;flex-grow:1;width:auto"><div class="Carousel__Outer relative flex overflow-hidden" role="listbox"><ul class="Carousel__Inner flex CarouselModule__Inner--padding items-center" style="transition:transform 350ms cubic-bezier(0.0, 0.0, 0.2, 1);margin-left:-20px;transform:translateX(0px)"><li class="CarouselSlide relative pointer CarouselSlide--active" style="margin:0 0 0 20px" role="option" data-carousel-id="0" aria-selected="true"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:what la palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/environment/article/life-lava-volcanic-eruption-la-palma"><span class="sr-only">What La Palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">What La Palma&#x27;s &#x27;lava tubes&#x27; tell us about life on other planets</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="1" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:how fungi form ‘fairy rings’ and inspire superstitions" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/environment/article/mushroom-fungi-mycelium-fairy-rings-myth"><span class="sr-only">How fungi form ‘fairy rings’ and inspire superstitions</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">How fungi form ‘fairy rings’ and inspire superstitions</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="2" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:your favorite foods may not taste the same in the future. here&#x27;s why." data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/environment/article/food-flavor-climate-change"><span class="sr-only">Your favorite foods may not taste the same in the future. Here&#x27;s why.</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Your favorite foods may not taste the same in the future. Here&#x27;s why.</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="3" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:are the great lakes the key to solving america’s emissions conundrum?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/environment/article/climate-change-great-lakes-shipping-green-transportation"><span class="sr-only">Are the Great Lakes the key to solving America’s emissions conundrum?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Are the Great Lakes the key to solving America’s emissions conundrum?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="4" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:the world’s historic sites face climate change. can petra lead the way?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/petra-ancient-technology-climate-change-floods"><span class="sr-only">The world’s historic sites face climate change. Can Petra lead the way?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">The world’s historic sites face climate change. Can Petra lead the way?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="5" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:england’s iconic chalk streams are in trouble" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/chalk-streams-uk-conservation"><span class="sr-only">England’s iconic chalk streams are in trouble</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/environment"><span>Environment</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">England’s iconic chalk streams are in trouble</div></div></div></div></li></ul></div></div></div></section></div></div><div class="CarouselModule CarouselModule--dark"><div class="CarouselModule__CarouselContainer"><section class="Carousel relative Carousel--dark CarouselModule__Carousel--undefined CarouselModule__Carousel--center" aria-labelledby="CarouselModule__Carousel-natgeo-globalpromo-frame1-history"><div class="Carousel__Header Carousel__Header--visible"><h3 id="CarouselModule__Carousel-natgeo-globalpromo-frame1-history" class="Carousel__Heading">History &amp; Culture</h3></div><div class="Carousel__Wrapper relative"><button aria-hidden="false" tabindex="0" type="button" class="CarouselArrow CarouselArrow--dark CarouselArrow--right"><svg focusable="false" aria-hidden="true" aria-label="Next" class="CarouselArrow__Icon icon__svg icon__svg--dark" viewBox="0 0 24 24"><use xlink:href="#icon__caret__right"></use></svg></button><div style="display:block;flex-grow:1;width:auto"><div class="Carousel__Outer relative flex overflow-hidden" role="listbox"><ul class="Carousel__Inner flex CarouselModule__Inner--padding items-center" style="transition:transform 350ms cubic-bezier(0.0, 0.0, 0.2, 1);margin-left:-20px;transform:translateX(0px)"><li class="CarouselSlide relative pointer CarouselSlide--active" style="margin:0 0 0 20px" role="option" data-carousel-id="0" aria-selected="true"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:a short history of tennis skirts" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/history/article/tennis-skirt-sports-fashion"><span class="sr-only">A short history of tennis skirts</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history"><span>History & Culture</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">A short history of tennis skirts</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="1" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:your tile floor may contain human fossils" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/travertine-tile-floor-human-hominin-fossil"><span class="sr-only">Your tile floor may contain human fossils</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history"><span>History & Culture</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Your tile floor may contain human fossils</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="2" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:meet the ruthless king who unified the kingdom of hawai&#x27;i" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/king-kamehameha-hawaii-unification"><span class="sr-only">Meet the ruthless king who unified the Kingdom of Hawai&#x27;i</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history/magazine"><span>History Magazine</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Meet the ruthless king who unified the Kingdom of Hawai&#x27;i</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="3" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:hawaii&#x27;s lei day is about so much more than flowers" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/culture/article/lei-day-hawaii-native-plants-history"><span class="sr-only">Hawaii&#x27;s Lei Day is about so much more than flowers</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history"><span>History & Culture</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Hawaii&#x27;s Lei Day is about so much more than flowers</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="4" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:when treasure hunters find artifacts, who gets to keep them?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/amateur-treasure-hunters-record-artifacts-uk"><span class="sr-only">When treasure hunters find artifacts, who gets to keep them?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history"><span>History & Culture</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">When treasure hunters find artifacts, who gets to keep them?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="5" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:the short, sweet, and sticky history of jam" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/history/article/history-of-jam-meghan-markle-lifestyle"><span class="sr-only">The short, sweet, and sticky history of jam</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/history"><span>History & Culture</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">The short, sweet, and sticky history of jam</div></div></div></div></li></ul></div></div></div></section></div></div><div class="CarouselModule CarouselModule--dark"><div class="CarouselModule__CarouselContainer"><section class="Carousel relative Carousel--dark CarouselModule__Carousel--undefined CarouselModule__Carousel--center" aria-labelledby="CarouselModule__Carousel-natgeo-globalpromo-frame1-science"><div class="Carousel__Header Carousel__Header--visible"><h3 id="CarouselModule__Carousel-natgeo-globalpromo-frame1-science" class="Carousel__Heading">Science</h3></div><div class="Carousel__Wrapper relative"><button aria-hidden="false" tabindex="0" type="button" class="CarouselArrow CarouselArrow--dark CarouselArrow--right"><svg focusable="false" aria-hidden="true" aria-label="Next" class="CarouselArrow__Icon icon__svg icon__svg--dark" viewBox="0 0 24 24"><use xlink:href="#icon__caret__right"></use></svg></button><div style="display:block;flex-grow:1;width:auto"><div class="Carousel__Outer relative flex overflow-hidden" role="listbox"><ul class="Carousel__Inner flex CarouselModule__Inner--padding items-center" style="transition:transform 350ms cubic-bezier(0.0, 0.0, 0.2, 1);margin-left:-20px;transform:translateX(0px)"><li class="CarouselSlide relative pointer CarouselSlide--active" style="margin:0 0 0 20px" role="option" data-carousel-id="0" aria-selected="true"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:is cracking your knuckles really a bad habit?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/science/article/is-cracking-your-knuckles-a-bad-habit"><span class="sr-only">Is cracking your knuckles really a bad habit?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science"><span>Science</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Is cracking your knuckles really a bad habit?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="1" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:what is topical steroid withdrawal?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/science/article/topical-steroid-withdrawal-eczema-treatment"><span class="sr-only">What is topical steroid withdrawal?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science"><span>Science</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">What is topical steroid withdrawal?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="2" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:why ovaries are so crucial to women’s health and longevity" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/slow-aging-ovaries-delay-menopause-boost-brain-heart-health"><span class="sr-only">Why ovaries are so crucial to women’s health and longevity</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science"><span>Science</span></a></li><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science/topic/health"><span>Mind, Body, Wonder</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Why ovaries are so crucial to women’s health and longevity</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="3" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:orangutan seen using plants to heal wound for first time" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/first-report-wound-treatment-wild-orangutan-using-medicinal-plant"><span class="sr-only">Orangutan seen using plants to heal wound for first time</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/animals"><span>Animals</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Orangutan seen using plants to heal wound for first time</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="4" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:is long covid forever? a new study has clues." data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/premium/article/long-covid-inflammation-immune-recover"><span class="sr-only">Is long COVID forever? A new study has clues.</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science"><span>Science</span></a></li><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science/topic/coronavirus-coverage"><span>Coronavirus Coverage</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Is long COVID forever? A new study has clues.</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="5" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:how sound helps quiet your mind for meditation" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/science/article/sound-meditation-benefits"><span class="sr-only">How sound helps quiet your mind for meditation</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/science"><span>Science</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">How sound helps quiet your mind for meditation</div></div></div></div></li></ul></div></div></div></section></div></div><div class="CarouselModule CarouselModule--dark"><div class="CarouselModule__CarouselContainer"><section class="Carousel relative Carousel--dark CarouselModule__Carousel--undefined CarouselModule__Carousel--center" aria-labelledby="CarouselModule__Carousel-natgeo-globalpromo-frame1-travel"><div class="Carousel__Header Carousel__Header--visible"><h3 id="CarouselModule__Carousel-natgeo-globalpromo-frame1-travel" class="Carousel__Heading">Travel</h3></div><div class="Carousel__Wrapper relative"><button aria-hidden="false" tabindex="0" type="button" class="CarouselArrow CarouselArrow--dark CarouselArrow--right"><svg focusable="false" aria-hidden="true" aria-label="Next" class="CarouselArrow__Icon icon__svg icon__svg--dark" viewBox="0 0 24 24"><use xlink:href="#icon__caret__right"></use></svg></button><div style="display:block;flex-grow:1;width:auto"><div class="Carousel__Outer relative flex overflow-hidden" role="listbox"><ul class="Carousel__Inner flex CarouselModule__Inner--padding items-center" style="transition:transform 350ms cubic-bezier(0.0, 0.0, 0.2, 1);margin-left:-20px;transform:translateX(0px)"><li class="CarouselSlide relative pointer CarouselSlide--active" style="margin:0 0 0 20px" role="option" data-carousel-id="0" aria-selected="true"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:a slow journey around the islands of southern vietnam" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/waterways-islands-southern-vietnam"><span class="sr-only">A slow journey around the islands of southern Vietnam</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/travel"><span>Travel</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">A slow journey around the islands of southern Vietnam</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="1" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:is it possible to climb mount everest responsibly?" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/how-to-climb-mount-everest-himalayas-responsibly"><span class="sr-only">Is it possible to climb Mount Everest responsibly?</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/travel"><span>Travel</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Is it possible to climb Mount Everest responsibly?</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="2" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:what&#x27;s new in the alps this summer" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/what-to-do-in-alps-summer-trains-trails"><span class="sr-only">What&#x27;s new in the Alps this summer</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/travel"><span>Travel</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">What&#x27;s new in the Alps this summer</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="3" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:5 of uganda’s most magnificent national parks" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/paid-content-ugandas-most-magnificent-national-parks"><span class="sr-only">5 of Uganda’s most magnificent national parks</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--sponsor"><span class="Truncate Truncate--collapsed"><span>Paid Content</span></span></li></ul><div><div class="RegularStandardPrismTile__Title">5 of Uganda’s most magnificent national parks</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="4" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:these 5 health customs are protected by unesco" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/wellness-experiences-protected-unesco"><span class="sr-only">These 5 health customs are protected by UNESCO</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/travel"><span>Travel</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">These 5 health customs are protected by UNESCO</div></div></div></div></li><li class="CarouselSlide relative pointer" style="margin:0 0 0 20px" role="option" data-carousel-id="5" aria-selected="false"><div class="RegularStandardPrismTile RegularStandardPrismTile--dark"><div class="BackgroundImage BackgroundImage--zoom RegularStandardPrismTile__Image"><div class="RatioFrame aspect-ratio--3x2"></div><span class="BackgroundImage__Image BackgroundImage__Image--highRes"></span></div><a class="AnchorLink AnchorLink--dark RegularStandardPrismTile__ContentLink" tabindex="0" data-track-event_name=":card:where to eat in fez, morocco" data-track-placement="footer" data-track-story_title="Here’s the latest on COVID-19 vaccines" href="https://www.nationalgeographic.com/travel/article/where-to-eat-fez-morocco"><span class="sr-only">Where to eat in Fez, Morocco</span></a><div><ul class="SectionLabelWrapper RegularStandardPrismTile__SectionLabel SectionLabelWrapper--dark"><li class="SectionLabel SectionLabel--link"><a class="AnchorLink AnchorLink--dark" tabindex="0" href="https://www.nationalgeographic.com/travel"><span>Travel</span></a></li></ul><div><div class="RegularStandardPrismTile__Title">Where to eat in Fez, Morocco</div></div></div></div></li></ul></div></div></div></section></div></div></div></div></div></div></div></div><div><div id="natgeo-marketing-inline-email-footer-frame1-module2" class="StackModule"></div></div><div class="ResponsiveWrapper"><div class="GlobalFooter"><div class="GlobalFooter__Wrapper"><div class="GlobalFooter__Container GlobalFooter__Menu"><div class="GlobalFooter__Menu__List"><div><h4 class="GlobalFooter__Menu__List--title" aria-label="Legal">Legal</h4><ul role="presentation"><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Terms of Use" target="_self" rel="noopener" href="https://disneytermsofuse.com/english/">Terms of Use</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Privacy Policy" target="_self" rel="noopener" href="https://privacy.thewaltdisneycompany.com/en/current-privacy-policy/">Privacy Policy</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Your US State Privacy Rights" target="_self" rel="noopener" href="https://privacy.thewaltdisneycompany.com/en/current-privacy-policy/your-us-state-privacy-rights/">Your US State Privacy Rights</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Children&#x27;s Online Privacy Policy" target="_self" rel="noopener" href="https://disneyprivacycenter.com/kids-privacy-policy/english/">Children&#x27;s Online Privacy Policy</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Interest-Based Ads" target="_self" rel="noopener" href="http://preferences-mgr.trustarc.com/?pid=disney01&amp;aid=natgeo01&amp;type=natgeo">Interest-Based Ads</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="About Nielsen Measurement" target="_self" rel="noopener" href="http://www.nielsen.com/digitalprivacy">About Nielsen Measurement</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link ot-sdk-show-settings" tabindex="0" data-track-event_name="Do Not Sell or Share My Personal Information" target="_self" rel="noopener" href="https://privacy.thewaltdisneycompany.com/en/dnssmpi/">Do Not Sell or Share My Personal Information</a></li></ul></div></div><div class="GlobalFooter__Menu__List"><div><h4 class="GlobalFooter__Menu__List--title" aria-label="Our Sites">Our Sites</h4><ul role="presentation"><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Nat Geo Home" href="/">Nat Geo Home</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Attend a Live Event" target="_self" href="https://www.nationalgeographic.com/events/">Attend a Live Event</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Book a Trip" target="_self" href="https://www.nationalgeographic.com/expeditions/?cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=exp_hp::int_add=ngpexp201904-book-footer">Book a Trip</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Buy Maps" target="_self" rel="noopener" href="https://www.natgeomaps.com">Buy Maps</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Inspire Your Kids" target="_self" rel="noopener" href="https://kids.nationalgeographic.com">Inspire Your Kids</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Shop Nat Geo" target="_self" rel="noopener" href="https://www.shopdisney.com/franchises/national-geographic/">Shop Nat Geo</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Visit the D.C. Museum" target="_self" rel="noopener" href="https://www.nationalgeographic.org/tickets/events/">Visit the D.C. Museum</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Watch TV" target="_self" href="https://www.nationalgeographic.com/tv/">Watch TV</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Learn About Our Impact" href="/impact">Learn About Our Impact</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Support Our Mission" target="_self" rel="noopener" href="https://www.nationalgeographic.org/give/">Support Our Mission</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Masthead" target="_self" href="https://www.nationalgeographic.com/pages/article/masthead">Masthead</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Press Room" target="_self" rel="noopener" href="https://nationalgeographicpartners.com/press/">Press Room</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Advertise With Us" target="_self" rel="noopener" href="https://www.disneyadsales.com/our-brands/national-geographic/">Advertise With Us</a></li></ul></div></div><div class="GlobalFooter__Menu__List"><div><h4 class="GlobalFooter__Menu__List--title" aria-label="Join Us">Join Us</h4><ul role="presentation"><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Subscribe" href="/subscribe">Subscribe</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Customer Service" target="_self" rel="noopener" href="https://help.nationalgeographic.com/">Customer Service</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Renew Subscription" href="/renew">Renew Subscription</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Manage Your Subscription" target="_self" rel="noopener" href="https://ngmservice.com">Manage Your Subscription</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Work at Nat Geo" target="_self" href="https://www.nationalgeographic.com/pages/topic/careers">Work at Nat Geo</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Sign Up for Our Newsletters" target="_blank" href="/newsletters/signup?gblftr">Sign Up for Our Newsletters</a></li><li class="GlobalFooter__Menu__List__Item"><a class="AnchorLink GlobalFooter__Menu__List__Item--link" tabindex="0" data-track-event_name="Contribute to Protect the Planet" target="_blank" rel="noopener" href="https://give.nationalgeographic.org/page/53299/donate/1?user_id=wb8em7wclp2gec8f8rj9f6lp88q9dftd">Contribute to Protect the Planet</a></li></ul></div></div><div class="GlobalFooter__Menu__ConstantContainer"><div class="GlobalFooter__Menu__ConstantContainer--share"><h4 class="GlobalFooter__Menu__List--title" aria-label="Follow us">Follow us</h4><section class="Share flex flex-no-wrap"><button aria-label="National Geographic Instagram" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--instagram__v2" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__instagram__v2"></use></svg><span class="Share__Text">National Geographic Instagram</span></button><button aria-label="National Geographic Facebook" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--facebook__v2" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__facebook__v2"></use></svg><span class="Share__Text">National Geographic Facebook</span></button><button aria-label="National Geographic Twitter" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--x__v2" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__x__v2"></use></svg><span class="Share__Text">National Geographic Twitter</span></button><button aria-label="National Geographic Youtube" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--youtube" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__youtube"></use></svg><span class="Share__Text">National Geographic Youtube</span></button><button aria-label="National Geographic Linkedin" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--linkedin__v2" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__linkedin__v2"></use></svg><span class="Share__Text">National Geographic Linkedin</span></button><button aria-label="National Geographic Tiktok" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--tiktok" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__tiktok"></use></svg><span class="Share__Text">National Geographic Tiktok</span></button><button aria-label="National Geographic Reddit" class="Button Button--default Button--icon-noLabel Share__Item Share__Item--reddit" tabindex="0"><svg focusable="false" aria-hidden="true" class="Share__Icon icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__social__reddit"></use></svg><span class="Share__Text">National Geographic Reddit</span></button></section></div><div class="CountryModal"><div data-track-event_name="United States (Change)" class="fitt-tracker"><button aria-label="United States - Current Market" aria-expanded="false" class="Button--unstyled CountryModal__Button" tabindex="0"><svg focusable="false" aria-hidden="true" class="CountryModal__Button--flag icon__svg" viewBox="0 0 24 24"><use xlink:href="#icon__flag__united-states"></use></svg><span>United States (Change)</span></button></div></div></div></div><hr class="GlobalFooter--hr"/></div></div></div><div class="ResponsiveWrapper"><div class="GlobalFooter__CopyrightWrapper"><div class="GlobalFooter__Container GlobalFooter__Copyright"><div class="GlobalFooter__Copyright__Item GlobalFooter__Copyright__Item--logoContainer"><div data-track-event_name="National Geographic Logo" class="fitt-tracker"><a class="AnchorLink" tabindex="0" title="National Geographic Logo" href="/"><img alt="National Geographic Logo - Home" class="Image Logo GlobalFooter__Copyright__Logo Logo__lg" data-mptype="image" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7"/></a></div></div><div class="GlobalFooter__Copyright__Item GlobalFooter__Copyright__Item--textContainer"><p class="GlobalFooter__Copyright__Item--text"><span class="GlobalFooter__Copyright__Item--line">Copyright © 1996-2015 National Geographic Society</span><span class="GlobalFooter__Copyright__Item--line">Copyright © 2015-2024 National Geographic Partners, LLC. All rights reserved</span></p></div></div></div></div></div></div></div>
                
                <script>window['__CONFIG__']={"uid":"natgeo","strictMode":false,"mode":"universal","logLevel":"info","logOutput":"json","tms":{"enabled":true,"env":"dev","tag":"https://nexus.ensighten.com/TWDC-DTCI/dev/Bootstrap.js","tagNS":"Boostrapper","emitEvent":"tms:ready","loadScript":false,"loadAsync":true},"allowMocks":true,"globalVar":"__natgeo__","cdnPath":"//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client","buildHash":false,"http":{"timeout":{"client":10000}},"apiEnv":"production","envName":"prod","mockDataPort":1981,"host":"localhost","basename":"","collateXhr":{}};window['__natgeo__']={"app":{"uid":"natgeo","mode":"universal","apiEnv":"production","envName":"prod","cdnPath":"//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client","collateXhr":{},"allowMocks":true,"mockDataPort":1981,"excludePageCSS":false,"assets":{"chunks":["//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/runtime-8e78a3d0.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/2611-b3d18e55.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/9479-8e515628.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/7708-e245d62e.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/2919-7dbda4b0.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3460-d596d2df.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/5437-3035472d.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/19-a19cabee.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4257-3ac25efc.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1156-e472ade1.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1551-561798d8.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/1636-3f742790.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3021-90467b73.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/8330-6af310aa.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/5427-0bf927ab.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4162-192c0a75.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/9381-56e8d894.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/533-7f729090.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/4343-b87c7e66.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/3641-760c8582.js"],"entries":["//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/natgeo-fce9ec0b.js","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/prismarticle-27bb034e.js"],"css":["//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/fusion-d44ee4ef.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/2611-e4f72c35.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/natgeo-c05299b9.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/3460-8ff104de.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1156-52e2914a.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1551-74bf7284.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/5427-d6305e79.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/4162-313cf2d3.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/9381-70992203.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/4135-c77030ec.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/7023-52a0e8dc.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/533-43a9546c.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/1575-5ae1fd34.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/9991-fa6749ac.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/3641-672ae602.css","//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/css/prismarticle-635a74d8.css"]},"device":"desktop","modifier":"","edition":{"key":"natgeo-en-us","config":{"dateTime":{"long":"dddd MMMM D, yyyy","medium":"MMMM D, yyyy","short":"M/D","timeFormat":"h:mm","firstDayOfWeek":"Sunday","timeZone":"US/Eastern","timeZoneBucket":"America/New_York","defaultFormat":"MMM D, yyyy","timeZoneString":"ET","ddd, M/D":"ddd, M/D","MMM D":"MMM D","age":{"seconds":"s","minutes":"m","hours":"h","days":"d"}},"numberFormat":{"long":"#,###","short":"###","currency":"#,###.00","percent":"#.00%"},"temperature":{"scale":"fahrenheit","symbol":"&deg; F"},"analytics":{},"ads":{},"meta":{"titleBranding":"natgeo.meta.title.branding","description":"natgeo.meta.description","schema":{"name":""},"defaultMetaImage":"","social":{"twitter":{"twitterId":"@NatGeo","card":"summary","site":"@NatGeo","language":"en"},"facebook":{"og_site_name":"National Geographic","og_type":"website","locale":"en_US"}}},"appDetails":{"ios":{"id":"","name":"","deepLinkUrl":"","deepLinkUrlScheme":""},"android":{"id":"","name":"","deepLinkUrl":"","deepLinkUrlScheme":""}},"videoAutoStart":{"index":false},"activeSite":true,"countries":[{"name":"United States","country-code":"us"}],"oneId":{"clientId":"DTCI-NATGEO.CONSUMER.WEB","responderPage":"/responder_v4","responderPageStg":"/stg/responder_v4","loginReload":"off","optionalConfigs":{"reporting":{"context":"NATGEOCONSUMERWEB","source":"NATGEO_CONSUMER_WEB"}}},"editionSettings":{"key":"natgeo-en-us","site":"natgeo","language":"en","country":"us","domain":"www.nationalgeographic.com","editionSiteId":"1","https":false,"showPremVideoAds":true,"pccApiKey":"11mxera6h5cl7174b5nrs17ytr"},"javaLocale":{"language":"en","region":"US"}},"translations":{"alertBanner.closeButtonAriaLabel":"Close ${position} alert banner","ambientVideo.aria.labelWithTitle":"Silent Video for ${title}","ambientVideo.aria.label":"Silent Video ${counter}","article.facebookShare.ariaLabel":"Share on Facebook","article.facebookShare.label":"Share","article.meterText":"You have <span>${count} free articles</span> left this month.","article.meterText.fallback":"You're almost out of free articles this month","article.lastFreeArticleText":"This is your last free article this month.","article.minuteRead":"${minRead} min read","Audio":"Audio","audio.and":"and","audio.aria.label":"Audio Player","audio.elapsedOutOf":"elapsed out of","audio.hour":"hour","audio.hours":"hours","audio.min":"minute","audio.mins":"minutes","audio.muted":"Audio muted. Unmute","audio.pausingContent":"Pausing content. ${elapsedTime}. Play","audio.play":"Play","audio.playingContent":"Playing content. Pause","audio.position":"Audio position","audio.sec":"second","audio.secs":"seconds","audio.skipBackwards":"Skip Backward ${skipTime} Seconds","audio.skipForwards":"Skip Forwards ${skipTime} Seconds","audio.sliderDetails":"Use the left or right arrow keys to decrease or increase the slider value.","audio.unmuted":"Audio Unmuted. Mute","Average Life Span In The Wild":"Average Life Span In The Wild","axolotl image":"Axolotl image","Clear search bar":"Clear search bar","Click to Search Button":"Click to Search Button","Close Description Modal":"Close Description Modal","Common Name":"Common Name","common.search":"Search","common.changeText":"Change","Current population trend":"Current population trend","Diet":"Diet","Extinct":"Extinct","fastfacts.logo.altText":"${logoName} Logo","Gallery":"Gallery","Headlines":"Headlines","Image":"Image","Learn more about IUCN Threatened Species Designations":"Learn more about IUCN Threatened Species Designations","Least Concern":"Least Concern","login":"Login","media.playIcon.ariaLabel":"play","menumodal.close":"Close Menu","natgeo.article.datePublishedLabel":"Published","natgeo.contentGating.slider.downarrow.aria":"Collapse","natgeo.contentGating.slider.uparrow.aria":"Expand","natgeo.ctaText.explore":"Explore","natgeo.ctaText.learnMore":"Learn More","natgeo.ctaText.play":"Play","natgeo.ctaText.read":"Read","natgeo.ctaText.seeGuide":"See Guide","natgeo.ctaText.seeMore":"See More","natgeo.ctaText.seePhotos":"See Photos","natgeo.ctaText.watch":"Watch","natgeo.error.heading":"Something went wrong","natgeo.error.text":"Please try again or <a href=\"/\">return home</a>.","natgeo.facebookShare.ariaLabel":"National Geographic Facebook","natgeo.fastfacts.averageLifeSpan":"Average Life Span","natgeo.fastfacts.common":"Common Name","natgeo.fastfacts.currentPopulation.decreasing":"Decreasing","natgeo.fastfacts.currentPopulation.increasing":"Increasing","natgeo.fastfacts.currentPopulation.stable":"Stable","natgeo.fastfacts.diet":"Diet","natgeo.fastfacts.groupName":"Group Name","natgeo.fastfacts.details":"Details","natgeo.fastfacts.lifespan.captivity.avg.desc":"${low} to ${high} years","natgeo.fastfacts.lifespan.captivity.high.desc":"Up to ${high} years","natgeo.fastfacts.lifespan.captivity.median.desc":"${median} years","natgeo.fastfacts.lifespan.captivity.title":"Average Life Span In Captivity","natgeo.fastfacts.lifespan.wild.avg.desc":"${low} to ${high} years","natgeo.fastfacts.lifespan.wild.high.desc":"Up to ${high} years","natgeo.fastfacts.lifespan.wild.median.desc":"${median} years","natgeo.fastfacts.lifespan.wild.title":"Average Life Span In The Wild","natgeo.fastfacts.scientific":"Scientific Name","natgeo.fastfacts.size":"Size","natgeo.fastfacts.type":"Type","natgeo.fastfacts.weight":"Weight","natgeo.home.title":"home (en)","natgeo.instagramShare.ariaLabel":"National Geographic Instagram","natgeo.leadslide.homelink.alt":"National Geographic logo - Home","natgeo.leadslide.homelink.target":"National Geographic logo - Home","natgeo.leadslide.downarrow.aria":"Scroll to next slide","natgeo.linkedinShare.ariaLabel":"National Geographic Linkedin","natgeo.logo.alt":"National Geographic Logo","natgeo.logo.alt.kids":"National Geographic Kids Logo","natgeo.logo.title.kids":"National Geographic Kids","natgeo.mediaspotlight.description":"Media Spotlight pagetype description.","natgeo.mediaspotlight.title":"Nat Geo Photo of the Day","natgeo.meta.description.kids":"National Geographic Kids","natgeo.meta.description":"Explore National Geographic. A world leader in geography, cartography and exploration.","natgeo.meta.title.branding.kids":"National Geographic Kids","natgeo.meta.title.branding":"National Geographic","natgeo.redditShare.ariaLabel":"National Geographic Reddit","natgeo.search.aria.nav":"Search Pages","natgeo.search.aria.next":"Next Page","natgeo.search.aria.pageLink":"Page ${page}","natgeo.search.aria.previous":"Previous Page","natgeo.search.enter":"Enter","natgeo.search.next":"Next","natgeo.search.noResults.found.kids":"Sorry, we couldn't find any results for that search. Try one of these pages!","natgeo.search.noResults.found":"No results found.","natgeo.search.popularSearches":"Popular Searches","natgeo.search.previous":"Previous","natgeo.search.suggested.didYouMean":"Did you mean","natgeo.search.suggested.searchInstead":"Search instead for","natgeo.search.suggested.showingFor":"Showing results for","natgeo.signin.copy":"Sign in with your email","natgeo.signin.title":"Sign In to National Geographic","natgeo.snapchatShare.ariaLabel":"National Geographic Snapchat","natgeo.sponsorBanner.ariaLabel":"Sponsor Banner","natgeo.sponsorNote.ariaLabel":"Sponsor Note","natgeo.tiktokShare.ariaLabel":"National Geographic Tiktok","natgeo.twitterShare.ariaLabel":"National Geographic Twitter","natgeo.video.nowPlaying":"Now Playing","natgeo.video.readMore":"Read More","natgeo.video.upNext":"Up Next","natgeo.youtubeShare.ariaLabel":"National Geographic Youtube","or":"or","paywall.already.subscriber":"Already a Subscriber?","paywall.link.subscription":"subscription is linked","paywall.family.link.subscription":"Link your subscription","paywall.family.subscribers":"Already a Nat Geo Premium Subscriber?","paywall.magazine.subscribers":"Already signed in? Check that your","paywall.meter.collapse":"Collapse subscribe message","paywall.meter.expand":"Expand subscribe message","paywall.signin":"Sign In","promoTile.videoStory":"Video Story","Error: Please enter a valid e-mail address.":"Error: Please enter a valid e-mail address.","Please select at least one newsletter and click Sign Up.":"Please select at least one newsletter and click Sign Up.","Read Description":"Read Description","Scientific Name":"Scientific Name","Sign Up":"Sign Up","Size":"Size","Sponsor Content":"Sponsor Content","Table":"Table","trips":"trips","Type":"Type","UCN red list status":"UCN red list status","Video":"Video","video.title":"Video Player","Weight":"Weight","Close Fast Facts Modal":"Close Fast Facts Modal","Close Search Modal":"Close Search Modal","Close User Modal":"Close User Modal","Close":"Close"}},"flags":{"ftr":true,"hdr":true,"prxy":false,"mktg":true},"tms":{"enabled":true,"env":"dev","tag":"https://dcf.espn.com/TWDC-DTCI/prod/Bootstrap.js","tagNS":"Boostrapper","emitEvent":"tms:ready","loadScript":false,"loadAsync":true,"frameTag":"https://dcf.espn.com/TWDC-DTCI/embed_privacy_prod/Bootstrap.js"},"oneIdEnv":"prod","featureGating":{"ensighten":{"enabled":true,"ns":"Boostrapper","scriptTag":"https://dcf.espn.com/TWDC-DTCI/prod/Bootstrap.js","frameTag":"https://dcf.espn.com/TWDC-DTCI/embed_privacy_prod/Bootstrap.js"},"adConfig":{"enabled":true,"insertedAdLimit":null,"insertedAdSpacing":900,"pzn":{"mode":"ltd","extra":true},"refreshInterval":30},"contentExclusions":{"disable":false},"sponsoredContent":{"enabled":true},"uvpUpgrade":{"enabled":false},"intrctvSlctrs":{"fullPage":{"key":"fullPage","value":"div:not(#natgeo)"},"markup":[{"key":"class=\"leaflet-container ","value":"div#map"}],"spredfast":{"key":"spredfast","value":"iframe"}},"intrctvAllowedSrcs":{"facebook":{"src":["//connect.facebook.net/en_US/sdk.js","//facebook.com/plugins/","//facebook.com/video/embed?video_id=","//interactives.natgeofe.com/","//www.facebook.com/plugins/","//www.facebook.com/video/embed?video_id="]},"fullPage":{"src":["//interactives.natgeofe.com/"]},"game":{"src":["//images.nationalgeographic.com/","//interactives.natgeofe.com/","//nationalgeographic.com/","//www.nationalgeographic.com/","//cdn1.edgedatg.com/"]},"iHeartRadio":{"src":["//iheart.com/podcast/","//interactives.natgeofe.com/","//www.iheart.com/podcast/"]},"instagram":{"src":["//instagram.com/p/","//instagram.com/embed.js","//interactives.natgeofe.com/","//platform.instagram.com/en_US/embeds.js","//www.instagram.com/embed.js"]},"markup":{"href":["//api.tiles.mapbox.com/mapbox-gl-js/","//fonts.googleapis.com/css?family=","//fonts.ngeo.com/","//interactives.natgeofe.com/","//nationalgeographic.com/","//ngm.nationalgeographic.com/","//s3.amazonaws.com/ng-plastic-prod","//www.nationalgeographic.com/"],"src":["//ajax.googleapis.com/ajax/libs/jquery/","//api.tiles.mapbox.com/mapbox-gl-js/","//assets.documentcloud.org/viewer/loader.js","//d3js.org/d3","//fonts.ngeo.com/","//images.nationalgeographic.com/","//interactives.natgeofe.com/","//nationalgeographic.com/","//news.nationalgeographic.com/","//ngm.nationalgeographic.com/","//platform.vine.co/static/scripts/embed.js","//s3.amazonaws.com/ng-plastic-prod","//www.nationalgeographic.com/"]},"soundCloud":{"src":["//interactives.natgeofe.com/","//soundcloud.com/","//w.soundcloud.com/"]},"source":{"src":["//interactives.natgeofe.com/"]},"spredfast":{"href":["//interactives.natgeofe.com/"],"src":["//interactives.natgeofe.com/"]},"twitter":{"src":["//interactives.natgeofe.com/","//platform.twitter.com/","//twitter.com/","//www.twitter.com/"]},"vimeo":{"src":["//interactives.natgeofe.com/","//player.vimeo.com/","//vimeo.com/moogaloop.swf?clip_id=","//www.vimeo.com/moogaloop.swf?clip_id="]}}},"debug":{"on":false},"baseURL":"https://www.nationalgeographic.com","webpack":{}},"ads":{},"analytics":{},"routing":{"location":{"pathname":"/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","port":"","hash":"","path":"/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","host":"","protocol":"","params":"","query":{}},"params":{"section":"science","slug":"coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","pageType":"prismarticle"}},"page":{"key":"","title":"","type":"prismarticle","meta":{"canonical":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","description":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","hrefLangs":[{"lcl":"en-us","url":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"}],"ogMetadata":{"type":"article","sclDsc":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","sclTtl":"Here’s the latest on COVID-19 vaccines","sclImg":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg?w=1200","sclImgHgt":675,"sclImgWdth":1200,"sctn":"Science","twtHndl":"@NatGeo","twttrCrd":"summary_large_image","pgTypDta":{"article:published_time":"10-29-2021","article:modified_time":"11-05-2021","article:section":"Science"}},"title":"Here’s the latest on COVID-19 vaccines","section":"science","subSection":"","section3":"","section4":"","pageName":"natgeo:science:prismarticle","id":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a"},"content":{"footer":{"frms":[{"id":"natgeo-marketing-inline-email-footer-frame1","mods":[{"id":"natgeo-marketing-inline-email-footer-frame1-module2","cmsType":"StackModule","align":"left","edgs":[{"id":"natgeo-marketing-inline-email-footer-frame1-module2-tile1","cmsType":"EmailInlineTile","title":"The best of National Geographic delivered to your inbox","backgroundImage":"https://i.natgeofe.com/n/2e2421a3-f3cb-485f-b482-753cce8baaa0/MossForest.adapt.885.1.jpg","errorMessage":"Please enter a valid e-mail address.","mrktngMeta":{"cpgnCd":"20210217_global_inline_email_signup_footer"},"placeholder":"Enter your email","subtitle":"Sign up for more inspiring photos, stories, and special offers from National Geographic.","success":{"description":"<p>Watch your inbox over the next few days for photos, stories, and special offers from us.<p>","header":"Thanks for signing up!"},"submitButton":"Sign Up","closeableGeos":{}}]}],"placement":"footer","chldOptns":{"bannerPlacement":"footer"}},{"placement":"footer","logoObj":{"key":"logoObj","alt":"National Geographic Logo - Home","href":"/","title":null,"logo":{"image":{"crps":[{"nm":"raw","aspRto":3.4364261168384878,"url":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}],"rt":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png","src":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}},"mobileLogo":{"image":{"crps":[{"nm":"raw","aspRto":3.4364261168384878,"url":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}],"rt":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png","src":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}}},"id":"natgeo-footer","cmsType":"FooterFrame","mods":[{"mnu":[{"title":"Legal","links":[{"url":"https://disneytermsofuse.com/english/","isExternal":null,"title":"Terms of Use"},{"url":"https://privacy.thewaltdisneycompany.com/en/current-privacy-policy/","isExternal":null,"title":"Privacy Policy"},{"url":"https://privacy.thewaltdisneycompany.com/en/current-privacy-policy/your-us-state-privacy-rights/","isExternal":null,"title":"Your US State Privacy Rights"},{"url":"https://disneyprivacycenter.com/kids-privacy-policy/english/","isExternal":null,"title":"Children's Online Privacy Policy"},{"url":"http://preferences-mgr.trustarc.com/?pid=disney01&aid=natgeo01&type=natgeo","isExternal":null,"title":"Interest-Based Ads"},{"url":"http://www.nielsen.com/digitalprivacy","isExternal":null,"title":"About Nielsen Measurement"},{"url":"https://privacy.thewaltdisneycompany.com/en/dnssmpi/","isExternal":null,"title":"Do Not Sell or Share My Personal Information","style":"ot-sdk-show-settings"}]},{"title":"Our Sites","links":[{"url":"/","isExternal":null,"title":"Nat Geo Home"},{"url":"https://www.nationalgeographic.com/events/","isExternal":null,"title":"Attend a Live Event"},{"url":"https://www.nationalgeographic.com/expeditions/?cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=exp_hp::int_add=ngpexp201904-book-footer","isExternal":null,"title":"Book a Trip"},{"url":"https://www.natgeomaps.com","isExternal":null,"title":"Buy Maps"},{"url":"https://kids.nationalgeographic.com","isExternal":null,"title":"Inspire Your Kids"},{"url":"https://www.shopdisney.com/franchises/national-geographic/","isExternal":null,"title":"Shop Nat Geo"},{"url":"https://www.nationalgeographic.org/tickets/events/","isExternal":null,"title":"Visit the D.C. Museum"},{"url":"https://www.nationalgeographic.com/tv/","isExternal":null,"title":"Watch TV"},{"url":"/impact","isExternal":null,"title":"Learn About Our Impact"},{"url":"https://www.nationalgeographic.org/give/","isExternal":null,"title":"Support Our Mission"},{"url":"https://www.nationalgeographic.com/pages/article/masthead","isExternal":null,"title":"Masthead"},{"url":"https://nationalgeographicpartners.com/press/","isExternal":null,"title":"Press Room"},{"url":"https://www.disneyadsales.com/our-brands/national-geographic/","isExternal":null,"title":"Advertise With Us"}]},{"title":"Join Us","links":[{"url":"/subscribe","isExternal":false,"title":"Subscribe"},{"url":"https://help.nationalgeographic.com/","isExternal":false,"title":"Customer Service"},{"url":"/renew","isExternal":false,"title":"Renew Subscription"},{"url":"https://ngmservice.com","isExternal":false,"title":"Manage Your Subscription"},{"url":"https://www.nationalgeographic.com/pages/topic/careers","isExternal":false,"title":"Work at Nat Geo"},{"url":"/newsletters/signup?gblftr","isExternal":true,"title":"Sign Up for Our Newsletters","target":"_blank"},{"url":"https://give.nationalgeographic.org/page/53299/donate/1?user_id=wb8em7wclp2gec8f8rj9f6lp88q9dftd","isExternal":true,"title":"Contribute to Protect the Planet","target":"_blank"}]}]},{"edtnSltr":{"rgns":[{"title":"Europe","countries":[{"title":"Bulgaria","flag":{"icon":"flag__bulgaria","alt":"bu"},"links":[{"url":"https://www.natgeotv.com/bg","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.nationalgeographic.bg/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Croatia","flag":{"icon":"flag__croatia","alt":"cr"},"links":[{"url":"https://www.natgeotv.com/hr","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.adriamedia.hr/izdanja/national-geographic-hrvatska","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Czech Republic","flag":{"icon":"flag__czech-republic","alt":"cz"},"links":[{"url":"https://www.natgeotv.com/cz","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.national-geographic.cz","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Denmark","flag":{"icon":"flag__denmark","alt":"de"},"links":[{"url":"https://www.natgeotv.com/dk","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Estonia","flag":{"icon":"flag__estonia","alt":"es"},"links":[{"url":"http://www.nationalgeographic.ee","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Finland","flag":{"icon":"flag__finland","alt":"fi"},"links":[{"url":"https://www.natgeotv.com/fi","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"France","flag":{"icon":"flag__france","alt":"fr"},"links":"https://www.nationalgeographic.fr"},{"title":"Georgia","flag":{"icon":"flag__georgia","alt":"ge"},"links":[{"url":"http://www.nationalgeographic.ge","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Germany","flag":{"icon":"flag__germany","alt":"ge"},"links":"https://www.nationalgeographic.de"},{"title":"Greece","flag":{"icon":"flag__greece","alt":"gr"},"links":[{"url":"https://www.natgeotv.com/gr","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Hungary","flag":{"icon":"flag__hungary","alt":"hu"},"links":[{"url":"https://www.natgeotv.com/hu","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.ng.hu","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Israel","flag":{"icon":"flag__israel","alt":"is"},"links":[{"url":"https://www.natgeotv.com/il","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Italy","flag":{"icon":"flag__italy","alt":"it"},"links":"http://www.nationalgeographic.it"},{"title":"Kazakhstan","flag":{"icon":"flag__kazakhstan","alt":"ka"},"links":[{"url":"https://www.nationalgeographic.kz","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Lithuania","flag":{"icon":"flag__lithuania","alt":"li"},"links":[{"url":"https://www.nationalgeographic.lt","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Netherlands","flag":{"icon":"flag__netherlands","alt":"ne"},"links":"https://www.nationalgeographic.nl"},{"title":"Norway","flag":{"icon":"flag__norway","alt":"no"},"links":[{"url":"https://www.natgeotv.com/no","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Poland","flag":{"icon":"flag__poland","alt":"po"},"links":[{"url":"https://www.natgeotv.com/pl","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.national-geographic.pl","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Portugal","flag":{"icon":"flag__portugal","alt":"po"},"links":[{"url":"https://www.natgeotv.com/pt","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://nationalgeographic.sapo.pt","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Romania","flag":{"icon":"flag__romania","alt":"ro"},"links":[{"url":"https://www.natgeotv.com/ro","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.natgeo.ro/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Russia","flag":{"icon":"flag__russia","alt":"ru"},"links":[{"url":"https://www.natgeotv.com/ru","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.nat-geo.ru/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Serbia","flag":{"icon":"flag__serbia","alt":"se"},"links":[{"url":"https://www.natgeotv.com/rs","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.nationalgeographic.rs/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Slovenia","flag":{"icon":"flag__slovenia","alt":"sl"},"links":[{"url":"https://www.natgeotv.com/si","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.nationalgeographic.si/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Spain","flag":{"icon":"flag__spain","alt":"sp"},"links":[{"url":"https://www.nationalgeographic.es/","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.nationalgeographic.com.es/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Sweden","flag":{"icon":"flag__sweden","alt":"sw"},"links":[{"url":"https://www.natgeotv.com/se","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Turkey","flag":{"icon":"flag__turkey","alt":"tu"},"links":[{"url":"https://www.natgeotv.com/tr","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.nationalgeographic.com.tr/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"United Kingdom","flag":{"icon":"flag__united-kingdom","alt":"uk"},"links":"https://www.nationalgeographic.co.uk/"}]},{"title":"The Americas","countries":[{"title":"Brazil","flag":{"icon":"flag__brazil","alt":"br"},"links":[{"url":"https://www.nationalgeographicbrasil.com/","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Canada","flag":{"icon":"flag__canada","alt":"ca"},"links":[{"url":"https://www.natgeotv.com/ca","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Mexico","flag":{"icon":null,"alt":"mx"},"links":[{"url":"https://www.ngenespanol.com/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Pan-Regional Latin America (Spanish)","flag":{"icon":null,"alt":"pa"},"links":"https://www.nationalgeographicla.com/"},{"title":"United States","flag":{"icon":"flag__united-states","alt":"us"},"links":"/"}]},{"title":"Asia, Australia & Oceania","countries":[{"title":"Australia","flag":{"icon":"flag__australia","alt":"au"},"links":[{"url":"https://www.nationalgeographic.com.au","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Mainland China","flag":{"icon":null,"alt":"ch"},"links":[{"url":"https://www.natgeo.com.cn/","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.ngchina.com.cn/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Hong Kong","flag":{"icon":null,"alt":"ho"},"links":[{"url":"https://www.natgeotv.com/hk","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"India","flag":{"icon":"flag__india","alt":"in"},"links":[{"url":"https://www.natgeotv.com/in","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.amarchitrakatha.com/in/magazines/national-geographic/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Indonesia","flag":{"icon":"flag__indonesia","alt":"in"},"links":[{"url":"https://nationalgeographic.grid.id/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Japan","flag":{"icon":"flag__japan","alt":"ja"},"links":[{"url":"http://www.ngcjapan.com/tv/","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.nationalgeographic.jp","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Korea","flag":{"icon":"flag__south-korea","alt":"ko"},"links":[{"url":"http://www.ngckorea.com","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.nationalgeographic.co.kr/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Pan-Regional Asia (English)","flag":{"icon":null,"alt":"pa"},"links":[{"url":"https://www.natgeotv.com/asia","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Taiwan","flag":{"icon":null,"alt":"ta"},"links":[{"url":"https://www.fng.tw/ngc/","isExternal":false,"title":"Channel","target":"_self"},{"url":"https://www.natgeomedia.com/","isExternal":false,"title":"Magazine","target":"_self"}]},{"title":"Thailand","flag":{"icon":"flag__thailand","alt":"th"},"links":[{"url":"http://www.ngthai.com","isExternal":false,"title":"Magazine","target":"_self"}]}]},{"title":"Middle East & Africa","countries":[{"title":"Farsi","flag":{"icon":null,"alt":"fa"},"links":[{"url":"https://www.natgeotv.com/farsi","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Persian","flag":{"icon":null,"alt":"pe"},"links":[{"url":"https://www.natgeotv.com/persian","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"South Africa","flag":{"icon":"flag__south-africa","alt":"so"},"links":[{"url":"https://www.natgeotv.com/za","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Middle East (English)","flag":{"icon":null,"alt":"mi"},"links":[{"url":"https://www.natgeotv.com/ae","isExternal":false,"title":"Channel","target":"_self"}]},{"title":"Middle East (Arabic)","flag":{"icon":null,"alt":"mi"},"links":[{"url":"https://www.natgeotv.com/me","isExternal":false,"title":"Channel","target":"_self"},{"url":"http://www.ngalarabiya.com","isExternal":false,"title":"Magazine","target":"_self"}]}]}],"crnt":{"title":"United States","flag":{"icon":"flag__united-states","alt":"us"},"links":"/"},"key":"edtnSltr"},"shrURLs":{"key":"shrURLs","fb":"https://www.facebook.com/natgeo","fbLabel":"natgeo.facebookShare.ariaLabel","fbIcon":"facebook__v2","fbButtonTracking":{"event_name":"share","share_method":"facebook","content_title":""},"twitter":"https://twitter.com/natgeo/","twitterLabel":"natgeo.twitterShare.ariaLabel","twitterIcon":"x__v2","twitterButtonTracking":{"event_name":"share","share_method":"twitter","content_title":""},"instagram":"https://www.instagram.com/natgeo/","instagramLabel":"natgeo.instagramShare.ariaLabel","instagramIcon":"instagram__v2","instagramButtonTracking":{"event_name":"share","share_method":"instagram","content_title":""},"tiktok":"https://www.tiktok.com/@natgeo?lang=en","tiktokLabel":"natgeo.tiktokShare.ariaLabel","tiktokButtonTracking":{"event_name":"share","share_method":"tiktok"},"youtube":"https://www.youtube.com/@NatGeo","youtubeLabel":"natgeo.youtubeShare.ariaLabel","youtubeButtonTracking":{"event_name":"share","share_method":"youtube"},"linkedin":"https://www.linkedin.com/company/national-geographic","linkedinLabel":"natgeo.linkedinShare.ariaLabel","linkedinIcon":"linkedin__v2","linkedinButtonTracking":{"event_name":"share","share_method":"linkedin"},"reddit":"https://www.reddit.com/r/nationalgeographic/s/7yv1etDW6q","redditLabel":"natgeo.redditShare.ariaLabel","redditButtonTracking":{"event_name":"share","share_method":"reddit"}}}]},{"placement":"footer","id":"frame10","mods":[{"logoObj":{"key":"logoObj","alt":"National Geographic Logo - Home","href":"/","title":null,"logo":{"image":{"crps":[{"nm":"raw","aspRto":3.4364261168384878,"url":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}],"rt":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png","src":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}},"mobileLogo":{"image":{"crps":[{"nm":"raw","aspRto":3.4364261168384878,"url":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}],"rt":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png","src":"https://i.natgeofe.com/n/4da26b5c-18ee-413f-96dd-4cf3fb4a68a0/2fl-white.png"}}},"cprt":{"key":"cprt","txt":["Copyright © 1996-2015 National Geographic Society","Copyright © 2015-2024 National Geographic Partners, LLC. All rights reserved"]}}],"cmsType":"CopyrightFrame"}]},"header":{"frms":[{"id":"natgeo-global-header-frame1","placement":"header","chldOptns":{"bannerPlacement":"header"}},{"placement":"header","id":"natgeo-nav","mods":[{"logoObj":{"key":"logoObj","alt":"National Geographic Logo - Home","href":"/","title":"National Geographic","logo":{"image":{"crps":[{"nm":"raw","aspRto":3.404255319148936,"url":"https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png"}],"rt":"https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png","src":"https://i.natgeofe.com/n/e76f5368-6797-4794-b7f6-8d757c79ea5c/ng-logo-2fl.png"}},"mobileLogo":{"image":{"crps":[{"nm":"raw","aspRto":0.7,"url":"https://i.natgeofe.com/n/1852daf6-1c8d-4428-8ee2-d9a82bd0401c/ng-border.png"}],"rt":"https://i.natgeofe.com/n/1852daf6-1c8d-4428-8ee2-d9a82bd0401c/ng-border.png","src":"https://i.natgeofe.com/n/1852daf6-1c8d-4428-8ee2-d9a82bd0401c/ng-border.png"}}},"usr":{"key":"usr","links":[{"url":"#oneid-profile","title":"Account Settings"},{"url":"https://w1.buysub.com/servlet/ECareGateway?cds_mag_code=NGM&cds_page_id=226717&cds_misc_1=NGM","title":"Manage Your Subscription"},{"url":"/subscribe/link-subscription","title":"Link Your Subscription"},{"url":"https://help.nationalgeographic.com/s/","title":"Help","target":"_blank"},{"url":"#oneid-logout","title":"Log Out"}],"lnk":{"url":"#oneid-login"}},"srch":{"title":null,"icon":null,"href":"/search","key":"srch","shw":true},"rnw":{"key":"rnw","shw":true,"title":"Newsletters","url":"https://www.nationalgeographic.com/newsletters/signup"},"sbcrb":{"key":"sbcrb","shw":true,"title":"Subscribe","url":"/subscribe"},"mnu":{"undefined":{"title":"","links":[{"url":"/subscribe","title":"Subscribe"},{"url":"/renew","title":"Renew"}]},"prmMnu":{"key":"prmMnu","title":"Topics","links":[{"url":"/animals","title":"Animals"},{"url":"/environment","title":"Environment"},{"url":"/history","title":"History & Culture"},{"url":"/science","title":"Science"},{"url":"/travel","title":"Travel"}]},"secMnu":{"key":"secMnu","title":"Sites","links":[{"url":"https://www.nationalgeographic.com/tv/","title":"Watch TV!"},{"url":"/magazine","title":"Read The Magazine"},{"url":"/family","title":"Visit Nat Geo Family"},{"url":"https://www.nationalgeographic.com/expeditions/","title":"Book A Trip"},{"url":"https://kids.nationalgeographic.com","title":"Inspire your Kids"},{"url":"/podcasts/overheard","title":"Listen to Podcasts"},{"url":"https://www.shopdisney.com/franchises/national-geographic/","title":"Shop Nat Geo"},{"url":"https://www.nationalgeographic.com/events/","title":"Attend a Live Event"},{"url":"/impact/","title":"Learn About Our Impact"},{"url":"https://www.nationalgeographic.org/give/","title":"Support Our Mission"}]},"key":"mnu"},"cmsType":"NavModule"}],"cmsType":"NavFrame"},{"id":"e17aa8d2-d11b-4156-88f1-93b2a532cac9","className":"stickyFrame stickyFrame--bottom","placement":"header","chldOptns":{"bannerPlacement":"footer"}}]},"prismarticle":{"frms":[{"id":"natgeo-template1-frame-1","mods":[{"id":"natgeo-template1-frame-1-module-1","cmsType":"StackModule","align":"left","edgs":[{"dvdr":{"hideLogo":true},"cmsType":"ArticleBodyTile","id":"natgeo-template1-frame-1-module-1","bdy":[{"id":"editors-notetracker-no-longer-being-updated","cntnt":{"id":"editors-notetracker-no-longer-being-updated","cmsType":"editorsNote","note":"<p><b>Editor’s note:</b> As of November 2021, this COVID-19 vaccine tracker is no longer being updated. <a href=\"https://www.nationalgeographic.com/science/article/covid-vaccines-latest-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Stay up-to-date on the latest vaccine developments and other COVID-19 news here</a>.</p>"},"type":"inline","style":{}},{"id":"inline-1","cntnt":{"lnkHrefs":["//interactives.natgeofe.com/vendor/css/partial-aem-main.css"],"cmsType":"markup","ariaLabel":"markup","align":"contentWidth","envNme":"prod","mrkup":"JTNDbGluayUyMHJlbCUzRCUyMnN0eWxlc2hlZXQlMjIlMjBocmVmJTNEJTIyLy9pbnRlcmFjdGl2ZXMubmF0Z2VvZmUuY29tL3ZlbmRvci9jc3MvcGFydGlhbC1hZW0tbWFpbi5jc3MlMjIlM0UlMEElM0NociUyMHN0eWxlJTNEJTIyJXUyMDFDd2lkdGglM0E1MCUyNSUzQiUyMiUyMGJvcmRlci10b3AlM0ExcHglMjBzb2xpZCUyMCUyM2NjYyUzQiUyMG1hcmdpbiUzQTFlbSUyMGF1dG8lM0IldTIwMUQlM0U=","qryStr":"forceMode=fitt","placement":"inline"},"type":"inline","style":{}},{"id":"html0","cntnt":{"mrkup":"COVID-19 vaccines have reached consumers in record time. Though the process can typically take <a href=\"https://www.weforum.org/agenda/2020/06/vaccine-development-barriers-coronavirus/\">10 to 15 years</a>, the U.S. Food and Drug Administration has granted emergency authorization to vaccines made by Pfizer, Moderna, and Johnson &amp; Johnson in less than a year. Before now, the fastest-ever vaccine—for mumps—<a href=\"https://www.nationalgeographic.com/science/article/why-coronavirus-vaccine-could-take-way-longer-than-a-year\">took four years</a> to develop in the 1960s."},"type":"p","style":{}},{"id":"html1","cntnt":{"mrkup":"Fortunately, scientists had started working on the seeds of these vaccines long before COVID-19 emerged–teams were doing <a href=\"https://www.nationalgeographic.com/science/article/these-scientists-spent-twelve-years-solving-puzzle-yielded-coronavirus-vaccines\" target=\"_blank\">breakthrough work on mRNA technology for 12 years</a> before the pandemic, and a global push to make clinical trials for COVID-19 more efficient helped ensure the world had safe, effective drugs in record time."},"type":"p","style":{}},{"id":"html2","cntnt":{"mrkup":"Even after a vaccine is authorized or fully licensed, it faces potential roadblocks when it comes to scaling up production and distribution, which also includes <a href=\"https://hub.jhu.edu/2020/07/01/covid-vaccine-ethics-faden/\">deciding which populations should get it first</a>—and at what cost."},"type":"p","style":{}},{"id":"html3","cntnt":{"mrkup":"Here’s everything you need to know—including primers on how vaccines and clinical trials work, the latest news on vaccine distribution and safety, and a detailed breakdown of the early candidates."},"type":"p","style":{}},{"id":"html4","cntnt":{"mrkup":"Vaccines and clinical trials<a id=\"vaccineclinicaltrials\"></a>"},"type":"h2","style":{}},{"id":"html5","cntnt":{"mrkup":"Vaccines go through <a href=\"https://www.cdc.gov/vaccines/basics/test-approve.html\" target=\"_blank\">a three-stage clinical trial process</a> that’s required before they are sent to regulatory agencies for approval. Given the urgent need, some vaccine developers compressed the clinical process for SARS-CoV-2 by running trial phases simultaneously."},"type":"p","style":{}},{"id":"listicle: clinical trial process","cntnt":{"cmsType":"listicle","id":"listicle: clinical trial process","hasCopyright":true,"text":"<p><b>Phase one:</b> Checks the safety of a vaccine and determines whether it triggers an immune response in a small group of healthy humans.&nbsp;</p><p><b>Phase two:</b> Widens the testing pool to include groups of people who may have the disease or be more likely to catch it, to gauge the vaccine’s effectiveness.&nbsp;</p><p><b>Phase three:</b> Expands the pool up to the thousands to make sure the vaccine is safe and effective among a wider array of people, given that immune response can vary by age, ethnicity, or by underlying health conditions.</p>","title":"VACCINE CLINICAL TRIAL PROCESS"},"type":"inline","style":{}},{"id":"html6","cntnt":{"mrkup":"The COVID-19 candidates, like all vaccines, essentially aim to instruct the immune system to mount a defense, which is sometimes <a href=\"https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-safety/immune-system-and-health\">stronger than what would be provided through natural infection</a> and <a href=\"https://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/\">comes</a> with <a href=\"https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html\">fewer health consequences</a>."},"type":"p","style":{}},{"id":"html7","cntnt":{"mrkup":"To do so, traditional vaccines use the whole coronavirus, but in a killed or weakened state. Others use only part of the virus—whether a protein or a fragment. Some transfer the instructions for coronavirus proteins into an unrelated virus that is unlikely or even incapable of causing disease. Finally, cutting-edge vaccines under development rely on deploying pieces of the coronavirus’s genetic material, enabling our cells to temporarily make coronavirus proteins needed to stimulate our immune systems. (<a href=\"https://www.nationalgeographic.com/science/article/searching-for-coronavirus-vaccine-how-would-it-work\">Find out more about vaccines and how they work</a>.)"},"type":"p","style":{}},{"id":"listicle: types of vaccine","cntnt":{"cmsType":"listicle","id":"listicle: types of vaccine","hasCopyright":true,"text":"<p><b>Nucleic acid:</b> Relies on injecting snippets of a virus’s genetic material, either DNA or messenger RNA (mRNA), into human cells. It spurs the production of viral proteins that mimic features of the coronavirus, training the immune system to recognize its presence.&nbsp;</p><p><b>Knocked-out virus:</b> Uses a non-infectious form of the coronavirus that can no longer cause full-blown disease but can still provoke an immune response. The virus can either be fully inactivated or weakened. These modes are considered the most classic ways to make vaccines.</p><p><b>Viral vector:</b> Essentially a “Trojan horse” presented to the immune system. One type involves introducing a piece of DNA from SARS-CoV-2 into another unrelated germ—for example, an adenovirus, which typically causes the common cold. When this modified adenovirus is injected into humans, the hope is that it will instruct cells to make coronavirus proteins and will trigger an immune response.</p><p><b>Protein:</b> These vaccines are typically made from coronavirus proteins, which can be synthesized or brewed in labs like beer. Some versions involve coating a carrier—such as nanoparticles—with proteins to better aid delivery and uptake by cells.</p>","title":"TYPES OF VACCINES"},"type":"inline","style":{}},{"id":"html8","cntnt":{"mrkup":"U.S. vaccine rollout<a id=\"vaccinerollout\"></a>"},"type":"h2","style":{}},{"id":"html9","cntnt":{"mrkup":"Three COVID-19 vaccines are available for use in the United States. U.S. regulators have approved Pfizer’s vaccine for adults and authorized it for emergency use in children and adolescents ages five to 17. The U.S. has also granted emergency use authorization to administer the Moderna and Johnson &amp; Johnson vaccines to adults."},"type":"p","style":{}},{"id":"html10","cntnt":{"mrkup":"Some populations in the country are eligible for booster doses. Anyone who received a Johnson &amp; Johnson single-shot jab can get a second dose after at least two months. People who received the Pfizer and Moderna vaccines are eligible for a third dose after six months if they are over 65 or have an underlying condition that makes them more susceptible to severe COVID-19. People whose institutional or occupational settings put them at high risk of exposure to the coronavirus may also get a booster shot. U.S. regulators have permitted people to mix-and-match their jabs in the wake of data suggesting that people who originally received the Johnson &amp; Johnson vaccine are protected by a booster dose of the Pfizer or Moderna vaccines."},"type":"p","style":{}},{"id":"html11","cntnt":{"mrkup":"U.S. regulators have also recommended a third dose of the Pfizer and Moderna vaccines for people with compromised immune systems. This extra dose is considered part of their primary vaccination series; CDC guidance <a href=\"https://www.nbcnews.com/health/health-news/immunocompromised-people-can-receive-4th-covid-shot-cdc-says-rcna3933\" target=\"_blank\">suggests</a> that immunocompromised people will be able to get a fourth booster dose six months after completing the primary series.<a href=\"https://www.npr.org/sections/health-shots/2021/09/02/1033299418/cdc-warns-against-off-label-use-of-covid-vaccine\" target=\"_blank\"></a>"},"type":"p","style":{}},{"id":"html12","cntnt":{"mrkup":"Global vaccine rollout"},"type":"h2","style":{}},{"id":"html13","cntnt":{"mrkup":"The World Health Organization is coordinating global efforts to administer vaccines, with an eye toward <a href=\"https://www.who.int/news-room/detail/26-06-2020-act-accelerator-update\" target=\"_blank\">delivering two billion doses</a> by the end of 2021. It is leading an initiative through the COVAX Facility to ensure that all countries have equitable access. The WHO has approved the Pfizer-BioNTech, AstraZeneca-Oxford, Johnson &amp; Johnson, Moderna, Sinopharm, Sinovac, and Bharat Biotech vaccines for emergency use."},"type":"p","style":{}},{"id":"html14","cntnt":{"mrkup":"Vaccine safety"},"type":"h2","style":{}},{"id":"html15","cntnt":{"mrkup":"On July 13, the U.S. Food and Drug Administration <a href=\"https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021\" target=\"_blank\">added a warning label</a> to Johnson &amp; Johnson’s vaccine after it was linked to rare cases of Guillain-Barré Syndrome, an autoimmune disorder that can lead to paralysis. There have been 100 preliminary reports of the syndrome among the approximately 12.5 million people who have received the vaccine. The FDA said that the benefits of receiving the vaccine outweigh the risks."},"type":"p","style":{}},{"id":"html16","cntnt":{"mrkup":"The FDA has also added a warning label to the Pfizer and Moderna vaccines about <a href=\"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly\" target=\"_blank\">rare cases of heart inflammation</a> in adolescents and young adults. The move came after the CDC’s Advisory Committee on Immunization Practices <a href=\"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly\" target=\"_blank\">announced</a> that it has identified more than 300 cases of myocarditis and pericarditis that it acknowledged are likely linked to the vaccines. The agency says these cases are rare but higher than expected. It also said the benefits of the shots outweigh the risks."},"type":"p","style":{}},{"id":"html17","cntnt":{"mrkup":"&nbsp;In April, the European Medicines Agency issued statements saying that unusual blood clots should be listed as a very rare but possible side effect of both the <a href=\"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood\" target=\"_blank\">AstraZeneca</a> and <a href=\"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood\" target=\"_blank\">Johnson &amp; Johnson</a> vaccines. In a review of 86 reported cases related to the AstraZeneca vaccine, the EMA’s safety committee found a potential link between it and the clots, with most known cases occurring in women under age 60 within two weeks of receiving the first dose. The EMA stressed that the odds of developing a clot after vaccination are extremely low, and that the benefits of getting vaccinated outweigh the risks. They also recommend that people seek immediate medical attention if they experience symptoms related to clotting, including persistent pain, shortness of breath, and headaches or blurred vision."},"type":"p","style":{}},{"id":"html18","cntnt":{"mrkup":"On August 27, a study published in the <i>British Medical Journal</i> affirmed the EMA’s risk-benefit analysis, showing that there’s <a href=\"https://www.bmj.com/content/374/bmj.n1931\" target=\"_blank\">a much higher risk of developing blood clots after SARS-CoV-2</a> infection than after immunization with the AstraZeneca or Pfizer vaccines."},"type":"p","style":{}},{"id":"html19","cntnt":{"mrkup":"On August 11, the CDC officially recommended that <a href=\"https://www.cdc.gov/media/releases/2021/s0811-vaccine-safe-pregnant.html\" target=\"_blank\">people who are pregnant, breastfeeding, or may become pregnant get a COVID-19 vaccine</a>. A new analysis of data from the vaccine rollout found no increased risk of miscarriage among people who received an mRNA vaccine before 20 weeks of pregnancy. Earlier studies also showed that the vaccine is safe later in pregnancy as well—for both pregnant people and their babies. The CDC <a href=\"https://emergency.cdc.gov/han/2021/han00453.asp\" target=\"_blank\">emphasized the urgency of vaccination among these groups</a> in a health alert issued on September 29, reporting new data showing a rise in COVID-19-related deaths among pregnant people."},"type":"p","style":{}},{"id":"html20","cntnt":{"mrkup":"Vaccine prospects<a id=\"vaccineprospects\"></a>"},"type":"h2","style":{}},{"id":"html21","cntnt":{"mrkup":"Here are some of the vaccines that have made it to phase three and beyond:"},"type":"p","style":{}},{"id":"html22","cntnt":{"mrkup":"<a href=\"https://www.pfizer.com/science/coronavirus/vaccine\" target=\"_blank\"><b>Pfizer</b></a>"},"type":"h2","style":{}},{"id":"html23","cntnt":{"mrkup":"<b>Name:&nbsp;</b>BNT162b2&nbsp;"},"type":"p","style":{}},{"id":"html24","cntnt":{"mrkup":"<b>Who:</b> One of the world’s largest pharmaceutical companies, based in New York, in collaboration with German biotech company BioNTech."},"type":"p","style":{}},{"id":"html25","cntnt":{"mrkup":"<b>What:&nbsp;</b>A nucleic-acid vaccine that requires two doses taken 21 days apart.&nbsp;"},"type":"p","style":{}},{"id":"html26","cntnt":{"mrkup":"<b>Approval status:</b> On December 2, the U.K. became <a href=\"https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine\" target=\"_blank\">the first Western country</a> to approve any COVID-19 vaccine when it authorized the Pfizer-BioNTech candidate—making the drug the first mRNA vaccine in history allowed for human use. The FDA <a href=\"https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html?action=click&amp;module=Top Stories&amp;pgtype=Homepage\" target=\"_blank\">granted emergency use authorization&nbsp;</a>to this vaccine on December 11, 2020, and fully approved it on August 23, 2021. The vaccine has also been <a href=\"https://www.cbc.ca/news/politics/vaccine-rollout-plan-phac-1.5833912\" target=\"_blank\">granted emergency approval</a> in Canada, the <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union\" target=\"_blank\">European Union</a>, and other countries."},"type":"p","style":{}},{"id":"html27","cntnt":{"mrkup":"U.S. regulators have also approved Pfizer’s vaccine for emergency use in children and adolescents ages five to 15. U.K. regulators have also <a href=\"https://www.reuters.com/world/uk/uk-approves-pfizerbiontech-covid-shot-12-15-year-olds-2021-06-04/\" target=\"_blank\">approved</a> this vaccine for use among adolescents ages 12 to 15, while the European Union <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european\" target=\"_blank\">granted conditional authorization</a>."},"type":"p","style":{}},{"id":"html28","cntnt":{"mrkup":"As of September 24 U.S. regulators granted emergency use authorization of a third dose of Pfizer’s vaccine—but only for certain subgroups of the national population, including older people and those with underlying conditions that put them at higher risk of disease and for people in occupational or institutional settings that put them at high risk of infection, such as health-care workers and teachers."},"type":"p","style":{}},{"id":"html29","cntnt":{"mrkup":"<b>Distribution:</b> Globally, Pfizer expects to be able to produce up to 1.3 billion doses by the end of 2021. Questions have been raised over the vaccine’s storage, which requires ultra-cold freezers set at minus 70 degrees Celsius (-94 degrees F). On February 19, however, Pfizer and BioNTech <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data\" target=\"_blank\">said</a> that their vaccine can remain stable for two weeks at temperatures between minus 25℃ and minus 15℃ (-13℉ to 5℉), a common range in pharmaceutical freezers and refrigerators. The finding would allow for easier distribution of the vaccine in communities where ultra-cold storage requirements present a challenge.&nbsp;"},"type":"p","style":{}},{"id":"html30","cntnt":{"mrkup":"<b>Efficacy:&nbsp;</b>On September 20, Pfizer <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results\" target=\"_blank\">announced</a> that a study of its clinical trials shows its vaccine is safe and highly effective in children ages five to 11. Researchers determined that two low doses administered three weeks apart elicit high levels of neutralizing antibodies among children, with side effects comparable to those seen in people ages 16 to 25. The 10-milligram doses of vaccine are a third of what has been approved among older age groups. The company later <a href=\"https://www.fda.gov/media/153409/download\" target=\"_blank\">released</a> an analysis of its clinical trials showing that the vaccine is 90.7 percent effective in preventing symptomatic disease among kids in this age group."},"type":"p","style":{}},{"id":"html31","cntnt":{"mrkup":"Pfizer also expects to release data soon on how well its vaccine works among children ages six months to five years, according to CEO Albert Bourla. In a public forum, he said the data <a href=\"https://www.cnbc.com/2021/09/14/pfizers-covid-vaccine-data-for-kids-under-age-5-may-come-in-late-october-ceo-says-.html\" target=\"_blank\">could be available as early as the end of October</a>."},"type":"p","style":{}},{"id":"html32","cntnt":{"mrkup":"On August 25, Pfizer announced new data showing that <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission\" target=\"_blank\">a third dose of its vaccine generates robust quantity of neutralizing antibodies</a> that is more than three times higher than what was observed one month after the second dose."},"type":"p","style":{}},{"id":"html33","cntnt":{"mrkup":"A preprint study out of the United Kingdom shows that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant <a href=\"https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf\" target=\"_blank\">but that their efficacy wanes over time</a>. Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, the both vaccines still significantly reduce the risk of infection.&nbsp;"},"type":"p","style":{}},{"id":"html34","cntnt":{"mrkup":"On July 8, a study published in <i>Nature</i> demonstrated that people who have received both doses of the Pfizer or AstraZeneca vaccines <a href=\"https://www.nature.com/articles/s41586-021-03777-9\" target=\"_blank\">remain fully protected against severe disease, hospitalization, and death</a> from the Delta and Beta variants. However, a single dose of either vaccine was not as protective."},"type":"p","style":{}},{"id":"html35","cntnt":{"mrkup":"The findings corroborate an earlier study <a href=\"https://www.nature.com/articles/s41586-021-03738-2_reference.pdf\" target=\"_blank\">published in <i>Nature</i></a> showing that the Pfizer and Moderna vaccines elicit “robust and prolonged” immune responses. <a href=\"https://www.nytimes.com/2021/06/28/health/coronavirus-vaccines-immunity.html?partner=slack&amp;smid=sl-share\" target=\"_blank\">As the <i>New York Times</i> reported at the time</a>, the findings suggested that people who are immunized with these vaccines may not need booster shots as protection may last for years so long as the virus doesn’t mutate to evade it."},"type":"p","style":{}},{"id":"html36","cntnt":{"mrkup":"On June 10, a study <a href=\"https://www.nature.com/articles/s41586-021-03693-y\" target=\"_blank\">published in the journal <i>Nature</i></a> showed that two doses of the Pfizer vaccine protects against several virus variants, including the <a href=\"https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/\" target=\"_blank\">Delta and Eta variants</a>. The news came a few days after the CDC <a href=\"https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html\" target=\"_blank\">announced</a> that the Pfizer and Moderna vaccines reduce the risk of infection by 91 percent for fully vaccinated people.&nbsp;"},"type":"p","style":{}},{"id":"html37","cntnt":{"mrkup":"In April, the CDC <a href=\"https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_e&amp;ACSTrackingID=USCDC_921-DM53321&amp;ACSTrackingLabel=MMWR Early Release - Vol. 70, March 29, 2021&amp;deliveryName=USCDC_921-DM53321\" target=\"_blank\">released a study</a> of the U.S. vaccine rollout showing that the Pfizer-BioNTech and Moderna vaccines are 90 percent effective in preventing symptomatic COVID-19 in real-world conditions. The study analyzed the efficacy of the two mRNA vaccines among nearly 4,000 health-care workers, first responders, and other frontline workers who were the first to receive the jab in the U.S. It also showed the vaccines are 80-percent effective after one dose. The findings confirmed earlier studies from <a href=\"https://www.nytimes.com/live/2021/02/26/world/covid-19-coronavirus#pfizer-vaccine-protection\" target=\"_blank\">the U.K.</a> and <a href=\"https://www.thelancet.com/action/showPdf?pii=S0140-6736(21)00448-7\" target=\"_blank\">Israel</a>."},"type":"p","style":{}},{"id":"html38","cntnt":{"mrkup":"On December 10, the <i>New England Journal of Medicine</i> <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2034577\" target=\"_blank\">published</a> the results of Pfizer’s phase three study, showing the vaccine was safe and 95-percent effective in protecting against COVID-19 in people 16 and older. Pfizer and BioNTech have also <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal\" target=\"_blank\">announced</a> that a phase three trial shows that their vaccine is safe and 100 percent efficacious among children between the ages of 12 and 15, and that it elicited robust antibody responses.&nbsp;"},"type":"p","style":{}},{"id":"html39","cntnt":{"mrkup":"<b>Safety:&nbsp;</b>On June 23, the U.S. Food and Drug Administration <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/\" target=\"_blank\">said</a> it plans to add a warning label to the Pfizer and Moderna vaccines about <a href=\"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly\" target=\"_blank\">rare cases of heart inflammation</a> in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks."},"type":"p","style":{}},{"id":"html40","cntnt":{"mrkup":"Severe allergic reactions following immunization with the Pfizer-BioNTech vaccine have been reported in many countries. White House advisor Anthony Fauci <a href=\"https://www.cnbc.com/video/2020/12/16/dr-anthony-fauci-with-meg-tirrell-for-special-edition-of-healthy-returns.html\" target=\"_blank\">told CNBC</a> in December that some adverse reactions are expected when a vaccine is distributed to a wider population. Regulators in the U.S. and U.K. have also released reports offering reassurances that severe reactions are rare."},"type":"p","style":{}},{"id":"html41","cntnt":{"mrkup":"<b>Clinical trials status:</b> On November 18, Pfizer and BioNTech <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine\" target=\"_blank\">announced</a> the conclusion of their phase three trials. The trials <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0\" target=\"_blank\">launched in July</a>, enrolling a diverse population in areas with significant SARS-CoV-2 transmission. Pfizer later <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19\" target=\"_blank\">expanded the trial&nbsp;</a>to include 44,000 people across multiple countries.&nbsp;"},"type":"p","style":{}},{"id":"html42","cntnt":{"mrkup":"On February 18, Pfizer and BioNTech <a href=\"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate\" target=\"_blank\">announced</a> the launch of a phase two/three clinical trial to study the vaccine’s safety and efficacy among 4,000 pregnant women over the age of 18. The companies also launched a phase 1/2/3 study in children between the ages of six months and 11 years."},"type":"p","style":{}},{"id":"html43","cntnt":{"mrkup":"On June 8, Pfizer <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-start-large-study-test-covid-19-vaccine-children-below-12-2021-06-08/\" target=\"_blank\">said</a> that it would expand its clinical trials to a larger group of children under age 12. After a phase one study showed that the vaccine was safe and effective in a group of 144 children, the clinical trials enrolled up to 4,500 children at more than 90 sites in the U.S., Finland, Poland, and Spain. Pfizer tested a dose of 10 micrograms in children ages 5 to 11, and three micrograms for children from six months to five years old.&nbsp;"},"type":"p","style":{}},{"id":"html44","cntnt":{"mrkup":"On July 8, Pfizer and Biotech <a href=\"https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-provide-update-booster-program-light-delta\" target=\"_blank\">announced</a> that they are developing an updated version of the vaccine <a href=\"https://cdn.pfizer.com/pfizercom/2021-07/Delta_Variant_Study_Press_Statement_Final_7.8.21.pdf?IPpR1xZjlwvaUMQ9sRn2FkePcBiRPGqw\" target=\"_blank\">that specifically targets the Delta variant</a>."},"type":"p","style":{}},{"id":"html45","cntnt":{"mrkup":"<a href=\"https://www.jnj.com/coronavirus\" target=\"_blank\"><b>Johnson &amp; Johnson</b></a>"},"type":"h2","style":{}},{"id":"html46","cntnt":{"mrkup":"<b>Name:&nbsp;</b>JNJ-78436735"},"type":"p","style":{}},{"id":"html47","cntnt":{"mrkup":"<b>Who:&nbsp;</b>One of the world’s largest multinational corporations, based in New Jersey, specializing in healthcare and pharmaceutical products."},"type":"p","style":{}},{"id":"html48","cntnt":{"mrkup":"<b>What:</b> A single-dose vector vaccine. (<a href=\"https://www.nationalgeographic.com/science/article/johnson-johnson-us-third-vaccine-how-it-works\" target=\"_blank\">Here’s how the Johnson &amp; Johnson vaccine works</a>.)"},"type":"p","style":{}},{"id":"html49","cntnt":{"mrkup":"<b>Approval status:</b> Approved for use in the U.S., <a href=\"https://www.reuters.com/article/us-health-coronavirus-bahrain/bahrain-first-to-approve-johnson-johnson-covid-19-vaccine-for-emergency-use-regulator-idUSKBN2AP21X?feedType=RSS&amp;feedName=healthNews\" target=\"_blank\">Bahrain</a>, Canada, and the European Union."},"type":"p","style":{}},{"id":"html50","cntnt":{"mrkup":"On October 21 the CDC cleared the way for the U.S. to begin rolling out booster shots of Johnson &amp; Johnson’s vaccine for all people ages 18 and older at least two months after a first dose.&nbsp;"},"type":"p","style":{}},{"id":"html51","cntnt":{"mrkup":"U.S. regulators also authorized mixing and matching vaccines—such as administering booster doses of the either Moderna or Pfizer vaccine to people who originally received the Johnson &amp; Johnson vaccine. A <a href=\"https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf\" target=\"_blank\">preprint analysis of a National Institutes of Health study</a> shows that a booster dose of the mRNA vaccines elicit a stronger immune response than another dose of the Johnson &amp; Johnson shot.&nbsp;"},"type":"p","style":{}},{"id":"html52","cntnt":{"mrkup":"<b>Distribution:</b> On March 2, the U.S. <a href=\"https://www.washingtonpost.com/politics/2021/03/02/joe-biden-live-updates/\" target=\"_blank\">announced</a> that Johnson &amp; Johnson has partnered with its competitor Merck to increase the supply of its COVID-19 vaccine. Merck will dedicate two facilities to producing the vaccine, which could double the amount of available doses. Biden said that the additional doses will allow the U.S. to vaccinate all adults by the end of May.&nbsp;"},"type":"p","style":{}},{"id":"html53","cntnt":{"mrkup":"On June 11, the <i>New York Times</i> reported that the FDA <a href=\"https://www.nytimes.com/live/2021/06/11/world/covid-vaccine-coronavirus-mask\" target=\"_blank\">has told</a> Johnson &amp; Johnson to throw out 60 million doses made at its plant in Baltimore. The news came a day after <a href=\"https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine\" target=\"_blank\">CNN reported</a> that the U.S. hasn’t sent any shipments of the vaccine since the first week of May due to a lack of supply caused by earlier issues at the plant. On June 10, Johnson &amp; Johnson also <a href=\"https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine\" target=\"_blank\">announced</a> that the FDA has approved an extension of the shelf life of its vaccine from three to four and a half months.&nbsp;"},"type":"p","style":{}},{"id":"html54","cntnt":{"mrkup":"<b>Efficacy:</b> In September 2021 Johnson &amp; Johnson <a href=\"https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s\" target=\"_blank\">announced</a> results of its studies of booster doses. When administered two months after the first jab, the booster is 100 percent effective against severe disease and causes antibody levels to rise four to six times higher than after the first shot. The second dose was also shown to be 75 percent effective against all symptomatic disease globally and 94 percent effective in the U.S. The company said that a booster shot administered six months after the first dose produced a 12-fold increase in antibody levels."},"type":"p","style":{}},{"id":"html55","cntnt":{"mrkup":"The company also said that real-world evidence shows that its single-dose vaccine remains effective against COVID-19. The press release cited <a href=\"https://www.medrxiv.org/content/10.1101/2021.09.10.21263385v2\" target=\"_blank\">a study published to a preprint server</a>, which shows that the vaccine remains 79 percent effective in preventing COVID-19 and 81 percent effective in preventing hospitalizations. An earlier study conducted by Johnson &amp; Johnson <a href=\"https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response\" target=\"_blank\">shows</a> that its vaccine offers strong protection against Delta that lasts for at least eight months.&nbsp;"},"type":"p","style":{}},{"id":"html56","cntnt":{"mrkup":"However, on July 20, the <i>New York Times</i> reported on a preliminary study showing that <a href=\"https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html?partner=slack&amp;smid=sl-share\" target=\"_blank\">Johnson &amp; Johnson’s vaccine is less effective against the Delta and Lambda variants</a> than it was against the original virus strain. The paper notes that the results were obtained in a lab experiment and may not reflect the vaccine’s real-world efficacy."},"type":"p","style":{}},{"id":"html57","cntnt":{"mrkup":"On February 24, an FDA analysis <a href=\"https://www.fda.gov/media/146217/download\" target=\"_blank\">confirmed</a> Johnson &amp; Johnson’s earlier report that its vaccine is safe and effective in preventing COVID-19. The report found the vaccine is 72-percent effective in preventing COVID-19 based on U.S. trials, and 85-percent effective in preventing severe disease across all regions. It also shows that the vaccine was 64-percent effective in preventing disease in the company’s South African trials, which is higher than had previously been reported."},"type":"p","style":{}},{"id":"html58","cntnt":{"mrkup":"On June 9, a study <a href=\"https://www.nature.com/articles/s41586-021-03681-2\" target=\"_blank\">published in the journal <i>Nature</i></a> showed that Johnson &amp; Johnson’s vaccine is effective in protecting against virus variants, including the <a href=\"https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/\" target=\"_blank\">Beta and Gamma variants of concern</a>. The study showed that the vaccine elicits neutralizing antibodies and a T-cell response among people who live in areas where the variants are widely circulating, including Brazil and South Africa.&nbsp;"},"type":"p","style":{}},{"id":"html59","cntnt":{"mrkup":"<b>Safety:</b> On July 13, U.S. regulators <a href=\"https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021\" target=\"_blank\">added a warning to Johnson &amp; Johnson’s vaccine</a> in response to rare reports linking the shot to Guillain-Barré Syndrome, a disorder in which the body’s immune system attacks the nerves. The FDA said there have been about a hundred preliminary reports of the syndrome among the 12.8 million people who have received the Johnson &amp; Johnson vaccine. It added that the benefits of receiving the vaccine still outweigh the risks.&nbsp;"},"type":"p","style":{}},{"id":"html60","cntnt":{"mrkup":"CDC officials told the <i>Washington Post</i> that the cases <a href=\"https://www.washingtonpost.com/health/2021/07/12/johnson-and-johnson-warning/\" target=\"_blank\">have mostly been reported about two weeks after vaccination among men</a>, many aged 50 or older, and that these cases will be discussed during an upcoming meeting of the CDC’s advisory committee.&nbsp;"},"type":"p","style":{}},{"id":"html61","cntnt":{"mrkup":"In the spring, the vaccine’s rollout was briefly halted <a href=\"https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine\" target=\"_blank\">in the U.S.</a> and across Europe as regulators investigated reports of blood clotting among people who have received the shot. The FDA and CDC reviewed 15 cases of blood clots. The cases—which the agencies noted are “extremely rare”—occurred in women between the ages of 18 and 48 within six to 13 days after vaccination. The Europeans Medicines Agency also said that the cases it <a href=\"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021\" target=\"_blank\">reviewed</a> occurred in people under 60—mostly women—within three weeks of vaccination.&nbsp;"},"type":"p","style":{}},{"id":"html62","cntnt":{"mrkup":"On April 23, the U.S. FDA and CDC <a href=\"https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough\" target=\"_blank\">lifted the pause</a> on Johnson &amp; Johnson’s vaccine and said that immunizations can resume immediately. The agencies said that the risk of blood clots is “very low” and that the benefits of getting the vaccine outweigh the risks. It will add information about the increased risk of blood clots to the vaccine’s label. The decision came days after the European Medicines Agency <a href=\"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood\" target=\"_blank\">said</a> that blood clots should be listed as a “very rare” side effect of Johnson &amp; Johnson’s COVID-19 vaccine.&nbsp;"},"type":"p","style":{}},{"id":"html63","cntnt":{"mrkup":"<b>Clinical trials status:</b> On September 23, 2020, Johnson &amp; Johnson <a href=\"https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate\" target=\"_blank\">announced</a> the launch of its phase three “ENSEMBLE” trial to evaluate the safety of the vaccine—and how well it works—among up to 60,000 adults from a variety of countries. The trial included “significant representation” from older populations and those with underlying conditions that make them more susceptible to COVID-19.&nbsp;"},"type":"p","style":{}},{"id":"html64","cntnt":{"mrkup":"On October 12, 2020, Johnson &amp; Johnson <a href=\"https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials\" target=\"_blank\">announced</a> that it paused phase three trials for an independent safety review due to an unexplained illness in a participant. The company didn’t provide any details, in part to protect the patient’s privacy, but said that illnesses and accidents are expected in large clinical studies. What’s more, study pauses are routine for clinical trials <a href=\"https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/\" target=\"_blank\">and aren’t typically reported</a>. Later that month, the company <a href=\"https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us\" target=\"_blank\">announced</a> it would resume trials, which were <a href=\"https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled\" target=\"_blank\">fully enrolled</a> with 45,000 participants by December 17."},"type":"p","style":{}},{"id":"html65","cntnt":{"mrkup":"On November 15, 2020, Johnson &amp; Johnson <a href=\"https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate\" target=\"_blank\">launched a second phase three trial</a> to study the safety and efficacy of a two-dose regimen of its vaccine candidate in up to 30,000 volunteers worldwide. The study intends to assess whether a second dose of the vaccine will offer longer-lasting protection."},"type":"p","style":{}},{"id":"html66","cntnt":{"mrkup":"On April 2, Johnson &amp; Johnson <a href=\"https://www.jnj.com/johnson-johnson-expands-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents\" target=\"_blank\">announced</a> that it has begun vaccinating children age 12 to 17 as part of its phase 2a clinical trial. The company said it will initially test the vaccine in adolescents age 16 to 17 before expanding it to younger children."},"type":"p","style":{}},{"id":"html67","cntnt":{"mrkup":"<a href=\"https://www.modernatx.com/\" target=\"_blank\"><b>Moderna Therapeutics</b></a>"},"type":"h2","style":{}},{"id":"html68","cntnt":{"mrkup":"<b>Name:</b> mRNA-1273&nbsp;"},"type":"p","style":{}},{"id":"html69","cntnt":{"mrkup":"<b>Who:&nbsp;</b>A Massachusetts-based biotech company, in collaboration with the National Institutes of Health."},"type":"p","style":{}},{"id":"html70","cntnt":{"mrkup":"<b>What:</b> A nucleic-acid vaccine that requires two doses.&nbsp;"},"type":"p","style":{}},{"id":"html71","cntnt":{"mrkup":"<b>Approval status:</b> On December 18, the FDA <a href=\"https://www.washingtonpost.com/health/2020/12/17/covid-fda-moderna-vaccine-2/\" target=\"_blank\">granted emergency approval</a> to Moderna’s COVID-19 vaccine, making it the second available in the United States. The vaccine has also been approved in the <a href=\"https://www.cnn.com/2021/01/06/europe/moderna-approval-eu-intl/index.html\" target=\"_blank\">European Union</a>, <a href=\"https://investors.modernatx.com/news-releases/news-release-details/health-canada-authorizes-moderna-covid-19-vaccine-canada\" target=\"_blank\">Canada</a>, the <a href=\"https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator\" target=\"_blank\">U.K.</a>, <a href=\"https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use\" target=\"_blank\">Israel</a>, and <a href=\"https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified\" target=\"_blank\">by the WHO</a>."},"type":"p","style":{}},{"id":"html72","cntnt":{"mrkup":"On October 21 the CDC cleared the way for some people to get booster shots of the Moderna vaccine. The agency endorsed the FDA’s emergency use authorization of booster doses for all people ages 65 and older, as well as those ages 18 to 64 who are at risk of severe COVID-19 because of their underlying conditions. It also includes people ages 18 to 64 who are at high risk of exposure because of where they work or live, such as health-care workers or incarcerated people."},"type":"p","style":{}},{"id":"html73","cntnt":{"mrkup":"Moderna has <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-initiation-rolling-submission-biologics\" target=\"_blank\">applied for full FDA approval</a> of its COVID-19 vaccine for use in people age 18 and older. The company also plans to file for emergency use authorization for teens ages 12 to 17.&nbsp;"},"type":"p","style":{}},{"id":"html74","cntnt":{"mrkup":"On October 5, Moderna <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-european-medicines-agency-authorizes-third\" target=\"_blank\">announced</a> that European Union regulators have authorized a third dose of its COVID-19 vaccine for “severely immunocompromised” people ages 12 and older.&nbsp;"},"type":"p","style":{}},{"id":"html75","cntnt":{"mrkup":"<b>Distribution:</b> The FDA has said that Moderna’s vaccine can now be kept at room temperature for up to a day. The vaccine <a href=\"https://www.nationalgeographic.com/science/2020/11/moderna-edges-pfizer-coronavirus-efficacy-and-refrigeration/\" target=\"_blank\">can otherwise be safely stored on ice</a> or in a normal refrigerator for 30 days. These changes are expected to help the company distribute its vaccine more quickly."},"type":"p","style":{}},{"id":"html76","cntnt":{"mrkup":"The company plans to deliver at least 500 million doses globally per year beginning in 2021, thanks in part to <a href=\"https://www.lonza.com/news/2020-05-01-04-50\" target=\"_blank\">a deal it has struck with Swiss manufacturer Lonza</a> that will allow it to manufacture up to a billion doses a year.&nbsp;"},"type":"p","style":{}},{"id":"html77","cntnt":{"mrkup":"<b>Efficacy:</b> A <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine\" target=\"_blank\">study</a> of clinical trials among adolescents ages 12 to 17 shows that its vaccine is safe and 100 percent effective. The study also showed the vaccine is 93 percent effective among participants in this age group two weeks after the first dose."},"type":"p","style":{}},{"id":"html78","cntnt":{"mrkup":"Moderna <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-submission-initial-data-us-fda-its-covid-19\" target=\"_blank\">has said</a> that the phase two clinical trials of its booster dose showed that a third dose administered six months after the second “induce robust antibody responses” and increased protections against the variants of concern. It has also said that a study of the phase two clinical trials of its three booster candidates produced robust antibody responses against the virus, including the Gamma, Beta, and Delta variants of concern.&nbsp;"},"type":"p","style":{}},{"id":"html79","cntnt":{"mrkup":"However, there is some doubt about whether people who received the Moderna shot will need boosters. A study <a href=\"https://www.nature.com/articles/s41586-021-03738-2_reference.pdf\" target=\"_blank\">published in the journal <i>Nature</i></a> in June 2021 showed that the vaccine elicits “robust and prolonged” immune responses—indicating that protection may last for years so long as the virus doesn’t mutate to evade it."},"type":"p","style":{}},{"id":"html80","cntnt":{"mrkup":"On September 10, the CDC <a href=\"https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w\" target=\"_blank\">released a study</a> of more than 32,000 real-world cases suggesting that Moderna’s vaccine is more effective at preventing hospitalizations than the Pfizer or Johnson &amp; Johnson vaccines. The overall efficacy of Moderna’s vaccine was 95 percent, compared to 80 percent for Pfizer and 60 percent for Johnson &amp; Johnson. &nbsp;"},"type":"p","style":{}},{"id":"html81","cntnt":{"mrkup":"The study backed up earlier studies suggesting that Moderna’s vaccine <a href=\"https://jamanetwork.com/journals/jama/fullarticle/2783797?guestAccessKey=6ead80fe-bf08-4d53-8c5c-607249932480&amp;utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_alert-jama&amp;utm_content=olf&amp;utm_term=083021\" target=\"_blank\">may provide stronger protection than Pfizer’s</a> jab. A study published on August 30 found that Moderna’s vaccine produces significantly more neutralizing antibodies than Pfizer’s, which might be attributed to the higher dosage or the longer interval between the first and second doses. On August 8, a preliminary <a href=\"https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf\" target=\"_blank\">Mayo Clinic study of more than 50,000 patients</a> showed that the efficacy of Moderna’s vaccine dropped from 86 percent in early 2021 to 76 percent in July, when the Delta variant was predominant. Meanwhile, the Pfizer vaccine’s efficacy dropped over the same time period from 76 percent to 42 percent.&nbsp;"},"type":"p","style":{}},{"id":"html82","cntnt":{"mrkup":"An earlier preprint analysis of Moderna’s vaccine also suggested that <a href=\"https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4\" target=\"_blank\">antibody levels can predict the vaccine’s efficacy</a> against COVID-19. The study showed that people with breakthrough infections who had lower levels of antibodies in their blood were more likely to develop symptomatic infections than those with higher levels of antibodies. The study authors tell <i>Nature</i> that the data doesn’t suggest a threshold of antibodies that ensures protection but it does show <a href=\"https://www.nature.com/articles/d41586-021-02237-8#ref-CR1\" target=\"_blank\">a relationship between higher levels of antibodies and lower risk of infection</a>."},"type":"p","style":{}},{"id":"html83","cntnt":{"mrkup":"On August 12, a study published in the journal <i>Science</i> showed that <a href=\"https://science.sciencemag.org/content/early/2021/08/11/science.abj4176?_ga=2.235822593.145620917.1628696888-1399774036.1602427045\" target=\"_blank\">Moderna’s vaccine protects against COVID-19 for at least six months</a> and is effective against the Delta variant. The findings confirm <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMc2103916?query=featured_home\" target=\"_blank\">earlier studies</a> and announcements made by the company that its vaccine <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial\" target=\"_blank\">remains 93 percent effective for at least six months</a> after administration of the second dose."},"type":"p","style":{}},{"id":"html84","cntnt":{"mrkup":"On July 9, <i>Nature</i> reported on a study showing that <a href=\"https://www.nature.com/articles/d41586-021-01893-0\" target=\"_blank\">two quarter-doses of Moderna’s vaccine generates long-lasting neutralizing antibodies and T cells</a>. The results suggest that it might be possible to administer fractional doses to help stretch the world’s vaccine supply, particularly in low- and middle-income countries that are facing shortages."},"type":"p","style":{}},{"id":"html85","cntnt":{"mrkup":"On February 17, the <i>New England Journal of Medicine</i> <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMc2102179?query=featured_home\" target=\"_blank\">published</a> a preliminary report showing that Moderna’s vaccine remains effective in protecting against the virus variant found in the U.K. However, it may be less effective in protecting against the South African variant—although researchers noted that further study is needed.&nbsp;"},"type":"p","style":{}},{"id":"html86","cntnt":{"mrkup":"In December 2020, an FDA <a href=\"https://www.fda.gov/media/144434/download\" target=\"_blank\">analysis</a> of the phase three study of Moderna’s vaccine confirmed that it is 94.1-percent effective in preventing mild cases of COVID-19 and 100-percent effective at preventing severe cases after taking two doses."},"type":"p","style":{}},{"id":"html87","cntnt":{"mrkup":"<b>Safety:&nbsp;</b>On June 23, 2021, the U.S. Food and Drug Administration <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/\" target=\"_blank\">said</a> it planned to add a warning label to the Pfizer and Moderna vaccines about <a href=\"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly\" target=\"_blank\">rare cases of heart inflammation</a> in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks."},"type":"p","style":{}},{"id":"html88","cntnt":{"mrkup":"<b>Clinical trials status:</b> Moderna announced on December 17, 2020, that it was launching clinical trials to evaluate the vaccine’s safety in <a href=\"https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_d8ba867ebfe7300a65bda99cc2e2babd\" target=\"_blank\">children and people with cancer</a>; it will also <a href=\"https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_9a24ba453f4fd361f19264327ac63a1a\" target=\"_blank\">establish a “pregnancy registry</a>” to track the vaccine’s safety in people who are pregnant.&nbsp;"},"type":"p","style":{}},{"id":"html89","cntnt":{"mrkup":"The company <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid\" target=\"_blank\">started</a> the third phase of its clinical trials in July 2020. Preliminary findings from its phase one trials showed that healthy subjects—<a href=\"https://www.cnbc.com/2020/08/26/moderna-says-its-coronavirus-vaccine-shows-promising-results-in-small-trial-of-elderly-patients.html\" target=\"_blank\">including elderly patients</a>—produced coronavirus antibodies and a reaction from T cells, another part of the human immune response. Phase three tested the vaccine in 30,000 U.S. participants.&nbsp;"},"type":"p","style":{}},{"id":"html90","cntnt":{"mrkup":"On February 24, Moderna <a href=\"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine\" target=\"_blank\">announced</a> that it has shipped doses of a booster vaccine to the U.S. National Institutes of Health for clinical trials. The phase one trial will determine whether the booster can improve immunity against the South Africa variant. Moderna is also investigating using a third dose of its approved vaccine to protect against variants.&nbsp;"},"type":"p","style":{}},{"id":"html91","cntnt":{"mrkup":"<a href=\"https://www.ovg.ox.ac.uk\" target=\"_blank\"><b>AstraZeneca-University of Oxford</b></a>"},"type":"h2","style":{}},{"id":"html92","cntnt":{"mrkup":"<b>Name:</b> ChAdOx1 nCoV-19&nbsp;"},"type":"p","style":{}},{"id":"html93","cntnt":{"mrkup":"<b>Who:</b> The U.K. university, in collaboration with the biopharmaceutical company AstraZeneca."},"type":"p","style":{}},{"id":"html94","cntnt":{"mrkup":"<b>What:</b> A viral vector vaccine that requires two doses."},"type":"p","style":{}},{"id":"html95","cntnt":{"mrkup":"<b>Approval status:&nbsp;</b>Approved for use in the United Kingdom, the European Union, Argentina, India, and other countries. It has also been authorized by the World Health Organization."},"type":"p","style":{}},{"id":"html96","cntnt":{"mrkup":"<b>Efficacy:</b> In August 2021 a preprint study out of the United Kingdom showed that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant <a href=\"https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf\" target=\"_blank\">but that their efficacy wanes over time</a>. Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, both vaccines still significantly reduce the risk of infection."},"type":"p","style":{}},{"id":"html97","cntnt":{"mrkup":"On July 8, <a href=\"https://www.nature.com/articles/s41586-021-03777-9\" target=\"_blank\">a study published in <i>Nature</i></a> demonstrated that people who have received both doses of the AstraZeneca of Pfizer vaccines remain fully protected from the Delta and Beta variants. However, a single dose of either vaccine was not as protective."},"type":"p","style":{}},{"id":"html98","cntnt":{"mrkup":"On June 25, <a href=\"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3874014\" target=\"_blank\">preliminary results from a British study</a> showed that mixing doses of the AstraZeneca and Pfizer vaccines provides strong protection against COVID-19. Researchers <a href=\"https://www.nytimes.com/2021/06/28/health/mixing-pfizer-astrazeneca-results.html\" target=\"_blank\">told the <i>New York Times</i></a> that the protection is strong regardless of the order in which the vaccines are administered. The findings will be useful for those who are unable to get a second AstraZeneca vaccine due to production delays and safety concerns, although researchers say it’s still best to get two doses of the same vaccine for now."},"type":"p","style":{}},{"id":"html99","cntnt":{"mrkup":"On March 24, AstraZeneca <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html\" target=\"_blank\">released</a> the primary analysis of its U.S. phase three clinical trials showing that its vaccine is 76 percent effective at preventing COVID-19, slightly lower than the 79 percent efficacy it had announced two days earlier based on a partial analysis of the data. It is also 85 percent effective in people 65 and older and 100 percent effective at preventing severe cases of the disease."},"type":"p","style":{}},{"id":"html100","cntnt":{"mrkup":"U.S. health officials had taken the unusual step of <a href=\"https://www.nih.gov/news-events/news-releases/niaid-statement-astrazeneca-vaccine\" target=\"_blank\">questioning the decision to release the interim results</a>, describing them as “outdated and potentially misleading.” In a letter <a href=\"https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html\" target=\"_blank\">obtained by the <i>Washington Post</i></a>, an independent panel of experts at the National Institutes of Health that oversees U.S. clinical trials said that it had recommended the company release a later analysis instead, showing the vaccine may be 69 to 74 percent effective."},"type":"p","style":{}},{"id":"html101","cntnt":{"mrkup":"The companies <a href=\"https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html#!\" target=\"_blank\">also said</a> that the vaccine’s efficacy increased to 82 percent when the second dose was taken after 12 weeks or longer, rather than the originally recommended four-week interval. The British government has recommended the longer gap in its rollout of the vaccine to prioritize getting the first shot to as many at-risk people as possible.&nbsp;"},"type":"p","style":{}},{"id":"html102","cntnt":{"mrkup":"On February 7, South Africa <a href=\"https://www.nytimes.com/2021/02/07/world/africa/covid-vaccine-astrazeneca-south-africa.html\" target=\"_blank\">halted</a> its use of the AstraZeneca-Oxford vaccine after preliminary laboratory studies showed it offered only minimal protection against the virus variant that is dominant in that country. The finding was later confirmed by <a href=\"https://www.nejm.org/doi/10.1056/NEJMoa2102214\" target=\"_blank\">a study published in the <i>New England Journal of Medicine</i></a> showing that the vaccine does not protect against mild to moderate cases of COVID-19 caused by the South African variant. <a href=\"https://www.reuters.com/article/uk-health-coronavirus-britain-vaccines-v/data-on-astrazeneca-vaccine-and-south-african-variant-should-come-soon-uk-expert-says-idUSKBN29I18P\" target=\"_blank\">Early data suggested&nbsp;</a>that the vaccine will still effectively protect against the variant that is prevalent throughout the U.K. &nbsp; &nbsp;"},"type":"p","style":{}},{"id":"html103","cntnt":{"mrkup":"<b>Safety:</b> On June 9, a study <a href=\"https://www.nature.com/articles/s41591-021-01408-4\" target=\"_blank\">published in the journal <i>Nature Medicine</i></a> found that people who have received the AstraZeneca vaccine have a slightly increased risk of a bleeding disorder. The analysis of 2.53 million people who received the vaccine found an incidence of 1.13 cases per 100,000 vaccines. Researchers said the benefits of getting the vaccine outweigh the risks. The study echoed an earlier <a href=\"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood\" target=\"_blank\">safety review conducted by the European Medicines Agency</a>."},"type":"p","style":{}},{"id":"html104","cntnt":{"mrkup":"In Canada, meanwhile, on June 29 regulatory officials advised people with a history of capillary leak syndrome against receiving the AstraZeneca vaccine. Health Canada i<a href=\"https://www.theglobeandmail.com/canada/article-heath-canada-adds-warning-of-very-rare-serious-condition-as-potential/\" target=\"_blank\">s also updating the vaccine’s label</a> to add the syndrome as a potential side effect."},"type":"p","style":{}},{"id":"html105","cntnt":{"mrkup":"<b>Distribution:</b> Project members say their candidate can be stored at temperatures seen in common refrigeration. Oxford and AstraZeneca expect to produce up to three billion doses of the vaccine in 2021."},"type":"p","style":{}},{"id":"html106","cntnt":{"mrkup":"On December 30, the U.K. <a href=\"https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator\" target=\"_blank\">announced</a> changes to its vaccine delivery plan to prioritize delivering the first dose of either vaccine to as many at-risk people as possible, based on data <a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948334/Information_for_UK_healthcare_professionals_on_COVID-19_Vaccine_AstraZeneca.pdf\" target=\"_blank\">provided to and released by</a> health regulators. It did so by delaying administration of the second dose of the AstraZeneca-Oxford drug. A similar rule was issued for the Pfizer-BioNTech vaccine, but regulators didn’t provide<a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948338/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020.pdf\" target=\"_blank\">&nbsp;data to back the&nbsp;</a>new regimen. Overall, the U.K. still recommends that recipients receive two doses of either vaccine for maximum benefit.&nbsp;"},"type":"p","style":{}},{"id":"html107","cntnt":{"mrkup":"<b>Clinical trials status:&nbsp;</b>On December 11, AstraZeneca and Russia’s Gamaleya Institute <a href=\"https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html\" target=\"_blank\">announced</a> plans to work together to study the possibility of combining Oxford’s vaccine with Gamaleya’s Sputnik V vaccine. Since both use the same adenovirus, researchers will investigate whether a combination of the two will improve efficacy.&nbsp;"},"type":"p","style":{}},{"id":"html108","cntnt":{"mrkup":"The AstraZeneca-Oxford vaccine’s phase three trial aimed to recruit up to 50,000 volunteers in Brazil, the U.K., the United States, and South Africa. On September 8, AstraZeneca paused the trials for a safety review due to an adverse reaction in one participant in the U.K., which the company described as a “routine action.” After an investigation by independent regulators, the trials <a href=\"https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html\" target=\"_blank\">resumed</a> in the U.K., Brazil, South Africa, and India in September and <a href=\"https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923\" target=\"_blank\">resumed in the U.S.</a> a month later."},"type":"p","style":{}},{"id":"html109","cntnt":{"mrkup":"<a href=\"https://novavax.com/\" target=\"_blank\"><b>Novavax</b></a>"},"type":"h2","style":{}},{"id":"html110","cntnt":{"mrkup":"<b>Name:&nbsp;</b>NVX-CoV2373"},"type":"p","style":{}},{"id":"html111","cntnt":{"mrkup":"<b>Who:</b> A biotechnology company based in Gaithersburg, Maryland."},"type":"p","style":{}},{"id":"html112","cntnt":{"mrkup":"<b>What:</b> A protein vaccine that involves a nanoparticle carrier to better aid delivery and uptake by cells. The vaccine is administered in two doses, 21 days apart.&nbsp;"},"type":"p","style":{}},{"id":"html113","cntnt":{"mrkup":"<b>Approval status:</b> Authorized for emergency use in Indonesia."},"type":"p","style":{}},{"id":"html114","cntnt":{"mrkup":"Novavax has not yet submitted <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-again-delays-seeking-us-approval-covid-19-vaccine-2021-08-05/\" target=\"_blank\">its vaccine to the FDA for emergency use authorization, but it is planning to do so</a>. Reuters reports that Novavax also said that it will file a separate application for booster shots once the emergency use authorization submission is processed; the company said its booster shot given six months after the two-dose regimen elicited a 4.6-fold increase in antibodies. The company has filed for authorization from regulators in India and the Philippines."},"type":"p","style":{}},{"id":"html115","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On June 14, Novavax <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and\" target=\"_blank\">announced</a> that its vaccine is safe and 90.4 percent effective in protecting against COVID-19—including the more contagious virus variants that are circulating. The vaccine is also 100 percent effective at preventing moderate and severe disease among 29,960 clinical trial participants age 18 and older in the U.S. and Mexico.&nbsp;"},"type":"p","style":{}},{"id":"html116","cntnt":{"mrkup":"On March 11, Novavax <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and\" target=\"_blank\">announced</a> that a final analysis of its phase three clinical trials in the U.K. shows that its vaccine is 96.4-percent effective in preventing COVID-19. It also announced the findings of its phase 2b clinical trial in South Africa, which showed the vaccine was only 48.6-percent effective against the strains circulating there. Both trials showed the vaccine is 100-percent effective at preventing severe cases of the disease.&nbsp;"},"type":"p","style":{}},{"id":"html117","cntnt":{"mrkup":"On January 28, 2021, Novavax had <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3\" target=\"_blank\">announced</a> preliminary results of its phase three trials in the U.K., which showed at the time that its vaccine is 89.3-percent effective in preventing COVID-19. On September 2, 2020, a study of the company’s phase one trial <a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2026920\" target=\"_blank\">published in the <i>New England Journal of Medicine</i></a> found that the vaccine was safe and produced coronavirus antibodies at a higher level than is seen among those who have recovered from COVID-19. It also stimulated T cells, another arm of the human immune response."},"type":"p","style":{}},{"id":"html118","cntnt":{"mrkup":"<b>Clinical trials status:</b> On September 24, 2020, Novavax <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united\" target=\"_blank\">announced</a> the launch of its phase three trial in the United Kingdom, which evaluated the vaccine in up to 10,000 people, both with and without underlying conditions. Up to 400 participants were also vaccinated against the seasonal flu as part of a sub-study to <a href=\"https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html\" target=\"_blank\">help determine</a> whether it is safe to give patients both vaccines at the same time. On November 30, Novavax <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress\" target=\"_blank\">said it had completed enrollment</a> in its phase three trial in the U.K."},"type":"p","style":{}},{"id":"html119","cntnt":{"mrkup":"On December 28, 2020, Novavax <a href=\"https://ir.novavax.com/news-releases/news-release-details/novavax-announces-initiation-prevent-19-pivotal-phase-3-efficacy\" target=\"_blank\">announced</a> the launch of a phase three study in the U.S. and Mexico, which evaluated the safety and efficacy of its vaccine in up to 30,000 adults.&nbsp;"},"type":"p","style":{}},{"id":"html120","cntnt":{"mrkup":"<a href=\"http://www.sinopharm.com/1156.html\" target=\"_blank\"><b>Sinopharm</b></a>"},"type":"h2","style":{}},{"id":"html121","cntnt":{"mrkup":"<b>Name:</b> None&nbsp;"},"type":"p","style":{}},{"id":"html122","cntnt":{"mrkup":"<b>Who:</b> China’s state-run pharmaceutical company, in collaboration with the Wuhan Institute of Biological Products."},"type":"p","style":{}},{"id":"html123","cntnt":{"mrkup":"<b>What:</b> Two inactivated SARS-CoV-2 vaccines.&nbsp;"},"type":"p","style":{}},{"id":"html124","cntnt":{"mrkup":"<b>Approval status:</b> China has approved one of the company’s vaccines for general use and another for limited use. One of the Sinopharm vaccines has also been approved by the World Health Organization as well as in Bahrain, the United Arab Emirates, and other countries."},"type":"p","style":{}},{"id":"html125","cntnt":{"mrkup":"Sinopharm <a href=\"https://www.scmp.com/news/china/society/article/3111347/coronavirus-sinopharm-applies-regulatory-approval-china-launch\" target=\"_blank\">filed for final regulatory approval</a> from China in late November, two months after the <i>New Yorker</i> <a href=\"https://www.newyorker.com/news/news-desk/the-november-surprise-of-chinas-coronavirus-vaccine\" target=\"_blank\">reported</a> that hundreds of thousands of Chinese civilians have already been vaccinated under the government’s emergency-use approval. China began to innoculate medical workers and other high-risk groups with the Sinopharm trial vaccines in July, making it the first experimental vaccine available to civilians beyond clinical volunteers.&nbsp;"},"type":"p","style":{}},{"id":"html126","cntnt":{"mrkup":"<b>Efficacy and safety:&nbsp;</b>On July 19 preliminary results from a study conducted in Sri Lanka found that Sinopharm’s vaccine was less effective against the Delta variant than the original SARS-CoV-2 strain. As Reuters reported, the study showed that the vaccine <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/sinopharms-covid-19-shot-induces-weaker-antibody-responses-delta-study-2021-07-21/\" target=\"_blank\">elicited a 1.38-fold reduction in antibody levels</a> against the variant."},"type":"p","style":{}},{"id":"html127","cntnt":{"mrkup":"On May 7, the World Health Organization <a href=\"https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations\" target=\"_blank\">estimated</a> the Sinopharm vaccine’s efficacy to be 79 percent among all age groups, affirming the company’s earlier <a href=\"https://www.nytimes.com/2020/12/29/world/a-chinese-covid-19-vaccine-has-proved-effective-its-maker-said.html?referringSource=articleShare\" target=\"_blank\">announcement</a> of the results of its phase three study."},"type":"p","style":{}},{"id":"html128","cntnt":{"mrkup":"Preliminary findings from two randomized trials, <a href=\"https://jamanetwork.com/journals/jama/fullarticle/2769612\" target=\"_blank\">published in the <i>Journal of the American Medical Association</i></a>, have shown the vaccine can trigger an antibody response with no serious adverse effects. The study did not measure T cell-mediated immune responses. These results are significant, though, as they are the first published data from human clinical trials for a COVID-19 vaccine that uses a whole, inactivated virus."},"type":"p","style":{}},{"id":"html129","cntnt":{"mrkup":"<b>Clinical trials status:</b> Sinopharm <a href=\"https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-uae-idUSKCN24H14T\" target=\"_blank\">launched its first phase three trial</a> in July 2020 among 15,000 volunteers—aged 18 to 60, with no serious underlying conditions—in the UAE. The company <a href=\"https://www.businesswire.com/news/home/20200717005085/en/World’s-Phase-III-Clinical-Trial-COVID-19-Inactivated\" target=\"_blank\">selected the UAE because</a> it has a diverse population made up of approximately 200 nationalities, making it an ideal testing ground. Sinopharm also conducted phase three trials in locations such as <a href=\"https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9\" target=\"_blank\">Peru</a> and <a href=\"https://www.reuters.com/article/us-health-coronavirus-bahrain-vaccine/chinas-sinopharm-starts-phase-iii-trial-of-covid-19-vaccine-in-bahrain-idUSKCN2561V1\" target=\"_blank\">Bahrain</a>."},"type":"p","style":{}},{"id":"html130","cntnt":{"mrkup":"<a href=\"http://www.sinovac.com/\" target=\"_blank\"><b>Sinovac</b></a>"},"type":"h2","style":{}},{"id":"html131","cntnt":{"mrkup":"<b>Name:&nbsp;</b>CoronaVac&nbsp;"},"type":"p","style":{}},{"id":"html132","cntnt":{"mrkup":"<b>Who:&nbsp;</b>A Chinese biopharmaceutical company, in collaboration with Brazilian research center Butantan."},"type":"p","style":{}},{"id":"html133","cntnt":{"mrkup":"<b>What:</b> An inactivated vaccine.&nbsp;"},"type":"p","style":{}},{"id":"html134","cntnt":{"mrkup":"<b>Approval status:&nbsp;</b>Approved for limited use by the WHO as well as in China, Indonesia, Brazil, and other countries."},"type":"p","style":{}},{"id":"html135","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On July 15 Reuters reported that the leaders of a Chilean study have <a href=\"https://www.reuters.com/world/americas/chilean-sinovac-trial-leaders-recommend-third-dose-covid-19-vaccine-2021-07-15/\" target=\"_blank\">recommended administering a third dose of Sinovac’s vaccine</a> as its efficacy has waned in the face of the Delta variant. The vaccine’s level of protection is lower than others—late-stage trials <a href=\"https://www.bbc.com/news/world-latin-america-55642648\" target=\"_blank\">found that it is 51 percent effective</a> in preventing COVID-19. Still, <a href=\"https://www.nature.com/articles/d41586-021-01497-8\" target=\"_blank\"><i>Nature</i> reports</a> that it is 100 percent effective at preventing severe disease and therefore is key to helping curb the pandemic.&nbsp;"},"type":"p","style":{}},{"id":"html136","cntnt":{"mrkup":"On April 7, <a href=\"https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1\" target=\"_blank\">a preliminary study</a> of CoronaVac’s vaccine rollout in Brazil showed that the vaccine is about 50 percent effective in protecting against COVID-19 in a region where the highly transmissible P.1 variant is circulating.&nbsp;"},"type":"p","style":{}},{"id":"html137","cntnt":{"mrkup":"<b>Clinical trials status:</b> CoronaVac <a href=\"http://www.sinovac.com/?optionid=754&amp;auto_id=907\" target=\"_blank\">entered phase three trials</a> in July, with plans to recruit nearly 9,000 healthcare professionals in Brazil, in addition to phase three trials in <a href=\"https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine/sinovac-launches-phase-3-trial-for-covid-19-vaccine-in-indonesia-reports-phase-2-details-idUSKCN2570E9\" target=\"_blank\">Indonesia</a>. A planned trial in Bangladesh was delayed, <a href=\"https://asia.nikkei.com/Spotlight/Coronavirus/China-forges-on-with-vaccine-diplomacy-amid-Pfizer-fanfare\" target=\"_blank\">after Bangladesh refused in October</a> to co-finance a late-stage trial.&nbsp;"},"type":"p","style":{}},{"id":"html138","cntnt":{"mrkup":"<a href=\"https://biomed.cigb.edu.cu/\" target=\"_blank\"><b>Center for Genetic Engineering and Biotechnology</b></a>"},"type":"h2","style":{}},{"id":"html139","cntnt":{"mrkup":"<b>Name:</b> Abdala"},"type":"p","style":{}},{"id":"html140","cntnt":{"mrkup":"<b>Who:</b> A government-run research institute in Cuba."},"type":"p","style":{}},{"id":"html141","cntnt":{"mrkup":"<b>What:</b> A protein subunit vaccine that’s administered in three doses."},"type":"p","style":{}},{"id":"html142","cntnt":{"mrkup":"<b>Approval status:</b> Approved for emergency use in Cuba and Vietnam. Prior to granting emergency use authorization, Cuba <a href=\"https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1\" target=\"_blank\">had already begun</a> administering the vaccine among health workers as part of an “intervention study.”"},"type":"p","style":{}},{"id":"html143","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On June 22 Cuba announced that the Abdala vaccine is 92.28 percent effective against COVID-19.&nbsp;"},"type":"p","style":{}},{"id":"html144","cntnt":{"mrkup":"<b>Clinical trials:</b> In March Cuba <a href=\"http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm\" target=\"_blank\">launched</a> phase three clinical trials for the Abdala vaccine among 48,000 volunteers."},"type":"p","style":{}},{"id":"html145","cntnt":{"mrkup":"<a href=\"https://www.finlay.edu.cu/en\" target=\"_blank\"><b>Finlay Institute for Vaccines</b></a>"},"type":"h2","style":{}},{"id":"html146","cntnt":{"mrkup":"<b>Name:</b> Soberana-02"},"type":"p","style":{}},{"id":"html147","cntnt":{"mrkup":"<b>Who:</b> A government-run research institute in Cuba."},"type":"p","style":{}},{"id":"html148","cntnt":{"mrkup":"<b>What:</b> A conjugate vaccine that uses part of the virus spike protein."},"type":"p","style":{}},{"id":"html149","cntnt":{"mrkup":"<b>Approval status:</b> Authorized for emergency use in Cuba and Iran."},"type":"p","style":{}},{"id":"html150","cntnt":{"mrkup":"<b>Efficacy:</b> On June 22 the <i>New York Times</i> <a href=\"https://www.nytimes.com/2021/06/22/world/americas/cuba-vaccine-abdala.html\" target=\"_blank\">reported</a> that the Soberana-02 vaccine was 62 percent effective at preventing COVID-19 after two of its three required doses.&nbsp;"},"type":"p","style":{}},{"id":"html151","cntnt":{"mrkup":"<b>Clinical trials:&nbsp;</b>On March 4, Cuba became the first country in Latin America to <a href=\"https://www.miamiherald.com/news/nation-world/world/americas/cuba/article249696913.html\" target=\"_blank\">announce the launch of a phase three clinical trial</a> for one of its COVID-19 vaccines, the <i>Miami Herald</i> reported. The Cuban government said the phase three trial would be conducted in Havana among 44,000 volunteers."},"type":"p","style":{}},{"id":"html152","cntnt":{"mrkup":"<a href=\"https://www.curevac.com/en/\" target=\"_blank\"><b>CureVac</b></a>"},"type":"h2","style":{}},{"id":"html153","cntnt":{"mrkup":"<b>Name:</b> CVnCoV"},"type":"p","style":{}},{"id":"html154","cntnt":{"mrkup":"<b>Who:&nbsp;</b>A German biopharmaceutical company <a href=\"https://www.curevac.com/en/2021/01/07/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/\" target=\"_blank\">in partnership with Bayer</a>, a German multinational pharmaceutical company."},"type":"p","style":{}},{"id":"html155","cntnt":{"mrkup":"<b>What:</b> An mRNA vaccine that’s administered in two doses taken 28 days apart."},"type":"p","style":{}},{"id":"html156","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use. On October 12, 2021, CureVac <a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-withdraw-first-generation-covid-19-vaccine-candidate-2021-10-12/\" target=\"_blank\">announced</a> that it was withdrawing its COVID-19 vaccine candidate months after it <a href=\"https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/\" target=\"_blank\">reported</a> disappointing results from a study of its clinical trials showing its vaccine was only 47 percent effective in preventing COVID-19, falling short of the company’s own criteria for success. CureVac attributed its results to the virus variants that were circulating at the time. It sequenced 124 cases of COVID-19 among clinical trial participants and found only one case was caused by the original SARS-CoV-2 virus and more than half were caused by variants of concern."},"type":"p","style":{}},{"id":"html157","cntnt":{"mrkup":"<b>Efficacy and safety:&nbsp;</b>On January 11, CureVac <a href=\"https://www.curevac.com/en/2021/01/11/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-primates-during-sars-cov-2-challenge-infection/\" target=\"_blank\">announced</a> that preliminary results show its vaccine prompted robust antibody and T-cell responses in rhesus macaques.&nbsp;"},"type":"p","style":{}},{"id":"html158","cntnt":{"mrkup":"<b>Clinical trials status:</b> On December 14, 2020, CureVac <a href=\"https://www.curevac.com/en/2020/12/14/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/\" target=\"_blank\">announced</a> it had begun enrolling participants in a phase 2b/3 study to assess its vaccine’s safety and efficacy in more than 35,000 participants in Europe and Latin America. One week later, the company <a href=\"https://www.curevac.com/en/2020/12/21/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/\" target=\"_blank\">launched</a> a separate phase three trial in healthcare workers in Mainz, Germany."},"type":"p","style":{}},{"id":"html159","cntnt":{"mrkup":"<a href=\"https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-2-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate\" target=\"_blank\"><b>Sanofi and GSK</b></a>"},"type":"h2","style":{}},{"id":"html160","cntnt":{"mrkup":"<b>Name:</b> None"},"type":"p","style":{}},{"id":"html161","cntnt":{"mrkup":"<b>Who:&nbsp;</b>A global biopharmaceutical company in partnership with a global healthcare company."},"type":"p","style":{}},{"id":"html162","cntnt":{"mrkup":"<b>What:</b> An adjuvant-supported recombinant-protein vaccine."},"type":"p","style":{}},{"id":"html163","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use."},"type":"p","style":{}},{"id":"html164","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On May 17, the companies <a href=\"https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-17-07-30-00-2230312\" target=\"_blank\">announced</a> that a study of their phase two clinical trials shows the vaccine generated a high level of neutralizing antibodies with no safety concerns."},"type":"p","style":{}},{"id":"html165","cntnt":{"mrkup":"<b>Clinical trials:</b> On May 27, 2021, Sanofi and GSK <a href=\"https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-27-07-30-00-2236989#\" target=\"_blank\">announced</a> that they had started to enroll participants in a phase three clinical study to test the safety and efficacy of their vaccine in 35,000 volunteers ages 18 and older in the U.S., Asia, Africa, and Latin America. The study’s broad geographic range was intended to allow the companies to evaluate the vaccine’s efficacy against variants of concern."},"type":"p","style":{}},{"id":"html166","cntnt":{"mrkup":"<a href=\"https://biologicale.com/index.html\" target=\"_blank\"><b>Biological E. Limited</b></a>"},"type":"h2","style":{}},{"id":"html167","cntnt":{"mrkup":"<b>Name:</b> None"},"type":"p","style":{}},{"id":"html168","cntnt":{"mrkup":"<b>Who:</b> An Indian vaccine and pharmaceutical company in partnership with the Baylor College of Medicine."},"type":"p","style":{}},{"id":"html169","cntnt":{"mrkup":"<b>What:</b> A protein-based subunit vaccine that requires two doses administered 28 days apart."},"type":"p","style":{}},{"id":"html170","cntnt":{"mrkup":"<b>Latest news:</b> On April 26, the companies <a href=\"https://www.bcm.edu/news/biological-e-limited-to-begin-phase-iii-clinical-trials-with-baylor-and-texas-childrens-vaccine\" target=\"_blank\">announced</a> that they received approval to launch a phase three clinical trial of their vaccine candidate. The trial will evaluate the efficacy and safety of the vaccine among more than 1,200 volunteers ages 18 to 80 at 15 sites across India."},"type":"p","style":{}},{"id":"html171","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use."},"type":"p","style":{}},{"id":"html172","cntnt":{"mrkup":"<b>Distribution:</b> If the vaccine is approved for use, it <a href=\"https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/\" target=\"_blank\">will be distributed</a> through the COVAX Facility, a global effort to ensure the equitable distribution of COVID-19 vaccines."},"type":"p","style":{}},{"id":"html173","cntnt":{"mrkup":"<a href=\"https://valneva.com/research-development/covid-19-vla2001/\" target=\"_blank\"><b>Valneva SE</b></a>"},"type":"h2","style":{}},{"id":"html174","cntnt":{"mrkup":"<b>Name:</b> VLA2001"},"type":"p","style":{}},{"id":"html175","cntnt":{"mrkup":"<b>Who:</b> A vaccine developer based in France."},"type":"p","style":{}},{"id":"html176","cntnt":{"mrkup":"<b>What:</b> An inactivated virus, adjuvant-supported vaccine, with two doses administered three weeks apart."},"type":"p","style":{}},{"id":"html177","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use. The company has initiatied rolling submission for approval with U.K. and European regulators."},"type":"p","style":{}},{"id":"html178","cntnt":{"mrkup":"<b>Safety and efficacy:&nbsp;</b>On October 18 Valneva <a href=\"https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/\" target=\"_blank\">announced</a> that its vaccine elicited higher antibody levels than the AstraZeneca vaccine and “significantly fewer” adverse events among participants age 30 and older."},"type":"p","style":{}},{"id":"html179","cntnt":{"mrkup":"On April 6, Valneva <a href=\"https://valneva.com/press-release/valneva-reports-positive-phase-1-2-data-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/\" target=\"_blank\">announced</a> that a study of its phase 1 and 2 clinical trials show that its vaccine prompted a strong immune response with no safety concerns."},"type":"p","style":{}},{"id":"html180","cntnt":{"mrkup":"<b>Clinical trials:</b> On April 21 Valneva <a href=\"https://valneva.com/press-release/valneva-initiates-phase-3-clinical-trial-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/#_ftn2\" target=\"_blank\">announced</a> the launch of phase three clinical trials to study the safety and efficacy of its COVID-19 vaccine compared to that of AstraZeneca’s conditionally approved vaccine. Approximately 4,000 volunteers were expected to receive two doses of either vaccine to determine the immune response of each. Valneva says it hopes to file for regulatory approval in the fall of 2021."},"type":"p","style":{}},{"id":"html181","cntnt":{"mrkup":"<a href=\"http://en.biokangtai.com/\" target=\"_blank\"><b>Shenzhen Kangtai Biological Products</b></a>"},"type":"h2","style":{}},{"id":"html182","cntnt":{"mrkup":"<b>Name:</b> None."},"type":"p","style":{}},{"id":"html183","cntnt":{"mrkup":"<b>Who:</b> A China-based pharmaceuticals company"},"type":"p","style":{}},{"id":"html184","cntnt":{"mrkup":"<b>What:</b> An inactivated vaccine that requires two doses administered 28 days apart."},"type":"p","style":{}},{"id":"html185","cntnt":{"mrkup":"<b>Approval status:</b> Authorized for emergency use in China. The country <a href=\"https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6\" target=\"_blank\">approved</a> the Kangtai shot for emergency use in May 2021, just weeks after the vaccine launched its phase three clinical trials."},"type":"p","style":{}},{"id":"html186","cntnt":{"mrkup":"<b>Clinical trials:&nbsp;</b>Kangtai’s phase three clinical trials <a href=\"https://clinicaltrials.gov/ct2/show/NCT04852705?term=kangtai&amp;draw=2&amp;rank=3\" target=\"_blank\">are underway</a>, testing the vaccine’s safety and efficacy among 28,000 adults age 18 and older."},"type":"p","style":{}},{"id":"html187","cntnt":{"mrkup":"<a href=\"https://medicago.com/en/\" rel=\"noopener noreferrer\" target=\"_blank\"><b>Medicago</b></a>"},"type":"h2","style":{}},{"id":"html188","cntnt":{"mrkup":"<b>Name:</b> CoVLP"},"type":"p","style":{}},{"id":"html189","cntnt":{"mrkup":"<b>Who:&nbsp;</b>A Canadian biotechnology company, in partnership with British multinational pharmaceutical company GlaxoSmithKline."},"type":"p","style":{}},{"id":"html190","cntnt":{"mrkup":"<b>What:</b> A plant-derived recombinant vaccine with an adjuvant that requires two doses administered 21 days apart."},"type":"p","style":{}},{"id":"html191","cntnt":{"mrkup":"<b>Efficacy and safety:&nbsp;</b>In May 2021 Medicago <a href=\"https://medicago.com/en/press-release/1751/\" target=\"_blank\">reported</a> that interim data from its phase two clinical trial showed that its COVID-19 vaccine elicited high levels of neutralizing antibodies with no severe adverse reactions."},"type":"p","style":{}},{"id":"html192","cntnt":{"mrkup":"<b>Clinical trials:</b> On March 16, Medicago and GlaxoSmithKline <a href=\"https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/\" target=\"_blank\">announced</a> that their vaccine had entered phase three clinical trials to study its safety and efficacy in up to 30,000 volunteers in 10 countries, including Canada and the U.S."},"type":"p","style":{}},{"id":"html193","cntnt":{"mrkup":"<a href=\"https://www.bharatbiotech.com/covaxin.html\" target=\"_blank\"><b>Bharat Biotech</b></a>"},"type":"h2","style":{}},{"id":"html194","cntnt":{"mrkup":"<b>Name:&nbsp;</b>COVAXIN"},"type":"p","style":{}},{"id":"html195","cntnt":{"mrkup":"<b>Who:</b> An Indian biotechnology company, in collaboration with the Indian Council of Medical Research and the National Institute of Virology."},"type":"p","style":{}},{"id":"html196","cntnt":{"mrkup":"<b>What:&nbsp;</b>An inactivated vaccine, which <a href=\"https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf\" target=\"_blank\">requires two doses</a> that are administered 28 days apart.&nbsp;"},"type":"p","style":{}},{"id":"html197","cntnt":{"mrkup":"<b>Approval status:&nbsp;</b>Authorized for emergency use <a href=\"https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html\" target=\"_blank\">in India</a>, Mexico, the Philippines, and other countries. The WHO has also listed the vaccine for emergency use."},"type":"p","style":{}},{"id":"html198","cntnt":{"mrkup":"<b>Efficacy and safety:</b> In November 2021 the WHO<a href=\"https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine\" target=\"_blank\">&nbsp;said</a> that its analysis of COVAXIN shows the vaccine is 78 percent effective against COVID-19 and “is extremely suitable for low-and-middle-income countries due to easy storage requirements.”&nbsp;"},"type":"p","style":{}},{"id":"html199","cntnt":{"mrkup":"On March 3 Bharat Biotech <a href=\"https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf\" target=\"_blank\">announced</a> that an interim analysis of its phase three trial showed its vaccine is 81-percent effective in protecting against COVID-19 after the second dose. A separate preliminary study <a href=\"https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2.full\" target=\"_blank\">also indicated</a> that the vaccine produces antibodies that can neutralize the virus variant that originated in the U.K.&nbsp;"},"type":"p","style":{}},{"id":"html200","cntnt":{"mrkup":"On January 21, <a href=\"https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext#seccestitle180\" target=\"_blank\"><i>The Lancet</i></a> published interim findings from COVAXIN’s phase one study that showed the vaccine elicited an immune response in participants. The study identified only one serious adverse event, and it was unrelated to the vaccine."},"type":"p","style":{}},{"id":"html201","cntnt":{"mrkup":"<b>Clinical trials status:</b> On November 16, Bharat Biotech <a href=\"https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf\" target=\"_blank\">announced</a> it had begun phase three trials involving 26,000 participants at more than 25 centers across India."},"type":"p","style":{}},{"id":"html202","cntnt":{"mrkup":"<a href=\"https://sputnikvaccine.com/\" target=\"_blank\"><b>The Gamaleya National Center of Epidemiology and Microbiology</b></a>"},"type":"h2","style":{}},{"id":"html203","cntnt":{"mrkup":"<b>Name:</b> Sputnik V"},"type":"p","style":{}},{"id":"html204","cntnt":{"mrkup":"<b>Who:</b> A Russian research institution, in partnership with the state-run Russian Direct Investment Fund."},"type":"p","style":{}},{"id":"html205","cntnt":{"mrkup":"<b>What:</b> A viral vector vaccine that uses two strains of adenovirus and requires a second injection after 21 days to boost the immune response.&nbsp;"},"type":"p","style":{}},{"id":"html206","cntnt":{"mrkup":"<b>Approval status:&nbsp;</b>In August, Russia cleared the Sputnik V vaccine for widespread use and <a href=\"https://www.cnbc.com/2020/08/11/russia-claims-to-have-registered-first-coronavirus-vaccine.html\" target=\"_blank\">claimed it</a> as the first registered COVID-19 vaccine on the market—before the vaccine’s phase three trials had begun and despite the lack of published evidence at the time. It has since been approved in Belarus, Argentina, Venezuela, and other countries. &nbsp;"},"type":"p","style":{}},{"id":"html207","cntnt":{"mrkup":"On March 4 the European Union <a href=\"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine\" target=\"_blank\">announced</a> that it would begin a rolling review of the Sputnik V vaccine. The announcement came after a handful of European countries said they would consider approving the vaccine without E.U. approval. Hungary has already authorized the vaccine. But on October 21 Reuters <a href=\"https://www.reuters.com/world/europe/exclusive-eu-decision-russias-sputnik-v-shot-impossible-this-year-source-2021-10-21/\" target=\"_blank\">reported</a> that European regulators are unlikely to make a final decision until early 2022."},"type":"p","style":{}},{"id":"html208","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On February 2, the medical journal <a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext\" target=\"_blank\"><i>The Lancet</i> published the results</a> of a phase three trial in Moscow that found the Sputnik V vaccine is safe and 91.6-percent effective in preventing COVID-19. The study, which involved more than 22,000 participants, also showed the vaccine is 100-percent effective in preventing moderate or severe cases of the disease, as no such cases were confirmed at least 21 days after receiving the first dose.&nbsp;"},"type":"p","style":{}},{"id":"html209","cntnt":{"mrkup":"<b>Distribution:</b> Global demand for Sputnik V <a href=\"https://fortune.com/2021/02/08/international-sputnik-russia-demand/\" target=\"_blank\">soared</a> in the weeks after the vaccine’s efficacy data was published. The vaccine makers <a href=\"https://www.businessinsider.com/russia-sputnik-vaccine-40-countries-west-hoards-shots-2021-3\" target=\"_blank\">reached deals</a> with more than 40 countries in Latin America, Eastern Europe, Asia, and Africa. On February 19, the African Union <a href=\"https://www.reuters.com/article/uk-health-coronavirus-africa-idUSKBN2AJ0ZP\" target=\"_blank\">announced</a> that Russia has offered them 300 million doses of the Sputnik V vaccine.&nbsp;"},"type":"p","style":{}},{"id":"html210","cntnt":{"mrkup":"<b>Clinical trials status:</b> On December 11, the Gamaleya Institute and biopharmaceutical company AstraZeneca <a href=\"https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html\" target=\"_blank\">announced</a> they will work together to study the possibility of combining Sputnik V with the candidate that AstraZeneca has developed with the University of Oxford. Since both candidates use the same adenovirus, researchers will investigate whether combining them will improve efficacy of the AstraZeneca vaccine, which is 70.4-percent effective in preventing COVID-19.&nbsp;"},"type":"p","style":{}},{"id":"html211","cntnt":{"mrkup":"<a href=\"http://www.chumakovs.ru/en/\" target=\"_blank\"><b>Chumakov Center</b></a>"},"type":"h2","style":{}},{"id":"html212","cntnt":{"mrkup":"<b>Name:&nbsp;</b>CoviVac"},"type":"p","style":{}},{"id":"html213","cntnt":{"mrkup":"<b>Who:</b> A Russian research center."},"type":"p","style":{}},{"id":"html214","cntnt":{"mrkup":"<b>What:</b> An inactivated vaccine given in two doses, 14 days apart."},"type":"p","style":{}},{"id":"html215","cntnt":{"mrkup":"<b>Approval status:</b> On February 20, Russia <a href=\"https://www.reuters.com/article/us-health-coronavirus-russia-vaccine/russia-approves-its-third-covid-19-vaccine-pm-idUSKBN2AK07H\" target=\"_blank\">approved</a> the CoviVac vaccine for use even though late-stage clinical trials to test its safety and efficacy have not yet begun. Reuters reports that early-stage trials with 200 participants showed the vaccine has no side effects."},"type":"p","style":{}},{"id":"html216","cntnt":{"mrkup":"<b>Distribution:</b> The Chumakov Center plans to produce half a million doses per month."},"type":"p","style":{}},{"id":"html217","cntnt":{"mrkup":"<a href=\"https://www.mcri.edu.au/BRACE\" target=\"_blank\"><b>Murdoch Children’s Research Institute</b></a>"},"type":"h2","style":{}},{"id":"html218","cntnt":{"mrkup":"<b>Name:</b> Bacillus Calmette-Guerin BRACE trial&nbsp;"},"type":"p","style":{}},{"id":"html219","cntnt":{"mrkup":"<b>Who:</b> The largest child health research institute in Australia, in collaboration with the University of Melbourne."},"type":"p","style":{}},{"id":"html220","cntnt":{"mrkup":"<b>What:</b> For nearly a hundred years, the Bacillus Calmette-Guerin (BCG) vaccine <a href=\"https://www.gavi.org/vaccineswork/can-bcg-vaccine-protect-against-covid-19\" target=\"_blank\">has been used</a> to prevent tuberculosis by exposing patients to <a href=\"https://www.uofmhealth.org/health-library/d08998a1#:~:text=BCG vaccine works by exposing,from disease in every person.\" target=\"_blank\">a small dose of live bacteria</a>. Evidence has emerged over the years that this vaccine may boost the immune system and help the body fight off other diseases as well.&nbsp;"},"type":"p","style":{}},{"id":"html221","cntnt":{"mrkup":"<b>Efficacy and safety:&nbsp;</b>On November 10, 2020, a U.S. study <a href=\"https://www.jci.org/articles/view/145157\" target=\"_blank\">published in the <i>Journal of Clinical Investigation</i></a> found that among 6,201 healthcare workers in Los Angeles, those who had previously received the BCG vaccine reported symptoms of COVID-19 less often than those who hadn’t, a finding that study authors say strengthens the case for further research. In October of that year, the U.K. <a href=\"https://www.reuters.com/article/health-coronavirus-britain-bcg/uk-study-tests-if-bcg-vaccine-protects-against-covid-idINKBN26W08C\" target=\"_blank\">launched a study</a> of the BCG vaccine that is part of the Australian-led trials. The study is seeking to recruit a thousand frontline health-care workers to test the vaccine’s effectiveness against COVID-19.&nbsp;"},"type":"p","style":{}},{"id":"html222","cntnt":{"mrkup":"<b>Clinical trials status:</b> In Apri 2020, researchers from the Murdoch Children’s Research Institute <a href=\"https://www.nytimes.com/2020/04/03/health/coronavirus-bcg-vaccine.html\" target=\"_blank\">began a series of randomized controlled trials</a> that will test whether BCG might work on the coronavirus as well. They aim to recruit <a href=\"https://www.mcri.edu.au/BRACE\" target=\"_blank\">10,000 healthcare workers</a> in the study. In an April 2020 scientific brief, the World Health Organization found that there is <a href=\"https://www.who.int/publications/i/item/bacille-calmette-guérin-(bcg)-vaccination-and-covid-19\" target=\"_blank\">no current evidence that the BCG vaccine protects</a> people against infection with the coronavirus.&nbsp;"},"type":"p","style":{}},{"id":"html223","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use."},"type":"p","style":{}},{"id":"html224","cntnt":{"mrkup":"<a href=\"http://www.cansinotech.com/\" target=\"_blank\"><b>CanSino Biologics</b></a>"},"type":"h2","style":{}},{"id":"html225","cntnt":{"mrkup":"<b>Name:</b> Ad5-nCoV"},"type":"p","style":{}},{"id":"html226","cntnt":{"mrkup":"<b>Who:</b> A Chinese biopharmaceutical company."},"type":"p","style":{}},{"id":"html227","cntnt":{"mrkup":"<b>What:</b> A viral vector vaccine.&nbsp;"},"type":"p","style":{}},{"id":"html228","cntnt":{"mrkup":"<b>Approval status:</b> On June 25, 2020, CanSino <a href=\"https://www.nature.com/articles/d41586-020-02244-1\" target=\"_blank\">became the first company to receive limited approval</a> to use its vaccine in people even though it was still in the second phase of its clinical trials. At the time, the Chinese government <a href=\"https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ\" target=\"_blank\">pproved</a> the vaccine for military use only, for a period of one year. Since then, the vaccine <a href=\"https://covid19.trackvaccines.org/vaccines/2/\" target=\"_blank\">has been approved</a> in China, Argentina, Hungary, and other countries."},"type":"p","style":{}},{"id":"html229","cntnt":{"mrkup":"<b>Efficacy and safety:</b> Preliminary results from phase two trials, <a href=\"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext\" target=\"_blank\">published in <i>The Lancet</i></a>, have shown that the vaccine produces “significant immune responses in the majority of recipients after a single immunisation.” There were no serious adverse reactions documented."},"type":"p","style":{}},{"id":"html230","cntnt":{"mrkup":"<b>Clinical trials status:</b> On December 21, CanSino <a href=\"https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio/china-cansinobios-covid-19-vaccine-trials-recruit-over-20000-people-idUSKBN28V1N8\" target=\"_blank\">announced</a> that it has recruited more than 20,000 participants for its phase three trials in Pakistan, Russia, Mexico, and Chile. On August 15, Russian biopharmaceutical company Petrovax <a href=\"http://petrovax.com/press_centre/news/2020/1878/\" target=\"_blank\">announced</a> it had launched the first phase three clinical trial of Ad5-nCoV."},"type":"p","style":{}},{"id":"html231","cntnt":{"mrkup":"<a href=\"http://www.vector.nsc.ru/\" target=\"_blank\"><b>Vector Institute</b></a>"},"type":"h2","style":{}},{"id":"html232","cntnt":{"mrkup":"<b>Name:</b> EpiVacCorona"},"type":"p","style":{}},{"id":"html233","cntnt":{"mrkup":"<b>Who:</b> A Russian biotechnology institute."},"type":"p","style":{}},{"id":"html234","cntnt":{"mrkup":"<b>What:</b> A protein vaccine, namely it uses small fragments of viral antigens called peptides to produce an immune response."},"type":"p","style":{}},{"id":"html235","cntnt":{"mrkup":"<b>Approval status:</b> On October 14, 2020, Russia <a href=\"https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html\" target=\"_blank\">granted</a> regulatory approval to EpiVacCorona even though the vaccine candidate had not published any results and had not entered phase three of its clinical trials. It is the second vaccine candidate that Russia approved for use despite a lack of published evidence about its safety and efficacy. It has since been approved for use in Turkmenistan and authorized for emergency use in Belarus."},"type":"p","style":{}},{"id":"html236","cntnt":{"mrkup":"<b>Efficacy and safety:</b> On January 13, 2021, Russian state news agency TASS <a href=\"https://tass.com/society/1244333\" target=\"_blank\">reported</a> that of the more than 2,000 volunteers who had received both doses of EpiVacCorona’s two-dose regimen, none reported adverse reactions from the vaccine.&nbsp;"},"type":"p","style":{}},{"id":"html237","cntnt":{"mrkup":"<b>Clinical trials:</b> In November 2020 Russia <a href=\"https://www.reuters.com/article/us-health-coronavirus-russia-cases-idUSKBN28A0P0\" target=\"_blank\">launched</a> mass trials of its EpiVacCorona vaccine; the trials will inoculate 150 people over the age of 60 and 3,000 volunteers over the age of 18."},"type":"p","style":{}},{"id":"html238","cntnt":{"mrkup":"<a href=\"https://zyduscadila.com/research\" target=\"_blank\"><b>Zydus Cadila</b></a>"},"type":"h2","style":{}},{"id":"html239","cntnt":{"mrkup":"<b>Name:</b> ZyCoV-D"},"type":"p","style":{}},{"id":"html240","cntnt":{"mrkup":"<b>Who:</b> An Indian pharmaceutical company."},"type":"p","style":{}},{"id":"html241","cntnt":{"mrkup":"<b>What:</b> A DNA-based vaccine that is <a href=\"https://timesofindia.indiatimes.com/india/vaccines-that-can-help-india-in-its-fight-against-covid-19/articleshow/79303893.cms\" target=\"_blank\">delivered by a skin patch</a>."},"type":"p","style":{}},{"id":"html242","cntnt":{"mrkup":"<b>Approval status:</b> Approved for emergency use in India."},"type":"p","style":{}},{"id":"html243","cntnt":{"mrkup":"<b>Safety and efficacy:</b> In December 2020 Zydus Cadila <a href=\"https://timesofindia.indiatimes.com/india/zydus-cadila-seeks-govt-nod-to-start-phase-iii-clinical-trials-of-covid-19-vaccine/articleshow/79944346.cms\" target=\"_blank\">said</a> that a combined phase one/two study of its vaccine showed it was safe and prompted an immunogenic response, but the company did not share any data."},"type":"p","style":{}},{"id":"html244","cntnt":{"mrkup":"<b>Clinical trials:</b> On January 3, 2021, Zydus Cadila <a href=\"https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_receives_approvals_from_the_DCGI_to_start_Phase_III_Clinical_Trial_of_ZyCoV_D_fully_indigenously_developed_vaccine_-3_1_2021.pdf\" target=\"_blank\">announced</a> it had received approval from Indian regulators to launch a phase three trial testing the safety and efficacy of its vaccine in about 30,000 volunteers."},"type":"p","style":{}},{"id":"html245","cntnt":{"mrkup":"<a href=\"http://en.zhifeishengwu.com/about/zfgk/\" target=\"_blank\"><b>Anhui Zhifei</b></a>"},"type":"h2","style":{}},{"id":"html246","cntnt":{"mrkup":"<b>Name:</b> ZF2001"},"type":"p","style":{}},{"id":"html247","cntnt":{"mrkup":"<b>Who:</b> A Chinese biopharmaceutical company, in partnership with the Institute of Microbiology at the Chinese Academy of Sciences."},"type":"p","style":{}},{"id":"html248","cntnt":{"mrkup":"<b>What:&nbsp;</b>A subunit vaccine that uses pieces of protein from a pathogen to trigger an immune response."},"type":"p","style":{}},{"id":"html249","cntnt":{"mrkup":"<b>Approval status:</b> Approved for use in China, Indonesia, and Uzbekistan."},"type":"p","style":{}},{"id":"html250","cntnt":{"mrkup":"<b>Efficacy and safety:</b> In August 2021 a study of the company’s phase one and two clinical trials <a href=\"https://linkinghub.elsevier.com/retrieve/pii/S1473309921001274\" target=\"_blank\">published in <i>The Lancet</i>&nbsp;</a>showed that the vaccine elicited neutralizing antibodies and that the most common adverse reactions were cough, fever, and headache."},"type":"p","style":{}},{"id":"html251","cntnt":{"mrkup":"<b>Clinical trials:</b> In November 2020 Chinese health officials <a href=\"http://en.nhc.gov.cn/2020-11/20/c_82209.htm\" target=\"_blank\">announced</a> the launch of phase three trials for the Anhui Zhifei vaccine. The trials—which aimed to recruit 29,000 volunteers aged 18 or older—were expected to be conducted in China, Indonesia, Pakistan, and Ecuador."},"type":"p","style":{}},{"id":"html252","cntnt":{"mrkup":"<a href=\"https://www.biosafety.kz/en/\" target=\"_blank\"><b>Research Institute for Biological Safety Problems</b></a>"},"type":"h2","style":{}},{"id":"html253","cntnt":{"mrkup":"<b>Name:</b> QazCovid-in"},"type":"p","style":{}},{"id":"html254","cntnt":{"mrkup":"<b>Who:</b> A research institute in Kazakhstan."},"type":"p","style":{}},{"id":"html255","cntnt":{"mrkup":"<b>What:</b> An inactivated vaccine."},"type":"p","style":{}},{"id":"html256","cntnt":{"mrkup":"<b>Approval status:</b> Granted temporary registration in Kazakhstan in January 2021 despite a lack of data from its phase three clinical trials."},"type":"p","style":{}},{"id":"html257","cntnt":{"mrkup":"<b>Efficacy and safety:&nbsp;</b>In August 2021 a study of the vaccines phase one and phase two clinical trials <a href=\"https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00358-8/fulltext\" target=\"_blank\">published in <i>The Lancet</i></a> found that the vaccine was safe with no severe adverse events recorded. The studies also found the vaccine elicited a neutralizing antibody response as well as a T-cell response."},"type":"p","style":{}},{"id":"html258","cntnt":{"mrkup":"<b>Clinical trials status:</b> In December 2020, the institute <a href=\"https://www.biosafety.kz/en/uncategorized/рабочий-визит-в-ниипбб-премьер-минист-2/\" target=\"_blank\">announced</a> that the Kazakh Ministry of Health approved the launch of phase three trials to assess the vaccine’s safety and efficacy in 3,000 volunteers."},"type":"p","style":{}},{"id":"html259","cntnt":{"mrkup":"<a href=\"http://www.imb.com.cn/en/about.aspx\" target=\"_blank\"><b>Institute of Medical Biology at the Chinese Academy of Medical Sciences</b></a>"},"type":"h2","style":{}},{"id":"html260","cntnt":{"mrkup":"<b>Name:</b> Unknown"},"type":"p","style":{}},{"id":"html261","cntnt":{"mrkup":"<b>Who:</b> A Chinese research institute."},"type":"p","style":{}},{"id":"html262","cntnt":{"mrkup":"<b>What:</b> An inactivated vaccine that requires two doses taken 14 days apart."},"type":"p","style":{}},{"id":"html263","cntnt":{"mrkup":"<b>Approval status:</b> Not approved for use."},"type":"p","style":{}},{"id":"html264","cntnt":{"mrkup":"<b>Clinical trials:</b> In December 2020, researchers <a href=\"https://clinicaltrials.gov/ct2/show/NCT04659239\" target=\"_blank\">launched phase three clinical trials</a> to test the efficacy and safety of the vaccine in 34,020 participants in Malaysia and Brazil.&nbsp;"},"type":"p","style":{}},{"id":"html265","cntnt":{"mrkup":"<b>Safety and efficacy:</b> Preliminary results of the vaccine’s phase one trial <a href=\"https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf\" target=\"_blank\">showed</a> that it prompted an immune response with no serious adverse incidents."},"type":"p","style":{}},{"id":"html266","cntnt":{"mrkup":"<a href=\"https://www.pfizer.com/science/coronavirus/vaccine\" rel=\"noopener noreferrer\" target=\"_blank\"></a>"},"type":"h2","style":{}},{"id":"inline-2","cntnt":{"id":"inline-2","cmsType":"editorsNote","note":"<p><b>Editor's note:</b> This story was originally published on July 31, 2020. It was regularly updated as developments occurred until November 2021.</p>"},"type":"inline","style":{}}],"cid":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a","cntrbGrp":[{"contributors":[{"displayName":"Amy McKeever"},{"displayName":"National Geographic Staff"}],"title":"By","rl":"Writer"}],"mode":"richtext","dt":"2021-10-29T19:32:02.702Z","dscrptn":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","enableAds":true,"endbug":true,"isMetered":false,"isUserAuthed":false,"isTruncated":false,"isEntitled":false,"freemiumContentGatingEnabled":true,"premiumContentGatingEnabled":false,"ldMda":{"cmsType":"image","hasCopyright":true,"id":"a00b6ac5-fc87-4ce4-8dad-0a75c51b17ab","lines":3,"positionMetaBottom":true,"showMore":true,"caption":"A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech COVID-19 vaccine at Boston Medical Center.","credit":"Photograph by Adam Glanzman, Bloomberg via Getty Images","image":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg","src":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg","altText":"A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston.","crdt":"Photograph by Adam Glanzman, Bloomberg via Getty Images","dsc":"A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech Covid-19 vaccine at Boston Medical Center in Boston, on Thursday, June 17, 2021.","ttl":"Covid Vaccine"},"imageAlt":"A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston.","imageSrc":[{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=374&h=561","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=748&h=1122"},"media":"(max-width: 374px)"},{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=413&h=620","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=826&h=1240"},"media":"(max-width: 413px)"},{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg?w=718&h=539","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg?w=1436&h=1078"},"media":"(min-width: 414px)"}],"hideTitle":true,"hideCredit":false,"hideEndBug":true,"type":"imageLead","hideLine":true,"deferImages":false},"mdDt":"2021-11-05T18:27:36.476Z","pbDt":"2021-10-29T19:32:02.702Z","readTime":"55 min read","schma":{"athrs":[{"name":"Amy McKeever"},{"name":"National Geographic Staff"}],"cnnicl":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","kywrds":"covid19, coronavirus vaccine, coronavirus vaccine tracker, vaccine tracker, immunization, moderna, johnson & johnson, sinopharm, vaccination, immune system, public health, epidemics, masks, delta, variants, booster shots","lg":"https://assets-cdn.nationalgeographic.com/natgeo/static/default.NG.logo.dark.jpg","pblshr":"National Geographic","abt":"Coronavirus","sclDsc":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","sclImg":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg?w=1200","sclTtl":"Here’s the latest on COVID-19 vaccines"},"sctn":"Science","sctnLbls":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"title":"Here’s the latest on COVID-19 vaccines","wrdcnt":10602,"trnctnMssg":{"id":"freemium-truncation-tile-1","cmsType":"PaywallTile","subtype":"truncation","title":"Unlock this story for free","subtitle":"Create an account to read the full story and get unlimited access to hundreds of Nat Geo articles.","ctas":[{"text":"Sign Up","target":"_self","type":"oneid","useOneID":true},{"text":"Sign In.","target":"_self","type":"oneid","useOneID":true}],"firstText":"for your free account.","secondText":"If you already have an account,","campaignName":"20230328_freemium_general_global_truncation"},"upsell":{"upsell":{"id":"48060d6c-224b-46fa-81ba-4d4164841dc8","cmsType":"PromoTile","title":"For Hungry Minds","description":" ","ctas":[{"text":"GIFT NAT GEO KIDS","url":"https://ngkidsubs.nationalgeographic.com/servlet/OrdersGateway?cds_mag_code=NKD&cds_page_id=276847&cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=bau_kids_may2024::int_add=article_promo","target":"_blank"}],"image":{"crps":[{"nm":"raw","url":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg"}],"rt":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg","src":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg"},"campaignName":"20240501_NGKBAU_MarketingPromo"}},"prismData":{"mainComponents":[{"name":"LeadMediaImage","props":{"caption":{"credit":"Photograph by Adam Glanzman, Bloomberg via Getty Images","source":null,"text":"A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech COVID-19 vaccine at Boston Medical Center.","lines":3,"showMoreText":"Read More"},"image":{"alt":"A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston.","src":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg","sources":[{"src":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=374&h=249","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=748&h=498"},"max":374,"nativeWidth":374},{"src":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=413&h=275","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=826&h=550"},"max":413,"min":375,"nativeWidth":413},{"src":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=718&h=479","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg?w=1436&h=958"},"min":414,"nativeWidth":718}],"fetchPriority":"high"},"marginTop":false,"ratio":"3x2"},"config":{},"usesArticleObject":true},{"name":"PrismBadgeTag","props":{"badge":null,"tags":{"tags":[{"label":"SCIENCE","href":"https://www.nationalgeographic.com/science"},{"label":"CORONAVIRUS COVERAGE","href":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}]},"isUserAuthed":false},"config":{}},{"name":"Headline","props":{"title":"Here’s the latest on COVID-19 vaccines","description":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout."},"config":{},"usesArticleObject":true},{"name":"Byline","props":{"contributors":[{"name":"Amy McKeever","role":"writer","labelOverride":"By"},{"name":"National Geographic Staff","role":"writer","labelOverride":"By"}],"logoRadius":true,"publishedDate":{"date":"2021-10-29T19:32:02.702Z","postFormat":"MMMM DD, YYYY","preFormat":"MMMM DD, YYYY"},"shareProps":{"title":"Here’s the latest on COVID-19 vaccines","url":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","pageType":"Story","source":"NatGeo","shareButton":"inline","size":"l","networks":["facebook","twitter","email","link"],"description":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout."},"readTime":"55 min read"},"config":{},"usesArticleObject":true},{"name":"Divider","props":{"className":"natgeoDivider"},"config":{},"usesArticleObject":true},{"name":"Body","props":{"body":[[{"type":"inline","content":{"name":"EditorsNote","props":{"body":"<p><b>Editor’s note:</b> As of November 2021, this COVID-19 vaccine tracker is no longer being updated. <a href=\"https://www.nationalgeographic.com/science/article/covid-vaccines-latest-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Stay up-to-date on the latest vaccine developments and other COVID-19 news here</a>.</p>","header":null},"context":{},"config":{"align":"full"}}},{"type":"inline","content":{"name":"MarkupEmbed","props":{"a11yCTAText":"More Details","markup":"%3Clink%20rel%3D%22stylesheet%22%20href%3D%22//interactives.natgeofe.com/vendor/css/partial-aem-main.css%22%3E%0A%3Chr%20style%3D%22%u201Cwidth%3A50%25%3B%22%20border-top%3A1px%20solid%20%23ccc%3B%20margin%3A1em%20auto%3B%u201D%3E","caption":{"title":null,"text":"","lines":3,"showMoreText":"Read More"},"encMethod":"esc","useSafeFrame":false,"requestProps":{"stateKey":"markup"},"tmsEnabled":true},"context":{},"config":{"align":"full","alignXxs":"full"}}},{"type":"p","content":["COVID-19 vaccines have reached consumers in record time. Though the process can typically take ",{"type":"a","content":["10 to 15 years"],"attrs":{"href":"https://www.weforum.org/agenda/2020/06/vaccine-development-barriers-coronavirus/"}},", the U.S. Food and Drug Administration has granted emergency authorization to vaccines made by Pfizer, Moderna, and Johnson ","&"," Johnson in less than a year. Before now, the fastest-ever vaccine—for mumps—",{"type":"a","content":["took four years"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/why-coronavirus-vaccine-could-take-way-longer-than-a-year"}}," to develop in the 1960s."]},{"type":"p","content":["Fortunately, scientists had started working on the seeds of these vaccines long before COVID-19 emerged–teams were doing ",{"type":"a","content":["breakthrough work on mRNA technology for 12 years"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/these-scientists-spent-twelve-years-solving-puzzle-yielded-coronavirus-vaccines","target":"_blank"}}," before the pandemic, and a global push to make clinical trials for COVID-19 more efficient helped ensure the world had safe, effective drugs in record time."]},{"type":"p","content":["Even after a vaccine is authorized or fully licensed, it faces potential roadblocks when it comes to scaling up production and distribution, which also includes ",{"type":"a","content":["deciding which populations should get it first"],"attrs":{"href":"https://hub.jhu.edu/2020/07/01/covid-vaccine-ethics-faden/"}},"—and at what cost."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-1"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["Here’s everything you need to know—including primers on how vaccines and clinical trials work, the latest news on vaccine distribution and safety, and a detailed breakdown of the early candidates."]},{"type":"h2","content":["Vaccines and clinical trials",{"type":"a","content":[],"attrs":{"id":"vaccineclinicaltrials"}}]},{"type":"p","content":["Vaccines go through ",{"type":"a","content":["a three-stage clinical trial process"],"attrs":{"href":"https://www.cdc.gov/vaccines/basics/test-approve.html","target":"_blank"}}," that’s required before they are sent to regulatory agencies for approval. Given the urgent need, some vaccine developers compressed the clinical process for SARS-CoV-2 by running trial phases simultaneously."]},{"type":"inline","content":{"name":"Listicle","props":{"title":"VACCINE CLINICAL TRIAL PROCESS","body":"<p><b>Phase one:</b> Checks the safety of a vaccine and determines whether it triggers an immune response in a small group of healthy humans.&nbsp;</p><p><b>Phase two:</b> Widens the testing pool to include groups of people who may have the disease or be more likely to catch it, to gauge the vaccine’s effectiveness.&nbsp;</p><p><b>Phase three:</b> Expands the pool up to the thousands to make sure the vaccine is safe and effective among a wider array of people, given that immune response can vary by age, ethnicity, or by underlying health conditions.</p>","description":"","richTextElement":"div"},"context":{},"config":{"align":"full"}}},{"type":"p","content":["The COVID-19 candidates, like all vaccines, essentially aim to instruct the immune system to mount a defense, which is sometimes ",{"type":"a","content":["stronger than what would be provided through natural infection"],"attrs":{"href":"https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-safety/immune-system-and-health"}}," and ",{"type":"a","content":["comes"],"attrs":{"href":"https://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/"}}," with ",{"type":"a","content":["fewer health consequences"],"attrs":{"href":"https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html"}},"."]},{"type":"inline","content":{"name":"CommercePromo","props":{"layout":"standard","headline":"For Hungry Minds","description":" ","imageSrc":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg","imageRatio":"4x3","actionLabel":"GIFT NAT GEO KIDS","actionHref":"https://ngkidsubs.nationalgeographic.com/servlet/OrdersGateway?cds_mag_code=NKD&cds_page_id=276847&cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=bau_kids_may2024::int_add=article_promo","immersive":true,"colorMode":"dark","campaignName":"20240501_NGKBAU_MarketingPromo","tint":1,"inlineId":"commerce-promo-inline","className":"prism-commerce-container","dividerEnabled":false},"context":{},"config":{"align":"center","alignXxs":"full"}}},{"type":"p","content":["To do so, traditional vaccines use the whole coronavirus, but in a killed or weakened state. Others use only part of the virus—whether a protein or a fragment. Some transfer the instructions for coronavirus proteins into an unrelated virus that is unlikely or even incapable of causing disease. Finally, cutting-edge vaccines under development rely on deploying pieces of the coronavirus’s genetic material, enabling our cells to temporarily make coronavirus proteins needed to stimulate our immune systems. (",{"type":"a","content":["Find out more about vaccines and how they work"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/searching-for-coronavirus-vaccine-how-would-it-work"}},".)"]},{"type":"inline","content":{"name":"Listicle","props":{"title":"TYPES OF VACCINES","body":"<p><b>Nucleic acid:</b> Relies on injecting snippets of a virus’s genetic material, either DNA or messenger RNA (mRNA), into human cells. It spurs the production of viral proteins that mimic features of the coronavirus, training the immune system to recognize its presence.&nbsp;</p><p><b>Knocked-out virus:</b> Uses a non-infectious form of the coronavirus that can no longer cause full-blown disease but can still provoke an immune response. The virus can either be fully inactivated or weakened. These modes are considered the most classic ways to make vaccines.</p><p><b>Viral vector:</b> Essentially a “Trojan horse” presented to the immune system. One type involves introducing a piece of DNA from SARS-CoV-2 into another unrelated germ—for example, an adenovirus, which typically causes the common cold. When this modified adenovirus is injected into humans, the hope is that it will instruct cells to make coronavirus proteins and will trigger an immune response.</p><p><b>Protein:</b> These vaccines are typically made from coronavirus proteins, which can be synthesized or brewed in labs like beer. Some versions involve coating a carrier—such as nanoparticles—with proteins to better aid delivery and uptake by cells.</p>","description":"","richTextElement":"div"},"context":{},"config":{"align":"full"}}},{"type":"h2","content":["U.S. vaccine rollout",{"type":"a","content":[],"attrs":{"id":"vaccinerollout"}}]},{"type":"p","content":["Three COVID-19 vaccines are available for use in the United States. U.S. regulators have approved Pfizer’s vaccine for adults and authorized it for emergency use in children and adolescents ages five to 17. The U.S. has also granted emergency use authorization to administer the Moderna and Johnson ","&"," Johnson vaccines to adults."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["Some populations in the country are eligible for booster doses. Anyone who received a Johnson ","&"," Johnson single-shot jab can get a second dose after at least two months. People who received the Pfizer and Moderna vaccines are eligible for a third dose after six months if they are over 65 or have an underlying condition that makes them more susceptible to severe COVID-19. People whose institutional or occupational settings put them at high risk of exposure to the coronavirus may also get a booster shot. U.S. regulators have permitted people to mix-and-match their jabs in the wake of data suggesting that people who originally received the Johnson ","&"," Johnson vaccine are protected by a booster dose of the Pfizer or Moderna vaccines."]},{"type":"p","content":["U.S. regulators have also recommended a third dose of the Pfizer and Moderna vaccines for people with compromised immune systems. This extra dose is considered part of their primary vaccination series; CDC guidance ",{"type":"a","content":["suggests"],"attrs":{"href":"https://www.nbcnews.com/health/health-news/immunocompromised-people-can-receive-4th-covid-shot-cdc-says-rcna3933","target":"_blank"}}," that immunocompromised people will be able to get a fourth booster dose six months after completing the primary series.",{"type":"a","content":[],"attrs":{"href":"https://www.npr.org/sections/health-shots/2021/09/02/1033299418/cdc-warns-against-off-label-use-of-covid-vaccine","target":"_blank"}}]},{"type":"h2","content":["Global vaccine rollout"]},{"type":"p","content":["The World Health Organization is coordinating global efforts to administer vaccines, with an eye toward ",{"type":"a","content":["delivering two billion doses"],"attrs":{"href":"https://www.who.int/news-room/detail/26-06-2020-act-accelerator-update","target":"_blank"}}," by the end of 2021. It is leading an initiative through the COVAX Facility to ensure that all countries have equitable access. The WHO has approved the Pfizer-BioNTech, AstraZeneca-Oxford, Johnson ","&"," Johnson, Moderna, Sinopharm, Sinovac, and Bharat Biotech vaccines for emergency use."]},{"type":"h2","content":["Vaccine safety"]},{"type":"p","content":["On July 13, the U.S. Food and Drug Administration ",{"type":"a","content":["added a warning label"],"attrs":{"href":"https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021","target":"_blank"}}," to Johnson ","&"," Johnson’s vaccine after it was linked to rare cases of Guillain-Barré Syndrome, an autoimmune disorder that can lead to paralysis. There have been 100 preliminary reports of the syndrome among the approximately 12.5 million people who have received the vaccine. The FDA said that the benefits of receiving the vaccine outweigh the risks."]},{"type":"p","content":["The FDA has also added a warning label to the Pfizer and Moderna vaccines about ",{"type":"a","content":["rare cases of heart inflammation"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly","target":"_blank"}}," in adolescents and young adults. The move came after the CDC’s Advisory Committee on Immunization Practices ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly","target":"_blank"}}," that it has identified more than 300 cases of myocarditis and pericarditis that it acknowledged are likely linked to the vaccines. The agency says these cases are rare but higher than expected. It also said the benefits of the shots outweigh the risks."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-2"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[" ","In April, the European Medicines Agency issued statements saying that unusual blood clots should be listed as a very rare but possible side effect of both the ",{"type":"a","content":["AstraZeneca"],"attrs":{"href":"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood","target":"_blank"}}," and ",{"type":"a","content":["Johnson ","&"," Johnson"],"attrs":{"href":"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood","target":"_blank"}}," vaccines. In a review of 86 reported cases related to the AstraZeneca vaccine, the EMA’s safety committee found a potential link between it and the clots, with most known cases occurring in women under age 60 within two weeks of receiving the first dose. The EMA stressed that the odds of developing a clot after vaccination are extremely low, and that the benefits of getting vaccinated outweigh the risks. They also recommend that people seek immediate medical attention if they experience symptoms related to clotting, including persistent pain, shortness of breath, and headaches or blurred vision."]},{"type":"p","content":["On August 27, a study published in the ",{"type":"i","content":["British Medical Journal"]}," affirmed the EMA’s risk-benefit analysis, showing that there’s ",{"type":"a","content":["a much higher risk of developing blood clots after SARS-CoV-2"],"attrs":{"href":"https://www.bmj.com/content/374/bmj.n1931","target":"_blank"}}," infection than after immunization with the AstraZeneca or Pfizer vaccines."]},{"type":"p","content":["On August 11, the CDC officially recommended that ",{"type":"a","content":["people who are pregnant, breastfeeding, or may become pregnant get a COVID-19 vaccine"],"attrs":{"href":"https://www.cdc.gov/media/releases/2021/s0811-vaccine-safe-pregnant.html","target":"_blank"}},". A new analysis of data from the vaccine rollout found no increased risk of miscarriage among people who received an mRNA vaccine before 20 weeks of pregnancy. Earlier studies also showed that the vaccine is safe later in pregnancy as well—for both pregnant people and their babies. The CDC ",{"type":"a","content":["emphasized the urgency of vaccination among these groups"],"attrs":{"href":"https://emergency.cdc.gov/han/2021/han00453.asp","target":"_blank"}}," in a health alert issued on September 29, reporting new data showing a rise in COVID-19-related deaths among pregnant people."]},{"type":"h2","content":["Vaccine prospects",{"type":"a","content":[],"attrs":{"id":"vaccineprospects"}}]},{"type":"p","content":["Here are some of the vaccines that have made it to phase three and beyond:"]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Pfizer"]}],"attrs":{"href":"https://www.pfizer.com/science/coronavirus/vaccine","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"BNT162b2"," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-3"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Who:"]}," One of the world’s largest pharmaceutical companies, based in New York, in collaboration with German biotech company BioNTech."]},{"type":"p","content":[{"type":"b","content":["What:"," "]},"A nucleic-acid vaccine that requires two doses taken 21 days apart."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," On December 2, the U.K. became ",{"type":"a","content":["the first Western country"],"attrs":{"href":"https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine","target":"_blank"}}," to approve any COVID-19 vaccine when it authorized the Pfizer-BioNTech candidate—making the drug the first mRNA vaccine in history allowed for human use. The FDA ",{"type":"a","content":["granted emergency use authorization"," "],"attrs":{"href":"https://www.nytimes.com/2020/12/11/health/pfizer-vaccine-authorized.html?action=click&module=Top%20Stories&pgtype=Homepage","target":"_blank"}},"to this vaccine on December 11, 2020, and fully approved it on August 23, 2021. The vaccine has also been ",{"type":"a","content":["granted emergency approval"],"attrs":{"href":"https://www.cbc.ca/news/politics/vaccine-rollout-plan-phac-1.5833912","target":"_blank"}}," in Canada, the ",{"type":"a","content":["European Union"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union","target":"_blank"}},", and other countries."]},{"type":"p","content":["U.S. regulators have also approved Pfizer’s vaccine for emergency use in children and adolescents ages five to 15. U.K. regulators have also ",{"type":"a","content":["approved"],"attrs":{"href":"https://www.reuters.com/world/uk/uk-approves-pfizerbiontech-covid-shot-12-15-year-olds-2021-06-04/","target":"_blank"}}," this vaccine for use among adolescents ages 12 to 15, while the European Union ",{"type":"a","content":["granted conditional authorization"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european","target":"_blank"}},"."]},{"type":"p","content":["As of September 24 U.S. regulators granted emergency use authorization of a third dose of Pfizer’s vaccine—but only for certain subgroups of the national population, including older people and those with underlying conditions that put them at higher risk of disease and for people in occupational or institutional settings that put them at high risk of infection, such as health-care workers and teachers."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Distribution:"]}," Globally, Pfizer expects to be able to produce up to 1.3 billion doses by the end of 2021. Questions have been raised over the vaccine’s storage, which requires ultra-cold freezers set at minus 70 degrees Celsius (-94 degrees F). On February 19, however, Pfizer and BioNTech ",{"type":"a","content":["said"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data","target":"_blank"}}," that their vaccine can remain stable for two weeks at temperatures between minus 25℃ and minus 15℃ (-13℉ to 5℉), a common range in pharmaceutical freezers and refrigerators. The finding would allow for easier distribution of the vaccine in communities where ultra-cold storage requirements present a challenge."," "]},{"type":"p","content":[{"type":"b","content":["Efficacy:"," "]},"On September 20, Pfizer ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results","target":"_blank"}}," that a study of its clinical trials shows its vaccine is safe and highly effective in children ages five to 11. Researchers determined that two low doses administered three weeks apart elicit high levels of neutralizing antibodies among children, with side effects comparable to those seen in people ages 16 to 25. The 10-milligram doses of vaccine are a third of what has been approved among older age groups. The company later ",{"type":"a","content":["released"],"attrs":{"href":"https://www.fda.gov/media/153409/download","target":"_blank"}}," an analysis of its clinical trials showing that the vaccine is 90.7 percent effective in preventing symptomatic disease among kids in this age group."]},{"type":"p","content":["Pfizer also expects to release data soon on how well its vaccine works among children ages six months to five years, according to CEO Albert Bourla. In a public forum, he said the data ",{"type":"a","content":["could be available as early as the end of October"],"attrs":{"href":"https://www.cnbc.com/2021/09/14/pfizers-covid-vaccine-data-for-kids-under-age-5-may-come-in-late-october-ceo-says-.html","target":"_blank"}},"."]},{"type":"p","content":["On August 25, Pfizer announced new data showing that ",{"type":"a","content":["a third dose of its vaccine generates robust quantity of neutralizing antibodies"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission","target":"_blank"}}," that is more than three times higher than what was observed one month after the second dose."]},{"type":"p","content":["A preprint study out of the United Kingdom shows that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant ",{"type":"a","content":["but that their efficacy wanes over time"],"attrs":{"href":"https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf","target":"_blank"}},". Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, the both vaccines still significantly reduce the risk of infection."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On July 8, a study published in ",{"type":"i","content":["Nature"]}," demonstrated that people who have received both doses of the Pfizer or AstraZeneca vaccines ",{"type":"a","content":["remain fully protected against severe disease, hospitalization, and death"],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03777-9","target":"_blank"}}," from the Delta and Beta variants. However, a single dose of either vaccine was not as protective."]},{"type":"p","content":["The findings corroborate an earlier study ",{"type":"a","content":["published in ",{"type":"i","content":["Nature"]}],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03738-2_reference.pdf","target":"_blank"}}," showing that the Pfizer and Moderna vaccines elicit “robust and prolonged” immune responses. ",{"type":"a","content":["As the ",{"type":"i","content":["New York Times"]}," reported at the time"],"attrs":{"href":"https://www.nytimes.com/2021/06/28/health/coronavirus-vaccines-immunity.html?partner=slack&smid=sl-share","target":"_blank"}},", the findings suggested that people who are immunized with these vaccines may not need booster shots as protection may last for years so long as the virus doesn’t mutate to evade it."]},{"type":"p","content":["On June 10, a study ",{"type":"a","content":["published in the journal ",{"type":"i","content":["Nature"]}],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03693-y","target":"_blank"}}," showed that two doses of the Pfizer vaccine protects against several virus variants, including the ",{"type":"a","content":["Delta and Eta variants"],"attrs":{"href":"https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/","target":"_blank"}},". The news came a few days after the CDC ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.cdc.gov/media/releases/2021/p0607-mrna-reduce-risks.html","target":"_blank"}}," that the Pfizer and Moderna vaccines reduce the risk of infection by 91 percent for fully vaccinated people."," "]},{"type":"p","content":["In April, the CDC ",{"type":"a","content":["released a study"],"attrs":{"href":"https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_e&ACSTrackingID=USCDC_921-DM53321&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20March%2029%2C%202021&deliveryName=USCDC_921-DM53321","target":"_blank"}}," of the U.S. vaccine rollout showing that the Pfizer-BioNTech and Moderna vaccines are 90 percent effective in preventing symptomatic COVID-19 in real-world conditions. The study analyzed the efficacy of the two mRNA vaccines among nearly 4,000 health-care workers, first responders, and other frontline workers who were the first to receive the jab in the U.S. It also showed the vaccines are 80-percent effective after one dose. The findings confirmed earlier studies from ",{"type":"a","content":["the U.K."],"attrs":{"href":"https://www.nytimes.com/live/2021/02/26/world/covid-19-coronavirus#pfizer-vaccine-protection","target":"_blank"}}," and ",{"type":"a","content":["Israel"],"attrs":{"href":"https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900448-7","target":"_blank"}},"."]},{"type":"p","content":["On December 10, the ",{"type":"i","content":["New England Journal of Medicine"]}," ",{"type":"a","content":["published"],"attrs":{"href":"https://www.nejm.org/doi/full/10.1056/NEJMoa2034577","target":"_blank"}}," the results of Pfizer’s phase three study, showing the vaccine was safe and 95-percent effective in protecting against COVID-19 in people 16 and older. Pfizer and BioNTech have also ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal","target":"_blank"}}," that a phase three trial shows that their vaccine is safe and 100 percent efficacious among children between the ages of 12 and 15, and that it elicited robust antibody responses."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-4"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Safety:"," "]},"On June 23, the U.S. Food and Drug Administration ",{"type":"a","content":["said"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/","target":"_blank"}}," it plans to add a warning label to the Pfizer and Moderna vaccines about ",{"type":"a","content":["rare cases of heart inflammation"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly","target":"_blank"}}," in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks."]},{"type":"p","content":["Severe allergic reactions following immunization with the Pfizer-BioNTech vaccine have been reported in many countries. White House advisor Anthony Fauci ",{"type":"a","content":["told CNBC"],"attrs":{"href":"https://www.cnbc.com/video/2020/12/16/dr-anthony-fauci-with-meg-tirrell-for-special-edition-of-healthy-returns.html","target":"_blank"}}," in December that some adverse reactions are expected when a vaccine is distributed to a wider population. Regulators in the U.S. and U.K. have also released reports offering reassurances that severe reactions are rare."]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On November 18, Pfizer and BioNTech ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine","target":"_blank"}}," the conclusion of their phase three trials. The trials ",{"type":"a","content":["launched in July"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0","target":"_blank"}},", enrolling a diverse population in areas with significant SARS-CoV-2 transmission. Pfizer later ",{"type":"a","content":["expanded the trial"," "],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19","target":"_blank"}},"to include 44,000 people across multiple countries."," "]},{"type":"p","content":["On February 18, Pfizer and BioNTech ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate","target":"_blank"}}," the launch of a phase two/three clinical trial to study the vaccine’s safety and efficacy among 4,000 pregnant women over the age of 18. The companies also launched a phase 1/2/3 study in children between the ages of six months and 11 years."]},{"type":"p","content":["On June 8, Pfizer ",{"type":"a","content":["said"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-start-large-study-test-covid-19-vaccine-children-below-12-2021-06-08/","target":"_blank"}}," that it would expand its clinical trials to a larger group of children under age 12. After a phase one study showed that the vaccine was safe and effective in a group of 144 children, the clinical trials enrolled up to 4,500 children at more than 90 sites in the U.S., Finland, Poland, and Spain. Pfizer tested a dose of 10 micrograms in children ages 5 to 11, and three micrograms for children from six months to five years old."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-5"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On July 8, Pfizer and Biotech ",{"type":"a","content":["announced"],"attrs":{"href":"https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-provide-update-booster-program-light-delta","target":"_blank"}}," that they are developing an updated version of the vaccine ",{"type":"a","content":["that specifically targets the Delta variant"],"attrs":{"href":"https://cdn.pfizer.com/pfizercom/2021-07/Delta_Variant_Study_Press_Statement_Final_7.8.21.pdf?IPpR1xZjlwvaUMQ9sRn2FkePcBiRPGqw","target":"_blank"}},"."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Johnson ","&"," Johnson"]}],"attrs":{"href":"https://www.jnj.com/coronavirus","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"JNJ-78436735"]},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"One of the world’s largest multinational corporations, based in New Jersey, specializing in healthcare and pharmaceutical products."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A single-dose vector vaccine. (",{"type":"a","content":["Here’s how the Johnson ","&"," Johnson vaccine works"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/johnson-johnson-us-third-vaccine-how-it-works","target":"_blank"}},".)"]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Approved for use in the U.S., ",{"type":"a","content":["Bahrain"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-bahrain/bahrain-first-to-approve-johnson-johnson-covid-19-vaccine-for-emergency-use-regulator-idUSKBN2AP21X?feedType=RSS&feedName=healthNews","target":"_blank"}},", Canada, and the European Union."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On October 21 the CDC cleared the way for the U.S. to begin rolling out booster shots of Johnson ","&"," Johnson’s vaccine for all people ages 18 and older at least two months after a first dose."," "]},{"type":"p","content":["U.S. regulators also authorized mixing and matching vaccines—such as administering booster doses of the either Moderna or Pfizer vaccine to people who originally received the Johnson ","&"," Johnson vaccine. A ",{"type":"a","content":["preprint analysis of a National Institutes of Health study"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf","target":"_blank"}}," shows that a booster dose of the mRNA vaccines elicit a stronger immune response than another dose of the Johnson ","&"," Johnson shot."," "]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," On March 2, the U.S. ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.washingtonpost.com/politics/2021/03/02/joe-biden-live-updates/","target":"_blank"}}," that Johnson ","&"," Johnson has partnered with its competitor Merck to increase the supply of its COVID-19 vaccine. Merck will dedicate two facilities to producing the vaccine, which could double the amount of available doses. Biden said that the additional doses will allow the U.S. to vaccinate all adults by the end of May."," "]},{"type":"p","content":["On June 11, the ",{"type":"i","content":["New York Times"]}," reported that the FDA ",{"type":"a","content":["has told"],"attrs":{"href":"https://www.nytimes.com/live/2021/06/11/world/covid-vaccine-coronavirus-mask","target":"_blank"}}," Johnson ","&"," Johnson to throw out 60 million doses made at its plant in Baltimore. The news came a day after ",{"type":"a","content":["CNN reported"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine","target":"_blank"}}," that the U.S. hasn’t sent any shipments of the vaccine since the first week of May due to a lack of supply caused by earlier issues at the plant. On June 10, Johnson ","&"," Johnson also ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-statement-on-fda-approval-of-shelf-life-extension-for-companys-covid-19-vaccine","target":"_blank"}}," that the FDA has approved an extension of the shelf life of its vaccine from three to four and a half months."," "]},{"type":"p","content":[{"type":"b","content":["Efficacy:"]}," In September 2021 Johnson ","&"," Johnson ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s","target":"_blank"}}," results of its studies of booster doses. When administered two months after the first jab, the booster is 100 percent effective against severe disease and causes antibody levels to rise four to six times higher than after the first shot. The second dose was also shown to be 75 percent effective against all symptomatic disease globally and 94 percent effective in the U.S. The company said that a booster shot administered six months after the first dose produced a 12-fold increase in antibody levels."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["The company also said that real-world evidence shows that its single-dose vaccine remains effective against COVID-19. The press release cited ",{"type":"a","content":["a study published to a preprint server"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2021.09.10.21263385v2","target":"_blank"}},", which shows that the vaccine remains 79 percent effective in preventing COVID-19 and 81 percent effective in preventing hospitalizations. An earlier study conducted by Johnson ","&"," Johnson ",{"type":"a","content":["shows"],"attrs":{"href":"https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response","target":"_blank"}}," that its vaccine offers strong protection against Delta that lasts for at least eight months."," "]},{"type":"p","content":["However, on July 20, the ",{"type":"i","content":["New York Times"]}," reported on a preliminary study showing that ",{"type":"a","content":["Johnson ","&"," Johnson’s vaccine is less effective against the Delta and Lambda variants"],"attrs":{"href":"https://www.nytimes.com/2021/07/20/health/coronavirus-johnson-vaccine-delta.html?partner=slack&smid=sl-share","target":"_blank"}}," than it was against the original virus strain. The paper notes that the results were obtained in a lab experiment and may not reflect the vaccine’s real-world efficacy."]},{"type":"p","content":["On February 24, an FDA analysis ",{"type":"a","content":["confirmed"],"attrs":{"href":"https://www.fda.gov/media/146217/download","target":"_blank"}}," Johnson ","&"," Johnson’s earlier report that its vaccine is safe and effective in preventing COVID-19. The report found the vaccine is 72-percent effective in preventing COVID-19 based on U.S. trials, and 85-percent effective in preventing severe disease across all regions. It also shows that the vaccine was 64-percent effective in preventing disease in the company’s South African trials, which is higher than had previously been reported."]},{"type":"p","content":["On June 9, a study ",{"type":"a","content":["published in the journal ",{"type":"i","content":["Nature"]}],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03681-2","target":"_blank"}}," showed that Johnson ","&"," Johnson’s vaccine is effective in protecting against virus variants, including the ",{"type":"a","content":["Beta and Gamma variants of concern"],"attrs":{"href":"https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/","target":"_blank"}},". The study showed that the vaccine elicits neutralizing antibodies and a T-cell response among people who live in areas where the variants are widely circulating, including Brazil and South Africa."," "]},{"type":"p","content":[{"type":"b","content":["Safety:"]}," On July 13, U.S. regulators ",{"type":"a","content":["added a warning to Johnson ","&"," Johnson’s vaccine"],"attrs":{"href":"https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021","target":"_blank"}}," in response to rare reports linking the shot to Guillain-Barré Syndrome, a disorder in which the body’s immune system attacks the nerves. The FDA said there have been about a hundred preliminary reports of the syndrome among the 12.8 million people who have received the Johnson ","&"," Johnson vaccine. It added that the benefits of receiving the vaccine still outweigh the risks."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-6"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["CDC officials told the ",{"type":"i","content":["Washington Post"]}," that the cases ",{"type":"a","content":["have mostly been reported about two weeks after vaccination among men"],"attrs":{"href":"https://www.washingtonpost.com/health/2021/07/12/johnson-and-johnson-warning/","target":"_blank"}},", many aged 50 or older, and that these cases will be discussed during an upcoming meeting of the CDC’s advisory committee."," "]},{"type":"p","content":["In the spring, the vaccine’s rollout was briefly halted ",{"type":"a","content":["in the U.S."],"attrs":{"href":"https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine","target":"_blank"}}," and across Europe as regulators investigated reports of blood clotting among people who have received the shot. The FDA and CDC reviewed 15 cases of blood clots. The cases—which the agencies noted are “extremely rare”—occurred in women between the ages of 18 and 48 within six to 13 days after vaccination. The Europeans Medicines Agency also said that the cases it ",{"type":"a","content":["reviewed"],"attrs":{"href":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021","target":"_blank"}}," occurred in people under 60—mostly women—within three weeks of vaccination."," "]},{"type":"p","content":["On April 23, the U.S. FDA and CDC ",{"type":"a","content":["lifted the pause"],"attrs":{"href":"https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough","target":"_blank"}}," on Johnson ","&"," Johnson’s vaccine and said that immunizations can resume immediately. The agencies said that the risk of blood clots is “very low” and that the benefits of getting the vaccine outweigh the risks. It will add information about the increased risk of blood clots to the vaccine’s label. The decision came days after the European Medicines Agency ",{"type":"a","content":["said"],"attrs":{"href":"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood","target":"_blank"}}," that blood clots should be listed as a “very rare” side effect of Johnson ","&"," Johnson’s COVID-19 vaccine."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On September 23, 2020, Johnson ","&"," Johnson ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate","target":"_blank"}}," the launch of its phase three “ENSEMBLE” trial to evaluate the safety of the vaccine—and how well it works—among up to 60,000 adults from a variety of countries. The trial included “significant representation” from older populations and those with underlying conditions that make them more susceptible to COVID-19."," "]},{"type":"p","content":["On October 12, 2020, Johnson ","&"," Johnson ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials","target":"_blank"}}," that it paused phase three trials for an independent safety review due to an unexplained illness in a participant. The company didn’t provide any details, in part to protect the patient’s privacy, but said that illnesses and accidents are expected in large clinical studies. What’s more, study pauses are routine for clinical trials ",{"type":"a","content":["and aren’t typically reported"],"attrs":{"href":"https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/","target":"_blank"}},". Later that month, the company ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us","target":"_blank"}}," it would resume trials, which were ",{"type":"a","content":["fully enrolled"],"attrs":{"href":"https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled","target":"_blank"}}," with 45,000 participants by December 17."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-7"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On November 15, 2020, Johnson ","&"," Johnson ",{"type":"a","content":["launched a second phase three trial"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate","target":"_blank"}}," to study the safety and efficacy of a two-dose regimen of its vaccine candidate in up to 30,000 volunteers worldwide. The study intends to assess whether a second dose of the vaccine will offer longer-lasting protection."]},{"type":"p","content":["On April 2, Johnson ","&"," Johnson ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.jnj.com/johnson-johnson-expands-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents","target":"_blank"}}," that it has begun vaccinating children age 12 to 17 as part of its phase 2a clinical trial. The company said it will initially test the vaccine in adolescents age 16 to 17 before expanding it to younger children."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Moderna Therapeutics"]}],"attrs":{"href":"https://www.modernatx.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," mRNA-1273"," "]},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"A Massachusetts-based biotech company, in collaboration with the National Institutes of Health."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A nucleic-acid vaccine that requires two doses."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Approval status:"]}," On December 18, the FDA ",{"type":"a","content":["granted emergency approval"],"attrs":{"href":"https://www.washingtonpost.com/health/2020/12/17/covid-fda-moderna-vaccine-2/","target":"_blank"}}," to Moderna’s COVID-19 vaccine, making it the second available in the United States. The vaccine has also been approved in the ",{"type":"a","content":["European Union"],"attrs":{"href":"https://www.cnn.com/2021/01/06/europe/moderna-approval-eu-intl/index.html","target":"_blank"}},", ",{"type":"a","content":["Canada"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/health-canada-authorizes-moderna-covid-19-vaccine-canada","target":"_blank"}},", the ",{"type":"a","content":["U.K."],"attrs":{"href":"https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator","target":"_blank"}},", ",{"type":"a","content":["Israel"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use","target":"_blank"}},", and ",{"type":"a","content":["by the WHO"],"attrs":{"href":"https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified","target":"_blank"}},"."]},{"type":"p","content":["On October 21 the CDC cleared the way for some people to get booster shots of the Moderna vaccine. The agency endorsed the FDA’s emergency use authorization of booster doses for all people ages 65 and older, as well as those ages 18 to 64 who are at risk of severe COVID-19 because of their underlying conditions. It also includes people ages 18 to 64 who are at high risk of exposure because of where they work or live, such as health-care workers or incarcerated people."]},{"type":"p","content":["Moderna has ",{"type":"a","content":["applied for full FDA approval"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-initiation-rolling-submission-biologics","target":"_blank"}}," of its COVID-19 vaccine for use in people age 18 and older. The company also plans to file for emergency use authorization for teens ages 12 to 17."," "]},{"type":"p","content":["On October 5, Moderna ",{"type":"a","content":["announced"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-european-medicines-agency-authorizes-third","target":"_blank"}}," that European Union regulators have authorized a third dose of its COVID-19 vaccine for “severely immunocompromised” people ages 12 and older."," "]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," The FDA has said that Moderna’s vaccine can now be kept at room temperature for up to a day. The vaccine ",{"type":"a","content":["can otherwise be safely stored on ice"],"attrs":{"href":"https://www.nationalgeographic.com/science/2020/11/moderna-edges-pfizer-coronavirus-efficacy-and-refrigeration/","target":"_blank"}}," or in a normal refrigerator for 30 days. These changes are expected to help the company distribute its vaccine more quickly."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["The company plans to deliver at least 500 million doses globally per year beginning in 2021, thanks in part to ",{"type":"a","content":["a deal it has struck with Swiss manufacturer Lonza"],"attrs":{"href":"https://www.lonza.com/news/2020-05-01-04-50","target":"_blank"}}," that will allow it to manufacture up to a billion doses a year."," "]},{"type":"p","content":[{"type":"b","content":["Efficacy:"]}," A ",{"type":"a","content":["study"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine","target":"_blank"}}," of clinical trials among adolescents ages 12 to 17 shows that its vaccine is safe and 100 percent effective. The study also showed the vaccine is 93 percent effective among participants in this age group two weeks after the first dose."]},{"type":"p","content":["Moderna ",{"type":"a","content":["has said"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-submission-initial-data-us-fda-its-covid-19","target":"_blank"}}," that the phase two clinical trials of its booster dose showed that a third dose administered six months after the second “induce robust antibody responses” and increased protections against the variants of concern. It has also said that a study of the phase two clinical trials of its three booster candidates produced robust antibody responses against the virus, including the Gamma, Beta, and Delta variants of concern."," "]},{"type":"p","content":["However, there is some doubt about whether people who received the Moderna shot will need boosters. A study ",{"type":"a","content":["published in the journal ",{"type":"i","content":["Nature"]}],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03738-2_reference.pdf","target":"_blank"}}," in June 2021 showed that the vaccine elicits “robust and prolonged” immune responses—indicating that protection may last for years so long as the virus doesn’t mutate to evade it."]},{"type":"p","content":["On September 10, the CDC ",{"type":"a","content":["released a study"],"attrs":{"href":"https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w","target":"_blank"}}," of more than 32,000 real-world cases suggesting that Moderna’s vaccine is more effective at preventing hospitalizations than the Pfizer or Johnson ","&"," Johnson vaccines. The overall efficacy of Moderna’s vaccine was 95 percent, compared to 80 percent for Pfizer and 60 percent for Johnson ","&"," Johnson. "," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-8"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["The study backed up earlier studies suggesting that Moderna’s vaccine ",{"type":"a","content":["may provide stronger protection than Pfizer’s"],"attrs":{"href":"https://jamanetwork.com/journals/jama/fullarticle/2783797?guestAccessKey=6ead80fe-bf08-4d53-8c5c-607249932480&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=083021","target":"_blank"}}," jab. A study published on August 30 found that Moderna’s vaccine produces significantly more neutralizing antibodies than Pfizer’s, which might be attributed to the higher dosage or the longer interval between the first and second doses. On August 8, a preliminary ",{"type":"a","content":["Mayo Clinic study of more than 50,000 patients"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf","target":"_blank"}}," showed that the efficacy of Moderna’s vaccine dropped from 86 percent in early 2021 to 76 percent in July, when the Delta variant was predominant. Meanwhile, the Pfizer vaccine’s efficacy dropped over the same time period from 76 percent to 42 percent."," "]},{"type":"p","content":["An earlier preprint analysis of Moderna’s vaccine also suggested that ",{"type":"a","content":["antibody levels can predict the vaccine’s efficacy"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4","target":"_blank"}}," against COVID-19. The study showed that people with breakthrough infections who had lower levels of antibodies in their blood were more likely to develop symptomatic infections than those with higher levels of antibodies. The study authors tell ",{"type":"i","content":["Nature"]}," that the data doesn’t suggest a threshold of antibodies that ensures protection but it does show ",{"type":"a","content":["a relationship between higher levels of antibodies and lower risk of infection"],"attrs":{"href":"https://www.nature.com/articles/d41586-021-02237-8#ref-CR1","target":"_blank"}},"."]},{"type":"p","content":["On August 12, a study published in the journal ",{"type":"i","content":["Science"]}," showed that ",{"type":"a","content":["Moderna’s vaccine protects against COVID-19 for at least six months"],"attrs":{"href":"https://science.sciencemag.org/content/early/2021/08/11/science.abj4176?_ga=2.235822593.145620917.1628696888-1399774036.1602427045","target":"_blank"}}," and is effective against the Delta variant. The findings confirm ",{"type":"a","content":["earlier studies"],"attrs":{"href":"https://www.nejm.org/doi/full/10.1056/NEJMc2103916?query=featured_home","target":"_blank"}}," and announcements made by the company that its vaccine ",{"type":"a","content":["remains 93 percent effective for at least six months"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial","target":"_blank"}}," after administration of the second dose."]},{"type":"p","content":["On July 9, ",{"type":"i","content":["Nature"]}," reported on a study showing that ",{"type":"a","content":["two quarter-doses of Moderna’s vaccine generates long-lasting neutralizing antibodies and T cells"],"attrs":{"href":"https://www.nature.com/articles/d41586-021-01893-0","target":"_blank"}},". The results suggest that it might be possible to administer fractional doses to help stretch the world’s vaccine supply, particularly in low- and middle-income countries that are facing shortages."]},{"type":"p","content":["On February 17, the ",{"type":"i","content":["New England Journal of Medicine"]}," ",{"type":"a","content":["published"],"attrs":{"href":"https://www.nejm.org/doi/full/10.1056/NEJMc2102179?query=featured_home","target":"_blank"}}," a preliminary report showing that Moderna’s vaccine remains effective in protecting against the virus variant found in the U.K. However, it may be less effective in protecting against the South African variant—although researchers noted that further study is needed."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-9"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["In December 2020, an FDA ",{"type":"a","content":["analysis"],"attrs":{"href":"https://www.fda.gov/media/144434/download","target":"_blank"}}," of the phase three study of Moderna’s vaccine confirmed that it is 94.1-percent effective in preventing mild cases of COVID-19 and 100-percent effective at preventing severe cases after taking two doses."]},{"type":"p","content":[{"type":"b","content":["Safety:"," "]},"On June 23, 2021, the U.S. Food and Drug Administration ",{"type":"a","content":["said"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-panel-review-heart-inflammation-cases-after-pfizer-moderna-vaccines-2021-06-23/","target":"_blank"}}," it planned to add a warning label to the Pfizer and Moderna vaccines about ",{"type":"a","content":["rare cases of heart inflammation"],"attrs":{"href":"https://www.nationalgeographic.com/science/article/heart-problems-after-vaccinations-are-very-rareand-often-resolve-quickly","target":"_blank"}}," in adolescents and young adults. The news comes after the CDC convened an emergency meeting of its advisory committee to discuss “rare but higher-than-expected” cases of myocarditis and pericarditis among young people who have received the vaccines. The committee acknowledged that these cases are likely linked to the vaccines but that the benefits of the shots outweigh the risks."]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," Moderna announced on December 17, 2020, that it was launching clinical trials to evaluate the vaccine’s safety in ",{"type":"a","content":["children and people with cancer"],"attrs":{"href":"https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_d8ba867ebfe7300a65bda99cc2e2babd","target":"_blank"}},"; it will also ",{"type":"a","content":["establish a “pregnancy registry"],"attrs":{"href":"https://www.cnn.com/world/live-news/coronavirus-pandemic-vaccine-updates-12-17-20/h_9a24ba453f4fd361f19264327ac63a1a","target":"_blank"}},"” to track the vaccine’s safety in people who are pregnant."," "]},{"type":"p","content":["The company ",{"type":"a","content":["started"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid","target":"_blank"}}," the third phase of its clinical trials in July 2020. Preliminary findings from its phase one trials showed that healthy subjects—",{"type":"a","content":["including elderly patients"],"attrs":{"href":"https://www.cnbc.com/2020/08/26/moderna-says-its-coronavirus-vaccine-shows-promising-results-in-small-trial-of-elderly-patients.html","target":"_blank"}},"—produced coronavirus antibodies and a reaction from T cells, another part of the human immune response. Phase three tested the vaccine in 30,000 U.S. participants."," "]},{"type":"p","content":["On February 24, Moderna ",{"type":"a","content":["announced"],"attrs":{"href":"https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine","target":"_blank"}}," that it has shipped doses of a booster vaccine to the U.S. National Institutes of Health for clinical trials. The phase one trial will determine whether the booster can improve immunity against the South Africa variant. Moderna is also investigating using a third dose of its approved vaccine to protect against variants."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["AstraZeneca-University of Oxford"]}],"attrs":{"href":"https://www.ovg.ox.ac.uk","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," ChAdOx1 nCoV-19"," "]},{"type":"p","content":[{"type":"b","content":["Who:"]}," The U.K. university, in collaboration with the biopharmaceutical company AstraZeneca."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A viral vector vaccine that requires two doses."]},{"type":"p","content":[{"type":"b","content":["Approval status:"," "]},"Approved for use in the United Kingdom, the European Union, Argentina, India, and other countries. It has also been authorized by the World Health Organization."]},{"type":"p","content":[{"type":"b","content":["Efficacy:"]}," In August 2021 a preprint study out of the United Kingdom showed that the Pfizer and AstraZeneca vaccines remain protective against the Delta variant ",{"type":"a","content":["but that their efficacy wanes over time"],"attrs":{"href":"https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf","target":"_blank"}},". Among study participants, Pfizer’s vaccine waned more rapidly. Within four to five months after a second dose, the vaccine’s efficacy was on par with the AstraZeneca shot. The study emphasizes, however, both vaccines still significantly reduce the risk of infection."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On July 8, ",{"type":"a","content":["a study published in ",{"type":"i","content":["Nature"]}],"attrs":{"href":"https://www.nature.com/articles/s41586-021-03777-9","target":"_blank"}}," demonstrated that people who have received both doses of the AstraZeneca of Pfizer vaccines remain fully protected from the Delta and Beta variants. However, a single dose of either vaccine was not as protective."]},{"type":"p","content":["On June 25, ",{"type":"a","content":["preliminary results from a British study"],"attrs":{"href":"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3874014","target":"_blank"}}," showed that mixing doses of the AstraZeneca and Pfizer vaccines provides strong protection against COVID-19. Researchers ",{"type":"a","content":["told the ",{"type":"i","content":["New York Times"]}],"attrs":{"href":"https://www.nytimes.com/2021/06/28/health/mixing-pfizer-astrazeneca-results.html","target":"_blank"}}," that the protection is strong regardless of the order in which the vaccines are administered. The findings will be useful for those who are unable to get a second AstraZeneca vaccine due to production delays and safety concerns, although researchers say it’s still best to get two doses of the same vaccine for now."]},{"type":"p","content":["On March 24, AstraZeneca ",{"type":"a","content":["released"],"attrs":{"href":"https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html","target":"_blank"}}," the primary analysis of its U.S. phase three clinical trials showing that its vaccine is 76 percent effective at preventing COVID-19, slightly lower than the 79 percent efficacy it had announced two days earlier based on a partial analysis of the data. It is also 85 percent effective in people 65 and older and 100 percent effective at preventing severe cases of the disease."]},{"type":"p","content":["U.S. health officials had taken the unusual step of ",{"type":"a","content":["questioning the decision to release the interim results"],"attrs":{"href":"https://www.nih.gov/news-events/news-releases/niaid-statement-astrazeneca-vaccine","target":"_blank"}},", describing them as “outdated and potentially misleading.” In a letter ",{"type":"a","content":["obtained by the ",{"type":"i","content":["Washington Post"]}],"attrs":{"href":"https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html","target":"_blank"}},", an independent panel of experts at the National Institutes of Health that oversees U.S. clinical trials said that it had recommended the company release a later analysis instead, showing the vaccine may be 69 to 74 percent effective."]},{"type":"p","content":["The companies ",{"type":"a","content":["also said"],"attrs":{"href":"https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html#!","target":"_blank"}}," that the vaccine’s efficacy increased to 82 percent when the second dose was taken after 12 weeks or longer, rather than the originally recommended four-week interval. The British government has recommended the longer gap in its rollout of the vaccine to prioritize getting the first shot to as many at-risk people as possible."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-10"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":["On February 7, South Africa ",{"type":"a","content":["halted"],"attrs":{"href":"https://www.nytimes.com/2021/02/07/world/africa/covid-vaccine-astrazeneca-south-africa.html","target":"_blank"}}," its use of the AstraZeneca-Oxford vaccine after preliminary laboratory studies showed it offered only minimal protection against the virus variant that is dominant in that country. The finding was later confirmed by ",{"type":"a","content":["a study published in the ",{"type":"i","content":["New England Journal of Medicine"]}],"attrs":{"href":"https://www.nejm.org/doi/10.1056/NEJMoa2102214","target":"_blank"}}," showing that the vaccine does not protect against mild to moderate cases of COVID-19 caused by the South African variant. ",{"type":"a","content":["Early data suggested"," "],"attrs":{"href":"https://www.reuters.com/article/uk-health-coronavirus-britain-vaccines-v/data-on-astrazeneca-vaccine-and-south-african-variant-should-come-soon-uk-expert-says-idUSKBN29I18P","target":"_blank"}},"that the vaccine will still effectively protect against the variant that is prevalent throughout the U.K. "," "," "," "]},{"type":"p","content":[{"type":"b","content":["Safety:"]}," On June 9, a study ",{"type":"a","content":["published in the journal ",{"type":"i","content":["Nature Medicine"]}],"attrs":{"href":"https://www.nature.com/articles/s41591-021-01408-4","target":"_blank"}}," found that people who have received the AstraZeneca vaccine have a slightly increased risk of a bleeding disorder. The analysis of 2.53 million people who received the vaccine found an incidence of 1.13 cases per 100,000 vaccines. Researchers said the benefits of getting the vaccine outweigh the risks. The study echoed an earlier ",{"type":"a","content":["safety review conducted by the European Medicines Agency"],"attrs":{"href":"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood","target":"_blank"}},"."]},{"type":"p","content":["In Canada, meanwhile, on June 29 regulatory officials advised people with a history of capillary leak syndrome against receiving the AstraZeneca vaccine. Health Canada i",{"type":"a","content":["s also updating the vaccine’s label"],"attrs":{"href":"https://www.theglobeandmail.com/canada/article-heath-canada-adds-warning-of-very-rare-serious-condition-as-potential/","target":"_blank"}}," to add the syndrome as a potential side effect."]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," Project members say their candidate can be stored at temperatures seen in common refrigeration. Oxford and AstraZeneca expect to produce up to three billion doses of the vaccine in 2021."]},{"type":"p","content":["On December 30, the U.K. ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.gov.uk/government/news/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator","target":"_blank"}}," changes to its vaccine delivery plan to prioritize delivering the first dose of either vaccine to as many at-risk people as possible, based on data ",{"type":"a","content":["provided to and released by"],"attrs":{"href":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948334/Information_for_UK_healthcare_professionals_on_COVID-19_Vaccine_AstraZeneca.pdf","target":"_blank"}}," health regulators. It did so by delaying administration of the second dose of the AstraZeneca-Oxford drug. A similar rule was issued for the Pfizer-BioNTech vaccine, but regulators didn’t provide",{"type":"a","content":[" ","data to back the"," "],"attrs":{"href":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948338/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020.pdf","target":"_blank"}},"new regimen. Overall, the U.K. still recommends that recipients receive two doses of either vaccine for maximum benefit."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-11"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Clinical trials status:"," "]},"On December 11, AstraZeneca and Russia’s Gamaleya Institute ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html","target":"_blank"}}," plans to work together to study the possibility of combining Oxford’s vaccine with Gamaleya’s Sputnik V vaccine. Since both use the same adenovirus, researchers will investigate whether a combination of the two will improve efficacy."," "]},{"type":"p","content":["The AstraZeneca-Oxford vaccine’s phase three trial aimed to recruit up to 50,000 volunteers in Brazil, the U.K., the United States, and South Africa. On September 8, AstraZeneca paused the trials for a safety review due to an adverse reaction in one participant in the U.K., which the company described as a “routine action.” After an investigation by independent regulators, the trials ",{"type":"a","content":["resumed"],"attrs":{"href":"https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html","target":"_blank"}}," in the U.K., Brazil, South Africa, and India in September and ",{"type":"a","content":["resumed in the U.S."],"attrs":{"href":"https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923","target":"_blank"}}," a month later."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Novavax"]}],"attrs":{"href":"https://novavax.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"NVX-CoV2373"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A biotechnology company based in Gaithersburg, Maryland."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A protein vaccine that involves a nanoparticle carrier to better aid delivery and uptake by cells. The vaccine is administered in two doses, 21 days apart."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Authorized for emergency use in Indonesia."]},{"type":"p","content":["Novavax has not yet submitted ",{"type":"a","content":["its vaccine to the FDA for emergency use authorization, but it is planning to do so"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-again-delays-seeking-us-approval-covid-19-vaccine-2021-08-05/","target":"_blank"}},". Reuters reports that Novavax also said that it will file a separate application for booster shots once the emergency use authorization submission is processed; the company said its booster shot given six months after the two-dose regimen elicited a 4.6-fold increase in antibodies. The company has filed for authorization from regulators in India and the Philippines."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On June 14, Novavax ",{"type":"a","content":["announced"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and","target":"_blank"}}," that its vaccine is safe and 90.4 percent effective in protecting against COVID-19—including the more contagious virus variants that are circulating. The vaccine is also 100 percent effective at preventing moderate and severe disease among 29,960 clinical trial participants age 18 and older in the U.S. and Mexico."," "]},{"type":"p","content":["On March 11, Novavax ",{"type":"a","content":["announced"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and","target":"_blank"}}," that a final analysis of its phase three clinical trials in the U.K. shows that its vaccine is 96.4-percent effective in preventing COVID-19. It also announced the findings of its phase 2b clinical trial in South Africa, which showed the vaccine was only 48.6-percent effective against the strains circulating there. Both trials showed the vaccine is 100-percent effective at preventing severe cases of the disease."," "]},{"type":"p","content":["On January 28, 2021, Novavax had ",{"type":"a","content":["announced"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3","target":"_blank"}}," preliminary results of its phase three trials in the U.K., which showed at the time that its vaccine is 89.3-percent effective in preventing COVID-19. On September 2, 2020, a study of the company’s phase one trial ",{"type":"a","content":["published in the ",{"type":"i","content":["New England Journal of Medicine"]}],"attrs":{"href":"https://www.nejm.org/doi/full/10.1056/NEJMoa2026920","target":"_blank"}}," found that the vaccine was safe and produced coronavirus antibodies at a higher level than is seen among those who have recovered from COVID-19. It also stimulated T cells, another arm of the human immune response."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On September 24, 2020, Novavax ",{"type":"a","content":["announced"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united","target":"_blank"}}," the launch of its phase three trial in the United Kingdom, which evaluated the vaccine in up to 10,000 people, both with and without underlying conditions. Up to 400 participants were also vaccinated against the seasonal flu as part of a sub-study to ",{"type":"a","content":["help determine"],"attrs":{"href":"https://www.nytimes.com/2020/09/24/health/covid-19-vaccine-novavax.html","target":"_blank"}}," whether it is safe to give patients both vaccines at the same time. On November 30, Novavax ",{"type":"a","content":["said it had completed enrollment"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress","target":"_blank"}}," in its phase three trial in the U.K."]},{"type":"p","content":["On December 28, 2020, Novavax ",{"type":"a","content":["announced"],"attrs":{"href":"https://ir.novavax.com/news-releases/news-release-details/novavax-announces-initiation-prevent-19-pivotal-phase-3-efficacy","target":"_blank"}}," the launch of a phase three study in the U.S. and Mexico, which evaluated the safety and efficacy of its vaccine in up to 30,000 adults."," "]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Sinopharm"]}],"attrs":{"href":"http://www.sinopharm.com/1156.html","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," None"," "]},{"type":"p","content":[{"type":"b","content":["Who:"]}," China’s state-run pharmaceutical company, in collaboration with the Wuhan Institute of Biological Products."]},{"type":"p","content":[{"type":"b","content":["What:"]}," Two inactivated SARS-CoV-2 vaccines."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-12"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Approval status:"]}," China has approved one of the company’s vaccines for general use and another for limited use. One of the Sinopharm vaccines has also been approved by the World Health Organization as well as in Bahrain, the United Arab Emirates, and other countries."]},{"type":"p","content":["Sinopharm ",{"type":"a","content":["filed for final regulatory approval"],"attrs":{"href":"https://www.scmp.com/news/china/society/article/3111347/coronavirus-sinopharm-applies-regulatory-approval-china-launch","target":"_blank"}}," from China in late November, two months after the ",{"type":"i","content":["New Yorker"]}," ",{"type":"a","content":["reported"],"attrs":{"href":"https://www.newyorker.com/news/news-desk/the-november-surprise-of-chinas-coronavirus-vaccine","target":"_blank"}}," that hundreds of thousands of Chinese civilians have already been vaccinated under the government’s emergency-use approval. China began to innoculate medical workers and other high-risk groups with the Sinopharm trial vaccines in July, making it the first experimental vaccine available to civilians beyond clinical volunteers."," "]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"," "]},"On July 19 preliminary results from a study conducted in Sri Lanka found that Sinopharm’s vaccine was less effective against the Delta variant than the original SARS-CoV-2 strain. As Reuters reported, the study showed that the vaccine ",{"type":"a","content":["elicited a 1.38-fold reduction in antibody levels"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/sinopharms-covid-19-shot-induces-weaker-antibody-responses-delta-study-2021-07-21/","target":"_blank"}}," against the variant."]},{"type":"p","content":["On May 7, the World Health Organization ",{"type":"a","content":["estimated"],"attrs":{"href":"https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations","target":"_blank"}}," the Sinopharm vaccine’s efficacy to be 79 percent among all age groups, affirming the company’s earlier ",{"type":"a","content":["announcement"],"attrs":{"href":"https://www.nytimes.com/2020/12/29/world/a-chinese-covid-19-vaccine-has-proved-effective-its-maker-said.html?referringSource=articleShare","target":"_blank"}}," of the results of its phase three study."]},{"type":"p","content":["Preliminary findings from two randomized trials, ",{"type":"a","content":["published in the ",{"type":"i","content":["Journal of the American Medical Association"]}],"attrs":{"href":"https://jamanetwork.com/journals/jama/fullarticle/2769612","target":"_blank"}},", have shown the vaccine can trigger an antibody response with no serious adverse effects. The study did not measure T cell-mediated immune responses. These results are significant, though, as they are the first published data from human clinical trials for a COVID-19 vaccine that uses a whole, inactivated virus."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-13"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," Sinopharm ",{"type":"a","content":["launched its first phase three trial"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-uae-idUSKCN24H14T","target":"_blank"}}," in July 2020 among 15,000 volunteers—aged 18 to 60, with no serious underlying conditions—in the UAE. The company ",{"type":"a","content":["selected the UAE because"],"attrs":{"href":"https://www.businesswire.com/news/home/20200717005085/en/World%E2%80%99s-Phase-III-Clinical-Trial-COVID-19-Inactivated","target":"_blank"}}," it has a diverse population made up of approximately 200 nationalities, making it an ideal testing ground. Sinopharm also conducted phase three trials in locations such as ",{"type":"a","content":["Peru"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm/peru-to-test-china-sinopharms-covid-19-vaccine-in-phase-3-trial-idUSKCN25G0G9","target":"_blank"}}," and ",{"type":"a","content":["Bahrain"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-bahrain-vaccine/chinas-sinopharm-starts-phase-iii-trial-of-covid-19-vaccine-in-bahrain-idUSKCN2561V1","target":"_blank"}},"."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Sinovac"]}],"attrs":{"href":"http://www.sinovac.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"CoronaVac"," "]},{"type":"inline","content":{"name":"ContentPromo","props":{"cards":[{"headline":"COVID-19 can ruin your sleep in many different ways—here's why","image":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-19-can-ruin-your-sleep-in-many-different-waysheres-why","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}],"type":"floating","inline":true},{"headline":"How the additives in your vaccines rev up your immune system","image":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_square.jpg","link":"https://www.nationalgeographic.com/premium/article/vaccines-immune-system-inflammation","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}],"type":"floating","inline":true},{"headline":"Multiple COVID infections can lead to chronic health issues. Here’s what to know.","image":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-reinfections-chronic-booster-vaccine","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}],"type":"floating","inline":true}],"title":"You May Also Like","dividerEnabled":true},"context":{},"config":{"align":"center"}}},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"A Chinese biopharmaceutical company, in collaboration with Brazilian research center Butantan."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated vaccine."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"," "]},"Approved for limited use by the WHO as well as in China, Indonesia, Brazil, and other countries."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On July 15 Reuters reported that the leaders of a Chilean study have ",{"type":"a","content":["recommended administering a third dose of Sinovac’s vaccine"],"attrs":{"href":"https://www.reuters.com/world/americas/chilean-sinovac-trial-leaders-recommend-third-dose-covid-19-vaccine-2021-07-15/","target":"_blank"}}," as its efficacy has waned in the face of the Delta variant. The vaccine’s level of protection is lower than others—late-stage trials ",{"type":"a","content":["found that it is 51 percent effective"],"attrs":{"href":"https://www.bbc.com/news/world-latin-america-55642648","target":"_blank"}}," in preventing COVID-19. Still, ",{"type":"a","content":[{"type":"i","content":["Nature"]}," reports"],"attrs":{"href":"https://www.nature.com/articles/d41586-021-01497-8","target":"_blank"}}," that it is 100 percent effective at preventing severe disease and therefore is key to helping curb the pandemic."," "]},{"type":"p","content":["On April 7, ",{"type":"a","content":["a preliminary study"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1","target":"_blank"}}," of CoronaVac’s vaccine rollout in Brazil showed that the vaccine is about 50 percent effective in protecting against COVID-19 in a region where the highly transmissible P.1 variant is circulating."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," CoronaVac ",{"type":"a","content":["entered phase three trials"],"attrs":{"href":"http://www.sinovac.com/?optionid=754&auto_id=907","target":"_blank"}}," in July, with plans to recruit nearly 9,000 healthcare professionals in Brazil, in addition to phase three trials in ",{"type":"a","content":["Indonesia"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-indonesia-vaccine/sinovac-launches-phase-3-trial-for-covid-19-vaccine-in-indonesia-reports-phase-2-details-idUSKCN2570E9","target":"_blank"}},". A planned trial in Bangladesh was delayed, ",{"type":"a","content":["after Bangladesh refused in October"],"attrs":{"href":"https://asia.nikkei.com/Spotlight/Coronavirus/China-forges-on-with-vaccine-diplomacy-amid-Pfizer-fanfare","target":"_blank"}}," to co-finance a late-stage trial."," "]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Center for Genetic Engineering and Biotechnology"]}],"attrs":{"href":"https://biomed.cigb.edu.cu/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Abdala"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A government-run research institute in Cuba."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["What:"]}," A protein subunit vaccine that’s administered in three doses."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Approved for emergency use in Cuba and Vietnam. Prior to granting emergency use authorization, Cuba ",{"type":"a","content":["had already begun"],"attrs":{"href":"https://www.nytimes.com/2021/05/12/world/cuba-vaccine.html?searchResultPosition=1","target":"_blank"}}," administering the vaccine among health workers as part of an “intervention study.”"]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On June 22 Cuba announced that the Abdala vaccine is 92.28 percent effective against COVID-19."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," In March Cuba ",{"type":"a","content":["launched"],"attrs":{"href":"http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm","target":"_blank"}}," phase three clinical trials for the Abdala vaccine among 48,000 volunteers."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Finlay Institute for Vaccines"]}],"attrs":{"href":"https://www.finlay.edu.cu/en","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Soberana-02"]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-14"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Who:"]}," A government-run research institute in Cuba."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A conjugate vaccine that uses part of the virus spike protein."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Authorized for emergency use in Cuba and Iran."]},{"type":"p","content":[{"type":"b","content":["Efficacy:"]}," On June 22 the ",{"type":"i","content":["New York Times"]}," ",{"type":"a","content":["reported"],"attrs":{"href":"https://www.nytimes.com/2021/06/22/world/americas/cuba-vaccine-abdala.html","target":"_blank"}}," that the Soberana-02 vaccine was 62 percent effective at preventing COVID-19 after two of its three required doses."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"," "]},"On March 4, Cuba became the first country in Latin America to ",{"type":"a","content":["announce the launch of a phase three clinical trial"],"attrs":{"href":"https://www.miamiherald.com/news/nation-world/world/americas/cuba/article249696913.html","target":"_blank"}}," for one of its COVID-19 vaccines, the ",{"type":"i","content":["Miami Herald"]}," reported. The Cuban government said the phase three trial would be conducted in Havana among 44,000 volunteers."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"kvps":{"pos":"fitt-article-inline-outstream-15"},"type":"fitt-article-inline-outstream","className":"fitt-article-inline-outstream"},"className":"natgeo-ad","placeholders":{"compact":{"size":[320,50]},"regular":{"size":[728,90]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["CureVac"]}],"attrs":{"href":"https://www.curevac.com/en/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," CVnCoV"]},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"A German biopharmaceutical company ",{"type":"a","content":["in partnership with Bayer"],"attrs":{"href":"https://www.curevac.com/en/2021/01/07/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/","target":"_blank"}},", a German multinational pharmaceutical company."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An mRNA vaccine that’s administered in two doses taken 28 days apart."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use. On October 12, 2021, CureVac ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-withdraw-first-generation-covid-19-vaccine-candidate-2021-10-12/","target":"_blank"}}," that it was withdrawing its COVID-19 vaccine candidate months after it ",{"type":"a","content":["reported"],"attrs":{"href":"https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/","target":"_blank"}}," disappointing results from a study of its clinical trials showing its vaccine was only 47 percent effective in preventing COVID-19, falling short of the company’s own criteria for success. CureVac attributed its results to the virus variants that were circulating at the time. It sequenced 124 cases of COVID-19 among clinical trial participants and found only one case was caused by the original SARS-CoV-2 virus and more than half were caused by variants of concern."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"," "]},"On January 11, CureVac ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.curevac.com/en/2021/01/11/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-primates-during-sars-cov-2-challenge-infection/","target":"_blank"}}," that preliminary results show its vaccine prompted robust antibody and T-cell responses in rhesus macaques."," "]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On December 14, 2020, CureVac ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.curevac.com/en/2020/12/14/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/","target":"_blank"}}," it had begun enrolling participants in a phase 2b/3 study to assess its vaccine’s safety and efficacy in more than 35,000 participants in Europe and Latin America. One week later, the company ",{"type":"a","content":["launched"],"attrs":{"href":"https://www.curevac.com/en/2020/12/21/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/","target":"_blank"}}," a separate phase three trial in healthcare workers in Mainz, Germany."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Sanofi and GSK"]}],"attrs":{"href":"https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-2-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," None"]},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"A global biopharmaceutical company in partnership with a global healthcare company."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An adjuvant-supported recombinant-protein vaccine."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use."]}],{"type":"inline","content":{"name":"Ad","props":{"ad":{"type":"fitt-article-inline-box","className":"fitt-article-inline-box"},"className":"natgeo-ad","placeholders":{"compact":{"size":[300,250]},"regular":{"size":[300,250]}},"initSelf":true},"context":{},"config":{"gridDisplayMode":"none"}}},[{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On May 17, the companies ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-17-07-30-00-2230312","target":"_blank"}}," that a study of their phase two clinical trials shows the vaccine generated a high level of neutralizing antibodies with no safety concerns."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," On May 27, 2021, Sanofi and GSK ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-27-07-30-00-2236989#","target":"_blank"}}," that they had started to enroll participants in a phase three clinical study to test the safety and efficacy of their vaccine in 35,000 volunteers ages 18 and older in the U.S., Asia, Africa, and Latin America. The study’s broad geographic range was intended to allow the companies to evaluate the vaccine’s efficacy against variants of concern."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Biological E. Limited"]}],"attrs":{"href":"https://biologicale.com/index.html","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," None"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," An Indian vaccine and pharmaceutical company in partnership with the Baylor College of Medicine."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A protein-based subunit vaccine that requires two doses administered 28 days apart."]},{"type":"p","content":[{"type":"b","content":["Latest news:"]}," On April 26, the companies ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.bcm.edu/news/biological-e-limited-to-begin-phase-iii-clinical-trials-with-baylor-and-texas-childrens-vaccine","target":"_blank"}}," that they received approval to launch a phase three clinical trial of their vaccine candidate. The trial will evaluate the efficacy and safety of the vaccine among more than 1,200 volunteers ages 18 to 80 at 15 sites across India."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use."]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," If the vaccine is approved for use, it ",{"type":"a","content":["will be distributed"],"attrs":{"href":"https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/","target":"_blank"}}," through the COVAX Facility, a global effort to ensure the equitable distribution of COVID-19 vaccines."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Valneva SE"]}],"attrs":{"href":"https://valneva.com/research-development/covid-19-vla2001/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," VLA2001"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A vaccine developer based in France."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated virus, adjuvant-supported vaccine, with two doses administered three weeks apart."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use. The company has initiatied rolling submission for approval with U.K. and European regulators."]},{"type":"p","content":[{"type":"b","content":["Safety and efficacy:"," "]},"On October 18 Valneva ",{"type":"a","content":["announced"],"attrs":{"href":"https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/","target":"_blank"}}," that its vaccine elicited higher antibody levels than the AstraZeneca vaccine and “significantly fewer” adverse events among participants age 30 and older."]},{"type":"p","content":["On April 6, Valneva ",{"type":"a","content":["announced"],"attrs":{"href":"https://valneva.com/press-release/valneva-reports-positive-phase-1-2-data-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/","target":"_blank"}}," that a study of its phase 1 and 2 clinical trials show that its vaccine prompted a strong immune response with no safety concerns."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," On April 21 Valneva ",{"type":"a","content":["announced"],"attrs":{"href":"https://valneva.com/press-release/valneva-initiates-phase-3-clinical-trial-for-its-inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/#_ftn2","target":"_blank"}}," the launch of phase three clinical trials to study the safety and efficacy of its COVID-19 vaccine compared to that of AstraZeneca’s conditionally approved vaccine. Approximately 4,000 volunteers were expected to receive two doses of either vaccine to determine the immune response of each. Valneva says it hopes to file for regulatory approval in the fall of 2021."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Shenzhen Kangtai Biological Products"]}],"attrs":{"href":"http://en.biokangtai.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," None."]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A China-based pharmaceuticals company"]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated vaccine that requires two doses administered 28 days apart."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Authorized for emergency use in China. The country ",{"type":"a","content":["approved"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6","target":"_blank"}}," the Kangtai shot for emergency use in May 2021, just weeks after the vaccine launched its phase three clinical trials."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"," "]},"Kangtai’s phase three clinical trials ",{"type":"a","content":["are underway"],"attrs":{"href":"https://clinicaltrials.gov/ct2/show/NCT04852705?term=kangtai&draw=2&rank=3","target":"_blank"}},", testing the vaccine’s safety and efficacy among 28,000 adults age 18 and older."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Medicago"]}],"attrs":{"href":"https://medicago.com/en/","rel":"noopener noreferrer","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," CoVLP"]},{"type":"p","content":[{"type":"b","content":["Who:"," "]},"A Canadian biotechnology company, in partnership with British multinational pharmaceutical company GlaxoSmithKline."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A plant-derived recombinant vaccine with an adjuvant that requires two doses administered 21 days apart."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"," "]},"In May 2021 Medicago ",{"type":"a","content":["reported"],"attrs":{"href":"https://medicago.com/en/press-release/1751/","target":"_blank"}}," that interim data from its phase two clinical trial showed that its COVID-19 vaccine elicited high levels of neutralizing antibodies with no severe adverse reactions."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," On March 16, Medicago and GlaxoSmithKline ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/","target":"_blank"}}," that their vaccine had entered phase three clinical trials to study its safety and efficacy in up to 30,000 volunteers in 10 countries, including Canada and the U.S."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Bharat Biotech"]}],"attrs":{"href":"https://www.bharatbiotech.com/covaxin.html","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"COVAXIN"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," An Indian biotechnology company, in collaboration with the Indian Council of Medical Research and the National Institute of Virology."]},{"type":"p","content":[{"type":"b","content":["What:"," "]},"An inactivated vaccine, which ",{"type":"a","content":["requires two doses"],"attrs":{"href":"https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf","target":"_blank"}}," that are administered 28 days apart."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"," "]},"Authorized for emergency use ",{"type":"a","content":["in India"],"attrs":{"href":"https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html","target":"_blank"}},", Mexico, the Philippines, and other countries. The WHO has also listed the vaccine for emergency use."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," In November 2021 the WHO",{"type":"a","content":[" ","said"],"attrs":{"href":"https://www.who.int/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine","target":"_blank"}}," that its analysis of COVAXIN shows the vaccine is 78 percent effective against COVID-19 and “is extremely suitable for low-and-middle-income countries due to easy storage requirements.”"," "]},{"type":"p","content":["On March 3 Bharat Biotech ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf","target":"_blank"}}," that an interim analysis of its phase three trial showed its vaccine is 81-percent effective in protecting against COVID-19 after the second dose. A separate preliminary study ",{"type":"a","content":["also indicated"],"attrs":{"href":"https://www.biorxiv.org/content/10.1101/2021.01.26.426986v2.full","target":"_blank"}}," that the vaccine produces antibodies that can neutralize the virus variant that originated in the U.K."," "]},{"type":"p","content":["On January 21, ",{"type":"a","content":[{"type":"i","content":["The Lancet"]}],"attrs":{"href":"https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext#seccestitle180","target":"_blank"}}," published interim findings from COVAXIN’s phase one study that showed the vaccine elicited an immune response in participants. The study identified only one serious adverse event, and it was unrelated to the vaccine."]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On November 16, Bharat Biotech ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.bharatbiotech.com/images/press/Bharat-biotech-starts-phase-III-trials-for-covaxin.pdf","target":"_blank"}}," it had begun phase three trials involving 26,000 participants at more than 25 centers across India."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["The Gamaleya National Center of Epidemiology and Microbiology"]}],"attrs":{"href":"https://sputnikvaccine.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Sputnik V"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Russian research institution, in partnership with the state-run Russian Direct Investment Fund."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A viral vector vaccine that uses two strains of adenovirus and requires a second injection after 21 days to boost the immune response."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"," "]},"In August, Russia cleared the Sputnik V vaccine for widespread use and ",{"type":"a","content":["claimed it"],"attrs":{"href":"https://www.cnbc.com/2020/08/11/russia-claims-to-have-registered-first-coronavirus-vaccine.html","target":"_blank"}}," as the first registered COVID-19 vaccine on the market—before the vaccine’s phase three trials had begun and despite the lack of published evidence at the time. It has since been approved in Belarus, Argentina, Venezuela, and other countries. "," "]},{"type":"p","content":["On March 4 the European Union ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine","target":"_blank"}}," that it would begin a rolling review of the Sputnik V vaccine. The announcement came after a handful of European countries said they would consider approving the vaccine without E.U. approval. Hungary has already authorized the vaccine. But on October 21 Reuters ",{"type":"a","content":["reported"],"attrs":{"href":"https://www.reuters.com/world/europe/exclusive-eu-decision-russias-sputnik-v-shot-impossible-this-year-source-2021-10-21/","target":"_blank"}}," that European regulators are unlikely to make a final decision until early 2022."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On February 2, the medical journal ",{"type":"a","content":[{"type":"i","content":["The Lancet"]}," published the results"],"attrs":{"href":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext","target":"_blank"}}," of a phase three trial in Moscow that found the Sputnik V vaccine is safe and 91.6-percent effective in preventing COVID-19. The study, which involved more than 22,000 participants, also showed the vaccine is 100-percent effective in preventing moderate or severe cases of the disease, as no such cases were confirmed at least 21 days after receiving the first dose."," "]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," Global demand for Sputnik V ",{"type":"a","content":["soared"],"attrs":{"href":"https://fortune.com/2021/02/08/international-sputnik-russia-demand/","target":"_blank"}}," in the weeks after the vaccine’s efficacy data was published. The vaccine makers ",{"type":"a","content":["reached deals"],"attrs":{"href":"https://www.businessinsider.com/russia-sputnik-vaccine-40-countries-west-hoards-shots-2021-3","target":"_blank"}}," with more than 40 countries in Latin America, Eastern Europe, Asia, and Africa. On February 19, the African Union ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.reuters.com/article/uk-health-coronavirus-africa-idUSKBN2AJ0ZP","target":"_blank"}}," that Russia has offered them 300 million doses of the Sputnik V vaccine."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On December 11, the Gamaleya Institute and biopharmaceutical company AstraZeneca ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.cnbc.com/2020/12/11/coronavirus-astrazeneca-to-work-on-vaccine-with-russias-gamaleya.html","target":"_blank"}}," they will work together to study the possibility of combining Sputnik V with the candidate that AstraZeneca has developed with the University of Oxford. Since both candidates use the same adenovirus, researchers will investigate whether combining them will improve efficacy of the AstraZeneca vaccine, which is 70.4-percent effective in preventing COVID-19."," "]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Chumakov Center"]}],"attrs":{"href":"http://www.chumakovs.ru/en/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"," "]},"CoviVac"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Russian research center."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated vaccine given in two doses, 14 days apart."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," On February 20, Russia ",{"type":"a","content":["approved"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-russia-vaccine/russia-approves-its-third-covid-19-vaccine-pm-idUSKBN2AK07H","target":"_blank"}}," the CoviVac vaccine for use even though late-stage clinical trials to test its safety and efficacy have not yet begun. Reuters reports that early-stage trials with 200 participants showed the vaccine has no side effects."]},{"type":"p","content":[{"type":"b","content":["Distribution:"]}," The Chumakov Center plans to produce half a million doses per month."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Murdoch Children’s Research Institute"]}],"attrs":{"href":"https://www.mcri.edu.au/BRACE","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Bacillus Calmette-Guerin BRACE trial"," "]},{"type":"p","content":[{"type":"b","content":["Who:"]}," The largest child health research institute in Australia, in collaboration with the University of Melbourne."]},{"type":"p","content":[{"type":"b","content":["What:"]}," For nearly a hundred years, the Bacillus Calmette-Guerin (BCG) vaccine ",{"type":"a","content":["has been used"],"attrs":{"href":"https://www.gavi.org/vaccineswork/can-bcg-vaccine-protect-against-covid-19","target":"_blank"}}," to prevent tuberculosis by exposing patients to ",{"type":"a","content":["a small dose of live bacteria"],"attrs":{"href":"https://www.uofmhealth.org/health-library/d08998a1#:~:text=BCG%20vaccine%20works%20by%20exposing,from%20disease%20in%20every%20person.","target":"_blank"}},". Evidence has emerged over the years that this vaccine may boost the immune system and help the body fight off other diseases as well."," "]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"," "]},"On November 10, 2020, a U.S. study ",{"type":"a","content":["published in the ",{"type":"i","content":["Journal of Clinical Investigation"]}],"attrs":{"href":"https://www.jci.org/articles/view/145157","target":"_blank"}}," found that among 6,201 healthcare workers in Los Angeles, those who had previously received the BCG vaccine reported symptoms of COVID-19 less often than those who hadn’t, a finding that study authors say strengthens the case for further research. In October of that year, the U.K. ",{"type":"a","content":["launched a study"],"attrs":{"href":"https://www.reuters.com/article/health-coronavirus-britain-bcg/uk-study-tests-if-bcg-vaccine-protects-against-covid-idINKBN26W08C","target":"_blank"}}," of the BCG vaccine that is part of the Australian-led trials. The study is seeking to recruit a thousand frontline health-care workers to test the vaccine’s effectiveness against COVID-19."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," In Apri 2020, researchers from the Murdoch Children’s Research Institute ",{"type":"a","content":["began a series of randomized controlled trials"],"attrs":{"href":"https://www.nytimes.com/2020/04/03/health/coronavirus-bcg-vaccine.html","target":"_blank"}}," that will test whether BCG might work on the coronavirus as well. They aim to recruit ",{"type":"a","content":["10,000 healthcare workers"],"attrs":{"href":"https://www.mcri.edu.au/BRACE","target":"_blank"}}," in the study. In an April 2020 scientific brief, the World Health Organization found that there is ",{"type":"a","content":["no current evidence that the BCG vaccine protects"],"attrs":{"href":"https://www.who.int/publications/i/item/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19","target":"_blank"}}," people against infection with the coronavirus."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["CanSino Biologics"]}],"attrs":{"href":"http://www.cansinotech.com/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Ad5-nCoV"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Chinese biopharmaceutical company."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A viral vector vaccine."," "]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," On June 25, 2020, CanSino ",{"type":"a","content":["became the first company to receive limited approval"],"attrs":{"href":"https://www.nature.com/articles/d41586-020-02244-1","target":"_blank"}}," to use its vaccine in people even though it was still in the second phase of its clinical trials. At the time, the Chinese government ",{"type":"a","content":["pproved"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUSKBN2400DZ","target":"_blank"}}," the vaccine for military use only, for a period of one year. Since then, the vaccine ",{"type":"a","content":["has been approved"],"attrs":{"href":"https://covid19.trackvaccines.org/vaccines/2/","target":"_blank"}}," in China, Argentina, Hungary, and other countries."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," Preliminary results from phase two trials, ",{"type":"a","content":["published in ",{"type":"i","content":["The Lancet"]}],"attrs":{"href":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext","target":"_blank"}},", have shown that the vaccine produces “significant immune responses in the majority of recipients after a single immunisation.” There were no serious adverse reactions documented."]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," On December 21, CanSino ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-vaccine-cansinobio/china-cansinobios-covid-19-vaccine-trials-recruit-over-20000-people-idUSKBN28V1N8","target":"_blank"}}," that it has recruited more than 20,000 participants for its phase three trials in Pakistan, Russia, Mexico, and Chile. On August 15, Russian biopharmaceutical company Petrovax ",{"type":"a","content":["announced"],"attrs":{"href":"http://petrovax.com/press_centre/news/2020/1878/","target":"_blank"}}," it had launched the first phase three clinical trial of Ad5-nCoV."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Vector Institute"]}],"attrs":{"href":"http://www.vector.nsc.ru/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," EpiVacCorona"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Russian biotechnology institute."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A protein vaccine, namely it uses small fragments of viral antigens called peptides to produce an immune response."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," On October 14, 2020, Russia ",{"type":"a","content":["granted"],"attrs":{"href":"https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html","target":"_blank"}}," regulatory approval to EpiVacCorona even though the vaccine candidate had not published any results and had not entered phase three of its clinical trials. It is the second vaccine candidate that Russia approved for use despite a lack of published evidence about its safety and efficacy. It has since been approved for use in Turkmenistan and authorized for emergency use in Belarus."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," On January 13, 2021, Russian state news agency TASS ",{"type":"a","content":["reported"],"attrs":{"href":"https://tass.com/society/1244333","target":"_blank"}}," that of the more than 2,000 volunteers who had received both doses of EpiVacCorona’s two-dose regimen, none reported adverse reactions from the vaccine."," "]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," In November 2020 Russia ",{"type":"a","content":["launched"],"attrs":{"href":"https://www.reuters.com/article/us-health-coronavirus-russia-cases-idUSKBN28A0P0","target":"_blank"}}," mass trials of its EpiVacCorona vaccine; the trials will inoculate 150 people over the age of 60 and 3,000 volunteers over the age of 18."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Zydus Cadila"]}],"attrs":{"href":"https://zyduscadila.com/research","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," ZyCoV-D"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," An Indian pharmaceutical company."]},{"type":"p","content":[{"type":"b","content":["What:"]}," A DNA-based vaccine that is ",{"type":"a","content":["delivered by a skin patch"],"attrs":{"href":"https://timesofindia.indiatimes.com/india/vaccines-that-can-help-india-in-its-fight-against-covid-19/articleshow/79303893.cms","target":"_blank"}},"."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Approved for emergency use in India."]},{"type":"p","content":[{"type":"b","content":["Safety and efficacy:"]}," In December 2020 Zydus Cadila ",{"type":"a","content":["said"],"attrs":{"href":"https://timesofindia.indiatimes.com/india/zydus-cadila-seeks-govt-nod-to-start-phase-iii-clinical-trials-of-covid-19-vaccine/articleshow/79944346.cms","target":"_blank"}}," that a combined phase one/two study of its vaccine showed it was safe and prompted an immunogenic response, but the company did not share any data."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," On January 3, 2021, Zydus Cadila ",{"type":"a","content":["announced"],"attrs":{"href":"https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_receives_approvals_from_the_DCGI_to_start_Phase_III_Clinical_Trial_of_ZyCoV_D_fully_indigenously_developed_vaccine_-3_1_2021.pdf","target":"_blank"}}," it had received approval from Indian regulators to launch a phase three trial testing the safety and efficacy of its vaccine in about 30,000 volunteers."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Anhui Zhifei"]}],"attrs":{"href":"http://en.zhifeishengwu.com/about/zfgk/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," ZF2001"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Chinese biopharmaceutical company, in partnership with the Institute of Microbiology at the Chinese Academy of Sciences."]},{"type":"p","content":[{"type":"b","content":["What:"," "]},"A subunit vaccine that uses pieces of protein from a pathogen to trigger an immune response."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Approved for use in China, Indonesia, and Uzbekistan."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"]}," In August 2021 a study of the company’s phase one and two clinical trials ",{"type":"a","content":["published in ",{"type":"i","content":["The Lancet"]}," "],"attrs":{"href":"https://linkinghub.elsevier.com/retrieve/pii/S1473309921001274","target":"_blank"}},"showed that the vaccine elicited neutralizing antibodies and that the most common adverse reactions were cough, fever, and headache."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," In November 2020 Chinese health officials ",{"type":"a","content":["announced"],"attrs":{"href":"http://en.nhc.gov.cn/2020-11/20/c_82209.htm","target":"_blank"}}," the launch of phase three trials for the Anhui Zhifei vaccine. The trials—which aimed to recruit 29,000 volunteers aged 18 or older—were expected to be conducted in China, Indonesia, Pakistan, and Ecuador."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Research Institute for Biological Safety Problems"]}],"attrs":{"href":"https://www.biosafety.kz/en/","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," QazCovid-in"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A research institute in Kazakhstan."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated vaccine."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Granted temporary registration in Kazakhstan in January 2021 despite a lack of data from its phase three clinical trials."]},{"type":"p","content":[{"type":"b","content":["Efficacy and safety:"," "]},"In August 2021 a study of the vaccines phase one and phase two clinical trials ",{"type":"a","content":["published in ",{"type":"i","content":["The Lancet"]}],"attrs":{"href":"https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00358-8/fulltext","target":"_blank"}}," found that the vaccine was safe with no severe adverse events recorded. The studies also found the vaccine elicited a neutralizing antibody response as well as a T-cell response."]},{"type":"p","content":[{"type":"b","content":["Clinical trials status:"]}," In December 2020, the institute ",{"type":"a","content":["announced"],"attrs":{"href":"https://www.biosafety.kz/en/uncategorized/%d1%80%d0%b0%d0%b1%d0%be%d1%87%d0%b8%d0%b9-%d0%b2%d0%b8%d0%b7%d0%b8%d1%82-%d0%b2-%d0%bd%d0%b8%d0%b8%d0%bf%d0%b1%d0%b1-%d0%bf%d1%80%d0%b5%d0%bc%d1%8c%d0%b5%d1%80-%d0%bc%d0%b8%d0%bd%d0%b8%d1%81%d1%82-2/","target":"_blank"}}," that the Kazakh Ministry of Health approved the launch of phase three trials to assess the vaccine’s safety and efficacy in 3,000 volunteers."]},{"type":"h2","content":[{"type":"a","content":[{"type":"b","content":["Institute of Medical Biology at the Chinese Academy of Medical Sciences"]}],"attrs":{"href":"http://www.imb.com.cn/en/about.aspx","target":"_blank"}}]},{"type":"p","content":[{"type":"b","content":["Name:"]}," Unknown"]},{"type":"p","content":[{"type":"b","content":["Who:"]}," A Chinese research institute."]},{"type":"p","content":[{"type":"b","content":["What:"]}," An inactivated vaccine that requires two doses taken 14 days apart."]},{"type":"p","content":[{"type":"b","content":["Approval status:"]}," Not approved for use."]},{"type":"p","content":[{"type":"b","content":["Clinical trials:"]}," In December 2020, researchers ",{"type":"a","content":["launched phase three clinical trials"],"attrs":{"href":"https://clinicaltrials.gov/ct2/show/NCT04659239","target":"_blank"}}," to test the efficacy and safety of the vaccine in 34,020 participants in Malaysia and Brazil."," "]},{"type":"p","content":[{"type":"b","content":["Safety and efficacy:"]}," Preliminary results of the vaccine’s phase one trial ",{"type":"a","content":["showed"],"attrs":{"href":"https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf","target":"_blank"}}," that it prompted an immune response with no serious adverse incidents."]},{"type":"h2","content":[{"type":"a","content":[],"attrs":{"href":"https://www.pfizer.com/science/coronavirus/vaccine","rel":"noopener noreferrer","target":"_blank"}}]},{"type":"inline","content":{"name":"EditorsNote","props":{"body":"<p><b>Editor's note:</b> This story was originally published on July 31, 2020. It was regularly updated as developments occurred until November 2021.</p>","header":null},"context":{},"config":{"align":"full"}}}]],"blockquote":{"disableQuotationMark":true,"simple":true},"dateline":null,"datelineSeparator":"—","wordCount":9315,"className":"PrismArticleBody SingleColumn StartsWithInline"},"config":{"gridDisplayMode":"none"},"usesArticleObject":true}],"endComponents":[{"name":"RelatedTags","props":{"heading":"Related Topics","tags":[{"label":"CORONAVIRUS","href":"/related/f8408099-1b29-30de-af0d-3c172303e501/coronavirus"},{"label":"VACCINATION","href":"/related/26945195-72a1-3529-9d2a-cc4d85de992a/vaccination"},{"label":"IMMUNE SYSTEM","href":"/related/4ae5b950-6a04-33cd-94ed-b34a8ab3beba/immune-system"},{"label":"PUBLIC HEALTH","href":"/related/c1e8ee84-032b-3fb7-992e-8380b2ef0e13/public-health"},{"label":"DISEASES","href":"/related/f01c74a1-1ac8-3227-aec9-a76ea1805776/diseases"},{"label":"EPIDEMICS","href":"/related/f13ad5d0-f78b-39ea-a136-f8064e68bc33/epidemics"}]},"config":{"gridDisplayMode":"normal"},"usesArticleObject":true},{"name":"ContentPromoGrid","props":{"cards":[{"type":"floating","headline":"What is 'immune amnesia?' This long-term side effect of measles is newly relevant.","image":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_4x3.jpg","link":"https://www.nationalgeographic.com/premium/article/rising-measles-cases","imageRatio":"4x3","tags":[{"value":"SCIENCE","type":"text"}]},{"type":"floating","headline":"Now we know how COVID attacks your heart","image":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_4x3.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-19-risk-heart-attack-stroke","imageRatio":"4x3","tags":[{"value":"SCIENCE","type":"text"}]},{"type":"floating","headline":"What is white lung syndrome? Here's what to know about pneumonia","image":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_4x3.jpg","link":"https://www.nationalgeographic.com/premium/article/different-types-of-pneumonia-risk-treatments","imageRatio":"4x3","tags":[{"value":"SCIENCE","type":"text"}]},{"type":"floating","headline":"Is long COVID forever? A new study has clues.","image":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_4x3.jpg","link":"https://www.nationalgeographic.com/premium/article/long-covid-inflammation-immune-recover","imageRatio":"4x3","tags":[{"value":"SCIENCE","type":"text"}]},{"type":"floating","headline":"Why does COVID-19 cause brain fog? Scientists may finally have an answer.","image":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_4x3.jpg","link":"https://www.nationalgeographic.com/premium/article/why-does-covid-19-cause-brain-fog-answer-immune-inflammation-synapse","imageRatio":"4x3","tags":[{"value":"SCIENCE","type":"text"}]}],"heading":"You May Also Like","gridType":"five_promoted"},"config":{}}],"topComponents":[{"name":"Ad","props":{"ad":{"type":null,"className":null},"initSelf":true},"config":{}}],"SEO":{"JSONLD":{"article":{"@context":"http://schema.org/","@type":"NewsArticle","mainEntityOfPage":{"@id":"","@type":"WebPage"},"author":[{"name":"Amy McKeever","@type":"Person"},{"name":"National Geographic Staff","@type":"Person"}],"dateline":null,"datePublished":"2021-10-29T19:32:02.702Z","description":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","headline":"Here’s the latest on COVID-19 vaccines","image":{"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg","@type":"ImageObject"},"publisher":{"name":"","logo":{"url":"","width":0,"height":0,"@type":"ImageObject"},"@type":"Organization"}},"video":{}}},"layoutOptions":{"top":{"colorMode":"light"},"sidebar":{"isSticky":true,"isStackable":true},"main":{"spacing":{"top":40,"compactTop":24,"bottom":32,"childBottom":24}}},"analyticsData":{"storyTitle":"Here’s the latest on COVID-19 vaccines"}},"prismOptions":{"showSidebar":false,"ads":{"disabled":false,"fillInlineAds":true,"inlineAdsLimit":30,"minWords":0,"allowNearInline":true,"outstreamSlots":[3,13,18],"boxSlots":[8]},"everscrollEnabled":true,"endComponents":[{"name":"RelatedTags","data":{"articleConfig":{"gridDisplayMode":"normal"},"relatedTags":{"heading":"Related Topics","tags":[{"label":"CORONAVIRUS","href":"/related/f8408099-1b29-30de-af0d-3c172303e501/coronavirus"},{"label":"VACCINATION","href":"/related/26945195-72a1-3529-9d2a-cc4d85de992a/vaccination"},{"label":"IMMUNE SYSTEM","href":"/related/4ae5b950-6a04-33cd-94ed-b34a8ab3beba/immune-system"},{"label":"PUBLIC HEALTH","href":"/related/c1e8ee84-032b-3fb7-992e-8380b2ef0e13/public-health"},{"label":"DISEASES","href":"/related/f01c74a1-1ac8-3227-aec9-a76ea1805776/diseases"},{"label":"EPIDEMICS","href":"/related/f13ad5d0-f78b-39ea-a136-f8064e68bc33/epidemics"}]}}},"ContentPromoGrid"],"components":["LeadMediaImage",{"name":"PrismBadgeTag","data":{"badge":null,"tags":{"tags":[{"label":"SCIENCE","href":"https://www.nationalgeographic.com/science"},{"label":"CORONAVIRUS COVERAGE","href":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}]},"isUserAuthed":false}},"Headline","Byline","Divider","Body"],"Byline":{"dateFormat":{"postFormat":"MMMM DD, YYYY","preFormat":"MMMM DD, YYYY"}},"layoutOptions":{"top":{"colorMode":"light"},"sidebar":{"isSticky":true,"isStackable":true},"main":{"spacing":{"top":40}}},"Divider":{"className":"natgeoDivider"},"Body":{"inlines":[{"type":"editorsNote","data":{"articleConfig":{"align":"full"},"body":"<p><b>Editor’s note:</b> As of November 2021, this COVID-19 vaccine tracker is no longer being updated. <a href=\"https://www.nationalgeographic.com/science/article/covid-vaccines-latest-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Stay up-to-date on the latest vaccine developments and other COVID-19 news here</a>.</p>","header":null,"inlineId":"editors-notetracker-no-longer-being-updated"}},{"type":"markup","data":{"articleConfig":{"alignXxs":"full","align":"full"},"useSafeFrame":false,"a11yCTAText":"More Details","caption":{"title":null,"text":"","lines":3,"showMoreText":"Read More"},"encMethod":"esc","inlineId":"inline-1","tmsEnabled":true,"markup":"%3Clink%20rel%3D%22stylesheet%22%20href%3D%22//interactives.natgeofe.com/vendor/css/partial-aem-main.css%22%3E%0A%3Chr%20style%3D%22%u201Cwidth%3A50%25%3B%22%20border-top%3A1px%20solid%20%23ccc%3B%20margin%3A1em%20auto%3B%u201D%3E"}},{"type":"listicle","data":{"articleConfig":{"align":"full"},"title":"VACCINE CLINICAL TRIAL PROCESS","body":"<p><b>Phase one:</b> Checks the safety of a vaccine and determines whether it triggers an immune response in a small group of healthy humans.&nbsp;</p><p><b>Phase two:</b> Widens the testing pool to include groups of people who may have the disease or be more likely to catch it, to gauge the vaccine’s effectiveness.&nbsp;</p><p><b>Phase three:</b> Expands the pool up to the thousands to make sure the vaccine is safe and effective among a wider array of people, given that immune response can vary by age, ethnicity, or by underlying health conditions.</p>","description":"","inlineId":"listicle: clinical trial process","richTextElement":"div"}},{"type":"CommercePromo","data":{"layout":"standard","headline":"For Hungry Minds","description":" ","imageSrc":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg","imageRatio":"4x3","actionLabel":"GIFT NAT GEO KIDS","actionHref":"https://ngkidsubs.nationalgeographic.com/servlet/OrdersGateway?cds_mag_code=NKD&cds_page_id=276847&cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=bau_kids_may2024::int_add=article_promo","immersive":true,"colorMode":"dark","campaignName":"20240501_NGKBAU_MarketingPromo","tint":1,"inlineId":"commerce-promo-inline","articleConfig":{"alignXxs":"full","align":"center"},"className":"prism-commerce-container"}},{"type":"listicle","data":{"articleConfig":{"align":"full"},"title":"TYPES OF VACCINES","body":"<p><b>Nucleic acid:</b> Relies on injecting snippets of a virus’s genetic material, either DNA or messenger RNA (mRNA), into human cells. It spurs the production of viral proteins that mimic features of the coronavirus, training the immune system to recognize its presence.&nbsp;</p><p><b>Knocked-out virus:</b> Uses a non-infectious form of the coronavirus that can no longer cause full-blown disease but can still provoke an immune response. The virus can either be fully inactivated or weakened. These modes are considered the most classic ways to make vaccines.</p><p><b>Viral vector:</b> Essentially a “Trojan horse” presented to the immune system. One type involves introducing a piece of DNA from SARS-CoV-2 into another unrelated germ—for example, an adenovirus, which typically causes the common cold. When this modified adenovirus is injected into humans, the hope is that it will instruct cells to make coronavirus proteins and will trigger an immune response.</p><p><b>Protein:</b> These vaccines are typically made from coronavirus proteins, which can be synthesized or brewed in labs like beer. Some versions involve coating a carrier—such as nanoparticles—with proteins to better aid delivery and uptake by cells.</p>","description":"","inlineId":"listicle: types of vaccine","richTextElement":"div"}},{"type":"ContentPromo","data":{"inlineId":"recirculation-inline","articleConfig":{"align":"center"},"layout":"standard","cards":[{"headline":"COVID-19 can ruin your sleep in many different ways—here's why","image":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-19-can-ruin-your-sleep-in-many-different-waysheres-why","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]},{"headline":"How the additives in your vaccines rev up your immune system","image":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_square.jpg","link":"https://www.nationalgeographic.com/premium/article/vaccines-immune-system-inflammation","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]},{"headline":"Multiple COVID infections can lead to chronic health issues. Here’s what to know.","image":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-reinfections-chronic-booster-vaccine","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]}],"title":"You May Also Like"}},{"type":"editorsNote","data":{"articleConfig":{"align":"full"},"body":"<p><b>Editor's note:</b> This story was originally published on July 31, 2020. It was regularly updated as developments occurred until November 2021.</p>","header":null,"inlineId":"inline-2"}}],"Blockquote":{"disableQuotationMark":true,"simple":true},"datelineSeparator":"—","stripBr":false,"className":"PrismArticleBody SingleColumn StartsWithInline"},"dataConstructorMap":{}}}]}],"cmsType":"ArticleBodyFrame"},null,{"id":"paywall-meter-frame1"},{"id":"paywall-frame1"},{"id":"premium-frame"},{"id":"freemium-frame","mods":[{"id":"freemium-module-1","cmsType":"StackModule","align":"left","edgs":[{"id":"freemium-slider-tile-1","cmsType":"PaywallTile","subtype":"slider","heading":"Enter your email to read this article","description":"Plus, get the best of Nat Geo delivered to your inbox, and unlimited access to free content.","cta":{"text":"SUBMIT","type":"oneid","useOneID":true},"marketingCampaign":"20240201_freemium_general_slider_USCA","contentPackageId":"22b9ab2a-e784-429e-9421-36d997fff940","ftrTxt":"Already have an account?","ftrCta":{"text":"SIGN IN","type":"oneid","useOneID":true},"sldrTyp":"freemium","pgType":"prismarticle","scsMsg":"Thank you for signing up. Explore more now and look for National Geographic in your inbox soon!"}]}]},{"id":"upsell-frame","mods":[{"id":"8ab2946b-6e26-4eea-a4fa-e631c49cb678","cmsType":"StackModule","align":"left"}]},{"id":"newsletter-frame"},{"id":"ng-similarity-frame1","mods":[{"id":"ng-similarity-frame1-module1","cmsType":"RecirculationGridModule","itemTruncate":{"description":4,"title":4},"contentList":[{"description":"Scientists are learning more about the havoc that viruses and bacteria wreak on sleep. Here's what you need to know about seeking care for insomnia.","img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157.jpg","src":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157.jpg","altText":"A woman sitting in bed, seen from behind as she looks out the window at a city at night.","crdt":"Photograph by recep-bg, Getty Images","dsc":"The SARS-CoV-2 virus impacts systems throughout the body, including those that impact sleep.","ttl":"GettyImages-1388405157","rchDsc":{"markup":"The SARS-CoV-2 virus impacts systems throughout the body, including those that impact sleep."},"rchTtl":{"markup":"GettyImages-1388405157"},"ratio":"3x2"},"isFeatured":true,"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"COVID-19 can ruin your sleep in many different ways—here's why","link":"https://www.nationalgeographic.com/premium/article/covid-19-can-ruin-your-sleep-in-many-different-waysheres-why"},{"description":"Additives like aluminum in vaccines can amp up their effectiveness, creating just the right balance of inflammation to prevent disease.","img":{"crps":[{"nm":"raw","aspRto":1.313662604233483,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes.jpg","src":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes.jpg","altText":"An illustration of a silver needle piercing a vein and releasing tan, molecule like shapes into the vain with large, red blood cells.","crdt":"Photograph by NOBEASTSOFIERCE, Science Source","dsc":"mRNA vaccine, conceptual illustration.","rchDsc":{"markup":"mRNA vaccine, conceptual illustration. ​"},"rchTtl":{"markup":""}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"}],"headline":"How the additives in your vaccines rev up your immune system","link":"https://www.nationalgeographic.com/premium/article/vaccines-immune-system-inflammation"},{"description":"A previous SARS-CoV-2 infection can protect you for a little while, but the immunity wanes—and each new infection, no matter how mild, takes a toll on your body.","img":{"crps":[{"nm":"raw","aspRto":0.7998046875,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016.jpg","src":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016.jpg","altText":"A close-up view as a pharmacist extracts a COVID-19 booster vaccination from a vial.","crdt":"Photograph by Kenny Holston, The New York Times/Redux","dsc":"A pharmacist prepares a COVID-19 booster shot in the vaccination clinic at Meritus Medical Center in Hagerstown, Md., Feb. 22, 2022. TK","ttl":"vaccine_booster","rchDsc":{"markup":"A pharmacist prepares a COVID-19 booster shot in the vaccination clinic at Meritus Medical Center in Hagerstown, Md., Feb. 22, 2022. ​TK"},"rchTtl":{"markup":"​vaccine_booster"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"Multiple COVID infections can lead to chronic health issues","link":"https://www.nationalgeographic.com/premium/article/covid-reinfections-chronic-booster-vaccine"},{"description":"Measles, one of the most contagious viruses in existence, can have devastating impacts, including deadly complications that arise years after the initial infection. Here’s what we know.","img":{"crps":[{"nm":"raw","aspRto":1.2525993883792048,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM.jpg","src":"https://i.natgeofe.com/n/f87f55b7-c17e-4970-816a-a1f6975ca0c8/M0501241-Measles_virus_particles_TEM.jpg","altText":"A colored transmission electron micrographic view of measles virus particles, which appear as three amorphous blobs surrounded by grey protein envelopes.","crdt":"Micrograph by UK HEALTH SECURITY AGENCY/SCIENCE PHOTO LIBRARY","dsc":"Colored transmission electron micrograph (TEM) of measles virus particles. Each particle is surrounded by a lipoprotein envelope (grey), acquired from the host cell's cytoplasmic membrane as the virus buds off from the cell surface. The envelope is studded with surface proteins and encloses the nucleocapsid: a helical structure consisting of a single-stranded ribonucleic acid (RNA) core (genetic material). Measles is highly infectious and mainly affects children, producing fever and rash.","ttl":"M0501241-Measles_virus_particles_TEM","rchDsc":{"markup":"Colored transmission electron micrograph (TEM) of measles virus particles. Each particle is surrounded by a lipoprotein envelope (grey), acquired from the host cell's cytoplasmic membrane as the virus buds off from the cell surface. The envelope is studded with surface proteins and encloses the nucleocapsid: a helical structure consisting of a single-stranded ribonucleic acid (RNA) core (genetic material). Measles is highly infectious and mainly affects children, producing fever and rash."},"rchTtl":{"markup":"M0501241-Measles_virus_particles_TEM"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Mind, Body, Wonder","id":"28559e65-cecd-3fa3-89da-d2313b927934","type":"series","uri":"https://www.nationalgeographic.com/science/topic/health"}],"headline":"These are the long-term side effects of measles","link":"https://www.nationalgeographic.com/premium/article/rising-measles-cases"},{"description":"Even patients with mild COVID symptoms could face a higher risk of developing heart disease and stroke","img":{"crps":[{"nm":"raw","aspRto":1,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP.jpg","src":"https://i.natgeofe.com/n/3869cd9a-116d-43c1-9976-0ce717e63ed4/P2160002-Heart_with_arteries_CROP.jpg","altText":"A human heart, showing the arteries and veins which supply blood to the cardiac muscles.","crdt":"Photograph by SCIENCE PHOTO LIBRARY","dsc":"A human heart, showing the arteries and veins which supply blood to the cardiac muscles. The blood vessels, which lie immediately below the surface of the heart, have been injected with dyed gelatine, making visible the smallest capillaries which form this exquisite arterial network. The heart itself has been dehydrated by passing it through increasingly strong solutions of alcohol; it has then been transferred to a clearing agent which makes its surface transparent to a depth of 1-2 millimetres, enabling the blood vessels to become visible. The original black-and-white photo is here tinted pink.","ttl":"P2160002-Heart_with_arteries_CROP","rchDsc":{"markup":"A human heart, showing the arteries and veins which supply blood to the cardiac muscles. The blood vessels, which lie immediately below the surface of the heart, have been injected with dyed gelatine, making visible the smallest capillaries which form this exquisite arterial network. The heart itself has been dehydrated by passing it through increasingly strong solutions of alcohol; it has then been transferred to a clearing agent which makes its surface transparent to a depth of 1-2 millimetres, enabling the blood vessels to become visible. The original black-and-white photo is here tinted pink."},"rchTtl":{"markup":"P2160002-Heart_with_arteries_CROP"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"Now we know how COVID attacks your heart","link":"https://www.nationalgeographic.com/premium/article/covid-19-risk-heart-attack-stroke"},{"description":"Experts say a recent outbreak in Ohio is likely just typical pediatric pneumonia. They spoke to Nat Geo about the different types of pneumonia, plus the risks and treatments.","img":{"crps":[{"nm":"raw","aspRto":0.83544921875,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia.jpg","src":"https://i.natgeofe.com/n/55febcfd-0d6c-4ebe-9229-81e0b6aa7491/M2400651-Pneumonia.jpg","altText":"An x-ray showing increased opacity in the right lower lung field, suggestive of pneumonia","crdt":"Photograph by LIVING ART ENTERPRISES, LLC/SCIENCE PHOTO LIBRARY","dsc":"This anterior-posterior chest x-ray showing increased density adjacent to the lower right heart border consistent with a right lower lobe pneumonia (left side of the frame).","ttl":"M2400651-Pneumonia","rchDsc":{"markup":"This anterior-posterior chest x-ray showing increased density adjacent to the lower right heart border consistent with a right lower lobe pneumonia (left side of the frame)."},"rchTtl":{"markup":"M2400651-Pneumonia"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Mind, Body, Wonder","id":"28559e65-cecd-3fa3-89da-d2313b927934","type":"series","uri":"https://www.nationalgeographic.com/science/topic/health"}],"headline":"Here's what to know about pneumonia","link":"https://www.nationalgeographic.com/premium/article/different-types-of-pneumonia-risk-treatments"},{"description":"Research hints that those with symptoms may see an improvement after two years—but not everyone.","img":{"crps":[{"nm":"raw","aspRto":1.4143646408839778,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg","src":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg","altText":"A micrographic view of a large macrophage; two smaller, spiky appearing dendritic cells; and several small, round white blood cells.","crdt":"Composite Micrograph by STEVE GSCHMEISSNER, SCIENCE PHOTO LIBRARY","dsc":"Infection by the SARS-CoV-2 virus can result in both acute and chronic deregulation of inflammatory cytokines. Recent observations reported in Nature Communications suggest that by 24 months, the immune system of most patients enduring long-covid will have returned to normal levels. Pictured above: A composite colored scanning electron micrograph (SEM) of immune cells involved in a cytokine storm, including a single macrophage, two dendritic cells and numerous white blood cells. This type of hyperactivation of the immune system triggers inflammation that can lead to multi-organ failure and death.","ttl":"C0501068-Cytokine_storm_SEM","rchDsc":{"markup":"Infection by the SARS-CoV-2 virus can result in both acute and chronic deregulation of inflammatory cytokines. Recent observations reported in <i>Nature Communications&nbsp;</i>suggest that by 24 months, the immune system of most patients enduring long-covid will have returned to normal levels. Pictured above: A composite colored scanning electron micrograph (SEM) of immune cells involved in a cytokine storm, including a single macrophage, two dendritic cells and numerous white blood cells. This type of hyperactivation of the immune system triggers inflammation that can lead to multi-organ failure and death."},"rchTtl":{"markup":"C0501068-Cytokine_storm_SEM"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"Is long COVID forever? A new study has clues.","link":"https://www.nationalgeographic.com/premium/article/long-covid-inflammation-immune-recover"},{"description":"Nearly 40 percent of long COVID patients suffer from the disorienting condition. Destroyed connections between brain cells may be to blame.","img":{"crps":[{"nm":"raw","aspRto":1.159682899207248,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM.jpg","src":"https://i.natgeofe.com/n/092249b2-ff4d-4330-9459-92a963deee53/C0169112-Microglial_white_blood_cells_SEM.jpg","altText":"A scanning electron microscopic view of microglia, which appear as rough spheres connected by stretching strands.","crdt":"Micrograph by STEVE GSCHMEISSNER, SCIENCE PHOTO LIBRARY","dsc":"Colored scanning electron micrograph (SEM) of microglial cells. Microglia are phagocytic macrophage white blood cells that are the main form of immune system in the central nervous system (CNS).","ttl":"C0169112-Microglial_white_blood_cells_SEM","rchDsc":{"markup":"Colored scanning electron micrograph (SEM) of microglial cells. Microglia are phagocytic macrophage white blood cells that are the main form of immune system in the central nervous system (CNS)."},"rchTtl":{"markup":"C0169112-Microglial_white_blood_cells_SEM"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"Why does COVID-19 cause brain fog?","link":"https://www.nationalgeographic.com/premium/article/why-does-covid-19-cause-brain-fog-answer-immune-inflammation-synapse"},{"description":"New research suggests that the worse your symptoms are after getting the COVID-19 vaccine, the better. Here’s why.","img":{"crps":[{"nm":"raw","aspRto":1.5863671572424478,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641.jpg","src":"https://i.natgeofe.com/n/240df404-0fe1-4461-9729-bde216051e4c/h_16094641.jpg","altText":"A tight view of an older man in a white t-shirt with his right sleeve rolled up as he receives a shot of the COVID vaccine.","crdt":"Photograph by Koen van Weel, ANP/Redux","dsc":"A patient is inoculated against SARS-CoV-2 in the Netherlands on October 2, 2023. While unpleasant, side-effects of the vaccine such as headaches and chills may be an indication that the vaccine is building a stronger immune response and defense against future infections.","ttl":"h_16094641","rchDsc":{"markup":"A patient is inoculated against SARS-CoV-2 in the Netherlands on October 2, 2023. While unpleasant, side-effects of the vaccine such as headaches and chills may be an indication that the vaccine is ​building a ​stronger immune response and defense against future infections."},"rchTtl":{"markup":"h_16094641"}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}],"headline":"It’s good to feel bad after your COVID shot","link":"https://www.nationalgeographic.com/premium/article/covid-19-vaccine-shot-reaction"},{"description":"The human body’s defensive lineup is impressive—from made-to-order antibodies to natural-born killers. Here’s how it wards off sickness in every season.","img":{"crps":[{"nm":"raw","aspRto":1.0987124463519313,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop.jpg","src":"https://i.natgeofe.com/n/592d9a21-3ff5-4a38-a642-85341d93611a/GettyImages-1218405793_crop.jpg","altText":"Head shot of young woman having allergy symptoms, covering her nose with tissue while sneezing. She is standing outside on a balcony with a buildings and trees in the background.","crdt":"Photography by Oscar Wong, Getty Images","dsc":"Head shot of young woman having allergy symptoms, covering her nose with tissue while sneezing.","rchDsc":{"markup":"Head shot of young woman having allergy symptoms, covering her nose with tissue while sneezing.<br id=\"isPasted\"><div data-testid=\"asset-card\" style=\"box-sizing: inherit; align-items: center; display: flex; flex: 1 1 0%; flex-direction: column; height: 904.102px; justify-content: flex-start; position: relative; color: rgb(8, 8, 8); font-family: Lato, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;\"><div style=\"box-sizing: inherit; position: absolute; top: 271.227px; width: 815px; z-index: 3;\"><br></div><div tabindex=\"0\" style=\"box-sizing: inherit;\"><br></div></div>"},"rchTtl":{"markup":""}},"sections":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"}],"headline":"Got a cold? Here’s how your immune system is fighting it.","link":"https://www.nationalgeographic.com/premium/article/cold-sick-immune-system-response"}]}],"cmsType":"EnhancedFrame"},{"id":"natgeo-web-template-readthisnext-frame","cmsType":"EnhancedFrame"},{"id":"natgeo-globalpromo-frame1","fullWidth":true,"mods":[{"id":"natgeo-globalpromo-frame1-headline","cmsType":"StackModule","align":"left","edgs":[{"id":"natgeo-globalpromo-headline-tile","cmsType":"HeadlineTile","heading":"Go Further"}]},{"id":"natgeo-globalpromo-frame1-animals","cmsType":"CarouselModule","centerHeading":true,"edgs":[{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_9f143cac-e2f3-4b6c-a9df-3da512510260","description":"The world’s largest canine draws both reverence and ire. Here are some of the most common misunderstandings, according to scientists.","ctas":[{"url":"https://www.nationalgeographic.com/animals/article/myths-gray-wolves-north-america-predators","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.3884745762711865,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400.jpg","src":"https://i.natgeofe.com/n/8ec991d4-81d5-471a-b803-15593b80969a/NationalGeographic_2736400.jpg","altText":"A group of wolves travel together.","crdt":"Photograph By Ronan Donovan, National Geographic Image Collection","dsc":"A yearling male, known to our film crew as Gray Mane, walks ahead of a pack of arctic wolves in search of prey. This hunt lasted almost two days and covered some 65 miles. Filmmakers were able to follow the pack closely during the summer of 2018.","rchDsc":{"markup":"A yearling male, known to our film crew as Gray Mane, walks ahead of a pack of arctic wolves in search of prey. This hunt lasted almost two days and covered some 65 miles. Filmmakers were able to follow the pack closely during the summer of 2018.<br id=\"isPasted\"><div data-testid=\"prism-GridContainer\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0); box-sizing: border-box; display: flex; background: rgb(255, 255, 255); margin: 0px 92px; justify-content: center; flex-wrap: wrap; align-items: flex-start; --grid-columns: 24; --grid-gutters: 24px; color: rgb(0, 0, 0); font-family: GrosvenorBook; font-size: 18px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;\"><div data-testid=\"prism-GridRow\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0); box-sizing: border-box; width: 1248px; display: grid; max-width: 1248px; column-gap: var(--grid-gutters); grid-template-columns: repeat(var(--grid-columns),1fr);\"><div data-testid=\"prism-GridColumn\" style=\"-webkit-tap-highlight-color: rgba(0, 0, 0, 0); box-sizing: border-box; grid-column-start: var(--grid-column-start); grid-column-end: span var(--grid-column-span); --grid-column-span: var(--grid-column-span-xxl); --grid-column-start: var(--grid-column-start-xxl); --grid-column-span-xxs: var(--grid-columns); --grid-column-span-xs: var(--grid-columns); --grid-column-span-sm: var(--grid-columns); --grid-column-span-md: 20; --grid-column-span-lg: 16; --grid-column-span-xl: 16; --grid-column-span-xxl: 14; --grid-column-start-xxs: auto; --grid-column-start-xs: auto; --grid-column-start-sm: auto; --grid-column-start-md: 3; --grid-column-start-lg: 5; --grid-column-start-xl: 5; --grid-column-start-xxl: 6;\"><br></div></div></div>"},"rchTtl":{"markup":""}},"abstract":"The world’s largest canine draws both reverence and ire. Here are some of the most common misunderstandings, according to scientists.","title":"Top 4 myths about wolves, busted by experts","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]},{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_c0252ba9-bb8f-421d-aac6-e93d1abb2bbe","description":"These are some of our favorite stories about the ocean predators, from sinking boats to taking down sperm whales.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/orcas-hunting-sharks-killer-whales","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238.jpg","src":"https://i.natgeofe.com/n/20332c5c-d149-4b2d-9f5e-d5f746644d83/NationalGeographic_2274238.jpg","altText":"12 orcas swim together in a pod.","crdt":"Photograph By PAUL NICKLEN, National Geographic Image Collection","dsc":"A pod of orcas in the northern fjords of Norway.","rchDsc":{"markup":"A pod of orcas in the northern fjords of Norway."},"rchTtl":{"markup":""}},"abstract":"These are some of our favorite stories about the ocean predators, from sinking boats to taking down sperm whales.","title":"5 ways orcas are surprising scientists","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]},{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_e5cedd64-3b61-4d33-81cd-6dfd92112cd6","description":"The observation provides a window into how our own ancestors may have developed their natural medicines.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/first-report-wound-treatment-wild-orangutan-using-medicinal-plant","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.333955223880597,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_16x9.jpeg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_3x2.jpeg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_square.jpeg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_2x3.jpeg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_3x4.jpeg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_4x3.jpeg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_2x1.jpeg"}],"rt":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg","src":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg","altText":"An adult male orangutan, the wound below its right eye healed and no longer visible","crdt":"Photograph by Safruddin","dsc":"By August 25 the wound was barely visible anymore. Picture taken two months after wound treatment.","ttl":"Image_1","rchDsc":{"markup":"By August 25 the wound was barely visible anymore. Picture taken two months after wound treatment."},"rchTtl":{"markup":"Image_1"}},"abstract":"The observation provides a window into how our own ancestors may have developed their natural medicines.","title":"Orangutan seen using plants to heal wound for first time","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]},{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_76af0228-275d-4261-a6fb-88886cbc0b24","description":"A Canary Islands volcano pushed rivers of molten lava through the earth. Now scientists and explorers trek through the cooling underground, looking for insights into life on this planet—and perhaps on others.","ctas":[{"url":"https://www.nationalgeographic.com/environment/article/life-lava-volcanic-eruption-la-palma","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg","src":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg","altText":"Two scientists wearing silver-colored, full-body protective suits collecting samples from a bed of black volcanic rocks, while a volcano continues to erupt in the background.","crdt":"Photograph by Arturo Rodríguez","dsc":"Military responders Armando Salazar and Álvaro Heredia measure and sample lava flows in October 2021. La Palma’s 85-day eruption, after a 50-year dormant stretch, engulfed 2,800 buildings and displaced 7,000 residents.","ttl":"STOCKPKG_MM10175__XP20282","rchDsc":{"markup":"Military responders Armando Salazar and Álvaro Heredia measure and sample lava flows in October 2021. La Palma’s 85-day eruption, after a 50-year dormant stretch, engulfed 2,800 buildings and displaced 7,000 residents."},"rchTtl":{"markup":"STOCKPKG_MM10175__XP20282"}},"abstract":"A Canary Islands volcano pushed rivers of molten lava through the earth. Now scientists and explorers trek through the cooling underground, looking for insights into life on this planet—and perhaps on others.","title":"What La Palma's 'lava tubes' tell us about life on other planets","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_8cd36a68-c449-470e-b3e3-4aefb70b7098","description":"Massospora consumes cicadas from the inside out then drives them to mate—in the process making infected males more attractive to both sexes.","ctas":[{"url":"https://www.nationalgeographic.com/animals/article/cicadas-fungus-massospora-parasite","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":0.66650390625,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499.jpg","src":"https://i.natgeofe.com/n/be0fdd9d-a88b-4ed5-a43b-c2a6e8942b6f/GettyImages-1320075499.jpg","altText":"A cicada on a branch with the fungus an its rear.","crdt":"Photograph By Chip Somodevilla/Getty Images","dsc":"MAY 25: Showing a plug of yellow spores where its abdomen used to be, a Magicicada periodical cicada is infected with the fungal parasite Massospora cicadina May 25, 2021 in Takoma Park, Maryland. The fungus hijacks the sexual signals of periodical cicadas, turning them into zombies and forcing them to behave in ways that spread the fungus. Billions of periodical cicadas, members of the Brood X emergence, are emerging out of the ground in the eastern United States and Midwest to molt, mate, lay eggs and die after living underground for 17 years.","rchDsc":{"markup":"MAY 25: Showing a plug of yellow spores where its abdomen used to be, a Magicicada periodical cicada is infected with the fungal parasite Massospora cicadina May 25, 2021 in Takoma Park, Maryland. The fungus hijacks the sexual signals of periodical cicadas, turning them into zombies and forcing them to behave in ways that spread the fungus. Billions of periodical cicadas, members of the Brood X emergence, are emerging out of the ground in the eastern United States and Midwest to molt, mate, lay eggs and die after living underground for 17 years.&nbsp;"},"rchTtl":{"markup":""}},"abstract":"Massospora consumes cicadas from the inside out then drives them to mate—in the process making infected males more attractive to both sexes.","title":"This fungus turns cicadas into zombies who procreate—then die","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]},{"id":"natgeo-globalpromo-frame1-animals-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-animals-tile_b4417543-85be-4de9-bfc1-32fb3d9a9ce8","description":"Railways are a magnet for hungry grizzlies in their critical habitat along the Continental Divide. Conservationists are racing to find solutions.","ctas":[{"url":"https://www.nationalgeographic.com/animals/article/grizzly-bear-train-strikes-northern-rockies","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4938001458789205,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510.jpg","src":"https://i.natgeofe.com/n/9ff929d0-312c-4282-9879-c84b362662b0/NationalGeographic_2715510.jpg","altText":"A close up of a grizzly bear.","crdt":"Photograph By IAN MCALLISTER, National Geographic Image Collection","dsc":"A grizzly bear, Ursus arctos, glances curiously around.","rchDsc":{"markup":"A grizzly bear, Ursus arctos, glances curiously around.<br id=\"isPasted\"><br>"},"rchTtl":{"markup":""}},"abstract":"Railways are a magnet for hungry grizzlies in their critical habitat along the Continental Divide. Conservationists are racing to find solutions.","title":"How can we protect grizzlies from their biggest threat—trains?","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]}],"heading":"Animals","pageInfo":{"endCursor":"NTpSRmxPUVY4d0kwbEVPa1JTVG54a2NtNDZjM0pqT201aGRHZGxienAxYm1semIyNDZPbkJ5YjJRNllqUTBNVGMxTkRNdE9EVmlaUzAwWkdVNUxXSm1ZekV0TXpKbVlqTmtPV0U1WTJVNEkxTlBVbFE2YjNKcFoybHVZV3hRZFdKc2FYTm9aV1JFWVhSbGZERTNNVFF4TlRNMk9EUTVNalE9","hasNextPage":true},"templateContext":"eyJjb250ZW50VHlwZSI6IlVuaXNvbkFydGljbGVDb250ZW50IiwidmFyaWFibGVzIjp7ImluY2x1ZGVNZWRpYUNvbnRlbnRzIjoidHJ1ZSIsImxvY2F0b3IiOiIvc2NpZW5jZS9hcnRpY2xlL2Nvcm9uYXZpcnVzLXZhY2NpbmUtdHJhY2tlci1ob3ctdGhleS13b3JrLWxhdGVzdC1kZXZlbG9wbWVudHMtY3ZkIiwicG9ydGZvbGlvIjoibmF0Z2VvIiwicXVlcnlUeXBlIjoiTE9DQVRPUiJ9LCJtb2R1bGVJZCI6bnVsbH0","storyTitle":"Here’s the latest on COVID-19 vaccines"},{"id":"natgeo-globalpromo-frame1-environment","cmsType":"CarouselModule","centerHeading":true,"edgs":[{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_76af0228-275d-4261-a6fb-88886cbc0b24","description":"A Canary Islands volcano pushed rivers of molten lava through the earth. Now scientists and explorers trek through the cooling underground, looking for insights into life on this planet—and perhaps on others.","ctas":[{"url":"https://www.nationalgeographic.com/environment/article/life-lava-volcanic-eruption-la-palma","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg","src":"https://i.natgeofe.com/n/fdab90c9-01fb-42ec-af24-a02b51de0e43/STOCKPKG_MM10175__XP20282.jpg","altText":"Two scientists wearing silver-colored, full-body protective suits collecting samples from a bed of black volcanic rocks, while a volcano continues to erupt in the background.","crdt":"Photograph by Arturo Rodríguez","dsc":"Military responders Armando Salazar and Álvaro Heredia measure and sample lava flows in October 2021. La Palma’s 85-day eruption, after a 50-year dormant stretch, engulfed 2,800 buildings and displaced 7,000 residents.","ttl":"STOCKPKG_MM10175__XP20282","rchDsc":{"markup":"Military responders Armando Salazar and Álvaro Heredia measure and sample lava flows in October 2021. La Palma’s 85-day eruption, after a 50-year dormant stretch, engulfed 2,800 buildings and displaced 7,000 residents."},"rchTtl":{"markup":"STOCKPKG_MM10175__XP20282"}},"abstract":"A Canary Islands volcano pushed rivers of molten lava through the earth. Now scientists and explorers trek through the cooling underground, looking for insights into life on this planet—and perhaps on others.","title":"What La Palma's 'lava tubes' tell us about life on other planets","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_88c7d6b3-ceef-45fd-812d-7083c0373dda","description":"Circles made of mushrooms have inspired superstitions for centuries, but what’s really behind these cryptic rings?","ctas":[{"url":"https://www.nationalgeographic.com/environment/article/mushroom-fungi-mycelium-fairy-rings-myth","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4981711777615216,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos.jpg","src":"https://i.natgeofe.com/n/4d9032f1-cb6e-4301-b2b5-e4474ce8ac63/Fairy-Rings-Agorastos.jpg","altText":"Datail of a Amanita muscaria in the woods.","crdt":"Photograph by Agorastos Papatsanis","dsc":"Amanita muscaria. The grandiose presence, the famous and mysterious physiognomy, makes her “the strong personality of the autumn forest”.I used wide angle lens and aperture such as to highlight the grandeur and majesty of the master-piece in the foreground, which was in full bloom. The lines of gills, the wavy circumference of the hat and membranous \"skirts\" created make a very elegant figure. With 16mm showing much of the beech forest, which in the presence of fog seemed magical.Countless stories about Amanita, which balances between the myth and reality, stimulate the imagination of the forest's visitor.Deskati Grevena region, North GREECE.","rchDsc":{"markup":"Amanita muscaria. The grandiose presence, the famous and mysterious physiognomy, makes her “the strong personality of the autumn forest”.I used wide angle lens and aperture such as to highlight the grandeur and majesty of the master-piece in the foreground, which was in full bloom. The lines of gills, the wavy circumference of the hat and membranous \"skirts\" created make a very elegant figure. With 16mm showing much of the beech forest, which in the presence of fog seemed magical.Countless stories about Amanita, which balances between the myth and reality, stimulate the imagination of the forest's visitor.Deskati Grevena region, North GREECE.&nbsp;"},"rchTtl":{"markup":""}},"abstract":"Circles made of mushrooms have inspired superstitions for centuries, but what’s really behind these cryptic rings?","title":"How fungi form ‘fairy rings’ and inspire superstitions","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_d61287da-484b-4b92-8a33-7afabfdcef0d","description":"Everything from temperature, soil conditions, and rainfall can affect how food tastes. As the climate changes, it’s messing with our favorite flavors.","ctas":[{"url":"https://www.nationalgeographic.com/environment/article/food-flavor-climate-change","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4104683195592287,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020.jpg","src":"https://i.natgeofe.com/n/6ccc9e4c-0980-40cc-ad15-3592f1e763d9/h_15885020.jpg","altText":"Strawberries in a bowl.","crdt":"Photograph by NORIKO HAYASHI, The New York Times/Redux","dsc":"Wintertime strawberries in a bowl, in Tokyo on Feb. 23, 2023. In Japan, the strawberry crop peaks in wintertime -- a chilly season of picture-perfect berries, the most immaculate ones selling for hundreds of dollars apiece to be given as special gifts.","rchDsc":{"markup":"Wintertime strawberries in a bowl, in Tokyo on Feb. 23, 2023. In Japan, the strawberry crop peaks in wintertime -- a chilly season of picture-perfect berries, the most immaculate ones selling for hundreds of dollars apiece to be given as special gifts."},"rchTtl":{"markup":""}},"abstract":"Everything from temperature, soil conditions, and rainfall can affect how food tastes. As the climate changes, it’s messing with our favorite flavors.","title":"Your favorite foods may not taste the same in the future. Here's why.","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_8c262e3b-a284-4e8d-908f-a81ddb6348ba","description":"A single cargo ship can carry enough goods to replace nearly 3,000 semi-trucks—that's why some are calling for a shipping boom in America's famous lakes.","ctas":[{"url":"https://www.nationalgeographic.com/environment/article/climate-change-great-lakes-shipping-green-transportation","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704.jpg","src":"https://i.natgeofe.com/n/2f2d6cbf-80f5-4972-ab6c-aba1e69f5826/DJI_0704.jpg","altText":"The Mark W Barker coming into Sturgeon Bay through the shipping canal.","crdt":"Photograph by Luke Collins","dsc":"On January 21, 2023, the Mark W Barker arrived in Sturgeon Bay for a winter layup after its first shipping season. The Barker was built in Sturgeon Bay by Fincantieri Bay Shipbuilding for Interlake Steamship Company. The ship was delivered in 2022 and set out on her maiden shipping season that same year.","rchDsc":{"markup":"On January 21, 2023, the Mark W Barker arrived in Sturgeon Bay for a winter layup after its first shipping season. &nbsp;The Barker was built in Sturgeon Bay by Fincantieri Bay Shipbuilding for Interlake Steamship Company. The ship was delivered in 2022 and set out on her maiden shipping season that same year.<br><br><br>"},"rchTtl":{"markup":""}},"abstract":"A single cargo ship can carry enough goods to replace nearly 3,000 semi-trucks—that's why some are calling for a shipping boom in America's famous lakes.","title":"Are the Great Lakes the key to solving America’s emissions conundrum?","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_03aad1ff-e91e-417e-8178-e18cc6aeca05","description":"The 2,000-year-old desert city created an adventurous backdrop for Indiana Jones, but today, drought, floods, and sandstorms imperil it. Ancient technology could be the key to surviving.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/petra-ancient-technology-climate-change-floods","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7.jpg","src":"https://i.natgeofe.com/n/15c9a581-f853-4dca-b8d8-575067d1b33a/Michael_SnyderPetraNational-Geographic7.jpg","altText":"Ad Deir, also known as The Monastery, at sunset in Petra World Heritage Site","crdt":"Photograph by Michael O. Snyder","dsc":"Ad Deir, also known as The Monastery, at sunset in Petra World Heritage Site. Now regarded as one of the New Seven Wonders of the World, Petra has become a world famous destination, drawing nearly a million visitors each year. Yet, only about 15% of the site has been explored by archaeologist. “The past has secrets. It has things to say, if we know how to listen” says Hani Falahat. “The keys to the future of this site are hidden in its past.”","ttl":"Michael_SnyderPetraNational-Geographic7","rchDsc":{"markup":"Ad Deir, also known as The Monastery, at sunset in Petra World Heritage Site. Now regarded as one of the New Seven Wonders of the World, Petra has become a world famous destination, drawing nearly a million visitors each year. Yet, only about 15% of the site has been explored by archaeologist. “The past has secrets. It has things to say, if we know how to listen” says Hani Falahat. “The keys to the future of this site are hidden in its past.”"},"rchTtl":{"markup":"Michael_SnyderPetraNational-Geographic7"}},"abstract":"The 2,000-year-old desert city created an adventurous backdrop for Indiana Jones, but today, drought, floods, and sandstorms imperil it. Ancient technology could be the key to surviving.","title":"The world’s historic sites face climate change. Can Petra lead the way?","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_3942cc37-9b14-4346-bcf6-6dc72adc1130","description":"There are fewer than 300 of these streams on the planet, and they’re teeming with life. But in recent years, detergents, microplastics, and other waste have taken a toll.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/chalk-streams-uk-conservation","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.501466275659824,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008.jpg","src":"https://i.natgeofe.com/n/43426d64-f93e-40b5-b13d-0e6413a64ffb/MM9659_220604_25008.jpg","altText":"A person in a square raft is seen cutting down the green growth on the stream.","asstSrc":"Assignment","crdt":"Photograph by Charlie Hamilton James","dsc":"Riverkeepers cut back water crowfoots in the Hampshire Avon. Such plants provide shade and shelter for river life, but summer excess can make fishing impossible.","ttl":"MM9659- riverkeepers","rchDsc":{"markup":"Riverkeepers cut back water crowfoots in the Hampshire Avon. Such plants provide shade and shelter for river life, but summer excess can make fishing impossible."},"rchTtl":{"markup":"MM9659- riverkeepers"}},"abstract":"There are fewer than 300 of these streams on the planet, and they’re teeming with life. But in recent years, detergents, microplastics, and other waste have taken a toll.","title":"England’s iconic chalk streams are in trouble","tags":[{"name":"Environment","id":"623ce370-3e67-3fb2-b9a5-070ceb9b2de5","type":"sources","uri":"https://www.nationalgeographic.com/environment"}]}],"heading":"Environment","pageInfo":{"endCursor":"NTpSRmxPUVY4d0kwbEVPa1JTVG54a2NtNDZjM0pqT201aGRHZGxienAxYm1semIyNDZPbkJ5YjJRNk16azBNbU5qTXpjdE9XSXhOQzAwTXpRMkxXSmpaall0Tm1Sak56SmhaR014TVRNd0kxTlBVbFE2YjNKcFoybHVZV3hRZFdKc2FYTm9aV1JFWVhSbGZERTNNVE00TnpBd01EQXdNREE9","hasNextPage":true},"templateContext":"eyJjb250ZW50VHlwZSI6IlVuaXNvbkFydGljbGVDb250ZW50IiwidmFyaWFibGVzIjp7ImluY2x1ZGVNZWRpYUNvbnRlbnRzIjoidHJ1ZSIsImxvY2F0b3IiOiIvc2NpZW5jZS9hcnRpY2xlL2Nvcm9uYXZpcnVzLXZhY2NpbmUtdHJhY2tlci1ob3ctdGhleS13b3JrLWxhdGVzdC1kZXZlbG9wbWVudHMtY3ZkIiwicG9ydGZvbGlvIjoibmF0Z2VvIiwicXVlcnlUeXBlIjoiTE9DQVRPUiJ9LCJtb2R1bGVJZCI6bnVsbH0","storyTitle":"Here’s the latest on COVID-19 vaccines"},{"id":"natgeo-globalpromo-frame1-history","cmsType":"CarouselModule","centerHeading":true,"edgs":[{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_dc8d63ce-96c8-42c2-bdc1-2a65b9e1ed17","description":"Controversy over shifting hemlines proves that women in sports have long been scrutinized for what they wear.","ctas":[{"url":"https://www.nationalgeographic.com/history/article/tennis-skirt-sports-fashion","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4133885438233265,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP.jpg","src":"https://i.natgeofe.com/n/9af49de4-1072-45b6-b89b-e807a74c4906/h_27.RTX6X6GP.jpg","altText":"Serena Williams of the U.S. in action during her second round match against Japan's Kurumi Nara.","crdt":"Photograph by Vincent Kessler, Reuters/Redux","dsc":"Tennis - French Open - Roland Garros, Paris, France - May 30, 2019. Serena Williams of the U.S. in action during her second round match against Japan's Kurumi Nara.","rchDsc":{"markup":"Tennis - French Open - Roland Garros, Paris, France - May 30, 2019. Serena Williams of the U.S. in action during her second round match against Japan's Kurumi Nara."},"rchTtl":{"markup":""}},"abstract":"Controversy over shifting hemlines proves that women in sports have long been scrutinized for what they wear.","title":"A short history of tennis skirts","tags":[{"name":"History & Culture","id":"b0c8dd52-23a8-34c0-a940-f46792bc9e70","type":"sources","uri":"https://www.nationalgeographic.com/history"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_13fd3d94-d601-4bd2-ae65-707e804033c6","description":"A visit to a home renovation caught the eye of a dentist—and is exciting researchers around the world.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/travertine-tile-floor-human-hominin-fossil","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.24954240390482,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2_.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2__2x1.jpg"}],"rt":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2_.jpg","src":"https://i.natgeofe.com/n/e9ad65c9-9813-4719-8ccc-ef465418b7c5/Unknown-2_.jpg","altText":"An ancient jawbone embedded in travertine tile.","crdt":"Photograph Courtesy Kidipadeli75","dsc":"An ancient jawbone embedded in travertine tile.","rchDsc":{"markup":"An ancient jawbone embedded in travertine tile.&nbsp;"},"rchTtl":{"markup":""}},"abstract":"A visit to a home renovation caught the eye of a dentist—and is exciting researchers around the world.","title":"Your tile floor may contain human fossils","tags":[{"name":"History & Culture","id":"b0c8dd52-23a8-34c0-a940-f46792bc9e70","type":"sources","uri":"https://www.nationalgeographic.com/history"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_01c73e61-1e59-4726-822a-37cdcafb9ea3","description":"The islands were once separate states until Kamehameha I brought them under his rule. Led by prophecy and driven to bloody battles, he overcame colonial threats and local rivals.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/king-kamehameha-hawaii-unification","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.499267935578331,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2.jpg","src":"https://i.natgeofe.com/n/f08e5080-06a8-49e8-a5f5-7b5e3bf9d74f/hawaii2.jpg","altText":"A 14-foot-tall statue of King Kamehameha stands in a park with palm trees","crdt":"Jim West/Alamy/ACI","dsc":"Standing in Wailoa River State Park, a 14-foot-tall statue of King Kamehameha watches over Hilo, the first official capital of the Hawaiian Islands after he unified them in 1810.","ttl":"Royal gaze","rchDsc":{"markup":"Standing in Wailoa River State Park, a 14-foot-tall statue of King Kamehameha watches over Hilo, the first official capital of the Hawaiian Islands after he unified them in 1810."},"rchTtl":{"markup":"Royal gaze"}},"abstract":"The islands were once separate states until Kamehameha I brought them under his rule. Led by prophecy and driven to bloody battles, he overcame colonial threats and local rivals.","title":"Meet the ruthless king who unified the Kingdom of Hawai'i","tags":[{"name":"History Magazine","id":"9e8034f6-2e16-3b86-998b-56f8ff9dffb7","type":"sources","uri":"https://www.nationalgeographic.com/history/magazine"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_2cc3b572-fab5-4566-93ac-90009b8be731","description":"Nothing quite symbolizes the essence of Hawai’i and the aloha spirit quite like the lei. But as native flora disappears, lei makers discuss how they see the future of their craft.","ctas":[{"url":"https://www.nationalgeographic.com/culture/article/lei-day-hawaii-native-plants-history","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884.jpg","src":"https://i.natgeofe.com/n/914bc417-9dc0-4db1-9e1e-36f7ac265270/DSC08884.jpg","altText":"flower lei on a rock","crdt":"Photograph by Haunani Miyasato","dsc":"Introduced to the Hawaiian Islands by early Polynesian voyagers, the lei custom has many symbolisms and meaning","rchDsc":{"markup":"Introduced to the Hawaiian Islands by early Polynesian voyagers, the lei custom has many symbolisms and meaning"},"rchTtl":{"markup":""}},"abstract":"Nothing quite symbolizes the essence of Hawai’i and the aloha spirit quite like the lei. But as native flora disappears, lei makers discuss how they see the future of their craft.","title":"Hawaii's Lei Day is about so much more than flowers","tags":[{"name":"History & Culture","id":"b0c8dd52-23a8-34c0-a940-f46792bc9e70","type":"sources","uri":"https://www.nationalgeographic.com/history"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_805d1c42-4bb6-4545-84fb-324dd95d6663","description":"Nearly all of England’s bonafide archaeological discoveries in recent years have been made by amateurs armed with metal detectors.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/amateur-treasure-hunters-record-artifacts-uk","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4473498233215547,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178.jpg","src":"https://i.natgeofe.com/n/e56311cc-f808-4885-8270-cb4dd20acc10/GettyImages-1211997178.jpg","altText":"A purple globed hand holds a jewelled late Medieval cluster brooch.","crdt":"Photograph by John Phillips, Getty Images","dsc":"In 2017, a metal detectorist uncovered a rare jeweled late Medieval cluster brooch in a former royal hunting ground known as Great Park in Northamptonshire. The brooch, dating from 1400-1450, and made in France or Germany, is the only one of its kind to be found in the U.K., and one of only seven known in the world.","rchDsc":{"markup":"In 2017, a metal detectorist uncovered a rare jeweled late Medieval cluster brooch in a former royal hunting ground known as Great Park in Northamptonshire. The brooch, dating from 1400-1450, and made in France or Germany, is the only one of its kind to be found in the U.K., and one of only seven known in the world."},"rchTtl":{"markup":""}},"abstract":"Nearly all of England’s bonafide archaeological discoveries in recent years have been made by amateurs armed with metal detectors.","title":"When treasure hunters find artifacts, who gets to keep them?","tags":[{"name":"History & Culture","id":"b0c8dd52-23a8-34c0-a940-f46792bc9e70","type":"sources","uri":"https://www.nationalgeographic.com/history"}]},{"id":"natgeo-globalpromo-frame1-history-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-history-tile_d3a840b6-f2a9-4504-ae4a-7ffdcc91e578","description":"From humble kitchens to opulent royal banquets, here's how this versatile treat became one of the world's favorite condiments.","ctas":[{"url":"https://www.nationalgeographic.com/history/article/history-of-jam-meghan-markle-lifestyle","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":0.7490234375,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022.jpg","src":"https://i.natgeofe.com/n/04208512-b6da-4117-8556-597730fd695c/GettyImages-84407022.jpg","altText":"A knife covered in jam against a blue background.","crdt":"Photograph by Sam Armstrong, Getty Images","dsc":"A knife covered in jam against a blue background.","rchDsc":{"markup":"A knife covered in jam against a blue background."},"rchTtl":{"markup":""}},"abstract":"From humble kitchens to opulent royal banquets, here's how this versatile treat became one of the world's favorite condiments.","title":"The short, sweet, and sticky history of jam","tags":[{"name":"History & Culture","id":"b0c8dd52-23a8-34c0-a940-f46792bc9e70","type":"sources","uri":"https://www.nationalgeographic.com/history"}]}],"heading":"History & Culture","pageInfo":{"endCursor":"NTpSRmxPUVY4d0kwbEVPa1JTVG54a2NtNDZjM0pqT201aGRHZGxienAxYm1semIyNDZPbkJ5YjJRNlpETmhPRFF3WWpZdFpqSmhPUzAwTlRBMExXRmxOR0V0TjJabVpHTmpPVEZsTlRjNEkxTlBVbFE2YjNKcFoybHVZV3hRZFdKc2FYTm9aV1JFWVhSbGZERTNNVFF4TXpneU1EQXdNREE9","hasNextPage":true},"templateContext":"eyJjb250ZW50VHlwZSI6IlVuaXNvbkFydGljbGVDb250ZW50IiwidmFyaWFibGVzIjp7ImluY2x1ZGVNZWRpYUNvbnRlbnRzIjoidHJ1ZSIsImxvY2F0b3IiOiIvc2NpZW5jZS9hcnRpY2xlL2Nvcm9uYXZpcnVzLXZhY2NpbmUtdHJhY2tlci1ob3ctdGhleS13b3JrLWxhdGVzdC1kZXZlbG9wbWVudHMtY3ZkIiwicG9ydGZvbGlvIjoibmF0Z2VvIiwicXVlcnlUeXBlIjoiTE9DQVRPUiJ9LCJtb2R1bGVJZCI6bnVsbH0","storyTitle":"Here’s the latest on COVID-19 vaccines"},{"id":"natgeo-globalpromo-frame1-science","cmsType":"CarouselModule","centerHeading":true,"edgs":[{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_cafdb960-3909-4923-a9b4-7ef662bf93aa","description":"Your friends and family may have told you knuckle cracking is bad for you. But is it really as harmful as some might think?","ctas":[{"url":"https://www.nationalgeographic.com/science/article/is-cracking-your-knuckles-a-bad-habit","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":0.7998046875,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG.jpg","src":"https://i.natgeofe.com/n/8e800082-d8d0-4c13-8b24-2ba6a03597e7/RY8GRG.jpg","altText":"A pair of outstretched hands with interlocking fingers bent back to crack the knuckles.","crdt":"Photograph by Sara Sadler, Alamy Stock Photo","dsc":"Cracking your knuckles can offer relief through the release of pressure built up by synovial fluid in joints and the satisfaction of hearing a crisp \"pop.\" However, does cracking out joints have deleterious effects?","ttl":"RY8GRG","rchDsc":{"markup":"Cracking your knuckles can offer relief through the release of pressure built up by synovial fluid in joints and the satisfaction of hearing a crisp \"pop.\" However, does cracking out joints have deleterious effects?"},"rchTtl":{"markup":"RY8GRG"}},"abstract":"Your friends and family may have told you knuckle cracking is bad for you. But is it really as harmful as some might think?","title":"Is cracking your knuckles really a bad habit?","tags":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"}]},{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_170c7bf4-3e3c-46e3-a506-4725e34a635a","description":"Experts debate whether these symptoms are simply a flare-up of underlying conditions, or a separate condition linked to use of the medicine.","ctas":[{"url":"https://www.nationalgeographic.com/science/article/topical-steroid-withdrawal-eczema-treatment","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726.jpg","src":"https://i.natgeofe.com/n/19965daf-93d0-4dab-8805-211336078f19/GettyImages-938019726.jpg","altText":"A close-up view of a person's hands as they squeeze out a dollop of ointment.","crdt":"Photograph by Marina Vol, Getty Images","dsc":"The abrupt discontinuation of topical corticosteroids following prolonged use to manage conditions such as eczema and psoriasis may lead to a condition called \"topical steroid withdrawal.\"","ttl":"GettyImages-938019726","rchDsc":{"markup":"The abrupt discontinuation of topical corticosteroids following prolonged use to manage conditions such as eczema and psoriasis may lead to a condition called \"topical steroid withdrawal.\""},"rchTtl":{"markup":"GettyImages-938019726"}},"abstract":"Experts debate whether these symptoms are simply a flare-up of underlying conditions, or a separate condition linked to use of the medicine.","title":"What is topical steroid withdrawal?","tags":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"}]},{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_ba6fd593-28ec-4f5e-b535-79c3d5bbf6f5","description":"Scientists are learning that ovaries aren't just important for making babies—they also keep the heart, brain, and bones healthy.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/slow-aging-ovaries-delay-menopause-boost-brain-heart-health","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN.jpg","src":"https://i.natgeofe.com/n/f4507bd6-2d95-4b35-9bb9-dadd15eb143f/STOCK_MIS_PEPIN.jpg","altText":"A mouse ovary treated with anti-Mullerian hormone, resulting in fewer large activated follicles compared to an untreated ovary","crdt":"Micrograph by David Pepin","dsc":"A mouse ovary treated with gene therapy delivering a high dose of anti-Mullerian hormone (AMH)—a hormone naturally produced by follicles in the ovary—shows fewer larger follicles and more small, dormant ones. At high levels, AMH acts as a contraceptive, preventing follicles from growing to release an egg. Reproductive biologist David Pépin’s lab has been testing AMH-based contraception for cats and hopes to develop AMH contraception for humans.","ttl":"STOCK_MIS_PEPIN","rchDsc":{"markup":"A mouse ovary treated with gene therapy delivering a high dose of anti-Mullerian hormone (AMH)—a hormone naturally produced by follicles in the ovary—shows fewer larger follicles and more small, dormant ones. At high levels, AMH acts as a contraceptive, preventing follicles from growing to release an egg. Reproductive biologist David Pépin’s lab has been testing AMH-based contraception for cats and hopes to develop AMH contraception for humans."},"rchTtl":{"markup":"STOCK_MIS_PEPIN"}},"abstract":"Scientists are learning that ovaries aren't just important for making babies—they also keep the heart, brain, and bones healthy.","title":"Why ovaries are so crucial to women’s health and longevity","tags":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Mind, Body, Wonder","id":"28559e65-cecd-3fa3-89da-d2313b927934","type":"series","uri":"https://www.nationalgeographic.com/science/topic/health"}]},{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_e5cedd64-3b61-4d33-81cd-6dfd92112cd6","description":"The observation provides a window into how our own ancestors may have developed their natural medicines.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/first-report-wound-treatment-wild-orangutan-using-medicinal-plant","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.333955223880597,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_16x9.jpeg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_3x2.jpeg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_square.jpeg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_2x3.jpeg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_3x4.jpeg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_4x3.jpeg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1_2x1.jpeg"}],"rt":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg","src":"https://i.natgeofe.com/n/6d88a314-0518-454a-9322-4c8fb80b96f2/Image_1.jpeg","altText":"An adult male orangutan, the wound below its right eye healed and no longer visible","crdt":"Photograph by Safruddin","dsc":"By August 25 the wound was barely visible anymore. Picture taken two months after wound treatment.","ttl":"Image_1","rchDsc":{"markup":"By August 25 the wound was barely visible anymore. Picture taken two months after wound treatment."},"rchTtl":{"markup":"Image_1"}},"abstract":"The observation provides a window into how our own ancestors may have developed their natural medicines.","title":"Orangutan seen using plants to heal wound for first time","tags":[{"name":"Animals","id":"fa010584-7bbf-3e92-90f9-586bb27fce94","type":"sources","uri":"https://www.nationalgeographic.com/animals"}]},{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_4f617be8-e836-4e30-9801-82328db7ea4c","description":"Research hints that those with symptoms may see an improvement after two years—but not everyone.","ctas":[{"url":"https://www.nationalgeographic.com/premium/article/long-covid-inflammation-immune-recover","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4143646408839778,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg","src":"https://i.natgeofe.com/n/25ab75a0-1651-4361-a5cc-af7ffbee1317/C0501068-Cytokine_storm_SEM.jpg","altText":"A micrographic view of a large macrophage; two smaller, spiky appearing dendritic cells; and several small, round white blood cells.","crdt":"Composite Micrograph by STEVE GSCHMEISSNER, SCIENCE PHOTO LIBRARY","dsc":"Infection by the SARS-CoV-2 virus can result in both acute and chronic deregulation of inflammatory cytokines. Recent observations reported in Nature Communications suggest that by 24 months, the immune system of most patients enduring long-covid will have returned to normal levels. Pictured above: A composite colored scanning electron micrograph (SEM) of immune cells involved in a cytokine storm, including a single macrophage, two dendritic cells and numerous white blood cells. This type of hyperactivation of the immune system triggers inflammation that can lead to multi-organ failure and death.","ttl":"C0501068-Cytokine_storm_SEM","rchDsc":{"markup":"Infection by the SARS-CoV-2 virus can result in both acute and chronic deregulation of inflammatory cytokines. Recent observations reported in <i>Nature Communications&nbsp;</i>suggest that by 24 months, the immune system of most patients enduring long-covid will have returned to normal levels. Pictured above: A composite colored scanning electron micrograph (SEM) of immune cells involved in a cytokine storm, including a single macrophage, two dendritic cells and numerous white blood cells. This type of hyperactivation of the immune system triggers inflammation that can lead to multi-organ failure and death."},"rchTtl":{"markup":"C0501068-Cytokine_storm_SEM"}},"abstract":"Research hints that those with symptoms may see an improvement after two years—but not everyone.","title":"Is long COVID forever? A new study has clues.","tags":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"},{"name":"Coronavirus Coverage","id":"a92c48ec-5e34-3b63-a1e1-2726bfc4c34e","type":"series","uri":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}]},{"id":"natgeo-globalpromo-frame1-science-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-science-tile_1ac1726a-0943-4ee1-857c-ba703f89b588","description":"Studies show that when it comes to silencing your mind, sound may be the most effective tool.","ctas":[{"url":"https://www.nationalgeographic.com/science/article/sound-meditation-benefits","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.4981711777615216,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320.jpg","src":"https://i.natgeofe.com/n/086f7264-27c3-4170-b415-bfe1d1007031/NationalGeographic_2713320.jpg","altText":"A woman sitting crosslegged as she meditates on tiny islet set in a mountain valley stream.","crdt":"Photograph by DAWN KISH, Nat Geo Image Collection","dsc":"Whether listening to to the sounds of a mountain stream, or the targeted frequencies of Tibetan singing bowls, sound has the ability to aide the mind as it relaxes into a meditative state.","ttl":"NationalGeographic_2713320","rchDsc":{"markup":"Whether listening to to the sounds of a mountain stream, or the targeted frequencies of Tibetan singing bowls, sound has the ability to aide the mind as it relaxes into a meditative state."},"rchTtl":{"markup":"NationalGeographic_2713320"}},"abstract":"Studies show that when it comes to silencing your mind, sound may be the most effective tool.","title":"How sound helps quiet your mind for meditation","tags":[{"name":"Science","id":"2af51eeb-09a8-3bcf-8467-6b2a08edb76c","type":"sources","uri":"https://www.nationalgeographic.com/science"}]}],"heading":"Science","pageInfo":{"endCursor":"NTpSRmxPUVY4d0kwbEVPa1JTVG54a2NtNDZjM0pqT201aGRHZGxienAxYm1semIyNDZPbkJ5YjJRNk1XRmpNVGN5Tm1FdE1EazBNeTAwWldVeExUZzFOMk10WW1FM01ETm1PRGxpTlRnNEkxTlBVbFE2YjNKcFoybHVZV3hRZFdKc2FYTm9aV1JFWVhSbGZERTNNVFEwTVRVd01Ua3pPVGM9","hasNextPage":true},"templateContext":"eyJjb250ZW50VHlwZSI6IlVuaXNvbkFydGljbGVDb250ZW50IiwidmFyaWFibGVzIjp7ImluY2x1ZGVNZWRpYUNvbnRlbnRzIjoidHJ1ZSIsImxvY2F0b3IiOiIvc2NpZW5jZS9hcnRpY2xlL2Nvcm9uYXZpcnVzLXZhY2NpbmUtdHJhY2tlci1ob3ctdGhleS13b3JrLWxhdGVzdC1kZXZlbG9wbWVudHMtY3ZkIiwicG9ydGZvbGlvIjoibmF0Z2VvIiwicXVlcnlUeXBlIjoiTE9DQVRPUiJ9LCJtb2R1bGVJZCI6bnVsbH0","storyTitle":"Here’s the latest on COVID-19 vaccines"},{"id":"natgeo-globalpromo-frame1-travel","cmsType":"CarouselModule","centerHeading":true,"edgs":[{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_b7c01a6c-674b-4ceb-982e-a2972d9cb253","description":"In the southern reaches of Vietnam, life has revolved around the water for hundreds of years. Here, in the Mekong Delta and on the Con Dao islands of the South China Sea, communities continue to embrace old ways while looking to the future in this rapidly developing pocket of Asia.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/waterways-islands-southern-vietnam","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR.jpg","src":"https://i.natgeofe.com/n/1626bbd2-1ce6-46ed-b9ea-5f935b8179ca/vietnam__DSC9957_HR.jpg","altText":"A lady is cycling through a back street in a rural area of Vietnam.","crdt":"Photograph by Ulf Svane","dsc":"The Vinh Long province is home to a large Khmer community — an ethnic group primarily based in Cambodia.","ttl":"Cycle","rchDsc":{"markup":"The Vinh Long province is home to a large Khmer community — an ethnic group primarily based in Cambodia."},"rchTtl":{"markup":"Cycle"}},"abstract":"In the southern reaches of Vietnam, life has revolved around the water for hundreds of years. Here, in the Mekong Delta and on the Con Dao islands of the South China Sea, communities continue to embrace old ways while looking to the future in this rapidly developing pocket of Asia.","title":"A slow journey around the islands of southern Vietnam","tags":[{"name":"Travel","id":"432c4f83-2d55-3974-b95f-a221c87c0fd1","type":"sources","uri":"https://www.nationalgeographic.com/travel"}]},{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_5c5c350b-5d9e-4b5d-8078-dcc15e98d27d","description":"New rules are changing the Everest Base Camp hiking experience, aiming to protect the Himalayas’ Sherpa communities and help trekkers make a more positive impact.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/how-to-climb-mount-everest-himalayas-responsibly","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ.jpg","src":"https://i.natgeofe.com/n/8b59ca0c-e0eb-4153-984a-1ebbe037b1e4/W9K8EJ.jpg","altText":"A queue of hikers following a trail at Mount Everest.","crdt":"Photograph by Robert Harding, Alamy","dsc":"New rules are changing the Everest Base Camp hiking experience to combat overtourism and climate change.","ttl":"Queue","rchDsc":{"markup":"New rules are changing the Everest Base Camp hiking experience to combat overtourism and climate change."},"rchTtl":{"markup":"Queue"}},"abstract":"New rules are changing the Everest Base Camp hiking experience, aiming to protect the Himalayas’ Sherpa communities and help trekkers make a more positive impact.","title":"Is it possible to climb Mount Everest responsibly?","tags":[{"name":"Travel","id":"432c4f83-2d55-3974-b95f-a221c87c0fd1","type":"sources","uri":"https://www.nationalgeographic.com/travel"}]},{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_826f0451-0a2f-4229-a2d8-ceb7b0400967","description":"From long-distance bike routes to new train rides whisking you to the heights, these are the latest openings across the Alps to have on your radar this summer.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/what-to-do-in-alps-summer-trains-trails","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR.jpg","src":"https://i.natgeofe.com/n/08bffe59-56ef-4c31-8982-96c50ff1e2e3/ST_whatsnew_T4H0BG_ukHR.jpg","altText":"Kayakers in a jewel-toned lake with green covered mountains in the distance.","crdt":"Photograph by Alamy","dsc":"Though it is widely lauded as a winter destination, new opening and activities are making the Alps a summer holiday dream.","ttl":"Slovenia","rchDsc":{"markup":"Though it is widely lauded as a winter destination, new opening and activities are making the Alps a summer holiday dream."},"rchTtl":{"markup":"Slovenia"}},"abstract":"From long-distance bike routes to new train rides whisking you to the heights, these are the latest openings across the Alps to have on your radar this summer.","title":"What's new in the Alps this summer","tags":[{"name":"Travel","id":"432c4f83-2d55-3974-b95f-a221c87c0fd1","type":"sources","uri":"https://www.nationalgeographic.com/travel"}]},{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_4d97f5c2-838e-4369-a5a1-c6e42c9558fb","description":"Few African nations can match Uganda in terms of the wide variety of parks and reserves to explore. From action-packed 4WD safari adventures to breathtaking mountain hikes, these five national parks offer memorable experiences to set your heart racing.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/paid-content-ugandas-most-magnificent-national-parks","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes.jpg","src":"https://i.natgeofe.com/n/a0bd36d7-a981-4992-a8b0-ba6b15d90460/giraffes.jpg","crdt":"Photograph by Museruka Emmanuel, Getty Images","dsc":"Uganda is home to ten spectacular national parks, each providing unique and memorable experiences. Those visiting Kidepo Valley National Park will get the chance to see Rothschild's giraffes.","rchDsc":{"markup":"Uganda\nis home to ten spectacular national parks, each providing unique and memorable\nexperiences. Those visiting Kidepo Valley National Park will get the chance to\nsee Rothschild's giraffes."},"rchTtl":{"markup":""}},"abstract":"Few African nations can match Uganda in terms of the wide variety of parks and reserves to explore. From action-packed 4WD safari adventures to breathtaking mountain hikes, these five national parks offer memorable experiences to set your heart racing.","title":"5 of Uganda’s most magnificent national parks","tags":["Paid Content"]},{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_d3b730bb-71bf-4983-ac64-afc55539bf16","description":"An Indonesian elixir is the latest ancient wellness tradition to be acknowledged for its distinct contribution to heritage.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/wellness-experiences-protected-unesco","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.3195876288659794,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689.jpg","src":"https://i.natgeofe.com/n/bd8dd676-654e-44f9-ac4c-506332632647/BAL_389689.jpg","altText":"A woman kneeling in front of a stone bowl with rice and a mat of other ingredients such as tumeric and other spices, next to a glass drinking bottle with an orange drink inside.","crdt":"Photograph by Luca Tettoni, Bridgeman Images","dsc":"Preparing jamu ; traditional Indonesian medicine made from roots, leaves and bark;","rchDsc":{"markup":"Preparing jamu ; traditional Indonesian medicine made from roots, leaves and bark;"},"rchTtl":{"markup":""}},"abstract":"An Indonesian elixir is the latest ancient wellness tradition to be acknowledged for its distinct contribution to heritage.","title":"These 5 health customs are protected by UNESCO","tags":[{"name":"Travel","id":"432c4f83-2d55-3974-b95f-a221c87c0fd1","type":"sources","uri":"https://www.nationalgeographic.com/travel"}]},{"id":"natgeo-globalpromo-frame1-travel-tile","cmsType":"RegularStandardPrismTile","isEntitled":false,"cId":"natgeo-globalpromo-frame1-travel-tile_df4596e0-67a7-4046-a283-2af340c81e9a","description":"The history of this imperial city is intertwined with many of Morocco’s greatest food traditions — a tour of its vast medieval medina can lead to centuries-old recipes, but also local wines and experimental kitchens.","ctas":[{"url":"https://www.nationalgeographic.com/travel/article/where-to-eat-fez-morocco","text":"natgeo.ctaText.read","icon":"article"}],"img":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2.jpg","src":"https://i.natgeofe.com/n/a5d0beab-96e8-48f4-80c5-6c594042390d/fez2.jpg","altText":"A selection of Moroccan souks to contain tajine, painted with a variation of colours and designs.","crdt":"Photograph by ISTOCKPHOTO, GETTY IMAGES","dsc":"Assorted Moroccan tajines in a souk.","ttl":"Moroccan souk","rchDsc":{"markup":"Assorted Moroccan tajines in a souk."},"rchTtl":{"markup":"Moroccan souk "}},"abstract":"The history of this imperial city is intertwined with many of Morocco’s greatest food traditions — a tour of its vast medieval medina can lead to centuries-old recipes, but also local wines and experimental kitchens.","title":"Where to eat in Fez, Morocco","tags":[{"name":"Travel","id":"432c4f83-2d55-3974-b95f-a221c87c0fd1","type":"sources","uri":"https://www.nationalgeographic.com/travel"}]}],"heading":"Travel","pageInfo":{"endCursor":"NTpSRmxPUVY4d0kwbEVPa1JTVG54a2NtNDZjM0pqT201aGRHZGxienAxYm1semIyNDZPbkJ5YjJRNlpHWTBOVGsyWlRBdE5qZGhOeTAwTURRMkxXRXlPRE10TW1GbU16UXdZemd4WlRsaEkxTlBVbFE2YjNKcFoybHVZV3hRZFdKc2FYTm9aV1JFWVhSbGZERTNNVFEyTlRFeU1EQXdNREE9","hasNextPage":true},"templateContext":"eyJjb250ZW50VHlwZSI6IlVuaXNvbkFydGljbGVDb250ZW50IiwidmFyaWFibGVzIjp7ImluY2x1ZGVNZWRpYUNvbnRlbnRzIjoidHJ1ZSIsImxvY2F0b3IiOiIvc2NpZW5jZS9hcnRpY2xlL2Nvcm9uYXZpcnVzLXZhY2NpbmUtdHJhY2tlci1ob3ctdGhleS13b3JrLWxhdGVzdC1kZXZlbG9wbWVudHMtY3ZkIiwicG9ydGZvbGlvIjoibmF0Z2VvIiwicXVlcnlUeXBlIjoiTE9DQVRPUiJ9LCJtb2R1bGVJZCI6bnVsbH0","storyTitle":"Here’s the latest on COVID-19 vaccines"}],"theme":"dark","cmsType":"EnhancedFrame"}],"meta":{"cnnicl":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","dsc":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","id":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a","mdfdDt":"2021-11-05T18:27:36.476Z","ttl":"Here’s the latest on COVID-19 vaccines","sctn":"Science","sclDsc":"Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout.","sclImg":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg?w=1200","sclImgHgt":675,"sclImgWdth":1200,"sclTtl":"Here’s the latest on COVID-19 vaccines","adKvps":{"objid":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a"},"pgTxnmy":{"audiences":["General"],"genres":["News"],"series":["Coronavirus Coverage"],"sources":["Science"],"subjects":["Coronavirus","Vaccination","Immune System","Public Health","Diseases","Epidemics"]},"pblshDt":"2021-10-29T19:32:02.702Z","hreflngs":[{"lcl":"en-us","url":"https://www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd"}]},"flags":{"freemiumContentGatingEnabled":true,"hideNumbering":true},"prtfloFlgs":{"hideSharing":false,"hideSource":false,"freemiumContentGatingEnabled":true,"premiumContentGatingEnabled":false,"disableFreemiumUpsell":false},"config":{"ads":{"enabled":true,"insertedAdLimit":null,"insertedAdSpacing":900,"pzn":{"mode":"ltd","extra":true},"refreshInterval":30},"logoIcon":"ng-border","numLines":3,"type":"default","IMAGE_CONFIGS":{"large":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":767,"screenWidth":767},{"cropName":"3x2","width":1024,"screenWidth":1024},{"cropName":"3x2","width":1260,"screenWidth":1440},{"cropName":"3x2","width":1440}],"immersiveLdBg":{"img":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":767,"screenWidth":767},{"cropName":"3x2","width":1024,"screenWidth":1024},{"cropName":"3x2","width":1260,"screenWidth":1440},{"cropName":"raw","width":1440}],"default":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":767,"screenWidth":767},{"cropName":"3x2","width":1024,"screenWidth":1024},{"cropName":"3x2","width":1260,"screenWidth":1440},{"cropName":"3x2","width":1440}]},"inline":{"x-small":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":718,"screenWidth":767},{"cropName":"2x3","width":300}],"small":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"2x3","width":718}],"medium":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":718,"screenWidth":767},{"cropName":"3x2","width":718,"screenWidth":1024},{"cropName":"3x2","width":1280}],"large":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":767,"screenWidth":767},{"cropName":"3x2","width":1024,"screenWidth":1024},{"cropName":"3x2","width":1260,"screenWidth":1440},{"cropName":"3x2","width":1440}],"default":[{"cropName":"3x2","width":374,"screenWidth":374},{"cropName":"3x2","width":413,"screenWidth":413},{"cropName":"3x2","width":718}]},"playlist":{"player":[{"cropName":"16x9","width":374,"screenWidth":374},{"cropName":"16x9","width":413,"screenWidth":413},{"cropName":"16x9","width":718}],"tile":[{"cropName":"raw","width":220,"screenWidth":767},{"cropName":"raw","width":300,"screenWidth":1119},{"cropName":"raw","width":195}]},"spnsrBanner":[{"cropName":"raw","height":32}],"tileStack":{"aspectRatio":0.75,"cropName":"3x4","width":400},"upsell":[{"cropName":"2x1","width":331,"screenWidth":767},{"cropName":"2x1","width":474,"screenWidth":1024}]}}}},"transition":{"hide":{"default":true,"rules":[{"priority":4,"retValue":false,"conditions":[{"type":"change","path":"pageType","val":false},{"type":"change","path":"section","val":false},{"type":"change","path":"subsection","val":false},{"type":"change","path":"subPageType","val":false},{"type":"change","path":"slug","val":false},{"type":"change","path":"taxonomy","val":false}]}]},"reload":{"default":true,"rules":[{"priority":4,"retValue":false,"conditions":[{"type":"change","path":"pageType","val":false},{"type":"change","path":"section","val":false},{"type":"change","path":"subsection","val":false},{"type":"change","path":"subPageType","val":false},{"type":"change","path":"slug","val":false},{"type":"change","path":"taxonomy","val":false}]}]}},"ads":{"kvps":[{"name":"pgtyp","value":"prismarticle"},{"name":"ed","value":"us"},{"name":"lang","value":"en"},{"name":"objid","value":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a"}]},"analytics":{"page_type":"prismarticle","page_url":"www.nationalgeographic.com/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","page_id":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a","page_taxonomy":{"srcs":"Science","frstSbj":"Coronavirus","sries":"Coronavirus Coverage","othrSbjs":"Vaccination, Immune System, Public Health, Diseases, Epidemics","gnres":"News","auds":"General"},"cntrbGrp":[{"contributors":[{"displayName":"Amy McKeever"},{"displayName":"National Geographic Staff"}],"title":"By","rl":"Writer"}],"pbDt":"2021-10-29T19:32:02.702Z","ldMda":{"cmsType":"image","hasCopyright":true,"id":"a00b6ac5-fc87-4ce4-8dad-0a75c51b17ab","lines":3,"positionMetaBottom":true,"showMore":true,"caption":"A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech COVID-19 vaccine at Boston Medical Center.","credit":"Photograph by Adam Glanzman, Bloomberg via Getty Images","image":{"crps":[{"nm":"raw","aspRto":1.5003663003663004,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg"},{"nm":"16x9","aspRto":1.7777777777777777,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_16x9.jpg"},{"nm":"3x2","aspRto":1.5,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x2.jpg"},{"nm":"square","aspRto":1,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_square.jpg"},{"nm":"2x3","aspRto":0.6666666666666666,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg"},{"nm":"3x4","aspRto":0.75,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_3x4.jpg"},{"nm":"4x3","aspRto":1.3333333333333333,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg"},{"nm":"2x1","aspRto":2,"url":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x1.jpg"}],"rt":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg","src":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613.jpg","altText":"A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston.","crdt":"Photograph by Adam Glanzman, Bloomberg via Getty Images","dsc":"A healthcare worker places a band-aid on a patient after administering a dose of the Pfizer-BioNTech Covid-19 vaccine at Boston Medical Center in Boston, on Thursday, June 17, 2021.","ttl":"Covid Vaccine"},"imageAlt":"A healthcare worker places a band-aid on a patient after administering a dose of the Covid-19 vaccine in Boston.","imageSrc":[{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=374&h=561","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=748&h=1122"},"media":"(max-width: 374px)"},{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=413&h=620","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_2x3.jpg?w=826&h=1240"},"media":"(max-width: 413px)"},{"sources":{"x1":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg?w=718&h=539","x2":"https://i.natgeofe.com/n/572cc2b9-4423-496d-9ab3-f89b291b1323/GettyImages_1233523613_4x3.jpg?w=1436&h=1078"},"media":"(min-width: 414px)"}],"hideTitle":true,"hideCredit":false,"hideEndBug":true,"type":"imageLead","hideLine":true,"deferImages":false},"mdDt":"2021-11-05T18:27:36.476Z","wrdcnt":10602,"prismOptions":{"showSidebar":false,"ads":{"disabled":false,"fillInlineAds":true,"inlineAdsLimit":30,"minWords":0,"allowNearInline":true,"outstreamSlots":[3,13,18],"boxSlots":[8]},"everscrollEnabled":true,"endComponents":[{"name":"RelatedTags","data":{"articleConfig":{"gridDisplayMode":"normal"},"relatedTags":{"heading":"Related Topics","tags":[{"label":"CORONAVIRUS","href":"/related/f8408099-1b29-30de-af0d-3c172303e501/coronavirus"},{"label":"VACCINATION","href":"/related/26945195-72a1-3529-9d2a-cc4d85de992a/vaccination"},{"label":"IMMUNE SYSTEM","href":"/related/4ae5b950-6a04-33cd-94ed-b34a8ab3beba/immune-system"},{"label":"PUBLIC HEALTH","href":"/related/c1e8ee84-032b-3fb7-992e-8380b2ef0e13/public-health"},{"label":"DISEASES","href":"/related/f01c74a1-1ac8-3227-aec9-a76ea1805776/diseases"},{"label":"EPIDEMICS","href":"/related/f13ad5d0-f78b-39ea-a136-f8064e68bc33/epidemics"}]}}},"ContentPromoGrid"],"components":["LeadMediaImage",{"name":"PrismBadgeTag","data":{"badge":null,"tags":{"tags":[{"label":"SCIENCE","href":"https://www.nationalgeographic.com/science"},{"label":"CORONAVIRUS COVERAGE","href":"https://www.nationalgeographic.com/science/topic/coronavirus-coverage"}]},"isUserAuthed":false}},"Headline","Byline","Divider","Body"],"Byline":{"dateFormat":{"postFormat":"MMMM DD, YYYY","preFormat":"MMMM DD, YYYY"}},"layoutOptions":{"top":{"colorMode":"light"},"sidebar":{"isSticky":true,"isStackable":true},"main":{"spacing":{"top":40}}},"Divider":{"className":"natgeoDivider"},"Body":{"inlines":[{"type":"editorsNote","data":{"articleConfig":{"align":"full"},"body":"<p><b>Editor’s note:</b> As of November 2021, this COVID-19 vaccine tracker is no longer being updated. <a href=\"https://www.nationalgeographic.com/science/article/covid-vaccines-latest-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Stay up-to-date on the latest vaccine developments and other COVID-19 news here</a>.</p>","header":null,"inlineId":"editors-notetracker-no-longer-being-updated"}},{"type":"markup","data":{"articleConfig":{"alignXxs":"full","align":"full"},"useSafeFrame":false,"a11yCTAText":"More Details","caption":{"title":null,"text":"","lines":3,"showMoreText":"Read More"},"encMethod":"esc","inlineId":"inline-1","tmsEnabled":true,"markup":"%3Clink%20rel%3D%22stylesheet%22%20href%3D%22//interactives.natgeofe.com/vendor/css/partial-aem-main.css%22%3E%0A%3Chr%20style%3D%22%u201Cwidth%3A50%25%3B%22%20border-top%3A1px%20solid%20%23ccc%3B%20margin%3A1em%20auto%3B%u201D%3E"}},{"type":"listicle","data":{"articleConfig":{"align":"full"},"title":"VACCINE CLINICAL TRIAL PROCESS","body":"<p><b>Phase one:</b> Checks the safety of a vaccine and determines whether it triggers an immune response in a small group of healthy humans.&nbsp;</p><p><b>Phase two:</b> Widens the testing pool to include groups of people who may have the disease or be more likely to catch it, to gauge the vaccine’s effectiveness.&nbsp;</p><p><b>Phase three:</b> Expands the pool up to the thousands to make sure the vaccine is safe and effective among a wider array of people, given that immune response can vary by age, ethnicity, or by underlying health conditions.</p>","description":"","inlineId":"listicle: clinical trial process","richTextElement":"div"}},{"type":"CommercePromo","data":{"layout":"standard","headline":"For Hungry Minds","description":" ","imageSrc":"https://i.natgeofe.com/n/73e6ebe2-a5c3-4e72-b1f8-ec30997bd883/NGKBAU.jpg","imageRatio":"4x3","actionLabel":"GIFT NAT GEO KIDS","actionHref":"https://ngkidsubs.nationalgeographic.com/servlet/OrdersGateway?cds_mag_code=NKD&cds_page_id=276847&cmpid=int_org=ngp::int_mc=website::int_src=ngp::int_cmp=bau_kids_may2024::int_add=article_promo","immersive":true,"colorMode":"dark","campaignName":"20240501_NGKBAU_MarketingPromo","tint":1,"inlineId":"commerce-promo-inline","articleConfig":{"alignXxs":"full","align":"center"},"className":"prism-commerce-container"}},{"type":"listicle","data":{"articleConfig":{"align":"full"},"title":"TYPES OF VACCINES","body":"<p><b>Nucleic acid:</b> Relies on injecting snippets of a virus’s genetic material, either DNA or messenger RNA (mRNA), into human cells. It spurs the production of viral proteins that mimic features of the coronavirus, training the immune system to recognize its presence.&nbsp;</p><p><b>Knocked-out virus:</b> Uses a non-infectious form of the coronavirus that can no longer cause full-blown disease but can still provoke an immune response. The virus can either be fully inactivated or weakened. These modes are considered the most classic ways to make vaccines.</p><p><b>Viral vector:</b> Essentially a “Trojan horse” presented to the immune system. One type involves introducing a piece of DNA from SARS-CoV-2 into another unrelated germ—for example, an adenovirus, which typically causes the common cold. When this modified adenovirus is injected into humans, the hope is that it will instruct cells to make coronavirus proteins and will trigger an immune response.</p><p><b>Protein:</b> These vaccines are typically made from coronavirus proteins, which can be synthesized or brewed in labs like beer. Some versions involve coating a carrier—such as nanoparticles—with proteins to better aid delivery and uptake by cells.</p>","description":"","inlineId":"listicle: types of vaccine","richTextElement":"div"}},{"type":"ContentPromo","data":{"inlineId":"recirculation-inline","articleConfig":{"align":"center"},"layout":"standard","cards":[{"headline":"COVID-19 can ruin your sleep in many different ways—here's why","image":"https://i.natgeofe.com/n/74649313-be0f-4413-bac8-0a40f9bcdedf/GettyImages-1388405157_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-19-can-ruin-your-sleep-in-many-different-waysheres-why","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]},{"headline":"How the additives in your vaccines rev up your immune system","image":"https://i.natgeofe.com/n/2341016f-79a8-46e2-8d2b-076591129c73/ScienceSourceImages_2464093_HighRes_square.jpg","link":"https://www.nationalgeographic.com/premium/article/vaccines-immune-system-inflammation","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]},{"headline":"Multiple COVID infections can lead to chronic health issues. Here’s what to know.","image":"https://i.natgeofe.com/n/57202b9d-6fed-46f9-beda-c72c13c2cb5f/h_15733016_square.jpg","link":"https://www.nationalgeographic.com/premium/article/covid-reinfections-chronic-booster-vaccine","imageRatio":"1x1","tags":[{"value":"SCIENCE","type":"text"}]}],"title":"You May Also Like"}},{"type":"editorsNote","data":{"articleConfig":{"align":"full"},"body":"<p><b>Editor's note:</b> This story was originally published on July 31, 2020. It was regularly updated as developments occurred until November 2021.</p>","header":null,"inlineId":"inline-2"}}],"Blockquote":{"disableQuotationMark":true,"simple":true},"datelineSeparator":"—","stripBr":false,"className":"PrismArticleBody SingleColumn StartsWithInline"},"dataConstructorMap":{}},"story_id":"drn:src:natgeo:unison::prod:d1ea2173-f31f-4f18-b938-fe6cbc58458a"}},"request":{"headers":{},"httpVersion":"1.1","method":"GET","url":"/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","vary":{"cached":true,"device":"pc","host":"www.nationalgeographic.com","path":"/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd","forwarded-proto":"https","country":"us","edition":"natgeo-en-us","edition-view":"natgeo-en-us","loggedin":"false"}},"viewport":{"width":1260,"height":0},"user":{}};</script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/_manifest.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/natgeo-fce9ec0b.js" defer></script><script src="//assets-cdn.nationalgeographic.com/natgeo/bfa4aecbdc63-release-04-25-24-revert.3/client/natgeo/prismarticle-27bb034e.js" defer></script>
                
            </body>
        </html>
     contentType 9 text/html url 120 https://www.nationalgeographic.com:443/science/article/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd responseCode 3 200 